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Mucosal associated invariant T (MAIT) cells are an unconventional T cell subset that are 
abundant in humans in blood, liver, and mucosal tissues. MAIT cells express a semi-invariant 
T cell receptor (TCR) (Vα7.2-Jα12/20/33) and are restricted to antigen presented by the non-
polymorphic, evolutionarily conserved MHC class IB molecule, MHC class I related protein 
(MR1). MR1 presents unstable pyrimidine derivatives of a metabolic precursor of microbial 
riboflavin synthesis, and trigger MAIT cell activation via their TCR.  Like other unconventional 
T cells, MAIT cells express cytokine receptors, such as interleukin (IL)-12R and IL-18R, at 
high levels and can respond to cytokines, produced during bacterial or viral infections, 
independently of TCR stimulation. As a result, MAIT cells may play a role in infection by a 
broad range of bacteria, fungi, and viruses, as well as in sterile inflammation. 
 
Activation via the two modes can occur independently or simultaneously, depending upon the 
stimuli. However, it is unclear whether the effector functions of human MAIT cells differ by 
mode of activation. Therefore, this study compared functional and genome wide transcriptional 
responses of blood and liver derived MAIT cells to riboflavin-producing bacteria (Escherichia 
coli), soluble pyrimidine ligands, and cytokines (IL-12+IL-18) to define the full array of 
effector functions. TCR stimulation of both blood and liver derived MAIT cells triggered rapid 
acquisition of a polyfunctional proinflammatory phenotype, with the expression of multiple 
cytokines and chemokines, while the response to cytokine activation was slower and narrower. 
In TCR activated MAIT cells, there was also enrichment of a tissue repair gene expression 
signature, indicating a potential homeostatic role for MAIT cells. Of note, the functional and 
genome-wide response of both blood and liver derived MAIT cells was strikingly similar. While 
liver-derived MAIT cells were more responsive to cytokine stimulation, there was no significant 
difference in the response to TCR stimulation between blood and liver-derived MAIT cells. 
When the transcriptome of unstimulated blood and liver-derived MAIT cells were compared, 
there was no substantial difference in the circulatory and tissue residency gene expression 
signatures, suggesting that MAIT cells may recirculate between blood and liver.  
 
Both commensals and pathogens synthesise riboflavin and could activate MAIT cells that are 
abundant in liver and in mucosal tissues, therefore their activation must be regulated to prevent 
immunopathology. Therefore, this study further explored the bacterial signals and the co-
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stimulatory molecules that they induce that are important in regulating TCR-mediated MAIT 
cell activation. Type I interferons were identified as a major regulatory signal that can directly 
activate MAIT cells as well as enhancing the response of MAIT cells to TCR activation. 
Furthermore, intact ligand deficient bacteria enhanced MAIT cell activation by pyrimidine 
ligand to a greater extent than lysed bacteria or TLR agonists, suggesting the physiological form 
of bacteria is essential to trigger robust MAIT cell activation. 
 
Overall, this study has significantly advanced our knowledge of MAIT immunobiology, 
highlighting differences in the response of MAIT cells to TCR and cytokine signals. The 
regulation of TCR responses by innate signals, which are abundantly present during bacterial 
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1.1 Human Immune system and T cells 
In humans, the multifaceted immune system consists of two main protective arms; innate and 
adaptive, to control and eliminate pathogenic microbes (Chaplin, 2010). The innate immune 
system consists of physiological barriers such as skin and immune cells with highly conserved 
receptors specific for common microbial signatures collectively known as pathogen associated 
molecular patterns (PAMPs), while the adaptive immune system consists of immune cells with 
recombined antigen receptors for variable epitopes such as B cells and T cells that rely on 
memory (Chaplin, 2010, Dempsey et al., 2003). Therefore, innate immune cells such as myeloid 
cells (neutrophils and monocytes), natural killer (NK) cells and innate lymphoid cells (ILCs), 
which are already abundantly present, can respond immediately after the invading pathogen is 
encountered and thus constitutes the initial host response (Chaplin, 2010, Dempsey et al., 2003, 
Vivier et al., 2018). By contrast, adaptive immune cells require expansion upon encountering 
the antigen to attain sufficient numbers and generally express after the innate immune response 
(Chaplin, 2010, Dempsey et al., 2003).  
T cells play an essential role in the adaptive immune response. T cells are characterized by the 
presence of a T cell receptor (TCR) on the surface, which consists of α and β chains or  and  
chains. T cells can be classified into groups on the basis of expression of the co-receptor CD4 
(cluster of differentiation 4) or CD8, and are abundant in peripheral blood, lymph nodes and 
tissues (such as skin and mucosa) (Pennington et al., 2005, Chien et al., 2014, Pennock et al., 
2013). A TCR is a highly diverse structure which undergoes an extensive VDJ (variable (V), 
diversity (D) and joining (J) gene segments) recombination during the T cell selection process 
against a specific antigen and therefore, each TCR is unique (Pennock et al., 2013, Xu and 
Davis, 2000). The highly variable complementary determining regions (CDRs), notably CDR3, 
of the TCR forms the antigen binding site (Xu and Davis, 2000). T cell development and TCR 
repertoire arrangement occurs in thymus (Nitta and Suzuki, 2016, Moran and Hogquist, 2012, 
Kurd and Robey, 2016). Stromal cells, especially thymic epithelial cells, host the hematopoietic 
stem cell-derived T cell lineage (known as thymocytes) and provide necessary signals for the 
sequential differentiation and survival of the immature thymocytes (Nitta and Suzuki, 2016). 
Thymocytes possessing a TCR with strong avidity to major histocompatibility complex (MHC) 
bound to self-peptide or agonist are terminated and thymocytes possessing a TCR with a low 
avidity interaction are allowed to differentiate further into T cells expressing either CD4 or CD8 
(positive selection) (Nitta and Suzuki, 2016, Moran and Hogquist, 2012). In the subsequent 




dendritic cells (DCs) are deleted or differentiated into regulatory T cells and other non-reactive 
T cells are selected (negative selection). Following negative selection, T cells possess a diverse 
TCR which is self-tolerant and only recognize its MHC-bound cognate non-self antigen (a 
peptide) (Nitta and Suzuki, 2016). MHC class I and II are highly polymorphic molecule 
expressed on an antigen presenting cells (APCs) (Chaplin, 2010, Wieczorek et al., 2017). 
During T cell activation, the CD4 co-receptor interacts with the MHC class II molecules 
whereas CD8 co-receptor liaise with MHC class I molecule (Wieczorek et al., 2017). 
Naïve T cells are antigen inexperienced and differentiate into effector T cells upon antigen 
exposure. Many of these effector T cell subsequently die and remaining T cells become memory 
T cells, which upon antigen exposure can be rapidly differentiated into effector T cells and 
provide protection (Sallusto et al., 2004, Mueller et al., 2013). Naïve and memory T cells can 
be distinguished based on the expression of different isoforms of CD45, a major leukocyte 
transmembrane protein-tyrosine phosphatase on the surface of leukocytes; CD45RA is 
expressed on naïve T cells and CD45RO on memory T cells following splicing of CD45RA 
(Altin and Sloan, 1997, Sallusto et al., 2004). CD45 is believed to associate with multiple 
membrane associated and surface molecules such as TCR-CD3 components and CD4/CD8 
(Altin and Sloan, 1997). Memory T cells can also be distinguished into central and effector 
memory T cell subsets based on the expression of lymph node homing receptors chemokine 
receptor (CCR) 7 (receptor for CCL19 produced by secondary lymphoid stromal cells) and 
CD62L (L-selectin), which are required for cell extravasation through high endothelial venules 
and migration to secondary lymphoid organs such as spleen and tonsils (Sallusto et al., 2004, 
Mueller et al., 2013). Like naïve T cells, the central memory T (TCM) cells express both of these 
molecules and are numerous in lymph nodes but are also found in blood, spleen, and bone 
marrow. TCM possess higher proliferative potential and produce IL-2 upon TCR triggering but 
following proliferation differentiate into effector cells and produce large amounts of cytokines, 
such as interferon gamma (IFNγ) (Sallusto et al., 2004, Mueller et al., 2013). In contrast, the 
effector memory T cells (TEM) have lost the expression of CCR7 and express very low CD62L 
but express certain sets of chemokine receptors and cell adhesion molecules that are required 
for homing to inflamed tissues. Thus, TEM are found less in lymph nodes but are abundant in 
blood, lung, liver, intestinal tract, and other mucosal tissues (Sallusto et al., 2004, Mueller et 
al., 2013, Mahnke et al., 2013). In blood, most TCM are CD4
+ T cells and most TEM are CD8
+ T 




IFNγ and IL-4 as well perforin within a few hours of stimulation and thus provide protective 
immunity (Sallusto et al., 2004, Mueller et al., 2013, Mahnke et al., 2013). 
T cells specific for a particular peptide-MHC combination are rare and must undergo clonal 
expansion upon antigen encounter to provide protection (Pennock et al., 2013). Therefore, in 
contrast to the rapidly responding, yet precise, innate immune response, which is triggered by 
the PAMPs, the adaptive immune response is specific for variable antigens but slower to 
respond (Chaplin, 2010, Dempsey et al., 2003, Hoebe et al., 2004). However, it is now evident 
that there are unconventional T cells which express an almost invariant TCR which have 
evolved to recognize broadly expressed non-protein antigens (Godfrey et al., 2015). 
1.2 Unconventional T cells 
Unconventional T cells bridge the innate and adaptive arms of the immune system. They are 
able to respond rapidly following antigen recognition and predominantly reside in an epithelial 
and mucosal tissues such as the skin, gut, and the genitourinary tract, as well as the liver and 
peripheral blood (Pennington et al., 2005, Chien et al., 2014, Godfrey et al., 2015). Interestingly, 
these unconventional T cells are abundant and can be efficiently activated following antigen 
presentation (Gapin, 2009, Godfrey et al., 2015). Unconventional T cell populations in humans 
include invariant natural killer T (iNKT) cells, mucosal associated invariant T (MAIT) cells, 
and gamma delta (γδ) T cells (Gapin, 2009, Godfrey et al., 2015). While the former two express 
an invariant αβ TCR (Vα24-Jα18 on iNKT cells and Vα7.2-Jα33 on MAIT cells), the later, 
express the γδ TCR; Vγ9Vδ2 TCR expressing being the major γδ subset in human blood (Chien 
et al., 2014, Porcelli et al., 1993, Provine et al., 2018). The antigens and the antigen presenting 
molecules these T cells recognize also differ: glycosphingolipids such as α-galactosylceramide 
are presented to iNKT cells by CD1d (MHC-like molecule); vitamin B2 precursor metabolites 
(pyrimidine derivatives) are presented to MAIT cells on MR1 (MHC-Ib related molecule); 
diverse range of antigens including prenyl pyrophosphate metabolites (phosphoantigens such 
as (E)-4-Hydroxy-3methyl-but-2-enyl pyrophosphate, (HMB-PP)) presented to Vγ9Vδ2 T cells 
on butyrin 3A1 (others antigens are also present by CD1 molecule) (Figure 1.1) (Bendelac et 
al., 2007, Chien et al., 2014, Ussher et al., 2014b, Davey et al., 2018). These antigens act as 
‘PAMPs’ but are recognized by recombined TCRs on T cells that have gone through thymic 
selection. Therefore, these unconventional T cells are often called ‘innate-like T cells’. 
Unconventional T cells have shared phenotypic features but also are distinct from each other. 




CD92/NKG2A and NKG2D (Dias et al., 2017, Fergusson et al., 2014, Garner et al., 2018, 
Provine et al., 2018, Davey et al., 2018). Unconventional T cells are also characterized by high 
expression of cytokine receptors, which can lead to the TCR-independent activation by innate 
signals, such as interleukin (IL)-12/IL-18/IL-15, produced during both infectious and non-
infectious inflammatory diseases (Garner et al., 2018, Provine et al., 2018, Ussher et al., 2014a). 
MAIT cells and γδ T cells (including both Vδ2+ and Vδ2-) are more abundant than iNKT cells 
in human blood (~ 1-10% vs ~ 0.1% of total T cells) and mucosal tissues however, MAIT cells 
and iNKT cells are enriched in liver and each can reach up to 30% of total T cells (Bendelac et 
al., 2007, Dusseaux et al., 2011, Garner et al., 2018, Martin et al., 2009, Rahimpour et al., 2015, 
Provine et al., 2018). Interestingly, iNKT cells are more abundant in mice than MAIT cells, 
however, CD1d knockout mice lacking iNKT cells have more MAIT cells, suggesting possible 
competition for a functional niche between these two unconventional T cell subsets (Ussher et 
al., 2014b, Koay et al., 2016). Additionally, recent studies outline major differences in the 
developmental requirements and phenotype of iNKT cells and MAIT cells (Godfrey et al., 2019, 
Koay et al., 2018, Martin et al., 2009). Hence, MAIT cells, iNKT cells, and γδ T cells are distinct 





Figure 1.1 Differences between conventional T cells and MAIT cells. (A) Conventional T cells with diverse 
TCRs of varying specificity are activated by their cognate peptide antigens presented by MHC molecules (either 
class I or II). (B-D) In contrast, MAIT cells, iNKT cells and γδ T cells express a semi-invariant TCR and are 
activated by limited set of antigens, derived from specific microbial pathways, presented by unconventional 
antigen presenting molecules. 
1.3 MAIT cell discovery and Vα7.2 TCR 
MAIT cells were discovered by Porcelli et al. during a study of TCRs expressed by human CD8-
CD4- double negative (DN) αβ T cells (Porcelli et al., 1993). Two TCR Vα chains, Vα24 and 
Vα7.2, were preferentially expressed by purified DN T cells in combination with JαQ and 
IGRJα14 (later renamed Jα33) respectively. Later Tilloy et al. described the Vα7.2 TCR 
expressing T cells as a new subset of T cells and reported their presence in human (Vα7.2-Jα33 
with Vβ6 or Vβ20), mice (Vα19-Jα33) and cattle (Tilloy et al., 1999). These T cells with Vα7.2-
Jα33 were abundant DN T cells and displayed an activated/memory phenotype (CD45RAlo 
CD45RO+). Their absence in mice lacking β2m but not in mice deficient in classical MHC I or 




these cells must be selected by non-classical MHC-Ib molecules (Tilloy et al., 1999). Treiner et 
al. confirmed the observation of Porcelli and Tilloy that MAIT cell express the TCR 
arrangement Vα7.2-Jα33 in humans and Vα19-Jα33 in mice and demonstrated distinct selection 
of MAIT cell from CD1d-restrcited NKT cells by non-classical MR1 (Porcelli et al., 1993, 
Tilloy et al., 1999, Treiner et al., 2003). They further went on to establish the role of commensal 
flora and B cells for MAIT cell development from the observation of MAIT cells being absent 
in germfree mice and in B cell deficiency in both humans and mice (Treiner et al., 2003). 
Interestingly, these Vα7.2-Jα33 cells  in both humans and mice were preferentially located in 
the gut lamina propria, thus these T cells earned the name mucosal associated invariant T 
(MAIT) cells (Treiner et al., 2003). While in humans, the TCRα chain of MAIT cells mostly 
consists Vα7.2-Jα33, Vα7.2-Jα12 and Vα7.2-Jα20 expressing MAIT cells have also been 
described by sequencing the TCR of MR1-tetramer positive cells (Reantragoon et al., 2013). 
These TCRα chains are most commonly paired with Vβ2 and Vβ13.2. In mice, MAIT cells 
consist of a constant TCRα chain (Vα19-Jα33) paired mostly with Vβ6 or Vβ8, with conserved 
length of TCRα complimentary determining region (CDR3) between the species (Reantragoon 
et al., 2013, Lepore et al., 2014, Tilloy et al., 1999, Gherardin et al., 2018). 
1.4 MAIT cell phenotype and development 
In addition to the unconventional TCR, MAIT cells in adults have an effector memory 
phenotype (CD45RO+CD45RA-CCR7-CD62L-), however, their expression of these memory 
markers differ in thymus and cord blood where they express a naive phenotype (Koay et al., 
2016, Leeansyah et al., 2014). Adult MAIT cells highly express CD161 (NK1.1), CD8αα, CD25 
(IL-2Rα; receptor for IL-2), CD26 (adenosine deaminase binding protein), cytokine receptors 
(interleukin receptors; IL-7R, IL-12R, IL-15R and IL-18R) and chemokine receptors (CCR5; 
receptor for CCL3 and CCL4, CCR6; receptor for CCL20 and CXCR6; receptor for CXCL16) 
(Billerbeck et al., 2010, Dusseaux et al., 2011, Kurioka et al., 2017, Leeansyah et al., 2014, 
Tang et al., 2013). 
Consistent with the thymic development of CD1d-restricted iNKT cells, MAIT cells are 
positively selected by CD4+CD8+ double positive (DP) thymocytes expressing MR1 (Seach et 
al., 2013, Gold et al., 2013). This was reported first by Seach et al. who demonstrated the 
requirement for DP thymocytes but not thymic B cells, DCs, or macrophages, for the selection 
of MAIT cells (Seach et al., 2013). While B cell are not important for intrathymic MAIT cell 




of MAIT cells is not dependent on MHC class II and TAP, as the abundance of MAIT cell 
transcripts remained the same in humans and mice lacking the respective molecules, but 
requires β2-microglobulin (β2m) (Tilloy et al., 1999, Treiner et al., 2003). The absence of 
MAIT cells in germ free mice suggests that bacteria derived ligands are important for 
intrathymic MAIT cell development, and might be presented by DP thymocytes (Seach et al., 
2013). Supporting this, Legoux et al. recently demonstrated that MR1 ligand controlled the 
intrathymic development of MAIT cells in mice (Legoux et al., 2019). 
The observation of unaltered MAIT cell frequency in SLAM associated protein (SAP) deficient 
humans lacking Vα24+ iNKT cells, suggested these two unconventional T cells differ in their 
developmental process (Martin et al., 2009). In contrast to iNKT cell development, which 
occurs completely in thymus, Koay et al. proposed a three-stage pathway demonstrating 
intrathymic developmental but extrathymic maturation of the murine MAIT cell lineage based 
on CD24 (a sialoglycoprotein which binds to molecules exhibiting danger-associated molecular 
patterns (DAMPs)) and CD44 (a hematopoietic cell E- and L-selectin ligand involved in cell-
cell ligation) expression; stage 1 (CD24+CD44-), stage 2 (CD24-CD44-), and stage 3 (CD24-
CD44+) MAIT cells were found in the thymus, while extrathymic maturation and an abundance 
of stage 3 MAIT cells was observed in peripheral tissues (Koay et al., 2016). Similar 
observations were also made with intrathymic MAIT cells from humans, identified by 
differential expression of CD161 and CD27 (tumor necrosis factor receptor superfamily, 
member 7, binds to CD70); stage 1 (CD27-CD161-), stage 2 (CD27+CD161-) and stage 3 
(CD27+CD161+) were identified (Koay et al., 2016). Interestingly, stage 1 consists mostly 
CD4+CD8+ and CD4+ cells, stage 2 consists of CD4+CD8+, CD4+ and CD8+ cells, and stage 3 is 
dominated by CD8+ and DN cells. Comparatively, stage 1 MAIT cells, which are restricted to 
the thymus, lack the expression of CD161, CD127 (IL-7Rα), and transcription factors (RORγt 
and T-bet) seen in mature MAIT cells, but express more CD69 (early leukocyte activation 
molecule) and CD62L. By contrast, stage 3 MAIT cells, which dominate in the blood, are 
characterized by high expression of CD161, CD127, CD218 (IL-18Rα), CD103 (Integrin, alpha 
E; required for epithelial localization), RORγt and T-bet. Only stage 3 MAIT cells respond to 
mitogen stimulation by producing IFNγ and IL-17A and expand gradually outside thymus with 
lifespan, suggesting that functional maturation occurs following thymic egress, in contrast to 
iNKT maturation which happens inside thymus. Additionally, the majority of M. tuberculosis 
reactive MAIT in thymus and cord blood expressed CCR7 (equivalent to Stage 1) but peripheral 




of thymic and cord MAIT cells and antigen experienced phenotype of peripheral MAIT cells 
(Gold et al., 2013). 
Consistent with the expansion of MAIT cells postthymic development, MAIT cells are enriched 
in peripheral organs (lung, liver, and small intestine) compared to the thymus and secondary 
lymphoid organs (spleen and mesenteric lymph nodes) of second trimester fetuses (Leeansyah 
et al., 2014). Fetal peripheral MAIT cells are more mature (CD45RO+CD62L-PLZFhiIL-18R+) 
and are more responsive to bacterial stimulation than MAIT cells from secondary lymphoid 
organs and thymus, suggesting maturation prior to the establishment of commensal bacteria 
(Leeansyah et al., 2014). Thymic MAIT cells also exclusively express CD8αβ co-receptor, in 
contrast to expression of either CD8αβ or CD8αα co-receptor on MAIT cells from fetal blood 
and mucosal tissues (Leeansyah et al., 2014). With the observation of increased CD8αα+ cells 
(including CD161++) in a seven day culture of isolated CD8β+ cells, it was suggested that 
extrathymic CD8αα+ MAIT cells could have been derived from thymic CD8αβ+ MAIT cells 
(Walker et al., 2012). Fetal CD8αβ+ or CD8αα+ MAIT cells may express different levels of 
memory markers during development, however, both MAIT cell subsets in adults express 
equivalent levels of CD161, chemokine receptors (CCR2 (receptor for CCL2 and CCL7), CCR6 
and CXCR6), and demonstrate comparable production of IFNγ, IL-17A and IL-22 upon 
PMA/ionomycin stimulation (Leeansyah et al., 2014, Walker et al., 2012).  
1.5 TCR mediated activation of MAIT cell by MR1 
1.5.1 MR1 
The MAIT cell restricting molecule, MR1 is highly conserved in most mammals (including 
humans, non-human primates, mice and rats), sharing ~ 90% homology in the α1 and α2 chains 
between mice and humans, much higher than for MHC class Ia (~70%) or Ib (50%) and other 
MHC class I related genes, including CD1 (between 60-70%), making it the most conserved 
antigen presenting molecule (Lamichhane and Ussher, 2017, Riegert et al., 1998, Huang et al., 
2005). Consistent with this, an early flow cytometry study of MR1 reported cross-reactivity of 
monoclonal antibodies (designated 12.2, 26.5, and 4) raised against the human ectodomain of 
MR1-β2m (β2-microglobulin), and detected MR1 on the surface of human and mice cells 
(Huang et al., 2005). Therefore, the highly evolutionary conserved nature of the MAIT cell TCR 





On the surface of APCs, MR1 can be found both in an open (without ligand) or a folded (with 
ligand) confirmation, however, only the folded MR1 possess MAIT cell activating ability 
(Huang et al., 2005). Like MHC class I proteins, MR1 has conserved cysteine residues and, 
β2m and CD8 contact sites (Walter and Gunther, 1998). We recently reviewed the expression 
and trafficking of MR1 (Appendix 2) which can be summarized in Figure 1.2. 
 
Figure 1.2. MR1 trafficking. In the absence of ligand, empty MR1 molecules accumulate in the endoplasmic 
reticulum (ER). (2) Binding of an endogenous unknown ligand, such as 6-formyl pterin (6-FP), to MR1, via Schiff 
base (a covalent bond), leads to folding and stable association with β2m, allowing exit from the ER. (3) MR1 
bound to endogenous ligand translocates through the Golgi, trans-golgi network (TGN) and reaches an 
endolysosomal/endocytic compartment (EC), either directly, potentially with the help of the invariant chain (li), or 
(4) indirectly via cell surface expression and subsequent endocytosis. (5) The low pH environment of the 
endolysosomal compartment favours ligand exchange with exogenous ligand (5-(2-oxoethylideneamino)-6-D-
ribitylaminouracil (5-OE-RU) or 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU)) derived from 
either phagocytosed bacteria or acquired directly from the extracellular environment by an unknown mechanism. 
(6) From the endolysosomal compartment, ligand-bound MR1 recycles to the cell surface where it can interact 
with the MAIT cell TCR. (7) Extracellular soluble exogenous ligand can be loaded onto MR1 at cell surface by 
displacing endogenous ligand or (8) by accessing the ER via an unknown mechanism. In the ER, exogenous ligand 
is loaded directly onto empty MR1, allowing its trafficking to the cell surface. (9) Xenophagy may deliver 
cytoplasmic bacteria to the endolysosomal compartment, where loading of bacterial-derived ligand can occur. (10) 





1.5.2 MAIT cell activating and non-activating MR1 ligands 
MR1 binds microbe derived vitamin B metabolites and presents them to the MAIT cell TCR, 
resulting in MAIT cell activation (Kjer-Nielsen et al., 2012, Patel et al., 2013). It was Kjer-
Nielsen et al. who first reported correct folding of MR1 and enhanced surface expression of 
MR1 in the presence of different folic acid sources such as RPMI-1640 medium, vitamin B 
complex tablets, or folic acid itself (Kjer-Nielsen et al., 2012). The compound leading to the 
folding and surface upregulation of MR1 was identified as 6-FP, a derivative of folic acid 
(vitamin B9) with a mass to charge ratio of 190.03, however, it did not activate MAIT cells. 
Mass spectroscopic analysis of MR1 folded in the presence of culture supernatant of 
Salmonella, which activated Jurkat.MAIT cells as measured by CD69 upregulation, revealed 
the presence of an activating ligand with a mass to charge ratio of 329.11 and assumed to be a 
ribityllumazine derivative of riboflavin, such as reduced-6-hydroxymethyl-8-D-ribityllumazine 
(rRL-6-CH2OH). Other potential matching compounds identified by Kjer Nielsen as having a 
similar structure as rRL-6-CH2OH were 7-hydroxy-6-methyl-8-D-ribityllumazine (RL-6-Me-
7-OH) and 6,7-dimethyl-8-D-ribityllumazine (RL-6,7-diMe), however, they were both less 
potent agonists of MAIT cell activation compared to rRL-6-CH2OH. Later, through sequential 
deletion of genes in the riboflavin biosynthesis pathway of Lactobacillus lactis, 5-amino-6-D-
ribitylaminouracil (5-A-RU), an early metabolite of the bacterial riboflavin (Vitamin B2) 
synthesis pathway, was found to be central for activation of the MAIT cells (Figure 1.3) 
(Corbett et al., 2014). Interestingly, 5-A-RU itself cannot bind MR1 or activate MAIT cells but 
undergoes non-enzymatic condensation with glycolysis byproducts glyoxal and methylglyoxal 
to form the activating ligands 5-OE-RU and 5-OP-RU respectively (Figure 1.3) (Corbett et al., 
2014). MR1 refolded in the presence of 5-A-RU and methylglyoxal yielded the same retention 
time and mass to charge ratio as observed with Salmonella supernatant by Kjer Nielsen (Corbett 
et al., 2014, Kjer-Nielsen et al., 2012). Of note, these activating ligands were present in bacteria 
with the riboflavin pathway but absent in bacteria with either a compromised riboflavin pathway 
which was unable to generate 5-A-RU or riboflavin pathway deficient bacteria, consistent with 
their MAIT cell activating ability (Corbett et al., 2014). A similar observation of 5-A-RU being 
central in the formation of the activating ligand, and its derivative formed by condensation with 
methylglyoxal activating MAIT cells in vivo was also made by Soudias et al (Soudais et al., 
2015). Consistently, many bacteria, including Escherichia coli, Staphylococcus aureus, 
Staphylococcus epidermidis, Salmonella enterica serovar Typhimurium, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Lactobacillus acidophilus, Mycobacterium 




Saccharomyces cerevisiae, and Aspergillus fumigatus, that harbour the riboflavin pathway, and 
thus produce 5-A-RU, have been shown to activate MAIT cells in an MR1-dependent fashion 
(Gold et al., 2010, Le Bourhis et al., 2010, Corbett et al., 2014, Ussher et al., 2014a, Dias et al., 
2017, Davey et al., 2014, Jahreis et al., 2018). 
There may be other MAIT cell activating ligands that bind MR1. The MR1 binding cleft seems 
more flexible than originally assumed and can incorporate a more diverse nature of MR1 
ligands, including pharmacological agents such as diclofenac, a common non-steroidal anti-
inflammatory drug (Keller et al., 2017). Despite being unable to upregulate MR1 surface 
expression, diclofenac was able to weakly activate Jurkat.MAIT cells, which was competitively 
inhibited by acetyl-6-formyl pterin (Ac-6-FP) in a similar manner observed for 5-OP-RU. 
Keller et al reported two more antagonists of MAIT cell activation, 3-formylsalicyclic acid (3-
F-SA), an aspirin analog, and 2-hydroxy-1-naphthaldehyde (2-OH-1-NA), a derivative of 
methotrexate, having similar kinetics and extent of MR1 upregulation as 6-FP. Another study 
by Hariff et al found two new agonists of MAIT cell activation, riboflavin derived 
photolumazine (PL) I and PLIII, whereas riboflavin and its analog 7,8-didemethyl-8-hydroxy-
5-deazariboflavin were inhibitory (Harriff et al., 2018). These studies suggest there may be a 
vast array of MR1 ligands which can modulate MR1 expression and MAIT cell activation, 5-
OP-RU being the most potent agonist known so far (Corbett et al., 2014, Keller et al., 2017, 
Mak et al., 2017). There are some other MAIT cell activating ligands which are more stable 
than 5-OP-RU and water soluble but possess lower activation potential (Mak et al., 2017). 
However, changes in the sugar backbone of lumazines, which can modulate the intensity of 
MAIT cell activation as demonstrated with RL-6-Me-7-OH and 5-OP-RU, could be a very 





Figure 1.3. Components and genes of bacterial riboflavin pathway in Escherichia coli. The central molecule 
for MAIT cell activation, 5-A-RU is formed from guanosine 5’-triphosphate (GTP) following sequential enzymatic 
reactions involving RibA and RibD (encoded by ribA and ribD) (A). Deletion of either of the genes in bacteria 
abrogates the production of 5-A-RU, which otherwise forms 5-OE-RU or 5-OP-RU through non-enzymatic 
condensation with glyoxal or methylglyoxal respectively (B), thus losing the ability to activate MAIT cells via 
their TCR. Adopted from Soudias et al. 2015 (Soudais et al., 2015). 
1.6 TCR-independent MAIT cell activation 
Like iNKT and γδ T cells, MAIT cell can be triggered in two independent ways: TCR-
dependent (by MR1 ligands) and TCR-independent activation (Figure 1.4) (Garner et al., 2018, 
Provine et al., 2018, Jo et al., 2014, Ussher et al., 2014a, Ussher et al., 2016). TCR-independent 
activation is driven by cytokines produced by infected cells such as IL-12 and was first 




Mycobacterium bovis BCG or Francisella tularensis LVS (Chua et al., 2012, Meierovics et al., 
2013). A later study by Ussher et al. demonstrated high expression of IL-18R on MAIT cells 
and the requirement of both IL-12 and IL-18 for efficient stimulation of human MAIT cells 
(Ussher et al., 2014a). The expression of IL-18R on MAIT cell is the highest among CD8+ T 
cells and higher than NK cells (Ussher et al., 2014a). IL-18R expression is enhanced in the 
presence of other cytokines, such as IL-12, and IL-18 can synergise with  IL-12 or IL-15 to 
stimulate production of IFNγ and TNFα by hematopoietic cells, including NK cells, as well as 
induce rapid and prolonged expression of CD25 (IL-2Rα), rendering cells responsive to IL-2 at 
very low concentrations (Yoshimoto et al., 1998, Nakamura et al., 2000, Leong et al., 2014). 
Blocking experiments during bacterial treatment for 24 hours confirmed the requirement of both 
MR1 and IL-12+IL-18 mediated activation for robust IFNγ production by MAIT cells (Jo et al., 
2014, Ussher et al., 2014a). For cytokine mediated activation of MAIT cells, bacteria do not 
need to possess riboflavin synthesizing ability, as demonstrated with Enterococcus faecalis (Jo 
et al., 2014, Ussher et al., 2014a). IL-15 was also shown to stimulate MAIT cells in an IL-18 
dependent manner, which was produced by IL-15 treated monocytes (Sattler et al., 2015). 
Demonstration of robust IFNγ production by hepatic MAIT cells in response to toll-like 
receptor (TLR)8 agonist (ssRNA40), which was dependent on IL-12 and IL-18 produced by 
TLR8-activated intrahepatic monocytes, suggested TCR-independent activation of MAIT cells 
might be possible in the absence of bacteria (Jo et al., 2014). Consistently, cytokines (mainly 
IL-18 with IL-12 and/or IL-15) produced during various viral infections, including with 
influenza virus, dengue virus and hepatitis C virus (HCV), triggers MAIT cells activation (Loh 
et al., 2016, van Wilgenburg et al., 2016). Interestingly, in addition to IL-12, IL-15, and IL-18, 
various other MAIT cell stimulatory cytokines, such as TNFα, IL-2, and IL-6, produced during 
sterile inflammatory diseases can modulate MAIT cell response in a TCR independent manner 
(Banki et al., 2019, Chiba et al., 2017). More recently, TNFRSF15 (TL1A) and type I 
interferons were shown to have an enhancing effect on cytokine mediated MAIT cell activation 
(van Wilgenburg et al., 2016, Leng et al., 2019). Therefore, various innate signals, in particular 





Figure 1.4. Illustration of the two modes of MAIT cell activation. While TCR mediated activation of MAIT 
cells is restricted to riboflavin producing bacteria (upper half), TCR-independent activation of MAIT cells is 
mediated by cytokines, such as IL-12 and IL-18 (lower half). 
1.7 Co-receptors on MAIT cells and their significance 
1.7.1 CD8 co-receptor 
Most MAIT cells (~80%) express the CD8α co-receptor. CD8+ MAIT cells are functionally 
more responsive to bacterial (including TCR-dependent ± independent) and cytokine 
stimulation (Dias et al., 2018a, Kurioka et al., 2017, Brozova et al., 2016, Booth et al., 2015). 
While, CD8+ MAIT cells produced more TNFα, IFNγ, and granzyme B when stimulated for 24 
hours by E. coli with or without the riboflavin pathway (Dias et al., 2018a), for 5 hours by 
PMA/ionomycin (a mitogen) (Dias et al., 2018a, Brozova et al., 2016), or overnight by H. pylori 
infected THP1 macrophages (Booth et al., 2015), they also produced more IFNγ when 
stimulated by PMA/ionomycin immediately after culture in Th2 skewing conditions (Kurioka 
et al., 2017). These studies collectively suggest that expression of CD8 on MAIT cells is 
important for their enhanced effector response. It has been speculated that expression of CD8 
stabilizes Vα7.2 TCR-MR1 interaction during activation by riboflavin producing bacteria, 
similar to the TCR-MHC interaction with conventional CD8+ T cells, however, the basis for the 
enhanced functional response of CD8+ MAIT cells during TCR-independent activation is not 
known,  (Dias et al., 2018a). The importance of CD8 co-receptor expression was also 




exposed THP1 monocytes for 5 hours; blocking CD8 significantly inhibited production of 
TNFα, IFNγ, CCL4, and degranulation (Kurioka et al., 2017), which suggests an important role 
for the CD8 co-receptor for MAIT cell function during bacterial infection. Blocking CD8 also 
abrogated IFNγ production by MR1 T-clones during activation by Mycobacterium tuberculosis 
infected DCs (Gold et al., 2013). 
1.7.2 CD161 
CD161, a C-type lection, was originally described as a marker on NK cells (>90% NK cells 
express CD161), but is expressed by a large proportion of T cells (highest on CD3+CD56+ 
compared to CD3+CD56- conventional CD4+ and CD8+ T cells) (Llibre et al., 2016). CD161 
expression distinguishes three distinct subsets within the CD8+and DN T cell populations: 
CD161high/++, CD161low/+ and CD161- (Billerbeck et al., 2010, Cosgrove et al., 2013, Ussher et 
al., 2014a). MAIT cells constitutes 80-85% of the CD161++ compartment, and therefore CD161 
has been one of the commonly used surrogate markers, together with Vα7.2 TCR, for the flow 
cytometric analysis of MAIT cells (Martin et al., 2009, Dusseaux et al., 2011). The first report 
on the function of CD161 on MAIT cells was made by Le Bourhis et al. by cross-linking CD161 
using antibody (clone unknown) during MAIT cell activation by E. coli infected Hela.hMR1 
cells or by antiCD3/CD28 antibodies (Le Bourhis et al., 2013). Ligating CD161 significantly 
reduced CD69 and inhibited CD25 expression during bacterial stimulation and reduced 
cytokine production (IL-2, TNFα, and IFNγ) by anti-CD3/CD28 activated MAIT cells. In 
contrast, the overall cytotoxicity, assessed either by granzyme B production or MAIT cell 
killing of bacterially infected cells, was not affected (Le Bourhis et al., 2013). In contrast, a 
different study found that ligating CD161 with anti-CD161 antibody (clone 191B8) 
significantly increased both TNFα and IFNγ production by Vα7.2+CD8+CD3+ cells during 
activation by anti-CD3/CD28 beads, suggesting CD161 is an important co-stimulatory 
molecule for TCR-dependent activation (Fergusson et al., 2014). The contrasting findings of 
these studies could be because of the use of different clones of anti-CD161 antibody. CD161 
expression is shared among both CD4+ and CD8+ T cells (including MAIT cells) which bear 
common innate-like features, including TCR-independent activation by IL-12 and IL-18, but 
CD161 does not regulate this response (Fergusson et al., 2014). Blocking CD161 interaction 
with lectin like transcript (LLT) 1, the ligand for CD161 which is highly expressed by 
monocytes and some B cells but is not detected in lung and liver-resident macrophages, 
negatively regulated NK cell degranulation (Llibre et al., 2016). Therefore, future investigations 




LLT1 transcript has been observed in immune privileged sites such as testes, brain, and placenta 
where MAIT cells could be differentially regulated, while in other tissues including lungs and 
liver that are populated with terminally differentiated macrophages, no LLT1 expression was 
detectable (Llibre et al., 2016). Additionally, it would be interesting to assess the role of CD161 
on IL-17 production by MAIT cells as CD161 is also regarded as marker of all IL-17 producing 
T cell subsets (Maggi et al., 2010).  
1.7.3 CD56 
NK cells can be identified as CD56 expressing CD3- lymphocytes, that make up to 10% of total 
human lymphocytes in blood (Vivier et al., 2008). CD56 expression on MAIT cells and its 
significance was unknown until recently. Almost half of CD8+ and DN MAIT cells from blood 
express CD56 on the surface, with no marked expression on CD4+ MAIT cells (Dias et al., 
2017, Kurioka et al., 2017, Salio et al., 2017). The pattern of greater CD56 expression on CD4- 
(CD8+ and DN) MAIT cells is consistent in blood from adults and children (2 years old) 
(Kurioka et al., 2017). Consistent with the observation made by Tang et al. that MAIT cells 
comprise ~40% of CD56+ innate lymphocytes in liver, more intrahepatic MAIT cells express 
CD56 compared to blood; in liver almost 80% of CD4- and half of CD4+ MAIT cells express 
CD56 (Kurioka et al., 2017, Tang et al., 2013). Interestingly, CD56+ MAIT cells expressed 
higher levels of cytokine receptors (IL-12R and IL-18R), transcription factors (PLZF, Helios, 
T-bet and Eomes), and perforin than their CD56- counterparts ex vivo (Dias et al., 2017). 
Moreover, CD56+ intrahepatic MAIT cells from both the CD8+ and CD4+ compartments 
produced more IFNγ in response to E. coli exposed THP1 cells or IL-12+IL-18 stimulation 
compared to CD56- MAIT cells (Kurioka et al., 2017, Dias et al., 2017). Therefore, expression 
of CD56 could potentially mark MAIT cells with enhanced innateness, as recently discussed 
(Dias et al., 2018b). 
1.8 Phenotype and functional comparison of CD8+, DN, and CD4+ MAIT 
cell subsets 
As discussed above, MAIT cells can be divided into three subsets based on the surface 
expression of CD8 and CD4 co-receptors: CD8+, DN (CD4-CD8-), and CD4+ MAIT cells 
(Tilloy et al., 1999, Martin et al., 2009, Reantragoon et al., 2013). Early studies suggested that 
the abundance of Vα7.2-Jα33 (human) or Vα19-Jα33 (in mice and bovine) mRNA was greater 
in DN αβ T cells than CD8α+ (including CD8αα+ and CD8αβ+) or CD4+ T cells isolated by flow 




et al., 1999). However, flow cytometric analysis demonstrated that MAIT cells are 
predominantly CD8α+ and CD8β-/lo  and represent  more than 80% of total CD8αα+ T cells 
(Walker et al., 2012). In fact, CD8+ MAIT cells are more dominant in both blood and tissues in 
humans, averaging 80% of the total MAIT cells followed by DN (< 20%) and CD4+ (< 5%) 
subsets (Kurioka et al., 2017). The three subsets were phenotypically and functionally assumed 
to be similar before two recent seminal studies (Dias et al., 2018a, Kurioka et al., 2017). Kurioka 
et al. compared the three subsets and demonstrated more MAIT cells expressing the chemokine 
receptors CCR2 and CCR5, the surface receptors CD69, IL-18Rα, and CD127 (IL-7R), and the 
transcription factors RORγt, PLZF, and EOMES within the CD8+ and DN compartments. With 
these phenotypic similarities, the two subsets possessed greater cytotoxic potential at rest and 
expressed more granzyme A/K and perforin than CD4+ MAIT cells (Kurioka et al., 2017). The 
low cytotoxic potential of CD4+ MAITs was linked to their low expression of NK receptors 
(CD56, NKG2A, and CD94) and EOMES. Following activation by E. coli, CD8+ and DN 
MAIT cells degranulated more and produced more cytotoxic molecules (granzyme B and 
perforin) and Th1 cytokines (TNFα and IFNγ) compared to CD4+ MAIT cells, with no 
significant difference in the production of IL-17 (Kurioka et al., 2017). In contrast, CD4+ MAIT 
cells expressed more CD62L, CD25, CCR6 and CCR7, and produced more IL-4 and IL-13 but 
less IFNγ, than other two MAIT subsets when cultured in Th2-skewing conditions (Kurioka et 
al., 2017). Using 5-OP-RU loaded MR1-tetramer, Dias et al. identified MAIT cells as 5-OP-
RU-MR1+ CD161++ T cells and reported that only half of the CD4+ CD161++ Vα7.2+ T cells 
were MR1 restricted (Dias et al., 2018a). Therefore, comparing only the 5-OP-RU-MR1+ CD8+ 
and DN MAIT cells, they went on to show significant differences in the expression of cell 
surface receptors, cytotoxic molecules, and transcription factors between CD8+ and DN MAIT 
cell subsets. Despite achieving robust responses, significantly more TNFα, IFNγ, and granzyme 
B was produced by CD8+ MAIT cells than the DN MAIT cells following stimulation with both 
riboflavin producing and deficient bacteria, as well as by IL-12+IL-18. In contrast, more IL-17 
was produced by DN MAIT cells (Dias et al., 2018a). These differences in the phenotype and 
capacity to produce Th1 and Th17 cytokines suggests distinct roles of these MAIT cell subsets 
in health and disease.  
1.9 MAIT cell identification 
Originally, MAIT cell were detected based on the presence of the Vα7.2-Jα33 mRNA transcript 
(Porcelli et al., 1993, Tilloy et al., 1999). In the absence of antibody against the MAIT cell TCR, 




fundamental discoveries on tissue trophism and fate of MAIT cell in HIV infection. The 
development of a specific antibody targeting the Vα7.2 TCR revolutionized the MAIT cell field 
(Martin et al., 2009). While, co-staining of CD161 and the Vα7.2 TCR can precisely identify a 
distinct MAIT cell population (Martin et al., 2009, Walker et al., 2012, Gherardin et al., 2018), 
there are numerous reports demonstrating co-staining with other surrogate markers CD26 
(Gherardin et al., 2018), IL-18Rα (Gherardin et al., 2018) or CCR6 (Lee et al., 2018) can also 
correctly identify MAIT cells (Figure 1.5). 
The combination with CD161 remained popular until the discovery of MR1 ligands and the 
development of MR1 tetramer reagents. It was first demonstrated by Reantragoon et al that 
staining with rRL-6-CH2OH loaded MR1 tetramer and CD161 specifically identifies all MAIT 
cells with greater accuracy (Reantragoon et al., 2013). Tetramer staining confirmed the previous 
observation of MAIT cells being CD8α+/CD8β-/lo and presence of two dominant CD8+ and CD4-
CD8- MAIT cell populations, and also confirmed that Vα7.2+CD161- populations are not MAIT 
cells (Reantragoon et al., 2013, Kurioka et al., 2017). The proportion of CD8+, DN and CD4+ 
subsets when MAIT cells were identified as Vα7.2+CD161++ T cells or 5-OP-RU-MR1 
tetramer+CD161++ T cells were remarkably equivalent, with some varying outcomes for CD4+ 
subsets (Dias et al., 2018a, Kurioka et al., 2017). The anomaly in CD4+ subset identification 
between the two staining techniques in the two studies could be due to the low abundance of 
the CD4+ subset, whose percentage could easily appear to fluctuate due to contaminating 
conventional CD4+ T cells. The generation of ligand bound MR1 tetramers conjugated with a 
fluorophore has made the use of Vα7.2+ TCR antibody optional, however, it is still commonly 
used since the availability of tetramers has been limited and in combination with CD161 it 





Figure 1.5. MAIT cell identification by flow cytometry. Staining one of the highly expressed surrogate markers 
such as CD161, CD26, or CCR6, can identify MAIT cells using flow cytometry. Comparison of CD161+Vα7.2 
TCR+ and CD26+Vα7.2 TCR+ cells amongst CD8+ T cells from one donor (left) and comparison of CD161+Vα7.2 
TCR+ and IL-18R+Vα7.2 TCR+ cells amongst CD8+ T cells from another donor (right). 
1.10 Tissue trophism of MAIT cells 
MAIT cells are characterized by high expression of certain chemokine receptors that help them 
traffic to the tissues, notably, CCR2 CCR5, CCR6, and CXCR6 (Dusseaux et al., 2011, Jeffery 
et al., 2016, Kurioka et al., 2017). The chemokine receptors CCR6 and CXCR6, which bind 
CCL20 and CXCL16 respectively, chemokines that are commonly present in liver, suggesting 
that MAIT cells may home to the liver, consistent with their abundance in the liver (representing 
20 to 50% of intrahepatic T cells) (Dusseaux et al., 2011, Jeffery et al., 2016, Kurioka et al., 
2016). The expression of LFA-1, VLA-4, and CXCR3 on MAIT cells may aid in their 
recruitment to inflamed/infected tissue (Jeffery et al., 2016). Additionally, they express the gut 
homing receptors α4β7 and low levels of CCR9, suggesting they might home to the gut mucosa 
(Dusseaux et al., 2011, Jeffery et al., 2016, Leeansyah et al., 2014). MAIT cells are also present 
in various other mucosal surfaces, such as lungs, skin, buccal mucosa, endometrium, and 
vaginal genitalia mucosa (Sobkowiak et al., 2019, Leeansyah et al., 2014, Dusseaux et al., 2011, 
Teunissen et al., 2014, Gibbs et al., 2017). Compared to other tissues, MAIT cells are rare in 
lymph nodes because of their lack of CCR7 and CD62L (Dusseaux et al., 2011, Leeansyah et 
al., 2014). Recent studies noted higher expression of CD69 and CD103 on tissue resident MAIT 
cells and their leaning towards a T17 phenotype, with the capacity to produce more IL-17 and 
IL-22 compared to blood MAIT cells (Sobkowiak et al., 2019, Gibbs et al., 2017).  
1.11 MAIT cells in liver and liver pathologies 
The liver acts as a firewall against the gut invading pathogens and harbours various innate 
immune cells including Kupffer cells, γδ T cells, NK cells ,and MAIT cells (Dusseaux et al., 
2011, Racanelli and Rehermann, 2006). MAIT cell frequency in humans is higher in liver 
compared to blood and other tissues, reaching up to 50% of total T cells (Kurioka et al., 2016). 
In liver, MAIT cells reside in the portal tract close to bile duct, with some also being detected 
in the hepatic parenchyma (Bottcher et al., 2018, Jeffery et al., 2016). Compared to peripheral 
MAIT cells, MAIT cells in liver express a more activated phenotype (high CD69, CD38, and 
HLA-DR) and respond better to certain signals, such as TLR8 and IL-7 (Jo et al., 2014, Tang 
et al., 2013). Demonstrating the ability of biliary epithelial cells to stimulate MAIT cells by E. 




cells are activated and protect the biliary mucosa against bacteria entering via inflamed gut 
(Jeffery et al., 2016). Like blood MAIT cells, hepatic MAIT cells also respond robustly to IL-
12 and IL-18 stimulation (Jo et al., 2014). Possessing the ability to be activated by TCR and 
innate cytokines, their specific accumulation in liver suggests an important role of MAIT cells 
in providing the first line of defense against infection. 
MAIT cell frequency in both blood and liver has been shown to be affected during various liver 
pathologies. Peripheral MAIT cells were reduced in frequency during viral hepatitis and 
inflammatory (both alcoholic and non-alcoholic) liver diseases (Li et al., 2018, Bolte et al., 
2017, Bottcher et al., 2018, Dias et al., 2019, Hegde et al., 2018, Beudeker et al., 2018, 
Billerbeck et al., 2010). Consistently, a severe reduction in intrahepatic MAIT cell frequency 
were also observed in patients with autoimmune liver disease (AILD), and during HCV-induced 
liver inflammation suggesting loss of MAIT cells from periphery and liver (Bolte et al., 2017, 
Bottcher et al., 2018, Dias et al., 2019, Hegde et al., 2018, Billerbeck et al., 2010). By contrast, 
Li et al. demonstrated increased MAIT cell number in liver during non-alcoholic fatty liver 
disease (NAFLD) (Li et al., 2018). MAIT cells were found to be scattered around portal tracts 
and accumulated around fibrotic septae and degenerated hepatocytes with fat deposits in the 
sinusoidal areas (Li et al., 2018). The consensus among these studies on chronic viral and 
inflammatory diseases was the acquisition of more activated phenotype (increased CD69, 
CD38, PD1, and HLA-DR) by peripheral and intrahepatic MAIT cells which many authors 
believed to be the exhausted phenotype due to constant exposure to stimuli (innate cytokines 
produced by inflamed/infected cells as well as TCR signals provided from infiltrated pathogens) 
with compromised effector responses upon re-stimulation (Hegde et al., 2018, Bolte et al., 2017, 
Dias et al., 2019, Li et al., 2018).  
While the role of MAIT cells during viral hepatitis still needs to be determined, the fate of 
MAIT cell during inflammatory liver disease is arguable. Two seminal studies demonstrated 
the ability of MAIT cells to activate hepatic stellate cells (HSCs) and hepatic myofibroblasts 
(both central in liver fibrosis), triggering production of inflammatory cytokine and proliferation 
of both cell types (Bottcher et al., 2018, Hegde et al., 2018). Profibrogenic properties of MAIT 
cells were also demonstrated in vivo and MAIT cells were suggested to be promoting liver 
cirrhosis (Hegde et al., 2018). By contrast, Li et al. demonstrated MAIT cell specific 
accumulation of anti-inflammatory tissue repairing CD206+ macrophages in liver and less 
severe inflammation in context of nonalcoholic fatty liver disease (Li et al., 2018). In the 




to wild type mice, highlighting importance of MAIT cell in improving liver diseases (Li et al., 
2018).  
1.12 Role of MAIT cells 
The potential roles of MAIT cells during various infectious and non-infectious settings are 
summarized in Figure 1.6 and are discussed below: 
1.12.1 Role of MAIT cells in bacterial infection 
MAIT cells recognize and kill the bacterially infected cells in vitro via rapid production of 
cytotoxic molecules, such as granulysin, perforin, and granzyme B (Gold et al., 2010, Le 
Bourhis et al., 2010, Le Bourhis et al., 2013, Kurioka et al., 2015). Many commensal and 
pathogenic bacteria, but not Enterococcus faecalis, Streptococcus pyogenes, and Listeria 
monocytogenes, have been shown to stimulate MAIT cells based on their ability to synthesize 
riboflavin (Corbett et al., 2014, Davey et al., 2014, Gold et al., 2010, Jo et al., 2014, Le Bourhis 
et al., 2013, Le Bourhis et al., 2010). Interestingly, almost all riboflavin deficient bacteria are 
gram positive, the reason being unknown. 
The first indirect evidence of MAIT cells providing protection against bacterial infection in vivo 
was reported by Georgel et al. who demonstrated increased susceptibility to Klebsiella 
pneumoniae infection in MR1-deficient mice that lack MAIT cells (Georgel et al., 2011). 
Subsequently,  Chua et al. confirmed a direct contribution of MAIT cells to controlling bacterial 
infection by aerosolised Mycobacterium bovis BCG in mice (Chua et al., 2012). Using an in 
vitro co-culture model, Chua et al. also demonstrated that the inhibition of BCG growth inside 
macrophages was mediated by IFNγ secreted by MAIT cells which enhanced the antimicrobial 
activity of macrophages, measured by nitric oxide production. Furthermore, they provided the 
first evidence of IL-12, produced by infected macrophages, dependent production of IFNγ and 
IL-17A by MAIT cells (Chua et al., 2012). They further demonstrated direct effect of IL-12 as 
MAIT cells from Vα19iTgMR1+/+ mice, but from not the control T cells from Vα19iTgMR1-/- 
background, produced significant IFNγ when stimulated with recombinant IL-12 for 24 hours. 
Later, Meierovics et al. demonstrated the importance of both MR1 and IL-12R signaling for the 
production of IFNγ and TNFα by MAIT cells co-cultured with Francisella tularensis LVS 
infected bone marrow derived macrophages (Meierovics et al., 2013). Interestingly, MAIT cells 
expanded in the lungs of wild-type mice during pulmonary F. tularensis infection and controlled 
long-term chronic infection even in the absence of conventional CD4+ and CD8+ T cells. 




antimicrobial response against F. tularensis in MR1-/- mice further highlighted the non-
redundant role of MAIT cells during bacterial infection (Meierovics et al., 2013). 
Recent murine infection studies by Chen et al. (Salmonella enterica serovar Typhimurium) and 
Wang et al. (Legionella longbeachae) confirmed a role for MAIT cells, identified using MR1 
tetramers (Chen et al., 2017, Wang et al., 2018). For the accumulation of MAIT cells in the 
lungs following intratracheal infection, Chen et al. demonstrated the requirement for MR1 
ligand (5-OP-RU) and a co-stimulatory signal, such as that provided by the TLR6 agonist 
Pam2Cys; both signals were furnished by the riboflavin synthesizing bacteria Salmonella 
enterica serovar Typhimurium (Chen et al., 2017). Consistently, MAIT cells failed to expand 
in response to 5-OP-RU alone or the riboflavin-deficient strain Salmonella Typhimurium 
∆ribDH (Chen et al., 2017). Furthermore, administration of 5-OP-RU with the TLR agonists 
prior to Legionella longbeachae infection as a ‘vaccine’ accelerated the expansion of MAIT 
cells in lungs and provided protection (Wang et al., 2018). The observation that adoptively 
transferred MAIT cells rescued immunodeficient Rag2-/-γC-/- mouse (which lack conventional 
T, B, and NK cells) from fatal Legionella longbeachae infection further highlighted the 
protective role of MAIT cells during bacterial infection (Wang et al., 2018).  
1.12.2 Role of MAIT cells in viral diseases 
While earlier studies depicted MAIT cell activation by bacterially infected cells but not against 
viruses, MAIT cells have been shown to be activated by a range of viruses, including hepatitis 
C virus, dengue virus, and infleunza virus (Loh et al., 2016, van Wilgenburg et al., 2016, Dias 
et al., 2019). During viral infections, MAIT cells are activated by cytokines such as IL-12, IL-
15 and IL-18; production of these cytokines during viral infections has been demonstrated (Loh 
et al., 2016, van Wilgenburg et al., 2016). Following viral activation, MAIT cells upregulate 
CD69 and produce TNFα, IFNγ, and granzyme B (van Wilgenburg et al., 2016). The cytokine 
dependent activation is supported by TLR8 signaling and type I interferons. While TLR8 
agonists ssRNA40 induced production of IL-12 and IL-18 by activated monocytes, blocking 
type I interferons signaling during virus treatment of PBMCs significantly reduced activation 
and production of IFNγ and granzyme B by MAIT cells (Jo et al., 2014, van Wilgenburg et al., 
2016).  
Interestingly, MAIT cells are significantly depleted from peripheral blood and suffered 
functional impairment during chronic viral infections, expressing an exhausted phenotype with 




al., 2013, Dias et al., 2019, Leeansyah et al., 2013, Leeansyah et al., 2015). The expression of 
exhaustion and apoptotic markers by MAIT cells following prolonged TCR- and cytokine-
stimulation suggests that MAIT cells depletion is due to activation induced cell death (AICD) 
during chronic viral infections, which are often associated with multiple bacterial infections 
(Bottcher et al., 2018, Dias et al., 2018a, Cosgrove et al., 2013). Alternatively, MAIT cells may 
migrate to infected tissue, leading to reduced frequency in blood. 
1.12.3 Role of MAIT cells in autoimmune disease 
The enrichment of MAIT cells at the gut mucosa in a commensal specific manner suggested the 
potential involvement of MAIT cells in the host response to infection at this major site of 
pathogen entry (Treiner et al., 2003). Similarly, soon after the discovery of MAIT cells, the 
accumulation of Vα7.2-Jα33 transcripts in central nervous system lesions and CSF in patients 
with multiple sclerosis (MS) and chronic inflammatory demyelinating polyneuropathy (CIPD) 
was shown, suggesting a role in autoimmunity (Illes et al., 2004). Therefore, the debate of 
whether MAIT cells play a protective function against bacterial invasion versus their 
involvement in inflammatory diseases started soon after these invariant T cells came into 
limelight.  
Consistent with the observation of Vα7.2-Jα33 transcript accumulation, CD161hi CD8+ T cells 
(which consist mostly of MAIT cells) and MAIT cells have been detected in the brains of MS 
patients (Annibali et al., 2011, Willing et al., 2014). Interestingly, MAIT cells express more 
very late antigen (VLA-4), which mediate the migration through blood brain barrier, and 
integrin subunits CD29 (α4) and CD49d (β1) upon in vitro stimulation by anti-CD3±IL-18 
(Willing et al., 2014). MAIT cells were also detected in skin psoriatic lesions (Teunissen et al., 
2014). The frequency of peripheral MAIT cells was found to be reduced in the blood of patients 
with systemic lupus erythematous, Chron’s disease and ulcerative colitis, with the activation 
status of remaining MAIT cells correlating with disease severity score (Chiba et al., 2017, 
Serriari et al., 2014). While Serriari et al. demonstrated enrichment of activated MAIT cells in 
the injured ileum, Chiba et al. argued that the loss of MAIT cells from blood was due to AICD 
(Chiba et al., 2017, Serriari et al., 2014). Interestingly, overexpressing Vα19 T cells in mice 
decreased the severity of experimental autoimmune encephalomyelitis (EAE), a mouse model 
of MS, by triggering IL-10 production by immune cells, such as B cells (Croxford et al., 2006). 
In contrast, the disease was exacerbated in Vα19i T (~MAIT) cell depleted mice. Further 
analysis of lymph node cells reveled concomitant reduction in inflammatory cytokines (IFNγ, 




following EAE induction (Croxford et al., 2006). Therefore, understanding the fate of MAIT 
cells during autoimmune disease requires further investigation. 
1.12.4 Role of MAIT cells in maintaining adaptive immunity and tissue 
homeostasis 
MAIT cells have also been shown to be involved in maintaining adaptive immunity. The 
importance of MAIT cells for the adaptive response during bacterial infection was demonstrated 
by Meierovis et al (Meierovics et al., 2013, Meierovics and Cowley, 2016). In the absence of 
MAIT cells in MR1-/- mice, recruitment of IFNγ producing CD4+ and CD8+ T cells to the murine 
lungs was delayed during F. tularennsis pulmonary infection. In a more recent study, MR1-/- 
mice had significantly lower proportions of cytokine producing HCV-specific CD8+ cells  
following vaccination against HCV, suggesting the significance of MAIT cells for the 
development of vaccine induced CD8+ T cell responses (Provine et al., 2019). In contrast to 
these findings, depletion of MAIT cells from human peripheral blood resulted in enhanced IFNγ 
production by phytoagglutination (PHA) activated T cells in a cell-contact dependent manner, 
suggesting a possible immunoregulatory role of MAIT cells (Miyazaki et al., 2011). This 
function of MAIT cells could have potential to suppress autoimmune disorders, as demonstrated 
previously in mice model of MS (Miyazaki et al., 2011, Croxford et al., 2006). 
MAIT cell have the capacity to modulate B cells and other APCs (monocytes and DCs) and 
thus, the adaptive response. Bennett et al. provided the first evidence of MAIT cells providing 
help to B cells by demonstrating enhanced IgA, IgG, and IgM production from autologous B 
cells in response to supernatant from microbe or cytokine stimulated human MAIT cells 
(Bennett et al., 2017). MAIT cell induced CD40L-dependent maturation of monocyte-derived 
and primary DCs has been demonstrated in vitro (Salio et al., 2017). Additionally, GM-CSF 
produced by MAIT cell helped monocyte differentiation in vivo. In the absence of MAIT cells, 
delayed differentiation of monocyte derived DCs resulted in delayed recruitment of activated 
CD4+ T cells to the F. tularensis infected lungs (Meierovics and Cowley, 2016).  
A few studies have also pointed to MAIT cells being important in enhancing barrier immunity 
and  possibly having a role in tissue repair. MR1 knockout mice, which lack MAIT cells, have  
increased gut permeability and suffer from defective epithelial gut function (Rouxel et al., 
2017). Additionally, soluble mediators (TNFα and IFNγ) produced by MAIT cells were recently 
shown to induce reprogramming of peritoneal mesothelial cells and thus maintain peritoneal 




repairing, commensal specific, MHC-Ib restricted CD8+ T cell in mice (Linehan et al., 2018). 
Therefore, MAIT cells, which are enriched in the gut and mucosal tissues, could possibly 
function as tissue repairing T cells during inflammation and infection in humans. Consistently, 
new findings support this hypothesis as the tissue repair signature is enriched in human MAIT 
cells following TCR stimulation and murine MAIT cells upon L. longbeachae infection (Hinks 
et al., 2019, Lamichhane et al., 2019, Leng et al., 2019) (see chapter 2). 
 
Figure 1.6. Potential functions of activated MAIT cells. MAIT cells mediate different functions in a cell-contact 
dependent manner via upregulated cell surface molecules or in a contact independent manner by producing soluble 
mediators, such as cytokines and cytotoxic molecules. 
1.13 Modulation of MAIT cell activation by bacteria 
Bacteria have the ability to modulate MAIT cell activation in two different ways: directly by 
furnishing agonists or antagonists of MAIT cell activation, or indirectly by triggering the 
production of innate signals by infected cells (including APCs). Since the MAIT cell activating 




riboflavin can trigger TCR mediated MAIT cell activation, which occurs within a few hours 
and in an MR1-dependent manner (Corbett et al., 2014, Jo et al., 2014, Soudais et al., 2015, 
Ussher et al., 2014a). Interestingly, MAIT cells do not discriminate between the riboflavin 
producing commensal and pathogenic bacteria as equivalent activation of MAIT cells has been 
achieved with both, with some variation in response according to the family of bacteria (Tastan 
et al., 2018). With longer bacterial stimulation, irrespective of their ability to produce riboflavin, 
APCs are activated and produce cytokines such as IL-12 and IL-18, which can trigger MAIT 
cell activation through the IL-12R and IL-18R without the involvement of TCR (Jo et al., 2014, 
Ussher et al., 2014a, Ussher et al., 2016). Therefore, late activation by riboflavin producing 
bacteria triggers MAIT cell activation in both an MR1-dependent and independent manner, 
leading to robust production of effector molecules from MAIT cells (Havenith et al., 2012, 
Slichter et al., 2016, Ussher et al., 2014a, Ussher et al., 2016). Therefore, the timing of activation 
can impact the response of MAIT cell. 
Among the signals provided by bacteria to the innate immune system, TLR agonists are the 
most studied in context of MAIT cell immunobiology. Overnight priming of APCs with 
Pam3Cys, heat-killed Listeria monocytogenes, or FSL-1, agonists of toll-like receptor (TLR) 1, 
2, and 6 respectively, has previously been shown to enhance MR1 surface expression by APCs 
and IFNγ production by MAIT cell subsequently stimulated by E. coli (Ussher et al., 2016). 
While an agonist of TLR9 (ODN2006) was shown to upregulate MR1 expression on APCs, 
knocking out TLR9 in B cells also resulted in impaired IFNγ production by MAIT cells upon 
activation by E. coli (Liu and Brutkiewicz, 2017). Interestingly, pretreating APCs with LPS, an 
agonist of TLR4, resulted in reduced IFNγ production by MAIT cells against E. coli stimulation, 
suggesting certain bacterial signals may dampen the hyperactivation of MAIT cells as a 
protective mechanism (Ussher et al., 2016). Chen et al. demonstrated CD69 upregulation in 
vitro and expansion of MAIT cells in vivo when 5-OP-RU was administered with riboflavin 
mutant Salmonella Typhimurium ∆ribDH or Pam2Cys (agonist of TLR6) (Chen et al., 2017).  
While these examples suggest TLR agonists are modulators of MAIT cell responses to a MR1 
ligand, the precise mechanism is unknown. Certain TLR agonists, such as agonist of TLR8 
(ssRNA40) can trigger IL-12 and/or IL-18 production by monocytes and trigger TCR-
independent activation of MAIT cells  (Jo et al., 2014). 
In addition to bacteria derived signals, various other factors affect MAIT cell activation. 
Blocking TNFα during bacterial stimulation, reduced IFNγ production by MAIT cells in a co-




I (IFNα) and type II (IFNγ) interferons can also activate APCs to enhance the MAIT cell 
response to bacteria with the mechanisms being unknown (Ussher et al., 2016). Additionally, 
phagocytosis induced during bacteria uptake also plays a role since robust MAIT cell activation 
was only achieved with the use of intact riboflavin producing bacteria, but not the equivalent 
amount of lysate or supernatant (Ussher et al., 2016). Supporting this, blocking actin 
polymerization and endosomal acidification significantly inhibited IFNγ production by MAIT 
cells. Therefore, a better understanding of the signals regulating MAIT cell activation is 
required. 
1.14 Aims of this thesis 
The overall aim of this research was to define the effector functions of activated MAIT cells 
and the signals that regulate their activation. As MAIT cells can be activated by both TCR-
dependent and -independent mechanisms, we sought to define differences in the effector 
response by mode of activation. Since, MAIT cells are numerous in blood and liver, we then 
sought to compare the functional and transcriptional response of TCR- or cytokine-stimulated 
blood and liver derived MAIT cells. Also, MAIT cells in mucosal sites can be activated by both 
commensal and pathogenic bacteria. However, the signals that regulate MAIT cell activation 
remain to be defined. In these studies, we sought to define the bacterial signals sensed by APCs 
and the co-stimulatory signals from APCs that regulate MAIT cell activation. 
The specific aims of this thesis can be summarized as: 
1. To assess the full range of effector functions of blood derived MAIT cells stimulated 
via TCR or by cytokines. (Paper I/Chapter 2) 
 
2. To compare the transcriptomic and functional response of blood and liver derived MAIT 
cells stimulated via TCR or by cytokines. (Paper II/Chapter 3) 
 
3. To assess the modulatory role of type I interferons on TCR-mediated MAIT cell 
activation. (Paper III/Chapter 4) 
 
4. To identify the bacterial signals that modulate TCR mediated MAIT cell activation. 
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Chapter 2 : TCR- and cytokine-
activated human CD8+ mucosal 
associated invariant T cells are 
polyfunctional T cells that can 




Mucosal associated invariant T (MAIT) cells can be activated via either their T cell receptor 
(TCR), which recognizes MR1-bound pyrimidines derived from microbial riboflavin 
biosynthesis, or via cytokines. These two modes of activation may act in concert or 
independently, depending upon the stimulus. It is unknown, however, how MAIT cell responses 
differ with the mode of activation. Here, we define transcriptional and effector responses of 
human CD8+ MAIT cells to TCR and cytokine stimulation. We report that MAIT cells rapidly 
respond to TCR stimulation, producing multiple cytokines and chemokines, altering their 
cytotoxic granule content and transcription factor expression, and upregulating co-stimulatory 
proteins. In contrast, cytokine-mediated activation is slower and results in a more limited 
response. Therefore, we propose that in infections by riboflavin-synthesizing bacteria, MAIT 
cells play a key early role in effecting and coordinating immune responses, while in the absence 





Mucosal associated invariant T (MAIT) cells are innate-like T cells, which are abundant in 
blood, mucosal surfaces, and liver in humans (Martin et al., 2009). MAIT cells express a semi-
invariant T cell receptor (TCR) consisting of Vα7.2-Jα12/20/33 combined with limited Vβ 
diversity (Gherardin et al., 2016). MAIT cells were originally discovered as CD4-CD8alpha- T 
cells (Porcelli et al., 1993), but are mostly CD8alpha+, expressing an effector memory 
phenotype (Leeansyah et al., 2014). They also share some features of natural killer (NK) cells, 
notably high expression of the C-type lectin CD161 (Dusseaux et al., 2011, Billerbeck et al., 
2010, Kurioka et al., 2018).  
Unlike conventional T cells, whose TCRs recognize peptides loaded on MHC molecules, the 
MAIT cell TCR recognizes bacteria-derived vitamin B precursor metabolites, recently 
identified as pyrimidine derivatives of 5-amino-6-D-ribitylaminouracil (5-A-RU), loaded on the 
non-polymorphic MHC class Ib related molecule 1 (MR1) (Corbett et al., 2014, Huang et al., 
2005, Kjer-Nielsen et al., 2012, Treiner et al., 2003). Consistent with this, many riboflavin 
producing bacteria, but not riboflavin deficient bacteria, have been shown to stimulate MAIT 
cells in a MR1 dependent fashion (Gold et al., 2010, Le Bourhis et al., 2013). Various studies 
have reported killing of bacterially infected cells by MAIT cells in vitro (Kurioka et al., 2015, 
Le Bourhis et al., 2013) and their importance in controlling bacterial infection in mice and 
humans, further establishing MAIT cells as important players in anti-bacterial immunity (Chua 
et al., 2012, Georgel et al., 2011, Grimaldi et al., 2014, Meierovics et al., 2013, Smith et al., 
2014, Le Bourhis et al., 2010, Wang et al., 2018).  
MAIT cells express high amounts of the interleukin-18 receptor (IL-18R) and IL-12R, and are 
able to respond to cytokine signals independent of their TCR (Ussher et al., 2014). This was 
initially shown with the combination of IL-12 and IL-18 (Ussher et al., 2014, Jo et al., 2014). 
IL-15 can also activate MAIT cells, but IL-15-induced MAIT cell activation is IL-18 dependent 
(Sattler et al., 2015). MAIT cells can be activated in a TCR independent manner by antigen 
presenting cells treated with bacteria (Wallington et al., 2018, Ussher et al., 2016) and by virally 
infected cells (Loh et al., 2016, van Wilgenburg et al., 2016). Additionally, MAIT cells are 
activated in both acute and chronic viral infections, and in patients with systemic lupus 
erythematous (van Wilgenburg et al., 2016, Chiba et al., 2017). Cytokine-mediated activation 
is important in vivo, as demonstrated by a recent study in mice which showed IL-18-dependent 
MAIT cell accumulation in lungs and MAIT cell-specific protection against challenge with a 




not only a TCR-dependent but also a TCR-independent component driven by cytokines. The 
synergy between TCR signals and cytokine mediated signals to achieve sustained activation of 
MAIT cells has also been observed in vitro (Slichter et al., 2016, Turtle et al., 2011, Ussher et 
al., 2014). 
In recent years, the phenotype and function of MAIT cell have been extensively explored (Dias 
et al., 2017, Kurioka et al., 2017). Based on the expression of CD8 and CD4, the MAIT cell 
compartment can be divided into functionally distinct subsets. CD8+ MAIT cells represent the 
most abundant subset and show greater functionality in response to stimulation with bacteria, 
mitogens, or cytokines than the less abundant CD8-CD4- and CD4+ MAIT cell subsets (Dias et 
al., 2018, Kurioka et al., 2017). However, the full array of effector functions of CD8+ MAIT 
cells upon activation is yet to be completely defined. Importantly, it remains unclear whether 
functions driven through the TCR are distinct from those driven in a TCR-independent manner. 
In this study, we have explored the full range of effector functions of TCR versus cytokine 
activated human CD8+ MAIT cells. Focusing on early events following triggering, we found 
marked differences in the production of cytokines, chemokines, and cytotoxic granule contents, 
and the expression of transcription factors in MAIT cells depending upon the mode of 
activation. These distinct early functional responses may reflect different roles for MAIT cells 
in response to diverse infectious threats and potentially in response to commensal organisms.  
2.2 Materials and Methods 
2.2.1 Cells and bacteria 
Peripheral blood was collected from healthy donors (n = 55; 53% male; median age = 25, range 
20-64) with approval from the University of Otago Human Ethics Committee and prior 
consultation with the Ngāi Tahu Research Consultation Committee; written informed consent 
was obtained from all donors. PBMCs were elutriated by density gradient centrifugation using 
LymphoprepTM (Axis-Shield PoC AS, Oslo, Norway) and stored in liquid nitrogen. Each 
experiment was performed after overnight resting of thawed and washed PBMCs in RPMI 1640 
supplemented with L-glutamine (Life Technologies Corporation, Carlsbad, USA), 10% fetal 
calf serum (Gibco, New Zealand and Sigma-Aldrich, St. Louis, USA), and Penicillin-
Streptomycin (Sigma-Aldrich) (now onwards referred to as R10). For some experiments, 
Vα7.2+ cells were isolated from PBMCs by labelling with anti-Vα7.2-PE antibody (Clone; 




MS columns (both from Miltenyi Biotec, Bergisch Gladbach, Germany). THP1 monocytic cells 
were maintained in R10. 
Escherichia coli HB101 was cultured overnight in Luria-Bertani (LB) broth, washed with PBS 
(Oxoid Ltd, Basingstoke, UK) and fixed with 2% formaldehyde for 20 minutes at 4 °C. After 
washing, fixed bacteria were resuspended in PBS and quantified with 123count eBeadsTM 
(eBioscience, San Diego, USA) by flow cytometry using a FACSCanto II (BD biosciences, San 
Jose, USA). 
2.2.2 MAIT cell activation 
Viable PBMCs were counted by a Neubauer hemocytometer excluding dead cells using Trypan 
Blue (Invitrogen, Carlsbad, USA) and 106 PBMCs/200 µL were seeded in U-bottom 96 well-
plates. Formaldehyde-fixed E. coli, 5-A-RU (synthesized in School of Pharmacy, University of 
Otago and stored in single use aliquots at -80 °C), or the combination of 50 ng/mL IL-12 
(Miltenyi Biotec) and 50 ng/mL IL-18 (R & D Systems, Minneapolis, USA), were added at the 
start of each experiment. Other than in the time course experiments, PBMCs were treated with 
5-A-RU or E. coli for 6 or 24 hours or IL-12+IL-18 for 24 hours. Some experiments were 
performed with 10 nM 5-A-RU/MG (5-A-RU and methyl glyoxal (MG, from Sigma-Aldrich) 
mixed at a molar ratio of 1:50 immediately prior to use) which was equivalent to 5 µM 5-A-RU 
at triggering TNFα and IFNγ production by MAIT cells (Figure S2.1B). For assessing the role 
of KDM6B, 105 CD8+ T cells were treated overnight with 5 µM GSK-J4 (Sigma-Aldrich) and 
then either co-cultured for 6 hours with 105 THP1 monocytes treated with 100 bacteria per 
PBMC/cell (BpC) E. coli or 5 µM 5-A-RU, or stimulated directly with IL-12+IL-18 (50 ng/mL 
each) for 24 hours. MR1 mediated activation of MAIT cells was blocked with 2.5 µg/mL anti-
MR1 antibody (clone 26.5, BioLegend, San Diego, USA). When assessing cytokine production 
and cytotoxic granule content by flow cytometry, brefeldin A (BioLegend) was added at 5 
µg/mL for final 4 hours of culture.  
2.2.3 Flow cytometry 
Cells were stained for surface markers, followed by fixing in 2% paraformaldehyde (except in 
sorting experiments), and treated with permeabilization buffer (BioLegend) for intracellular 
staining of cytokines and cytotoxic molecules or Foxp3/transcription factor buffer set 
(eBioscience) for transcription factors. MAIT cells were identified as CD8+ T-cells expressing 
semi-invariant TCR Vα7.2 and high levels of CD161 (Dusseaux et al., 2011); the gating strategy 




also examined. In all flow cytometry experiments, dead cells were excluded by live/dead fixable 
near IR (Invitrogen) staining. Antibodies used were: anti-CD3 PE-Cy7 (UCHT1, BioLegend), 
anti-CD3 BV510 (OKT3, BioLegend), anti-CD8 eFluor450 (RPA-18, eBioscience), anti-TCR 
Vα7.2 PE or PE-Cy7 or AF700 (3C10, BioLegend), anti-CD161 APC (191B8, Miltenyi 
Biotech), anti-CD161 BV605 (HP-3G10, BioLegend), anti-TCR γδ BV510 (B1, BioLegend), 
anti-CCR7 PerCP-Cy5.5 (G043H7, BioLegend), anti-TNFα FITC (Mab11, BioLegend), anti-
IFNγ PerCP-Cy5.5 (4S.B, BioLegend), anti-IL-26 PE (510414, R & D Systems), anti-CD56 
APC-Cy7, anti-CD107a PE (H4A3, BioLegend), anti-granzyme A PE (CB9, BioLegend), anti-
granzyme B FITC (QA16AO2, BioLegend), anti-perforin PerCP-Cy5.5 (B-D48, BioLegend), 
anti-FasL PE (NOK-1, BioLegend), anti-CD40L FITC (24-31, BioLegend), anti-4-1BB PE 
(4B4-1, BioLegend), anti-RORγt PE (Q21-559, BD Biosciences, San Jose, CA, USA), anti-
PLZF AF647 (R17-809, BD Biosciences), anti-T-bet PECy7 (4B10, BioLegend), anti-EOMES 
eFluor660 (WD1928, eBiosciences) and anti-Blimp1 PECF594 (6D3, BD Biosciences). 
Antibodies were used to assess preestablished effector response of MAIT cells or to validate 
the differentially expressed genes (DEGs) following RNA sequencing (Table S2.1 and 
Appendix 3). Flow cytometry antibodies and panels were selected considering the expression 
of the protein and brightness index of the fluorophores. Low expressing proteins were targeted 
by antibodies with brighter fluorophores and vice versa. Each of the antibodies were titrated 
before use for actual experiments (examples are shown, Appendix 1.1). Samples were acquired 
on a FACS CantoII, LSR Fortessa, or in sorting experiments a FACSAria II (all BD 
Biosciences), and analyzed by FlowJoTM V10 (TreeStar, Ashland, USA). For each experiment, 
single stained compensation beads (mixture of positive and negative beads) with each of the 
fluorophores were used for setting up voltages and compensation calculation. Heat killed cells 
were treated with and without the live/dead stain were used as positive and negative control 
respectively for live/dead staining (an example is shown in Appendix 1.2 for example of 
compensation setup and example compensation matrix for 7 color flow cytometry which was 
applied to the samples for analysis). For expression/functional analysis, gating was performed 
based on untreated MAIT cells (examples following E. coli stimulation for 6 hours, with or 
without blocking TCR-MR1 interaction, are shown in Appendix 1.3).  
2.2.4 Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) 
A total of 107 human PBMCs were treated with formaldehyde-fixed E. coli (10 BpC) or 5-A-
RU (5 µM) or IL-12+IL-18 (50 ng/mL each) for different durations or were left untreated. Cells 




CD161++Vα7.2+ cells) were isolated by fluorescence activated cell sorting on a FACSAria II. 
RNA from sorted MAIT cells was isolated using the Nucleospin RNA isolation kit (Macherey-
Nagel, Düren, Germany) as per the manufacturer’s instructions and stored at -80 °C. cDNA was 
synthesized using the Superscript IV system (Invitrogen) using oligo-dT primers. Real time 
PCR for gene expression was performed using the KAPA SYBR FAST mastermix on a ViiA7 
or QS6 Real-Time system (Applied Biosystems, Foster City, USA). Primers used are: TNFα 
(forward, AGCCTCTTCTCCTTCCTGATCGTG; reverse, 
GGCTGATTAGAGAGAGGTCCCTGG); IFNγ (forward, TGACCAGAGCATCCAAAAGA; 
reverse, CTCTTCGACCTCGAAACAGC); IL-17A (forward, 
AACCGATCCACCTCACCTT; reverse, GGCACTTTGCCTCCCAGAT); IL-22 (forward, 
GCAGGCTTGACAAGTCCAACT; reverse, GCCTCCTTAGCCAGCATGAA); CCL3 
(forward, TTCCGTCACCTGCTCAGAAT; reverse, GCAGCAAGTGATGCAGAGAA); 
CCL4 (forward, CCCAGCCAGCTGTGGTATTC; reverse, 
AGCAGCTCAGTTCAGTTCCA); CCL20 (forward, CTGGCTGCTTTGATGTCAGT; 
reverse, CGTGTGAAGCCCACAATAAA); granzyme B (forward, 
TGGGGGACCCAGAGATTAAAA; reverse, TTTCGTCCATAGGAGACAATGC); perforin 
(forward, CGCCTACCTCAGGCTTATCTC; reverse, CCTCGACAGTCAGGCAGTC); 
GAPDH (forward, CAACAGCGACACCCACTCCT; reverse, 
CACCCTGTTGCTGTAGCCAAA).  
2.2.5 RNA Sequencing  
A total of 107 human PBMCs per donor (n=7) were treated with formaldehyde-fixed E. coli (10 
BpC) or 5-A-RU (5 µM) for 6 hours or IL-12+IL-18 (50 ng/mL each) for 24 hours. MAIT cells 
were isolated from treated and untreated PBMCs by fluorescence activated cell sorting. RNA 
was extracted and sent to the Molecular Genetics Facility at the Liggins Institute, Auckland, 
New Zealand for library preparation and sequencing. Libraries were prepared with the Ion 
AmpliSeq™ Transcriptome Human Gene Expression Kit and were sequenced on an Ion Proton. 
Read count data files were generated with Torrent SuiteTM software. Downstream analysis for 
DEGs were performed using DESeq2 package in R-Bioconductor (Love, Huber, & Anders, 
2014). Log2 fold change and adjusted p-value (Padj) were arbitrarily set at 1 (fold change 2) 
and 0.05 respectively as cut-offs during DEG analysis. Principal component analysis (PCA) 
plot was generated in DESeq2. Venn-diagrams were created from DEGs in an online tool 
developed by Bioinformatics & Evolutionary genomics, VIB/UGent 




total and custom lists of DEGs against all stimuli were used to generate heat-maps on 
Heatmapper (http://www.heatmapper.ca/expression/) employing the average linkage clustering 
and Spearman rank correlation distance measurement methods. Gene set enrichment analysis 
was performed on GSEA software version 3.0 using normalized gene expression values of all 
genes from 28 samples as the expression database and compared either with the curated gene 
set databases; KEGG or Reactome, provided in the software/website or the tissue repair gene 
dataset obtained from the publication by Linehan et al. (Linehan et al., 2018). 
2.2.6 LEGENDplex immunoassays  
Some of the significantly DEGs for cytokines, chemokines, and cytotoxic granules identified 
by RNA sequencing of MAIT cells activated via TCR (E. coli or 5-A-RU) or by cytokines (IL-
12+IL-18) were validated by LEGENDplex immunoassays (Table S2.1 and Appendix 3). A 
total of 105 column purified Vα7.2+ MAIT cells per donor were co-cultured with 105 THP1 
monocytes and stimulated with either formaldehyde-fixed E. coli (100 BpC) or 5-A-RU (5 µM) 
± anti-MR1 antibody for 6 hours; for controls, THP1 monocytes were treated with E. coli or 5-
A-RU or were co-cultured with Vα7.2+ cells without any treatment. For cytokine stimulation, 
105 Vα7.2+ MAIT cells were treated with IL-12+IL-18 for 24 hours; untreated Vα7.2+ cells were 
used as a control. Cytokines, chemokines, and cytotoxic molecules in the supernatant were 
quantified by LEGENDplex bead-based immunoassay (BioLegend) following the 
manufacturer’s instructions using three multiplex panels: Human Proinflammatory Chemokine 
(mix and match 7-plex subpanel for CCL3, CCL4, CCL20, IL-8, CXCL9, CXCL10, and 
CXCL11), Human CD8/NK (mix and match 11-plex subpanel for IL-2, IL-6, IL-10, IL-17A, 
TNFα, IFNγ, sFasL, granzyme A, granzyme B, perforin, and granulysin), and Human custom 
panel (IL-1α, IL-1β, IL-17F, IL-21, IL-22, IL-23, and CD40L). 
2.2.7 Statistical analysis 
Data were analyzed using GraphPad Prism V7.03. Statistical significance was assessed with a 
one-way repeated measures ANOVA with Sidak’s multiple comparison tests for multiple 
groups and paired two tailed t-tests for two groups. Data were log transformed in some cases 





2.3.1 Timing of maximal activation and cytokine profile of MAIT cells differ 
between TCR and cytokine stimulation 
First, we treated human PBMCs with E. coli or IL-12+IL-18 and confirmed robust MAIT cell 
activation via TCR-dependent and -independent mechanisms (Figure 2.1A and B). The 
response to E. coli at 6 hours was completely MR1-dependent while at 24 hours it was only 
partially MR1-dependent (Figure 2.1A). The time course of the responses to both stimuli was 
then assessed at both the protein and the mRNA levels (Figure 2.1C-F). MAIT cells rapidly 
responded to E. coli with the transcription of multiple inflammatory cytokines genes (TNF 
[tumor necrosis factor α (TNFα)],  IFNG [interferon γ (IFNγ)], IL17A [IL-17A] and IL22 [IL-
22]) compared to the untreated control; the maximum response was observed at 4-6 hours 
(Figure 2.1C). Consistently, production of TNFα and IFNγ peaked at ~ 6 hours (Figure 2.1D). 
While MAIT cells were also robustly activated with IL-12+IL-18, the response was dominated 
by the production of IFNγ at both mRNA and protein levels and peaked at 24 and 20 hours 
respectively (Figure 2.1E and F). To determine whether the transcription of other genes 
followed similar kinetics to IFNγ with IL-12+IL-18 stimulation, we assessed the expression of 
GZMB (granzyme B), PRF1 (perforin), CCL3, CCL4, and CCL20. The expression of PRF1, 
CCL3, CCL4, and CCL20 peaked at 8-12 hours and then remained stably expressed at 24 hours, 
while the expression of GZMB gradually increased and peaked at 24 hours (Figure S2.1C). Of 
note, the expression levels of GZMB, PRF1, CCL3, CCL4, and CCL20 were considerably less 
than that of IFNG (Figure 2.1E and Figure S.2.1C). Therefore, MAIT cells respond rapidly to 
TCR stimulation and are polyfunctional, producing multiple pro-inflammatory cytokines, 
whereas cytokine driven activation is slower and is dominated by IFNγ production. 
Since bacteria provide signals in addition to the MAIT cell activating ligand (Ussher et al., 
2016), we assessed the response to the MR1 precursor ligand, 5-A-RU, as a pure TCR signal. 
MAIT cell activation with 5-A-RU at both 6 and 24 hours was predominantly TCR mediated 
(Figure 2.1G). Interestingly, MAIT cells stimulated with E. coli or 5-A-RU for 6 hours showed 
similar cytokine profiles, which were markedly different from those obtained by IL-12+IL-18 
stimulation for 24 hours; with TCR activation, TNFα mono-producers and TNFα/IFNγ double-
producers dominated while very few IFNγ mono-producing cells were observed, whereas with 
cytokine stimulation IFNγ mono-producers dominated with very few TNFα/IFNγ double-
producers seen (Figure 2.1H and I). These similar cytokine profiles of E. coli and 5-A-RU 




interaction during early E. coli treatment (Figure 2.1A) strongly suggests that the early bacterial 
activation of MAIT cells is purely TCR dependent. In contrast, E. coli treatment for 24 hours, 
which involved both TCR-dependent and -independent mechanisms (Figure 2.1A), elicited a 
cytokine profile similar to that induced by IL-12+IL-18 stimulation, although TNFα mono-
producers were only seen with E. coli (Figure 2.1H and I). These results suggest that the two 
MAIT cell activating pathways not only differ in the timing of activation, but also the resulting 
cytokine production profiles. 
 
Figure 2.1 T cell receptor and cytokine-activated MAIT cells differ in timing of maximal activation and 
cytokine profile. (A, B and G) IFNγ production by MAIT cells following stimulation of PBMCs with (A) 10 BpC 
E. coli ± anti-MR1 antibody or (G) 10 nM 5-A-RU/MG ± anti-MR1 antibody for 6 and 24 hours, or (B) IL-12+IL-




shown (n=9 for A and B, n=8 for G). Repeated measures one-way ANOVA with Sidak multiple comparison (A 
and G) and two tailed paired t-test (B). (C-F) Expression of cytokines by MAIT cells following stimulation of 
PBMCs with E. coli (10 BpC for C and 2 BpC for D) or IL-12+IL-18 (50 ng/mL each, E and F); assessed by RT-
PCR on sorted MAIT cells (n=3 for C and n=4 for E) or by flow cytometry (D and F; n=6). Data are presented as 
mean ± SEM and are pooled from two independent experiments. (H and I) Proportion of MAIT cells producing 
TNFα or IFNγ or both following stimulation with either 10 BpC E. coli or 5 µM 5-A-RU for 6 hours or IL-12+IL-
18 (50 ng/mL each) for 24 hours; (H) representative flow cytometry plots and (I) pie chart to show proportion 
producing each cytokine among the activated MAIT cell population (n=9-11). Data are pooled from two 
independent experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns = non-significant. 
 
Figure S2.1 (A) Flow cytometric gating strategy for phenotypic and functional analysis as well as isolation 
of MAIT cells, (B) equivalence of 5 μM 5-A-RU to 10 nM 5-A-RU/MG at triggering cytokine production by 
MAIT cells, and (C) kinetics of gene expression by cytokine stimulated MAIT cells. (A) MAIT cells were 
identified as CD3+CD8+CD161++Vα7.2+ cells for assessing effector functions by flow cytometry; for sorting 




to exclude γδ T cells and central memory CD8+ T cells respectively and MAIT cells were sorted as 
CD3+CD8+TCRγδ-CCR7-CD161++ Vα7.2+ cells. Number represents percentage of parent for respective population. 
(B) Percentage of TNFα and IFNγ producing MAIT cells (gated as shown in A ‘For general analysis’) assessed by 
flow cytometry following stimulation with either 5 µM 5-A-RU or 10 nM 5-A-RU/MG for 6 hours and. Biological 
replicate from two independent experiments and mean ± S.E.M are shown (n=8 for 5-A-RU and n=7 for 5-A-
RU/MG). (C) Kinetic of expression of CCL3, CCL4, CCL20, GZMB (granzyme B), and PRF1 (perforin) in flow-
sorted MAIT cells (isolated as shown in A for ‘For sorting pure MAITs’) determined by real-time RT-PCR 
following stimulation by IL-12+IL-18 (50 ng/mL each) for different durations. Data are presented as mean ± S.E.M 
and are pooled from two independent experiments (n=4). 
2.3.2 Distinct transcriptional profiles of TCR- and cytokine-stimulated MAIT 
cells 
To further investigate the differences observed with the two modes of activation, transcriptomic 
profiles of MAIT cells activated via TCR with either E. coli or 5-A-RU for 6 hours or via 
cytokine receptors with IL-12+IL-18 for 24 hours were generated by RNA sequencing; 
untreated MAIT cells were included for comparison. The timepoints were selected to allow 
comparison of the maximal transcriptional responses to TCR and IL-12+IL-18 stimulation 
(Figures 2.1C, 1E, and Figure S2.1C). First, we compared the response of MAIT cells to 
different treatments by principal component analysis. We observed good separation of activated 
MAIT cells from non-activated MAIT cells across the first two principal components that 
together accounted for 62% of total variability in the dataset (Figure 2.2A). MAIT cells 
activated by E. coli or 5-A-RU formed overlapping clusters that were separated from cytokine 
treated MAIT cells; this difference was largely driven by principal component 1 (PC1). We also 
observed some similarity between IL-12+IL-18 and E. coli treatments in PC2. 
Next, differentially expressed genes (DEGs) in activated MAIT cells with respect to rested 
MAIT cells were analyzed. Substantial transcriptional changes in MAIT cells were observed 
with the treatments; DEGs were more abundant with either E. coli (775) or 5-A-RU (685) 
treatment than with IL-12+IL-18 (116) (Figure 2.2B). Interestingly, more than a quarter of 
DEGs were downregulated with both E. coli and 5-A-RU but very few (8) with IL-12+IL-18 
(Figure 2.2B). A significant number of DEGs (53; which was 45% of total DEGs with cytokine 
stimulation) were shared in all three treatments, suggesting a core response of activated MAIT 
cells regardless of the mode of activation. This was evident with GSEA pathway analysis with 
pathways such as NK cell mediated cytotoxicity (Figure S2.2A), cytokine-cytokine receptor 
interaction, T cell receptor signaling pathway, apoptosis, NOD-like receptor signaling, and 




stimulated MAIT cells shared more DEGs (84; 72% of total) with E. coli treated MAIT cells 
but less (61; 52% of total) with 5-A-RU, suggesting bacteria and innate cytokines activate a 
similar response which cannot be triggered by the MR1 ligand alone. GSEA confirmed that 
many innate signaling pathways that were enriched with E. coli when compared to 5-A-RU 
were also enriched with IL-12+IL-18 (Table S2.2, Figure S2.2B). Transcriptomic signatures 
associated with TCR triggering could also be identified. A tissue repair signature proposed to 
be associated with TCR triggering of MAIT cells (Hinks et al., 2019, Leng et al., 2019) was 
enriched in MAIT cells following E. coli or 5-A-RU stimulation but not with IL-12+IL-18 
(Figure S2.2C). 
A heat-map illustrating the normalized expressions of total DEGs with all stimuli also showed 
marked differences in the response of MAIT cells at transcriptomic level; activation with E. coli 
or 5-A-RU had more pronounced effects on gene expression and were clustered separately from 
the cluster of untreated and cytokine treated MAIT cells (Figure 2.2C). Taken together, our data 
suggest MAIT cells are differentially regulated by TCR and cytokine stimuli and possess a 





Figure 2.2. T cell receptor and cytokine-activated MAIT cells have distinct transcriptional profiles. (A) 
Principal component analysis of MAIT cell transcriptome following stimulation with different stimuli; PBMCs 
were treated with 10 BpC E. coli or 5 µM 5-A-RU for 6 hours or IL-12+IL-18 (50 ng/mL each) for 24 hours, then 
sorted for RNA sequencing. (B) Venn-diagram showing shared and unique DEGs (fold change >2 and Padj <0.05) 
in TCR- and cytokine-stimulated MAIT cells; total, upregulated and downregulated DEGs with each treatment 
compared to untreated control were separately analyzed. (C) Heat map and dendrogram of the normalized 





Figure S2.2. Gene set enrichment analysis (GSEA) revealed shared and distinct features in MAIT cells 
activated with E. coli, 5-A-RU or IL-12+IL-18. Summary enrichment plots from GSEA analysis for (A) NK 
cell-mediated cytotoxicity (KEGG), (B) RIG-I like receptor signaling pathway (KEGG), and (C) tissue repair when 
log2 normalized total gene expression of E. coli (EC), 5-A-RU (5A), or IL-12+IL-18 (CY) stimulated MAIT cells 






2.3.3 MAIT cells activated via TCR produce more inflammatory cytokines than 
IL-12+IL-18-stimulated MAIT cells. 
We next investigated the effect of E. coli, 5-A-RU, or IL-12+IL-18 on the expression and 
production of inflammatory cytokines by MAIT cells. With all stimuli, increased expression of 
TNFA and IFNG genes was seen; nevertheless, higher TNFA expression was achieved with 
TCR stimuli and maximum IFNG expression with IL-12+IL-18 (Figure 2.3A). Consistent with 
this, more TNFα was detected in the culture supernatant following stimulation with E. coli than 
with IL-12+IL-18; more TNFα was produced in response to E. coli than to 5-A-RU (>10-fold) 
(Figure 2.3B). In contrast, more than 10-fold higher concentration of IFNγ was detected upon 
IL-12+IL-18 stimulation for 24 hours compared to stimulation with E. coli for 6 hours; ~100-
fold more IFNγ was produced in response to E. coli than to 5-A-RU (Figure 2.3B). MR1 
blocking significantly inhibited TNFα and IFNγ production by both E. coli and 5-A-RU treated 
MAIT cells (Figure 2.3B). TCR stimulation also triggered significant upregulation of 
expression of several other inflammatory genes, notably IL1A, IL1B, IL2, IL6, IL10, IL17A, 
IL17F, IL21, IL22, and GMCSF, while with IL-12+IL-18 stimulation significant upregulation 
of IL10, IL17A, and IL17F was seen, but to a much lesser degree than with TCR mediated 
activation (Figure 2.3A, 3C and Figure S2.3A). Of the cytokines assayed in the supernatant, we 
detected MR1-dependent production of IL-1β, IL-2, IL-6, and IL-10 in response to E. coli but 
not 5-A-RU, however, only IL-1β and IL-2 were significant (Figure 2.3D). Low level 
production of IL-1β, IL-6, and IL-10 was detected in response to IL-12+IL-18 (Figure 2.3D). 
Therefore, MAIT cells express and produce more pro-inflammatory cytokines in response to 
TCR stimulation than in response to IL-12+IL-18; the response to E. coli is stronger than to 5-
A-RU.  
Interestingly, cytokine stimulation, and to a lesser degree TCR stimulation, triggered significant 
upregulation of IL26 gene expression, a proinflammatory cytokine of the IL-10 superfamily 
(Figure S2.3B). Likewise, cytokine activated MAIT cells expressed IL-26 at the protein level, 
the highest amongst CD8+ T cells (Figure S2.3C and D), but early TCR stimulation failed to 
induce detectable IL-26 expression (Figure S2.3E and F). However, IL-26 expression was 
detectable upon late TCR activation by E. coli and 5-A-RU/MG and was significantly inhibited 
by MR1 blocking (Figure S2.3E and F). At 24 hours, both E. coli and 5-A-RU/MG treated 
MAIT cells expressed a small amount of IL-26 in an MR1-independent fashion (Figure S2.3E 
and F). IL-26 expression was also observed in NK cells (identified as CD3-CD161+Vα7.2- cells, 




for 24 hours; the response to E. coli was independent of MR1 (Figure S2.3G-I). Overall, this 
suggests that MAIT cells are the main source of IL-26 among CD8+ T cells in response to IL-
12+IL-18 and that they also produce it in response to TCR stimulation, but production is 
delayed. 
 
Figure 2.3. TCR stimulation results in expression and production of more inflammatory cytokines than IL-
12+IL-18 stimulation.(A and C) Log2 transformed gene counts of TNFA, IFNG, IL17A, IL22, IL1B, IL2, IL6, and 
IL10 from RNA sequencing of sorted MAIT cells following stimulation of PBMCs with 10 BpC E. coli or 5 µM 
5-A-RU for 6 hours or IL-12+IL-18 (50 ng/mL each) for 24 hours. Data are presented as mean ± SEM (n=7). 
Repeated measures one-way ANOVA with Sidak multiple comparison tests. (B and D) Quantification of cytokines 
(TNFα, IFNγ, IL-17A, IL-22, IL-1β, IL-2, IL-6, and IL-10) by LEGENDplexTM in either culture supernatant from 
co-cultures of purified Vα7.2+ cells and THP1 monocytes (1:1 ratio) stimulated with 100 BpC E. coli or 5 µM 5-
A-RU for 6 hours ± anti-MR1, or culture supernatant of purified Vα7.2+ cells alone or after IL-12+IL-18 (50 ng/mL 
each) treatment for 24 hours. Data are presented as mean ± SEM and are pooled from two independent experiments 









Figure S2.3. While T cell receptor and cytokine-activated MAIT cells have distinct inflammatory profiles, 
late activation leads to increased expression of IL-26 regardless of the mode of activation. (A) Normalized 
expression of a custom list of genes in MAIT cells in response to different stimuli and unstimulated MAIT cells 
was used to generate the heat map with dendrogram using the Heatmapper online tool. (B) Log2 transformed IL26 
counts were compared in flow-sorted MAIT cells activated with different stimuli; PBMCs were treated with 10 
BpC E. coli or 5 µM 5-A-RU for 6 hours or 50 ng/mL IL-12+IL-18 for 24 hours, then MAIT cells were FACS 
sorted for RNA-sequencing (n=7). Repetitive measures one-way ANOVA with Sidak multiple comparison tests 
was used for assessing statistical significance. **p<0.01, ****p<0.0001. (C and D) IL-26 production by MAIT 
cells and other non-MAIT CD8+ T cells was measured by intracellular staining after PBMCs were treated with 50 
ng/mL IL-12+IL-18 for 24 hours. Data are presented as mean ± S.E.M and are pooled from two independent 
experiments (n=9). Paired t-tests were used for statistical analysis. *p<0.05, ***p<0.001. (E and F) PBMCs were 
treated with (D) 10 BpC E. coli or (E) 10 nM 5-A-RU/MG for 6 and 24 hours and IL-26 production by MAIT cells 
was assessed; anti-MR1 antibody was also added for 6 hours or 24 hours. Each biological replicate and mean ± 
S.E.M are shown and are pooled from two independent experiments (n=9). Repetitive measures one-way ANOVA 
with Sidak multiple comparison tests were used for assessing statistical significance. **p<0.01, ***p<0.001, ns = 
non-significant. (G) CD3-CD161+ cells under live lymphocytes are mainly CD56+ NK cells. (H-I) PBMCs were 
treated with (G) E. coli for 6 and 24 hours or (H) IL-12+IL-18 for 24 hours and IL-26 production by CD3-CD161+ 
cells was assessed; anti-MR1 antibody was also added during E. coli treatments at 6 hours or 24 hours. Each 
biological replicate and mean ± S.E.M are shown and are pooled from two independent experiments (n=9). 
Repetitive measures one-way ANOVA with Sidak multiple comparison and paired t tests were performed. 
**p<0.01, ns = non-significant. 
 
2.3.4 Cytotoxic profile of MAIT cells is different between the two modes of 
activation 
MAIT cells can kill bacterially infected cells (Le Bourhis et al., 2013), which is mostly 
degranulation dependent (Kurioka et al., 2015). We asked whether degranulation and the 
cytotoxic granule content of MAIT cell differs with the mode of activation. First, we assessed 
MAIT cell degranulation by assessing surface expression of CD107a. CD107a surface 
expression rapidly increased with both TCR stimuli and with IL-12+IL-18, suggesting both 
modes of activation are equally potent at triggering degranulation in MAIT cells (Figure 2.4A). 
Consistent with this, E. coli-mediated CD107a expression at 6 hours was significantly reduced 
with MR1 blocking, whereas only partial inhibition was observed at 24 hours, confirming the 
previous finding of both TCR-dependent and -independent late degranulation in MAIT cells 
(Figure 2.4A) (Kurioka et al., 2015). 
Next, we compared cytotoxic granule content of MAIT cells upon activation. Activated MAIT 




of the mode of activation (Figure 2.4B). Likewise, the frequency of MAIT cells expressing 
granzyme B significantly increased upon both early TCR and cytokine stimulation (Figure 
2.4C). While the frequency of MAIT cells expressing perforin increased with E. coli and 
cytokines, it did not with 5-A-RU (Figure 2.4D). Nevertheless, 5-A-RU treatment for 24 hours 
induced significant granzyme B and perforin expression which was completely TCR mediated 
(Figure S2.4A and B). MR1 blockade abolished E. coli-induced granzyme B production 
completely at 6 hours and partially at 24 hours but had no effect on perforin production at 6 
hours and minimal effect at 24 hours (Figure 2.4C and D). Interestingly, E. coli or 5-A-RU 
treatment triggered GZMA (granzyme A) downregulation in MAIT cells but IL-12+IL-18 
treatment resulted in upregulation (Figure 2.4B). This difference in granzyme A expression was 
also evident at protein level; both early and late TCR-mediated activation reduced granzyme A 
whereas IL-12+IL-18 significantly increased expression (Figure 2.4E). E. coli-mediated 
granzyme A downregulation was reversed completely with MR1 blocking at 6 hours and 
partially at 24 hours (Figure 2.4E). Granzyme A, granzyme B, and perforin were detected in the 
culture supernatant of both TCR and cytokine stimulated MAIT cells; however, more granzyme 
A was detected in the supernatant of cytokine treated MAIT cells (Figure 2.4F). Differences 
were also evident in gene expression of other granzymes; GZMK (granzyme K) and GZMM 
(granzyme M) followed a similar trend to GZMA, while GZMH (granzyme H) followed that of 
GZMB except it was highest with IL-12+IL-18 stimulation (Figure S.2.4C). Overall, these data 
suggest that MAIT cells rapidly degranulate upon activation, however, granule content differs 





Figure 2.4. Cytotoxic granule content of MAIT cells differs with the mode of activation.(A, C-E) Percentage 
of MAIT cells expressing (A) CD107a, (C) granzyme B, (D) perforin, and (E) granzyme A following stimulation 
of PBMCs with either 10 BpC E. coli or 5 µM 5-A-RU for 6 hours or IL-12+IL-18 (50 ng/mL each) or 10 BpC E. 
coli for 24 hours; with E. coli stimulation, the effect of anti-MR1 was assessed. Biological replicates from two 
independent experiments and mean ± SEM are shown (n=7). Repeated measures one-way ANOVA with Sidak 
multiple comparison and two tailed paired t-tests. (B) Log2 transformed gene counts of GZMB, PRF1, and GZMAA 
from RNA sequencing of sorted MAIT cells following stimulation of PBMCs with 10 BpC E. coli or 5 µM 5-A-
RU for 6 hours or IL-12+IL-18 (50 ng/mL each) for 24 hours. Data are presented as mean ± SEM (n=7). Repeated 
measures one-way ANOVA with Sidak multiple comparison tests. (F) Quantification of cytotoxic molecules by 
LEGENDplexTM in either culture supernatant from co-cultures of purified Vα7.2+ cells and THP1 monocytes (1:1 




Vα7.2+ cells alone or after IL-12+IL-18 (50 ng/mL each) treatment for 24 hours. Data are presented as mean ± 
SEM and are pooled from two independent experiments (n=5). Paired t-test were performed on log transformed 
data. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns = non-significant. 
Cytotoxic T cells can also kill target cells through expression of FasL. Both TCR and cytokine 
activated MAIT cells rapidly upregulated FASLG (FasL) gene expression (Figure S2.4D). 
Although, FasL could not be detected on the surface of early activated MAIT cells, soluble FasL 
was detected in the culture supernatant of early TCR activated MAIT cells in a MR1-dependent 
fashion (Figure S2.4E and F). Late E. coli activation significantly increased FasL expression on 
the surface and was only partially reduced upon MR1 blocking (Figure S2.4E). IL-12+IL-18 
activation enhanced both FasL surface expression and sFasL release into the media (Figure 
S2.4E and F) suggesting both activation pathways contribute to FasL/sFasL expression. 
 
Figure S2.4. Expression of cytotoxic molecules and FasL/sFasL by TCR and cytokine activated MAIT cells.  
(A and B) Human PBMCs were treated with 5 µM 5-A-RU ± anti-MR1 antibody for 24 hours and percentage of 
MAIT cells expressing granzyme B (A) and perforin (B) were measured by flow cytometry. Each biological 
replicate and mean ± S.E.M are shown and are pooled from two independent experiments (n=6). Repeated 
measures one-way ANOVA with Sidak multiple comparison tests were used for statistical analysis. *p<0.05, 
****p<0.0001, ns = non-significant. (C and D) Gene counts (log2 transformed) of (C) GZMH, GZMK, and GZMM 
and (D) FASLG (FasL)with different stimuli; PBMCs were treated with 10 BpC E. coli or 5 µM 5-A-RU for 6 
hours or 50 ng/mL IL-12+IL-18 for 24 hours, then MAIT cells were flow-sorted for RNA sequencing. Data are 
presented as mean ± S.E.M (n=7); for FASLG, each biological replicate is shown. Repetitive measures one-way 




***p<0.001, ****p<0.0001 (E) Percentage of FasL expressing MAIT cells after PBMCs were treated with 10 BpC 
E. coli or 5 µM 5-A-RU for 6 hours or IL-12+IL-18 (50 ng/mL each) for 24 hours; MR1 was blocked in E. coli 
stimulation for 24 hours. Each biological replicate and mean ± S.E.M are shown and are pooled from two 
independent experiments (n=6-7). Repetitive measures one-way ANOVA with Sidak multiple comparison and 
paired t tests were performed. **p<0.01, ns = non-significant. (F) Soluble FasL was quantified by LEGENDplexTM 
in either culture supernatant from co-cultures of purified Vα7.2+ cells and THP1 monocytes (1:1 ratio) stimulated 
with 100 BpC E. coli or 5 µM 5-A-RU for 6 hours ± anti-MR1, or culture supernatant of purified Vα7.2+ cells 
alone or after IL-12+IL-18 treatment for 24 hours; controls (THP1 cells + MAIT cells, THP1 cells + E. coli, and 
THP1 cells + 5-A-RU)  are also shown. Data are presented as mean ± S.E.M (n=5). Paired t-test were performed 
on log transformed data for assessing statistical significance. **p<0.01, ***p<0.001. 
 
2.3.5 TCR and cytokine activated MAIT cells express different profiles of 
transcription factors 
MAIT cells are characterized by high expression of the transcription factors RAR-related 
orphan receptor γt (RORγt), promyelocytic leukemia zinc finger protein (PLZF) and 
eomesodermin (EOMES), which make them distinct from other CD4+ and CD8+ T cells (Figure 
2.5A) (Dias et al., 2017, Leeansyah et al., 2015). Expression of these transcription factors also 
varies among different MAIT cell subsets based on CD4 or CD8 co-receptor expression, 
resulting in heterogeneity in phenotype and function (Figure S2.5A) (Kurioka et al., 2017). 
Therefore, we assessed the expression of various transcription factors in MAIT cells to 
investigate whether the transcription factor profile changes with the mode of activation. 
Interestingly, compared to resting MAIT cells, the expression of RORC (RORγt) and ZBTB16 
(PLZF) significantly increased with TCR activation but not with IL-12+IL-18 (Figure 2.5B and 
C). At the protein level, we observed corresponding changes in RORγt expression but little 
change in PLZF expression was observed (Figure 2.5A-C). Upon activation, MAIT cells 
expressed high T-bet regardless of the stimuli, both at RNA (TBX21) and protein levels (Figure 
2.5A, C and D). Interestingly, with TCR stimulation an increase in MAIT cells expressing both 
RORγt and T-bet or RORγt alone were seen, whereas following IL-12+IL-18 treatment an 
increase in MAIT cells expressing T-bet alone was observed (Figure 2.5G). Expression of the 
PRDM1 (Blimp1) gene went up with both TCR stimuli and with cytokines, being one of the 
significantly DEGs, however, an increase at the protein level was only seen with E. coli and 
cytokines (Figure 2.5E). EOMES expression, both at the mRNA (EOMES) and protein levels, 
was significantly reduced by both TCR signals but was unchanged with cytokines (Figure 2.5F). 




IL-12+IL-18 were evident in double negative and CD4+ MAIT cell subsets (Figure S2.5B-F). 
Taken together, the profile of transcription factors in MAIT cells markedly changes upon 





Figure 2.5. MAIT cells express a distinct transcription factor profile which changes upon activation. (A) 
Expression of different transcription factors by MAIT cells and non-MAIT CD8+ T cells from PBMCs; the gating 
strategy for MAIT and non-MAIT cells and representative histograms with fluorescent minus one (FMO) control 
is shown. (B-F) Expression of different transcription by MAIT cells were compared following stimulation of 
PBMCs with 10 BpC E. coli or 5 µM 5-A-RU for 6 hours or IL-12+IL-18 (50 ng/mL each) for 24 hours. Log2 
transformed gene counts from RNA sequencing of sorted MAIT cells, and mean fluorescent intensity (MFI) of 
MAIT cells are shown for (B) RORC/RORγt, (C) ZBTB16/PLZF, (D) TBX21/T-bet, (E) PRDM1/Blimp1, and (F) 
EOMES/EOMES. Biological replicates from two independent experiments and mean ± SEM are shown (n=7 for 
RNA and n=8 for protein). Repeated measures one-way ANOVA with Sidak multiple comparison tests. (G) 
Upregulation of RORγt alone or T-bet alone or both in MAIT cells upon TCR- or cytokine-activation were 






Figure S.2.5. Similar shift in transcription factor expression in other MAIT cell subsets during activation. 
(A) MAIT cells were identified as CD3+CD161++Vα7.2+ T cells in human PBMCs and expression of different 
transcription factors were compared in double negative (DN; CD8-CD4-), CD4+, and double positive (DP; 
CD4+CD8+) MAIT cell subsets; representative histograms and the gating strategy for the different MAIT cell 
subsets are shown. An FMO (fluorescent minus one) control for each transcription factor was included. (B-F) 
Human PBMCs were treated with 10 BpC E. coli or 5 µM 5-A-RU for 6 hours or IL-12+IL-18 (50 ng/mL each) 
for 24 hours and expression of different transcription factors in different MAIT cell subsets was assessed by flow 
cytometry; (B) RORγt, (C) PLZF, (D) T-bet, (E) Blimp1, and (F) EOMES. Each biological replicate and mean ± 
S.E.M are shown and are pooled from two independent experiments (n=8). Repetitive measures one-way ANOVA 
with Sidak multiple comparison was performed for statistical analysis. *p<0.05, **p<0.01, ***p<0.001, 




2.3.6 TCR stimulation of MAIT cells results in chemokine production 
Production of chemokines by MAIT cells upon activation has previously been shown (Lepore 
et al., 2014, Turtle et al., 2011, Slichter et al., 2016). Next, we examined the expression of 
various chemokines by MAIT cells in response to different stimuli. Significant expression of 
CCL3 (encodes ligand for CCR1, CCR4, and CCR5), CCL4 (encodes ligand for CCR5), and 
CCL20 (encodes ligand for CCR6) was seen with all treatments but was significantly higher in 
MAIT cells activated with E. coli and 5-A-RU than with IL-12+IL-18 (Figure 2.6A). Consistent 
with this, CCL3, CCL4, and CCL20 production was detected in culture supernatant with E. coli 
or 5-A-RU treatment and was reduced by approximately 10-fold upon MR1 blocking, 
confirming production was MAIT cell specific (Figure 2.6B). Cytokine stimulation also 
triggered significant CCL3 and CCL4 production, albeit at lower levels (Figure 2.6B). 
We also observed enhanced CXCL9, CXCL10, and CXCL11 gene expression, all encoding 
ligands for CXCR3, with 5-A-RU and IL-12+IL-18 treatment, whereas E. coli treatment 
resulted in a lesser, non-significant enhancement (Figure 2.6C). In contrast, at the protein level, 
E. coli stimulated maximum CXCL9, CXCL10, and CXCL11 production by MAIT cells, 
followed by treatment with 5-A-RU and IL-12+IL-18 (Figure 2.6D); MR1 blocking completely 
abolished production of  CXCL9, CXCL10, and CXCL11 by E. coli and 5-A-RU treated MAIT 
cells (Figure 2.6D). Additionally, E. coli but not 5-A-RU or IL-12+IL-18, resulted in 
upregulation of CXCL8 (IL-8) gene expression (Figure 2.6C). Consistent with this, IL-8 
production was highest in supernatant from E. coli treated MAIT cells and was significantly 
blocked by anti-MR1 antibody (Figure 2.6D). 5-A-RU and IL-12+IL-18 stimulation also caused 
low level but significant IL-8 production (Figure 2.6D). Overall, MAIT cells produce multiple 
chemokines upon activation by both TCR-dependent and -independent mechanisms, however, 





Figure 2.6. Robust chemokine production by MAIT cells following TCR activation. (A and C) Log2 
transformed gene counts of CCL3, CCL4, CCL20, CXCL9, CXCL10, CCL20, and CXCL8 from RNA sequencing 
of sorted MAIT cells following stimulation of PBMCs with 10 BpC E. coli or 5 µM 5-A-RU for 6 hours or IL-
12+IL-18 (50 ng/mL each) for 24 hours. Data are presented as mean ± SEM (n=7). Repeated measures one-way 
ANOVA with Sidak multiple comparison tests. (B and D) Quantification of chemokines (CCL3, CCL4, CCL20, 
CXCL9, CXCL10, CCL20, and IL-8) by LEGENDplexTM in either culture supernatant from co-cultures of purified 
Vα7.2+ cells and THP1 monocytes (1:1 ratio) stimulated with 100 BpC E. coli or 5 µM 5-A-RU for 6 hours ± anti-
MR1, or culture supernatant of purified Vα7.2+ cells alone or after IL-12+IL-18 (50 ng/mL each) treatment for 24 
hours. Data are presented as mean ± SEM and are pooled from two independent experiments (n=5). Paired t-test 
were performed on log-transformed data. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns = non-significant. 
 
2.3.7 Activated MAIT cells rapidly upregulate co-stimulatory molecules 
Recently, MAIT cells were associated with maturation of monocyte-derived and primary 
dendritic cells in a CD40L dependent manner (Salio et al., 2017). We next investigated how 
CD40L, one of the DEGs following RNA sequencing (Table S2.1 and Appendix 3), is 
controlled in MAIT cells upon activation. Both TCR and cytokine stimulated MAIT cells 
rapidly upregulated CD40LG gene expression (Figure 2.7A). Unstimulated MAIT cells did not 
express CD40L on the surface but treatment with E. coli for 6 hours led to significant CD40L 




blocking reduced E. coli mediated CD40L surface expression completely at both 6 hours and at 
24 hours (Figure 2.7B). Also, significant CD40L was seen on the surface of MAIT cells 
following IL-12+IL-18 stimulation (Figure 2.7B). Soluble CD40L could not be detected in the 
culture media with any treatments (data not shown). 
To determine the kinetics of CD40L expression, PBMCs were treated with E. coli, 5-A-RU, or 
IL-12+IL-18 for different lengths of time; with E. coli treatment, the contribution of TCR 
signaling was assessed by blocking MR1. Interestingly, with both E. coli and 5-A-RU, CD40L 
expression increased rapidly, peaking at 6 hours, before decreasing to a trough at 12 hours and 
then increasing again by 24 hours (Figure 2.7C). This biphasic expression of CD40L has 
previously been reported on other T cells following TCR stimulation (Chakrabarty et al., 2011, 
Snyder et al., 2007). With E. coli stimulation, blocking MR1 completely inhibited CD40L 
expression on MAIT cells throughout the time-course. In contrast, with IL-12+IL-18 
stimulation, CD40L expression increased steadily throughout the time-course; this was 
consistent with the observation in Figure 7B. In contrast to CD40L, CD69 expression on MAIT 
cells gradually increased throughout the time-course with all treatments (Figure 2.7C).  
We also observed increased expression of TNFRSF9 (4-1BB or CD137), a gene encoding a co-
stimulatory molecule on activated T cells that can trigger maturation, activation, and migration 
of cells expressing 4-1BBL, such as dendritic cells (Lippert et al., 2008), by both TCR and 
cytokine activated MAIT cells, with the highest expression seen with TCR stimuli (Figure 
2.7D). TNFRSF9 was also one of the top 10 DEGs following TCR stimulation of MAIT cells 
(Table S2.1). Consistent with this, high surface expression of 4-1BB was seen following early 
TCR activation which was completely MR1 mediated (Figure 2.7E). A small percentage of 
MAIT cells also expressed 4-1BB upon stimulation by IL-12+IL-18, suggesting cytokines alone 
can induce 4-1BB on MAIT cells (Figure 2.7E). Late TCR activation by E. coli resulted in high 
expression of 4-1BB that was only partially blocked with anti-MR1 antibody (Figure 2.7E). 
Therefore, TCR stimulation induces robust 4-1BB surface expression on MAIT cells, however 





Figure 2.7. TCR and cytokine activation leads to increased expression of co-stimulatory molecules on MAIT 
cells. (A, D) Log2 transformed gene counts of (A) CD40LG and (D) TNFRSF9 from RNA sequencing of sorted 
MAIT cells following stimulation of PBMCs by 10 BpC E. coli or 5 µM 5-A-RU for 6 hours or IL-12+IL-18 (50 
ng/mL each) for 24 hours. Data are presented as mean ± SEM (n=7). Repeated measures one-way ANOVA with 
Sidak multiple comparison tests. (B, E) Percentage of MAITs expressing (B) CD40L or (E) 4-1BB following 
stimulation of PBMCs with either 10 BpC E. coli or 5 µM 5-A-RU for 6 hours or IL-12+IL-18 (50 ng/mL each) 
or 10 BpC E. coli for 24 hours; with E. coli treatment, the effect of anti-MR1 was assessed. Biological replicates 
from two independent experiments and mean ± SEM are shown (n=6-7 for B, n=7-8 for E). Repeated measures 
one-way ANOVA with Sidak multiple comparison and two-tailed paired t-tests. (C) Percentage of MAIT cell 
expressing CD40L and CD69 following stimulation of PBMCs with either 10 BpC E. coli (± anti-MR1), 5 µM 5-
A-RU, or IL-12+IL-18 (50 ng/mL each) for the time indicated. Data are presented as mean ± SEM and are pooled 




2.3.8 Lysine demethylase 6B is important for MAIT cell activation 
Finally, expression of KDM6B (lysine demethylase 6B, also known as Jumonji domain 
containing protein 3 [JMJD3]), was specifically enriched upon TCR activation, being one of 
the top 20 DEGs against E. coli or 5-A-RU activation (Figure 2.8A, Table S2.1). Inhibition of 
KDM6B by GSK-J4 demonstrated it was important for the upregulation of CD69 and 4-1BB 
following stimulation with E. coli, but not for TNFα and IFNγ production in MAIT cells (Figure 
2.8B-F). GSK-J4 treatment had a similar effect on the expression of CD69 and 4-1BB on 5-A-
RU stimulated MAIT cells (Figure 2.8G and H). Even though IL-12+IL-18 stimulation resulted 
in only a small upregulation of KDM6B expression (Figure 2.8A), inhibiting KDM6B also 
reduced CD69 and 4-1BB expression at 24 hours on IL-12+IL-18 stimulated MAIT cells 
(Figure 2.8I and J). In summary, the histone demethylase KDM6B is important for the MAIT 
cell activation. 
 
Figure 2.8. Histone demethylase KDM6B is important for MAIT cell activation. (A) Comparison of log2 
transformed gene counts of KDM6A and KDM6B in untreated MAIT cells (UT) and in response to different 




hours, then MAIT cells were flow-sorted for RNA-sequencing. Data are presented as mean ± S.E.M (n=7). 
Repetitive measures one-way ANOVA with Sidak multiple comparison tests was used for assessing statistical 
significance. **p<0.01, ****p<0.0001. (B-J) Column purified CD8+ T cells were treated overnight with KDM6B 
inhibitor GSK-J4 (5 µM) or vehicle control (DMSO) expression of (B, G and I) CD69 and percentage of (C, H 
and J) 4-1BB, (D) viable, and (E) TNFα and (F) IFNγ producing MAIT cells were assessed following either co-
culturing with THP1 monocytes and TCR stimulation  (100 BpC E. coli or 5 µM 5-A-RU) for 6 hours, or IL-
12+IL-18 stimulation for 24 hours. Each biological replicate and mean ± S.E.M are shown and are pooled from 
two independent experiments (n=7). Repetitive measures one-way ANOVA with Sidak multiple comparison was 
used for statistical analysis. **p<0.01, ****p<0.0001, ns = non-significant. 
2.4 Discussion 
MAIT cells are abundant unconventional T cells that can be activated either via their TCR or 
by innate cytokines. Here, we have characterized their responses to these two modes of 
activation. TCR activation of MAIT cells resulted in rapid activation with production of 
multiple proinflammatory cytokines; in contrast cytokine-mediated activation was slower and 
less polyfunctional. Substantial differences in the cytotoxic granule content upon TCR and 
cytokine stimulation were also noted. These differences in effector functions by mode of 
activation were underpinned by changes in transcription factors expression. Production of 
chemokines and upregulation of co-stimulatory molecules with activation was also 
demonstrated and suggests a role for MAIT cells in coordinating the recruitment and activation 
of other immune cells. 
Early TCR activation with 5-A-RU or with E. coli triggers higher TNFα production by MAIT 
cells than IL-12+IL-18. Upon stimulation with IL-12+IL-18, MAIT cell cytokine production 
shifts to IFNγ. This is consistent with an earlier study where human PBMCs were activated with 
either anti-CD3/CD28 beads or a combination of IL-12/15/18 (Slichter et al., 2016). A similar 
response has been reported when hepatic MAIT cells were stimulated with anti-CD3/CD28 
beads (Jo et al., 2014). Predominance of IFNγ production with little TNFα production was seen 
when hepatic MAIT cells were treated overnight with Pseudomonas aeruginosa, a riboflavin 
synthesizing bacteria (Jo et al., 2014); this is consistent with the response we observed from 
blood MAIT cells following treatment with E. coli for 24 hours. This highlights that the early 
MAIT cell response to riboflavin-synthesizing bacteria differs to the late response and is 
consistent between blood and hepatic MAIT cells. With the observation that production of 
IFNγ, IL-17A, and IL-22 accompany TNFα in early TCR activation, we propose that a TCR 




While MAIT cells stimulated via their TCR with either E. coli or 5-A-RU showed considerable 
overlap in their transcriptional and functional profiles, there were substantial differences in 
DEGs, which was evident in principal component 2 of the PCA analysis. Of note, cytokine 
stimulated MAIT cells shared more DEGs with E. coli than 5-A-RU, suggesting a role for innate 
signaling. It has now been established that bacteria furnish co-stimulatory signals, TLR agonists 
being most commonly studied, that result in APC activation and enhancement of MAIT cell 
activation (Chen et al., 2017, Ussher et al., 2016). Consistent with this, pathway analysis 
demonstrated similarities between E. coli and IL-12+IL-18 activated MAIT cells, with 
enrichment of innate signaling pathways including type I IFNs, pattern recognition receptors, 
and MYD88/TRIF. However, these signals must work in concert with TCR signaling to 
modulate MAIT cell activation as MR1 blockade almost completely inhibited the early MAIT 
cell response (IFNγ, granzyme B and chemokines) to E. coli. 
The hypothesis that TCR triggering leads to early polyfunctionality in MAIT cells was 
confirmed by RNA sequencing. In addition to TNFA, IFNG, IL17A, and IL22, the expression 
of many pro-inflammatory cytokine genes, including IL1B, IL6, IL21, and GMCSF was 
upregulated with TCR stimulation. However, significant production of only TNFα, IFNγ, and 
IL-1β could be detected in the culture supernatant of E. coli activated MAIT cells; GM-CSF 
was not assayed. These differences between gene expression and protein production could be 
due to the different culture systems used (PBMCs vs a co-culture of THP1 cells and Vα7.2+ 
cells which differ in their thresholds for MAIT cell activation (Banki et al., 2019)) and the 
presence or absence of necessary additional signals, for example IL-7 which enhances IL-17A 
production (Tang et al., 2013). Arguing against this, however, another study (Bennett et al., 
2017) reported significant detection of IL-2, IL-6, IL-10, IL-17A/F, IL-21, and IL-22 in the 
culture supernatant following overnight stimulation with E. coli using the same co-culture 
system as ours. In that study, TCR signaling was only partially responsible for the production 
of IL-6, IL-10, and IL-21. This may be due to the different times post-stimulation at which 
cytokine production was assessed. Of note, the major pro-inflammatory mediators TNFα, IL-6, 
and IL-1β are highly expressed at both mRNA and protein levels with E. coli but not with 5-A-
RU or IL-12+IL-18 stimulation, suggesting that TCR activation by riboflavin synthesizing 
bacteria is required for some pro-inflammatory responses by MAIT cells. 
A striking difference was observed in the cytotoxic granule content of MAIT cells with the two 
modes of activation. Perforin, granzyme A, and granzyme B were all substantially induced by 




decrease in granzyme A. By 24 hours, activation by E. coli triggered substantial granzyme B 
and perforin production which was partially TCR-dependent and partially -independent. 
Activation with the 5-A-RU for 24 hours induced significantly more granzyme B and perforin 
compared to activation for 6 hours; this suggests that changes in the cytotoxic granule content 
of MAIT cells is a time dependent process and for a strong response, either prolonged activation 
via the TCR, cytokines, or a combination of both is required. We and others have demonstrated 
granzyme A downregulation in MAIT cells with TCR signals which was an intriguing finding 
and demands further investigation (Kurioka et al., 2015). Conversely, granzyme A upregulation 
with cytokines could be of importance in the control of viral and bacterial infections as unlike 
granzyme B, granzyme A can potently mediate cytolysis in the presence of caspase inhibitors 
(Zhang et al., 2001, Blasche et al., 2013) or alternatively, may aid in the inflammatory response 
as discussed previously (Kurioka et al., 2015). Additionally, both modes of activation result in 
the upregulation of FasL on the surface of MAIT cells; FasL is involved in death receptor-
mediated killing of infected cells (Varanasi et al., 2014).  
MAIT cells may also exercise direct killing of extracellular bacteria through the release of 
antibacterial peptides such as IL-26 (Meller et al., 2015) and antimicrobial chemokines such as 
CXCL9 and CXCL10 (Margulieux et al., 2016, Reid-Yu et al., 2015). This makes MAIT cells 
one of many cell populations contributing to the pool of antimicrobial peptides at the site of 
infection/inflammation. Indirectly, MAIT cells can assist in bacterial killing by recruiting 
neutrophils to the site of infection, as suggested in our study, and by augmenting neutrophil 
survival via release of TNFα, IFNγ, and GM-CSF (Davey et al., 2014). In a positive feedback 
mechanism, MAIT cells could also promote DCs to produce type I interferons in an IL-26 
dependent manner, which augments IFNγ release by MAIT cells in response to other cytokines 
(Meller et al., 2015, van Wilgenburg et al., 2016). IFNγ production in MAIT cells was recently 
shown to be critical for protection against Legionella longbeachae and influenza virus infection 
in mice (Wang et al., 2018, Wilgenburg et al., 2018). 
Transcription factor profiling in activated MAIT cells was consistent with the observed acquired 
effector functions in previous studies on MAIT cells. Elevated RORγt expression was seen with 
TCR activation and is consistent with increased IL-17A expression (Wang et al., 2018).  Both 
TCR and cytokine activation resulted in increased expression of T-bet, which is consistent with 
the substantial IFNγ production. Increased Blimp1 expression with E. coli and cytokines was 
consistent with more granzyme B production than with 5-A-RU, whereas reduced EOMES 




response of early TCR activated MAIT cells compared to IL-12+IL-18 activation (Kurioka et 
al., 2017, Kurioka et al., 2015). Transcription factor profiles were also assessed in other MAIT 
cell populations. At rest, CD4-CD8- double negative (DN) MAIT cells expressed a similar 
transcription factor profile as CD8+ MAIT cells, consistent with the recent report where DN 
MAIT cells were shown to be functionally similar to CD8+ MAIT cells (Kurioka et al., 2017). 
On the other hand, CD4+ MAIT cells (<5% of the MAIT cell population) expressed lower levels 
of PLZF and EOMES, consistent with Kurioka et al, who demonstrated that they also possess 
lower cytotoxic potential than CD8+ and DN MAIT cells (Kurioka et al., 2017). Although not 
all changes reached statistical significance, the trends in changes of transcription factor 
expression upon activation were similar in all subsets, suggesting that all MAIT cells undergo 
similar functional changes during activation, although this was not formally assessed in this 
study. 
KDM6B is one of the two histone demethylases (the other being KDM6A or UTX) that removes 
the methyl mark from H3K27, relieving the suppression of transcription and inducing an 
inflammatory response (Falvo et al., 2013). Murine studies have confirmed demethylated 
H3K27 is heavily enriched at IL17A/IL17F locus in Th17 cells and also controls RORC 
expression (Mukasa et al., 2010). Our data suggest that upon TCR stimulation, MAIT cells 
significantly upregulate KDM6B (>13 and >10-fold change with E. coli and 5-A-RU 
respectively), which could lead to the subsequent upregulation of RORC and IL17A expression. 
We also demonstrated that H3K27me3 is an important epigenetic modification during 
activation of MAIT cells. Conversely, IL-12 treatment of Th17 cells was previously reported to 
lead to a substantial increase in H3K27me3 at the IL17A/IL17F locus and H3K4me 
accumulation at the IFNG locus, leading to reduction of IL-17 and increased IFNγ production, 
consistent with our data (Mukasa et al., 2010). Thus, the mode of activation modulates the fate 
of MAIT cells by epigenetic remodeling. 
We found that MAIT cells produce multiple chemokines upon activation which may aid in 
recruiting various immune subsets to the site of infection and promoting local inflammation. 
TCR signals induced stronger production of chemokines by MAIT cells. Previous studies have 
also reported substantial chemokine production by MAIT cells upon TCR activation via 
CD3/CD28 (Turtle et al., 2011, Slichter et al., 2016) or in a co-culture with bacteria-fed 
monocytes (Lepore et al., 2014, Wakao et al., 2013). However, these studies were performed 
with longer activation periods (16-24 hours or overnight). Here, we confirmed that MAIT cells 




that IL-12+IL-18 alone can stimulate modest chemokine production, particularly CCL3, CCL4, 
and CXCL10. These chemokines are involved in lymphocyte trafficking, and therefore could 
contribute to recruiting lymphocytes during infections with viruses or non-riboflavin-
synthesizing bacteria. Moreover, a combination of cytokines and TCR signal, can work in 
synergy to trigger robust chemokine production by MAIT cells (Havenith et al., 2012). 
In addition to this direct chemokine response, soluble mediators in the supernatant from 
stimulated MAIT cells have been shown to trigger the production of various chemokines, such 
as CCL2, IL-8, and CXCL10, by peritoneal epithelial and fibroblast cells (Liuzzi et al., 2016). 
MAIT cells and γδ T cells were shown to migrate to infected peritoneal tissues in response to 
locally elevated levels of CCL2, CCL3, CCL4, and CCL20 (Liuzzi et al., 2016). High 
production of CCL3, CCL4, and CCL20, along with moderate production of CXCL9 and 
CXCL10 by both TCR and cytokine stimulated MAIT cells were observed in our study; 
combined with high expression of CCR5, CCR6, and CXCR3 on MAIT cells (Dias et al., 2017, 
Kurioka et al., 2017), this suggests that MAIT cells, both in the presence of riboflavin-
synthesizing bacteria and other inflammatory stimuli, may directly recruit other MAIT cells 
and/or γδ T cells (Figure 2.9). Furthermore, significant production and release of TNFα and IL-
1β observed with bacterial stimulation can further facilitate this process by upregulating E-
selectins, I-CAM, and V-CAM on endothelial cells (Kim et al., 2017). Therefore, activated 
tissue resident MAIT cells could recruit peripheral MAIT cells, along with other 
proinflammatory leukocytes, to the site of infection. This hypothesis has been previously 
discussed by Tang et al. to highlight a possible role of MAIT cells in recruiting classical 
inflammatory CD4+ Th17 cells in liver via initial rapid production of IL-17A; IL-17A is an 
important cytokine for triggering CCL20 production by mucosal cells (e. g. gut mucosa) leading 
to the recruitment of inflammatory CCR6+ Th17 cells (Tang et al., 2013, Esplugues et al., 2011).  
Recent studies have demonstrated that MAIT cells do not just provide defense against invading 
pathogens but may have a broader role in the regulation of the immune response through the 
maturation of primary DCs and providing B cell help (Bennett et al., 2017, Salio et al., 2017). 
Both TCR and innate signals were found to upregulate helper molecules on MAIT cells. 
Additionally, MAIT cells were recently shown to induce local tissue remodeling (Liuzzi et al., 
2016). Here, we observed specific upregulation of genes associated with tissue repair and 
wound healing which was recently described to be a feature of commensal responsive skin 
resident CD8+ populations in non-human primates and mice (Linehan et al., 2018). This 




consistent with those of Leng et al., who demonstrated a similar enrichment of genes involved 
in tissue repair functions in TCR and TCR+cytokine but not cytokine triggered peripheral 
human MAIT cells (Leng et al., 2019), and Hinks et al., who reported enrichment of the tissue 
repair pathway in 5-OP-RU-stimulated human MAIT cells and MAIT cells from mice acutely 
infected with L. longbeachae (Hinks et al., 2019). Together, this confirms that the tissue repair 
function is a signature of TCR activated MAIT cells (Salou and Lantz, 2019). Therefore, it is 
now becoming clear that MAIT cells are not just inflammatory and cytolytic T cells but are also 
helper cells involved in tissue repair and maintaining homeostasis at the mucosal barrier and in 
the liver. Congruently, an essential role of bacterial exposure in early life to maintain MAIT 
cell abundance in the mucosa and bacteria (with riboflavin pathway) dependent tissue repair 
function of MAIT cells during skin wound healing were recently demonstrated in vivo 
(Constantinides et al., 2019).  
In this paper, we explored the response of TCR- and cytokine-stimulated MAIT cells from 
peripheral blood. Future investigations will shed light on whether effector function profiles of 
MAIT cells from different tissues also differ with the mode of activation and will enable us to 
understand the role of MAIT cells as a friend, foe, or merely a bystander in disease progression. 
The limited number of cytokines assessed in the time course studies gave us a snapshot of the 
timing of MAIT cell activation; other effector functions induced by a pure TCR signal should 
be assessed by a detailed transcriptomic analysis at later timepoints to better define the induction 
and persistence of particular effector functions following TCR stimulation.  
In summary, our findings show that TCR and cytokines are both potent modes of triggering 
MAIT cell activation. MAIT cells activated via IL-12+IL-18 upregulate T-bet, perforin, 
granzyme B, and IFNγ and are less pro-inflammatory, consistent with a Tc1 like phenotype, 
while TCR-activated MAIT cells robustly and rapidly upregulate RORγt, IL-17A, TNFα, and 
many other pro-inflammatory cytokines and chemokines, consistent with a Tc17 phenotype 
(Figure 2.9A). This plasticity in MAIT cell phenotype and function with the mode of activation 
is explained by changes at transcriptomic and epigenetic levels. During bacterial infection, both 
modes of activation cooperate to make MAIT cells potent early responders, combining direct 
antimicrobial activity with the recruitment of and provision of help to other proinflammatory 





Figure 2.9. Summary of differences in TCR-and cytokine-stimulated MAIT cells. (A) and role of MAIT cells 











Table S2.2. Enriched innate signaling pathways in MAIT cells treated with E. coli and IL-
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Chapter 3: Functional and 
transcriptional comparison of blood 





Mucosal associated T (MAIT) cells are anti-microbial innate like T cells that are abundant in 
blood and liver. MAIT cells express a semi invariant T cell receptor (TCR) that recognises a 
pyrimidine ligand, derived from microbial riboflavin synthesis, bound to MR1, an MHC class 
IB molecule. Both blood and liver derived MAIT cells can be robustly stimulated via either 
their TCR or by cytokines produced during bacterial or viral infection. However, it is yet to be 
defined how the effector functions of liver derived (ld)-MAIT cells differ in response to these 
different modes of activation. In this study, we compared the functional and transcriptomic 
response of human blood and ld-MAIT cells to TCR signals (E. coli or the pyrimidine ligand) 
and cytokines (IL-12+IL-18). While the response of blood and ld-MAIT cells to TCR signals 
were comparable, following cytokine stimulation ld-MAIT cells were more polyfunctional and 
produced more cytokines and cytotoxic molecules than blood MAIT cells. Transcriptomic 
analysis demonstrated different effector programmes of ld-MAIT cells with the two modes of 
activation, including the enrichment a tissue repair signature in TCR-stimulated MAIT cells. 
Interestingly, we observed no significant difference in the circulatory and tissue residency 
signature between blood and ld-MAIT cells. Additionally, MAIT cells from blood and liver 
were grouped together based on the treatment, but not the tissue origin, in our combined 
transcriptomic analysis. Therefore, we report that blood and ld-MAIT cells are fundamentally 





Mucosal associated invariant T (MAIT) cells are innate-like antibacterial T cells that in humans 
are abundant in the liver and in mucosal tissues. In contrast to conventional T cells which are 
activated by peptide epitopes bound to MHC I or II molecules on antigen presenting cells 
(APCs), mucosal associated invariant T (MAIT) cells are activated by pyrimidine ligands bound 
to MR1, a non-polymorphic MHC class Ib molecule (Treiner et al., 2003, Huang et al., 2005). 
The pyrimidine ligands, 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) and 5-
(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU), are derived from 5-amino-6-D-
ribitylaminouracil (5-A-RU), an intermediate metabolite of microbial riboflavin biosynthesis 
pathway, by condensation with methyglyoxal and glyoxal respectively (Walker et al., 2012, 
Corbett et al., 2014). MAIT cells express a semi-invariant T cell receptor (TCR) which consists 
of Vα7.2 mostly in combination with Jα33, Jα12, or Jα20, and a variety of beta chain, with 
diverse Vβ usage (Gherardin et al., 2018, Gold et al., 2014, Treiner et al., 2003). Additionally, 
MAIT cells are activated by proinflammatory cytokines, mainly IL-12 and IL-18, produced 
during bacterial and viral infections (Chua et al., 2012, Loh et al., 2016, Ussher et al., 2014, van 
Wilgenburg et al., 2016). 
The liver is a major site of immune surveillance against microbes crossing the gut barrier, 
enabling close contact between lymphocytes and the endothelial cells lining the sinusoids, as 
well as various antigen presenting cells (APCs); approximately 80% of the reticuloendothelial 
system is present in the liver (Racanelli and Rehermann, 2006). In addition to parenchymal 
hepatocytes (which comprise two thirds of cells in the liver), the liver contains many non-
parenchymal cells such as Kupffer cells, biliary and sinusoidal epithelial cells, stellate cells, and 
intrahepatic lymphocytes, including MAIT cells (Dusseaux et al., 2011, Racanelli and 
Rehermann, 2006). MAIT cells are highly enriched in liver compared to any other human 
tissues, comprising on average 15% of total CD3+ T cells in the liver (Dusseaux et al., 2011, 
Jo et al., 2014, Tang et al., 2013). In the liver, MAIT cells preferentially reside in peri-biliary 
areas of portal tracts close to bile ducts (Bottcher et al., 2018, Jeffery et al., 2016). Like their 
peripheral blood counterparts, liver-derived (ld-) MAIT cells can be activated via both their 
TCR and by cytokines (Bolte et al., 2017, Dias et al., 2019, Jeffery et al., 2016). Activation of 
MAIT cells, including ld-MAIT cells, leads to the production of pro-inflammatory cytokines, 
such as tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ), as well as cytotoxic 




of effector functions of liver derived MAIT cells in response to TCR or cytokine signals remains 
yet to be fully defined.  
Given the enrichment of MAIT cells in the liver and the presence of APCs, including Kupffer 
cells and biliary epithelial cells, capable of presenting pyrimidine ligands on MR1 (Jeffery et 
al., 2016, Li et al., 2018), MAIT cells may have an important role in regulating liver 
pathophysiology. Recently, we and others showed that human circulating MAIT cells express 
distinct transcriptional and functional profiles when activated by TCR signals or cytokines 
(Hinks et al., 2019, Lamichhane et al., 2019b, Leng et al., 2019). However, it is unknown 
whether the responses of ld-MAIT cells are comparable to those of circulating MAIT cells. 
Therefore, we compared the transcriptional response and effector functions of blood and ld-
MAIT cells in response to stimulation via the TCR (E. coli or 5-A-RU/MG) or with cytokines 
(IL-12+IL-18). 
3.2 Materials and Methods 
3.2.1 Blood and liver mononuclear cells isolation  
Patients undergoing liver resection for cancer metastasis at Dunedin Hospital were recruited. 
Collection of blood from healthy donors was approved by the University of Otago Human 
Ethics Committee (H14/046) and collection of liver from patients undergoing hepatic resection 
was approved by the New Zealand Health and Disability Ethics Committee (16/STH/83). 
Written informed consent was obtained from each donor. A piece of normal liver tissue as far 
away from the tumour as possible (usually >10 mm) was excised fresh from the main surgical 
specimen. Mononuclear cells were isolated from liver as previously described (Lamichhane et 
al., 2019a). Peripheral blood mononuclear cells (PBMCs) were isolated from blood (taken on 
the same day before liver resection) by Lymphoprep density gradient centrifugation, as 
previously described (Lamichhane et al., 2019b). Isolated cells were rested overnight in RPMI 
1640 pre-supplemented with L-glutamine (Life Technologies Corporation, NY, USA) with 10 
% fetal calf serum (Gibco, New Zealand) and Penicillin-Streptomycin (Sigma-Aldrich) (now 
onwards referred as R10) and stimulated the next day. 
3.2.2 Preparation of bacterial stocks and 5-A-RU/MG 
An overnight culture of Escherichia coli HB101 in Luria-Bertani (LB) broth was washed with 
Phosphate Buffered Saline (PBS) (Oxoid, England), then fixed with 2% paraformaldehyde for 




eBeads (Invitrogen, Carlsbad, USA) using a FACSCanto II (BD biosciences, San Jose, CA, 
USA). 
5-amino-6-D-ribitylaminouracil (5-A-RU) was synthesized as previously described 
(Lamichhane et al., 2019b).  Immediately prior to use, 5-A-RU was mixed with methylglyoxal 
(MG) (Sigma) at a molar ratio of 1:50 (referred to as 5-A-RU/MG) and diluted with milliQ 
water to the desired concentration. 
3.2.3 In vitro activation of MAIT cells from liver and blood 
LDMCs or PBMCs were treated with fixed E. coli (25 bacteria per cell (BpC)) or 5-A-RU/MG 
(100 nM) for 6 hours to stimulate MAIT cells via their TCR, or the combination of 50 ng/mL 
IL-12 (Miltenyi Biotec, Bergisch Gladbach, Germany) and 50 ng/mL IL-18 (R & D Systems, 
Minneapolis, USA) for 24 hours to activate MAIT cells by cytokines alone. Brefeldin A (10 
µg/mL) (BioLegend, San Diego, USA) was added for the final four hours of activation in all 
experiments where intracellular production of effector molecules (TNFα, IFNγ, granzyme A, 
granzyme B and perforin) was measured. Anti-CD107a PE antibody was added at the start of 
the experiment to capture trafficking of CD107a to the surface. 
3.2.4 Antibodies and flow cytometry 
Antibodies used were anti-CD3 PE-Cy7 (UCHT1, BioLegend) or BV510 (OKT3, BioLegend), 
anti-CD8 eFluor450 (RPA-T8, eBioscience), anti-TCR Vα7.2 PE or PE-Cy7 or AF700 (3C10, 
BioLegend), anti-CD161 APC (191B8, Miltenyi Biotech) or BV605 (HP-3G10, BioLegend), 
anti-TNFα FITC (Mab11, BioLegend), anti-IFNγ PerCP-Cy5.5 (4S.B, BioLegend), anti-
CD107a PE (H4A3, BioLegend), anti-granzyme A PE (CB9, BioLegend), anti-granzyme B 
FITC (QA16AO2, BioLegend), anti-perforin PerCP-Cy5.5 (B-D48, BioLegend), anti-CD40L 
FITC (24-31, BioLegend), CD69 FITC (FN50, BioLegend), anti-4-1BB PE (4B4-1, 
BioLegend), anti-RORγt PE (Q21-559, BD Biosciences, San Jose, CA, USA), anti-PLZF 
AF647 (R17-809, BD Biosciences), anti-T-bet PECy7 (4B10, BioLegend), anti-EOMES 
eFluor660 (WD1928, eBiosciences), and anti-Blimp1 PE-CF594 (6D3, BD Biosciences).  
All samples were stained with live/dead fixable near IR (Invitrogen) to exclude dead cells and 
acquired on a BD FACSCantoII, a BD LSRFortessa, or, for sorting, a BD FACSAriaII (all BD 
Biosciences). Flow cytometric analysis was performed in FlowJoTM V10 (TreeStar, Ashland, 
OR, USA). Ld-MAITs activated by E. coli, 5-A-RU/MG, or by IL-12+IL-18, or unstimulated 




3.2.5 Real time RT-PCR 
RNA was isolated from the sorted cells using Nucleospin RNA isolation kit (Macherey-Nagel, 
Düren, Germany) following the manufacturer’s protocol and first strand cDNA was synthesized 
using the Superscript IV (SSIV) system (Invitrogen). Briefly, Oligo-d(T)20 primers were 
annealed to template RNA at 65 °C for 5 mins followed by 1 min incubation on ice and mixed 
with reverse transcription (RT) mix (SSIV reverse transcriptase, SSIV buffer, DTT, 
ribonuclease inhibitor). This was followed by incubation at 55 °C for 10 mins and 80 °C for 10 
mins, before the addition of RNase H and incubation at 37 °C for 20 mins. To assess the 
expression of the MAIT cell TCR (Vα7.2-Jα33/12/20) and β2-microglobulin, KAPA PROBE 
FAST mastermix (KAPA Biosystems) was used. To assess the expression of cytokines (TNFα, 
IFNγ, IL-17A and IL-22) and GAPDH, KAPA SYBR FAST mastermix (KAPA Biosystems) 
was used. Primers used for MAIT cell TCR assessment were from Kurika et al. (Kurioka et al., 
2017) and Lamichhane et al. (Lamichhane et al., 2019b). Real time RT-PCR was performed on 
a Viia7 or QS6 Real-Time system (Applied Biosystems, Foster City, USA) with a PCR program 
of 95 °C for 3 mins followed by 40 cycles of 95 °C for 3 secs  and 60 °C (MAIT cell TCR and 
β2-microglobulin assays) or 61°C (cytokines and GAPDH assays)   for 20 secs; for the 
assessment of cytokine gene expression and GAPDH melt-curve analysis was performed to 
confirm the specificity of the product. Relative expression of MAIT cell TCR and β2-
microglobulin or cytokines and GAPDH were measured by the comparative CT method (2∆Ct). 
3.2.6 RNA Sequencing of MAIT cells and data analysis 
LDMCs were treated with E. coli (25 BpC) or 5-A-RU/MG (100 nM) for 6 hours or IL-12+IL-
18 (50ng/mL each) for 24 hours and MAIT cells (CD3+CD161++Vα7.2+ lymphocytes) from 
treated and untreated LDMCs were flow-sorted by BD FACSAria. RNA was isolated as 
described above, stored at -80 °C. This was performed on different days for each donor (n=4). 
RNA Sequencing was performed as described previously (Lamichhane et al., 2019b). Briefly, 
libraries were prepared with the Ion AmpliSeq™ Transcriptome Human Gene Expression Kit 
and were sequenced on an Ion S5 system. R-Bioconductor DESeq2 package was used for 
downstream analysis to obtain differentially expressed genes (DEG) from raw gene counts; log2 
fold change and adjusted p-value (Padj) were set at 1 (fold change 2) and 0.05 respectively as 
cut-offs. Strict filtering of lowly expressed genes was performed by setting an arbitrary cut-off 
for mean gene count from four donors of > 5, provided the count was > 10 in one donor. DEGs 
were used to generate Venn-diagram in an online tool 




performed using normalized gene expression of all genes. Heatmapper 
(http://www.heatmapper.ca/expression/), employing the average linkage clustering and 
Spearman rank correlation distance measurement methods, was used to make heat-maps 
(Babicki et al., 2016). Gene Set Enrichment Analysis (GSEA) was performed using normalized 
gene counts versus either a curated database (Reactome) provided in the software or tissue 
repair gene list obtained from the publication by Linehan et al. (Linehan et al., 2018).  
For transcriptomic comparison of MAIT cells from blood and liver, raw read counts of ld- 
(CD3+) and blood (CD8+) MAIT cells were merged and analyzed in DESeq2, assuming the 
treatments were comparable. For RNA-sequencing of blood, PBMCs were treated with E. coli 
(10 BpC) or 5-A-RU (5 µM) for 6 hours or IL-12+IL-18 (50ng/mL each) for 24 hours and 
MAIT cells were flow-sorted as CD3+ CD8+CD161++Vα7.2+ lymphocytes by BD FACSAria 
(Lamichhane et al., 2019b). Combined heat-map was generated by Heatmapper online tool and 
GSEA analysis was performed between non-activated blood and ld-MAIT cells against the 
circulatory and tissue-residency gene list obtained from the publication by Milner et al. (Milner 
et al., 2017). 
3.2.7 Statistical analysis 
GraphPad Prism V7.03 was used for statistical analysis. To test statistical significance, repeated 
measures one-way or two-way ANOVA with Sidak’s multiple comparison post hoc test was 
used for multiple comparisons and paired two tailed t-tests were performed for comparison 
between two groups. P < 0.05 was considered significant. Data are presented as mean ± standard 
error of mean (SEM). 
3.3 Results 
3.3.1 MAIT cell are enriched in liver 
First, we compared the frequency of MAIT cells in patient matched blood and liver; MAIT cells 
were identified as CD3+ T cells expressing the semi-invariant Vα7.2 TCR and CD161 
(Dusseaux et al., 2011, Martin et al., 2009). As previously reported (Dusseaux et al., 2011, Tang 
et al., 2013), MAIT cells were abundant in liver, accounting for 10.5% of total T cells and 
16.5% of CD8+ T cells in liver in comparison to 1.2% and 3.5% of respective cell types in blood 
(Figure 3.1A). Consistent with previous reports (Kurioka et al., 2017, Jeffery et al., 2016), 






Figure 3.1. MAIT cells are enriched in liver and can be robustly activated via both TCR-dependent and -
independent mechanisms. (A) Representative flow cytometry gating for distinguishing MAIT cells 
(CD3+CD161++Vα7.2 TCR+ lymphocytes) from other blood and liver mononuclear cells. Cumulative data 




cytometry plot and cumulative frequency of CD8+, CD8-CD4- and CD4+ MAIT cell subsets of total MAIT cells 
(CD3+CD161++Vα7.2 TCR+) in blood and liver. (C-F) Expression of (C and D) CD69 and (E and F) 4-1BB on 
blood and liver derived MAIT cells following (C and E) TCR activation by formaldehyde-fixed E. coli (25 BpC) 
or 5-A-RU/MG (100 nM) for 6 hours or (D and F) cytokine stimulation with 50 ng/mL IL-12 + 50 ng/mL IL-18 
for 24 hours; mononuclear cells from blood and liver were used. Data are presented as mean ± SEM and are pooled 
from independent experiments (n=13 for A, n=4 for B, n=7 for C-F). Repeated measures one-way ANOVA with 
Sidak multiple comparison tests (C and E) and two tailed paired t-tests (D and F) were used for assessing statistical 
significance. *p<0.05, **p<0.01, ***p<0.001. The p value is shown for non-significant comparisons. MFI = mean 
fluorescent intensity. Numbers on flow cytometry plots indicate frequency of parent. 
 
3.3.2 Similar activation marker expression and cytokine production by TCR-
stimulated blood and ld-MAIT cells, while ld-MAIT cells are more responsive to 
IL-12+IL-18   
To test whether ld-MAIT cells can be robustly stimulated by TCR and cytokines in vitro, we 
treated mononuclear cells from patient-matched blood and liver with E. coli or 5-A-RU/MG for 
6 hours or a combination of IL-12 and IL-18 for 24 hours. Ld-MAIT cells, compared to their 
blood counterparts, expressed significantly more CD69 (a T cell activation marker) on their 
surface at rest (Figure 3.1C) which is in line with a previous study (Tang et al., 2013). MAIT 
cells isolated from both blood and liver increased CD69 expression on their surface following 
activation via their TCR (E. coli or 5-A-RU/MG); higher CD69 expression was observed with 
E. coli than with 5-A-RU/MG (Figure 3.1C). Stimulation with IL-12+IL-18 also enhanced 
CD69 expression on blood and ld-MAIT cells, however, the level of expression was 
significantly greater on ld-MAIT cells (Figure 3.1D). Expression of 4-1BB (a T cell activation 
marker, established for MAIT cells in Chapter 2), which was absent on the surface of untreated 
blood and ld-MAITs, was significantly upregulated upon activation by TCR signals (Figure 
3.1E). Cytokine treatment also caused 4-1BB expression on blood and ld-MAIT cells, however, 
significantly more ld-MAITs expressed 4-1BB compared to blood MAIT cells following IL-
12+IL-18 activation (Figure 3.1F). Both TCR and cytokine stimulation resulted in a similar 





Figure S3.1. Expression of CD40L on liver derived MAIT cells following stimulation. Expression of CD40L 
on blood and liver derived MAIT cells following TCR activation by formaldehyde-fixed E. coli (25 BpC) or 5-A-
RU/MG (100 nM) for 6 hours or cytokine stimulation with 50 ng/mL IL-12 + 50 ng/mL IL-18 for 24 hours; 
mononuclear cells from blood and liver were used. Data are presented as mean ± SEM and are pooled from 
independent experiments (n=4). Repeated measures one-way ANOVA with Sidak multiple comparison test was 
used to assess statistical significance. *p<0.05. 
 
Next, we compared the ability of blood and ld-MAIT cells to produce cytokines following TCR 
and cytokine triggering. Similar to the equivalent upregulation of CD69 and 4-1BB expression 
following activation of blood and ld-MAIT cells by E. coli or 5-A-RU/MG (Figure 3.1C and 
E), the percentage of blood and ld-MAIT cells producing TNFα or IFNγ were also comparable 
(Figure 3.2A and C). Greater production of TNFα and IFNγ was observed in response to 5-A-
RU/MG than to E. coli. For both blood and ld-MAIT cells, stimulation with either E. coli or 5-
A-RU/MG resulted in mostly TNFα mono-producers and TNFα-IFNγ double producers, with 
very few IFNγ mono-producers (Figure 3.2E). In contrast, blood MAIT cells activated with IL-
12+IL-18 produced only IFNγ, while a significant minority of ld-MAIT cells produced both 
TNFα and IFNγ (Figure 3.2B, D, and E). Following IL-12+IL-18 treatment, more ld-MAIT 
cells produced cytokines than blood MAIT cells. Therefore, ld-MAIT cells are more responsive 
to cytokine stimulation than their blood counterparts, with a polyfunctional response. 
Expression of cytokine genes was also assessed in TCR or IL-12+IL-18-stimulated ld-MAIT 
cells. Consistent with the changes seen by flow cytometry, higher expression of TNF was seen 
with early TCR activation, while more IFNG expression was seen with IL-12+IL-18 stimulation 
(Figure S3.2A and B). Increased IL17A and IL22 expression was observed following TCR 




activation (Figure S3.2C and D). Taken together, TCR activation leads to expression of both 
T1 and T17 cytokines by ld-MAIT cells, while the response to IL-12+IL18 is more T1-focussed. 
 
Figure 3.2. Liver derived MAIT cells produce more pro-inflammatory cytokines in response to IL12+IL-18. 
Production of (A and B) TNFα and (C and D) IFNγ by blood and liver derived MAIT cells following (A and C) 
TCR activation by formaldehyde-fixed E. coli (25 BpC) or 5-A-RU/MG (100 nM) for 6 hours or (B and D) 




were used. (E) Representative flow cytometry flow plots and cumulative pie charts showing the proportion of 
MAIT cells producing TNFα only, IFNγ only, or both TNFα and IFNγ following TCR and cytokine stimulation, 
as in A-D. Data are presented as mean ± SEM (A-D) or average (E) and are pooled from independent experiments 
(n=6 for liver and n=5 for blood). Repeated measures one-way ANOVA with Sidak multiple comparison test (A-
D) were used for assessing statistical significance. *p<0.05, **p<0.01, ****p<0.0001. The p value is shown for 
non-significant comparisons. MFI = mean fluorescent intensity. Numbers on flow cytometry plots indicate 
frequency of parent. 
 
 
Figure S3.2. Expression of cytokine genes by liver derived MAIT cells differs with the mode of activation.  
(A-D) Liver derived mononuclear cells were treated with formaldehyde-fixed E. coli (25 BpC) or 5-A-RU/MG 
(100 nM) for 6 hours or cytokine stimulation with 50 ng/mL IL-12 + 50 ng/mL IL-18 for 24 hours and MAIT cells 
were flow sorted. Expression of (A) TNF, (B) IFNG, (C) IL17A, and (D) IL22 by activated and non-activated 
MAIT cells was assessed by real-time RT-PCR. Data are presented as mean ± SEM and are pooled from 
independent experiments (n=4). 
 
3.3.3 Similar changes in cytotoxic molecule expression in blood and ld-MAIT 
cells upon activation 
Following activation, MAIT cells degranulate and modify their expression of cytotoxic 




the expression of cytotoxic molecules (granzymes A, granzyme B, and perforin) by blood and 
ld-MAIT cells and the proportion of cells undergoing degranulation (CD107a) following 
activation with  E. coli, 5-A-RU/MG, or IL-12+IL-18. In both blood and ld-MAIT cells,  
stimulation with E. coli or 5-A-RU/MG resulted in increased granzyme B expression but 
reduced granzyme A expression; the extent of modulation of granzyme A was greater with 5-
A-RU/MG than with E. coli (Figure 3.3A, B, D, and E).  In both blood and ld-MAIT cells, IL-
12+IL-18 stimulation significantly increased granzyme B production but did not reduce 
granzyme A expression (Figure 3.3A, C, D, and F). A reduction in the proportion of blood and 
ld-MAIT cells expressing perforin was seen following stimulation with 5-A-RU/MG but not E. 
coli (Figure 3.3G and H). In contrast, stimulation with IL-12+IL-18 increased the proportion of 
both blood and ld-MAIT cells producing perforin (Figure 3.3G and I). Of note, a greater 
proportion of ld-MAIT cells produced granzyme B and perforin with IL-12+IL-18 stimulation 
compared to blood MAIT cells, although it did not reach significance (Figure 3.3F and I). 
Equivalent CD107a expression was seen on blood and ld-MAIT cells following TCR or 
cytokine stimulation, suggesting similar levels of degranulation (Figure 3.3J-L). In summary, 
blood and ld-MAIT cells rapidly degranulate and express comparable cytotoxic granule 





Figure 3.3. Changes in cytotoxic protein content of blood and liver derived MAIT cells following TCR or 
cytokine stimulation. Expression of (A-C) granzyme A, (D-F) granzyme B, (G-I) perforin, and (J-L) CD107a on 
blood and liver derived MAIT cells following (B, E, H, and K) TCR activation by formaldehyde-fixed E. coli (25 
BpC) or 5-A-RU/MG (100 nM) for 6 hours or (C, F, I, and L) cytokine stimulation with 50 ng/mL IL-12 + 50 
ng/mL IL-18 for 24 hours; mononuclear cells from blood and liver were used. Representative flow cytometry flow 
plots for ld-MAIT cells are shown (A, D, G, and J). Data are presented as mean ± SEM and are pooled from 




one-way ANOVA with Sidak multiple comparison test (B, E, H, and K) and two tailed paired t-tests (C, F, I ,and 
L) were used for assessing statistical significance. *p<0.05, **p<0.01, ***p<0.001. The p value is shown for non-
significant comparisons. MFI = mean fluorescent intensity.  
 
3.3.4 TCR and cytokine stimulated ld-MAIT cells have distinct transcriptional 
profile 
To further characterize the effect of TCR or cytokine stimulation on ld-MAIT cells, we 
generated transcriptomic profiles of ld-MAIT cells following stimulation with either E. coli, 5-
A-RU/MG, or IL-12+IL-18. Differentially expressed genes (DEGs) were determined by 
comparison with untreated ld-MAIT cells, with fold change >2 and adjusted p-value <0.05 used 
as cut-offs. More DEGs were obtained following TCR triggering (907 for E. coli and 561 for 
5-A-RU/MG) than with cytokines (262) (Figure 3.4A). Interestingly, 71 of 80 (89%) DEGs 
shared among all three treatments were upregulated (Figure 3.4A). IL-12+IL-18 stimulated ld-
MAIT cells shared more DEGs with E. coli stimulated ld-MAIT cells than 5-A-RU/MG 
stimulated ld-MAIT cells. The differences in TCR and cytokine stimulation of ld-MAIT cells 
were also evident by principal component analysis; E. coli and 5-A-RU/MG stimulated ld-
MAIT cells formed overlapping clusters away from the untreated and IL-12+IL-18 activated 
ld-MAIT cells; principle component 1 and principle component 2 accounted for 60% of the 
total variability (Figure 3.4B). The differences in response to different stimuli were also evident 
in the heat-map of the normalized expressions of total DEGs (1193) with all three treatments 
(Figure 3.4C). Taken together, TCR and cytokine stimulated ld-MAIT cells express distinct 
transcriptomic profiles. 
Next, we compared the expression of genes encoding effector molecules (cytokines, 
chemokines and cytotoxic molecules) by ld-MAIT cells following activation (Figure S3.3). Ld-
MAIT cells activated by 5-A-RU/MG or E. coli highly expressed TNF, IL17A, and IL22, 
consistent with our previous observations (Figure 3.2 and Figure S3.2). Increased expression of 
multiple other cytokines (including CSF2, IL17F, and IL2) and chemokines (including CCL3, 
CCL4, CCL3L3, and CCL20) was also observed following stimulation with E. coli or 5-A-
RU/MG, confirming that TCR stimulation leads to a strong inflammatory response by ld-MAIT 
cells (Figure S3.3). IFNG, CSF1, GZMA, IL32, and IL26 were markedly upregulated by IL-
12+IL-18 triggering. Expression of IL10 was restricted to E. coli and IL-12+IL-18 stimulation. 





Transcription of chemokine receptors also changed following activation: while CCR2 and 
CCR6 expression were reduced in TCR and cytokine activated ld-MAIT cells, expression of 
CXCR6 was increased with IL-12+IL-18 but reduced following TCR stimulation by both E. coli 
and 5-A-RU/MG (Figure S3.3).  
 
Figure 3.4. TCR and cytokine-activated liver derived MAIT cells have distinct transcriptional profiles. Liver 
derived mononuclear cells were treated with 25 BpC E. coli or 100 nM 5-A-RU/MG for 6 hours or 50 ng/mL IL-
12 + 50 ng/mL IL-18 for 24 hours; untreated liver derived mononuclear cells were used as control. Activated and 
non-activated MAIT cells were flow-sorted and RNA sequencing was performed. (A) Venn-diagram of common 
and unique differentially expressed genes (DEGs) in E. coli, 5-A-RU/MG, or IL-12+IL-18 stimulated ld-MAIT 
cells obtained using fold change >2 and Padj <0.05 cut-offs; separate Venn-diagrams of total (left), upregulated 
(middle) and downregulated (right) DEGs with each treatment are shown. (B) Principal component analysis of 




plot with two most variable principle components (PC) 1 and PC2 is shown. Each dot represents a sample and 
color represents different treatments as indicated. (C) Heat map and dendrogram of the normalized expression of 
total DEGs (1193) with all treatments compared to untreated control.  
 
 
Figure S3.3. TCR- and cytokine-stimulated liver derived MAIT cells have distinct effector function profiles. 
Liver derived mononuclear cells were treated with formaldehyde-fixed E. coli (25 BpC) or 5-A-RU/MG (100 nM) 
for 6 hours or cytokine stimulation with 50 ng/mL IL-12 + 50 ng/mL IL-18 for 24 hours and MAIT cells were 
flow-sorted for RNA sequencing. Heat map and dendrogram of the normalized expression of a custom gene list, 
with all treatments compared to untreated control using the Heatmapper online tool (Babicki et al., 2016). Blue 





3.3.5 Liver-derived MAIT cells upregulate genes associated with tissue repair 
following TCR-stimulation 
Recent studies on peripheral blood MAIT cells suggest that TCR activated MAIT have a role 
in tissue repair (Hinks et al., 2019, Lamichhane et al., 2019b, Leng et al., 2019). GSEA analysis 
confirmed that tissue repair genes were specifically enriched in ld-MAIT cells following TCR 
mediated activation (Figure 3.5A-C). Stronger enrichment was observed with 5-A-RU/MG 
(normalized enrichment score (NES) 2.13 and nominal p-value <0.001) than with E. coli (NES 
1.77 and p-value 0.007) (Figure 3.5). Some of the commonly enriched genes from the tissue 
repair gene list in ld-MAIT cells activated by E. coli or 5-A-RU/MG were CCL3, CSF1, CSF2, 
TNF, EGF2, HBEGF, AREG, and PDGFA (Figure 3.5A and B). Interestingly, some of these 
common genes between E. coli and 5-A-RU/MG stimulation (HBEGF, TNF, CSF1, CSF2, 
CCL3) were also upregulated following IL-12+IL-18 stimulation, however, the overall 
enrichment of the tissue repair signature following IL-12+IL-18 stimulation was not significant 
(NES 1.21 and p-value 0.101) (Figure 3.5C), consistent with our observations with blood MAIT 





Figure 3.5. Tissue repair signature is enriched in E. coli stimulated liver derived MAIT cells. (A-C) Gene set 
enrichment analysis and heatmap for the tissue repair gene list (obtained from Linehan et al., (Linehan et al., 2018) 
comparing the normalized whole gene expression of (A) E. coli, (B) 5-A-RU/MG, or (C) cytokine activated liver 
derived MAIT cells against untreated (UT) MAIT cells; Ecoli = E. coli, 5ARU = 5-A-RU/MG, and cytokines = 
IL-12+IL-18. Enrichment score (ES), normalized enrichment score (NES) and nominal p-value are shown on the 
plots. Heat-maps of 15 top hits from the list of tissue repair signature with each treatment are also shown; blue 
represents lower expression and red represents higher expression of genes. 
 
3.3.6 Profile of transcription factors and regulatory proteins is different in TCR 
and cytokine stimulated ld-MAIT cells 
Expression of certain transcription factors has been associated with specific effector functions 
following activation (Dias et al., 2018, Kurioka et al., 2017, Wang et al., 2018, Lamichhane et 
al., 2019b). Therefore, to explain the differences in the expression of effector molecules 
following TCR and cytokine stimulation, we compared gene expression of transcription factors 
among the DEGs with the different treatments (Figure 3.6A). Expression of RORC (encodes 
RORγt), which controls the expression of IL17, was increased in MAIT cells activated via their 
TCR but was unchanged with IL-12+IL-18 stimulation. Expression of IKZF2 (Helios) and 
TBX21 (T-bet) were also upregulated upon TCR stimulation, whereas expression of EOMES 
was downregulated. Interestingly, expression of PRDM1 (Blimp1) was increased with E. coli 
and IL-12+IL-18 whereas 5-A-RU/MG had no effect. This differential expression of 
transcription factors with the two modes of activation was consistent with our previous study 
on blood MAIT cells (Lamichhane et al., 2019b). Also, histone demethylase KDM6B 
expression, which we recently showed to be important for MAIT cell activation (Lamichhane 
et al., 2019b) was specifically increased by TCR stimulation. Finally, we confirmed by flow 
cytometry that ld-MAIT cells express high levels of RORγt and PLZF compared to other T cell 





Figure 3.6. Transcription factor profile of liver derived MAIT cells changes upon activation. (A) Heat map 
and dendrogram of the normalized gene expression of a custom list of transcription factors by sorted MAIT cells 
with all treatments (E. coli, 5-A-RU/MG, or IL-12+IL-18) compared to untreated controls. (B) Expression of 
different transcription factors were compared among MAIT cells and various non-MAIT CD3+ T cells subsets 
from liver derived mononuclear cells. The gating strategy for MAIT and non-MAIT cells with representative 
histograms of RORγt, PLZF, T-bet, Blimp1 and EOMES is shown. 
 
3.3.7 Type I interferon signaling is enriched in ld-MAIT cells following bacterial 
stimulation 
We recently demonstrated that genes involved in type I interferon (IFNs) signaling are enriched 
in blood MAIT cells following bacterial stimulation and that type I IFNs are important for the 
activation and effector response of MAIT cells. Therefore, we compared the transcriptome of 
E. coli and 5-A-RU/MG activated ld-MAIT cells. Interestingly, GSEA analysis revealed genes 
associated with IFN signaling, especially interferon alpha beta signaling, were highly enriched 
in ld-MAIT cells following E. coli activation compared to activation by 5-A-RU/MG (Figure 
3.7A). Consistent with blood MAIT cells, ld-MAIT cells also expressed high levels of type I 
interferon α and β receptor subunit 1 (IFNAR1) and subunit 2 (IFNAR2), equivalent to the 




both IFNAR1 and IFNAR2 was significantly downregulated following E. coli activation of ld-
MAIT cells (Figure 3.7C); downregulation was also seen with IL-12+IL-18 stimulation. 
 
Figure 3.7. Interferon signaling is enriched in E. coli stimulated liver derived MAIT cells compared to 5-A-
RU stimulated MAIT cells. (A) Gene set enrichment analysis leading edge analysis for the interferon signaling, 
interferon alpha beta signaling, and RIG-I-MDA5 mediated induction of IFN alpha beta pathways (all Reactome) 
comparing the normalized whole gene expression of E. coli activated liver derived MAIT cells against 5-A-
RU/MG activated MAIT cells. Enrichment score (ES), normalized enrichment score (NES) and nominal p-value 
are shown. (B) Comparison of gene expression of IFNAR1, IFNAR2, IL12RB1, IL12RB2, IL18R1 and IL18RAP in 
sorted untreated ld-MAIT cells (CD3+ CD161++ Vα7.2TCR+), determined by RNA sequencing. (C) Expression of 
IFNAR1 and IFNAR2 were compared by RNA sequencing of unactivated and activated (by E. coli, 5-A-RU/MG, 
or IL-12+IL-18) sorted ld-MAIT cells. Data are presented as mean ± S.E.M. (n=4). Each data point represents an 
individual healthy donor. Repeated measures one-way ANOVA with Sidak’s multiple comparison tests were 
performed for assessing statistical significance (C). **p<0.01,***p<0.001, ****p<0.0001, ns = non-significant. 
 
3.3.8 Comparison of the transcriptome of blood and liver MAIT cells 
The functional and transcriptomic response of ld-MAIT cells to TCR signals (E. coli or 5-A-
RU/MG) or cytokines (IL-12+IL-18) was comparable to our recent study on blood derived 




and ld-MAIT cells, comparison at the transcriptomic level was lacking (Tang et al., 2013). 
Therefore, to compare how different ld-MAIT cells behave from the blood MAIT cells during 
activation, we merged the MAIT cell RNA sequencing datasets from liver (this study) and blood 
(Lamichhane et al., 2019b). Despite difference in their tissue origin, changes in the 
transcriptome of blood and ld-MAIT cells following stimulation were similar (Figure 3.8A). 
Strikingly, ld-MAIT cells activated by either E. coli, 5-A-RU/MG, or IL-12+IL-18 were 
clustered with blood MAIT cells treated in the same way; MAIT cells without any stimulation 
also clustered together (Figure 3.8A). Overall, a clear separation of MAIT cells based on 
response to TCR and cytokine stimulation was observed irrespective of the tissue origin which 
suggested conserved changes in circulating and ld-MAIT cell transcriptomes following 
activation. Nevertheless, tissue specific changes were evident in the heatmap, with MAIT cells 
clustered by tissue of origin within treatments (Figure 3.8A). 
Enhanced expression of TNF and IL17A in response to TCR stimulation and of IFNG and 
GZMA in response to cytokine stimulation that we observed previously (Figure 3.2, 3.3, Figure 
S3.2 and S3.3) (Lamichhane et al., 2019b) was also evident following dataset merging, further 
supporting successful fusion of the two RNA datasets (Figure S3.4A-C, G). Better production 
of IFNγ and granzyme B by IL-12+IL-18 stimulated ld-MAIT cells compared to blood MAIT 
cells was also evident at transcriptomic level (IFNG and GZMB); no significant difference was 
observed in the expression of TNF, IL17A, IL17F and IL22 (Figure S3.4). To understand the 
better response of ld-MAITs to cytokines, we compared the expression of IL-12R and IL-18R 
(Figure S3.4I-L). Ld-MAIT cells, which already expressed high IL12RB1, significantly 
upregulated IL12RB2 to a greater extent than blood derived MAIT cells following IL-12+IL-18 
treatment. No differences were seen in the expression of IL18R1 and IL18RAP. Interestingly, 
expression of NCAM1 (CD56), which was recently associated with better stimulatory capacity 
in context of MAIT cells against both TCR- and cytokine-mediated stimulation (Dias et al., 
2017, Kurioka et al., 2017), was expressed at a much higher level in ld-MAIT cells stimulated 
with IL-12+IL-18 than blood MAIT cells stimulated with IL-12+IL-18 (Figure S3.4T). 
Interestingly, expressions of TBX21 and EOMES were modulated similarly in blood and ld-
MAIT cells following TCR or cytokine stimulation (Figure S3.4M and N). In contrast, 
expression of RORC was significantly higher in TCR-stimulated ld-MAIT cells than blood 
MAIT cells, whereas ld-MAIT cells expressed comparatively lower levels of ZBTB16 (PLZF) 




GSEA analysis of untreated blood and ld-MAIT cells showed no significant changes in their 
overall circulatory and tissue residency signature (Figure 3.8B). Nevertheless, upon 
investigating individual genes, the expression of ITGAE (encodes CD103; recently described 
marker on MAIT cells for tissue residency (Sobkowiak et al., 2019)) was found to be 
significantly upregulated in ld-MAIT cells compared to blood MAIT cells. Furthermore, ld-
MAIT cells expressed more CD38 (a marker for activation (Sandoval-Montes and Santos-
Argumedo, 2005)) following both TCR and cytokine activation compared to blood MAIT cells 





Figure 3.8. Transcriptomic profile of unactivated and activated blood and liver derived MAIT cells. (A) Heat 
map and dendrogram of the normalized expression of total differentially expressed genes (1411) by sorted liver 
derived MAIT cells with all treatments (E. coli, 5-A-RU/MG, or IL-12+IL-18)  compared to combined untreated 
controls in the merged datasets from blood and liver. (B) Gene set enrichment analysis for the circulatory (left) 
and tissue residency (right) gene sets against the normalized whole gene expression of untreated blood and liver 
samples. Enrichment score (ES), normalized enrichment score (NES) and nominal p-value are shown. 
 
 
Figure S3.4. TCR- and cytokine-stimulated blood and liver derived MAIT cells have distinct transcriptional 
responses. (A-T) Normalized gene counts of different effector molecules, cytokine receptors, transcription factors, 
and activation/tissue residency markers were compared in blood and liver derived MAIT cells without treatment 
and following treatment with formaldehyde-fixed E. coli (25 BpC) or 5-A-RU/MG (100 nM) for 6 hours or 
cytokine stimulation with 50 ng/mL IL-12 + 50 ng/mL IL-18 for 24 hours. After stimulation, MAIT cells were 
flow-sorted for RNA sequencing. (A) TNF, (B) IFNG, (C) IL17A, (D) IL17F, (E) IL22, (F) GZMB, (G) GZMA, 




(PLZF), (Q) CD69, (R) ITGAE (CD103), (S) CD38 and (T) NCAM1 (CD56). Data are presented as mean ± SEM 
and are pooled from independent experiments (n=7 for blood and =4 for liver). Two-way ANOVA with Sidak 




MAIT cells are highly abundant in liver, reaching up to 45% of the total hepatic lymphocytes 
(Dusseaux et al., 2011, Jo et al., 2014). While the detailed transcriptomic response of blood 
MAIT cells to TCR and cytokine-mediated activation has recently been defined (Hinks et al., 
2019, Lamichhane et al., 2019b, Leng et al., 2019), the response of ld-MAIT cells to different 
modes of activation is yet to be examined. In this study, we assessed the functional and 
transcriptomic response of resting and activated MAIT cells from blood and liver. While we 
demonstrated tissue-specific differences in the MAIT cell transcriptome, blood and ld-MAIT 
cells exhibited a shared response following TCR or cytokine stimulation. Ld-MAIT cells were 
found to be more responsive to stimulation with IL-12+IL-18, which may be relevant in 
infectious and inflammatory liver diseases. 
Interestingly, the response of circulating and liver derived MAIT cells to TCR signals were 
remarkably similar. Indeed, the TCRα diversity of MAIT cells from both compartments were 
previously reported to be similar (Lepore et al., 2014). It may reflect similarities in the 
frequency of antigen presenting cells present in blood and liver (Jo et al., 2014). In contrast, the 
response of ld-MAIT cells to cytokine stimulation (IL-12+IL-18) was more polyfunctional and 
a greater proportion of ld-MAIT cells produced cytokines compared to blood MAIT cells. The 
enhanced response to cytokine stimulation could reflect the constant exposure of ld-MAIT cells 
to bacterial and viral contaminates draining in the portal circulation (Konturek et al., 2018). 
Unstimulated Ld-MAIT cells were found to express more CD69 and IL12RB1 than their blood 
counterparts and rapidly upregulated expression of IL12RB2 and NCAM1 (encoding CD56) 
upon stimulation with cytokines. Expression of CD56 on intrahepatic MAIT cells has been 
shown to confer higher functional capacity towards bacterial stimulation (Kurioka et al., 2017). 
Additionally, the greater proportion of ld-MAIT cells producing TNFα and 4-1BB in 
comparison to blood MAIT cells following IL-12+IL-18 stimulation, suggests the presence of 
additional signals in the liver, such as TLA1 (TNFSF15) which is also highly expressed in liver 
tissue and macrophages during liver fibrosis,  can trigger a stronger pro-inflammatory response 




hyperresponsiveness of ld-MAIT cells to cytokine stimulation suggests a possible role of ld-
MAITs in inflammatory liver pathologies, such as autoimmune or viral hepatitis, and hepatic 
fibrosis.  
Our study differs from previous studies in that we assessed TCR-mediated ld-MAIT cell 
activation early (6 hours) post-stimulation, rather than at 20-24 hours (Jo et al., 2014, Tang et 
al., 2013). The early (5-6 hours) response of blood MAIT cells to bacterial stimulation has been 
shown to be solely via TCR, while later (18-24 hours) they are activated via both TCR and 
cytokines (Ussher et al., 2014, Ussher et al., 2016, Lamichhane et al., 2019b). The cytokine 
profile of MAIT cells early and late after bacterial stimulation differs (Bolte et al., 2017, 
Lamichhane et al., 2019b). In most earlier studies on ld-MAIT cells, activation was assessed at 
18-24 hours or after overnight incubation post bacterial stimulation (Tang et al., 2013, Jo et al., 
2014, Jeffery et al., 2016). While assessing the late response of MAIT cells to bacterial 
stimulation has the advantage of robust MAIT cell activation via both TCR dependent and 
independent signals, it may miss TCR specific features of the MAIT cell response which peak 
early, such as TNFα production (Lamichhane et al., 2019b). Focusing on earlier events 
following activation of ld-MAIT cells by bacteria or 5-A-RU/MG, we showed that MAIT cells 
attain a strong inflammatory phenotype, with high expression of TNFα and low expression of 
IFNγ, in line with previous studies on blood MAIT cells (Slichter et al., 2016, Lamichhane et 
al., 2019b). TCR stimulated ld-MAIT cells also strongly expressed chemokines such as CCL3, 
CCL4 and CCL20. In contrast, cytokine stimulation triggered strong production of IFNγ and 
less TNFα production at a later timepoint (24 hours). Therefore, early TCR activation leads to 
a polyfunctional response by MAIT cells, while cytokine-mediated activation is narrower.  
High GMCSF (CSF2) along with CCL3, CCL4, and CCL20 expression in ld-MAIT cells 
stimulated with E. coli or 5-A-RU/MG suggests that ld-MAIT cell have the potential to directly 
recruit lymphocytes, including CD4+ T cells and MAIT cells, that express CCR5 and CCR6 to 
the liver during bacterial infection (Jeffery et al., 2016, Kurioka et al., 2017). Moreover, both 
TCR and cytokine mediated activation triggered CD40L expression on blood and ld-MAIT 
cells; CD40L facilitates DC maturation and enhances antigen cross-presentation (Salio et al., 
2017, Hoffmann et al., 2001). Indeed, MAIT cell activation was recently shown to be important 
for the development of HCV specific CD8+ T cell responses following vaccination with a 
Chimpanzee Adenovirus Ox1 HCV vaccine vector (Provine et al., 2019). MAIT cell dependent 
GM-CSF production has also been shown to contribute to the differentiation of inflammatory 




F. tularensis LVS infection in mice (Meierovics and Cowley, 2016). Therefore, our findings 
also support a role for both blood and ld-MAIT cells in enhancing the adaptive immune 
response via recruiting and/or supporting other immune subsets. 
Consistent with our recent findings (Lamichhane et al., 2019b), only a small number of early 
TCR activated MAIT cells produced granzyme B and perforin, irrespective of their tissue 
origin, despite ~80% of MAIT cells showing evidence of degranulation (CD107a). In contrast, 
cytokine stimulation resulted in less MAIT cell degranulation but greater production of 
granzyme B and perforin in comparison to TCR activation. Unlike granzyme B and perforin, 
granzyme A was expressed at high levels at rest, as previously shown (Kurioka et al., 2015, 
Lamichhane et al., 2019b). Granzyme A expression was significantly reduced by TCR but not 
cytokine stimulation. This may suggest rapid release of granzyme A in TCR stimulated MAIT 
cells as demonstrated previously (Lamichhane et al., 2019b). Additionally, CD107a expression 
not only reflects cytotoxic potential but also the release of chemokines (Fauriat et al., 2010). 
Therefore, the expression and release of multiple chemokines by MAIT cells early after TCR 
stimulation could contribute to the high expression of CD107a. 
In addition to an effector memory phenotype (CD45RA-CD45RO+CD95hiCD62Llo) and 
elevated CD69 expression, tissue resident MAIT cells display higher expression of certain 
chemokine receptors, such as CCR6 and CXCR6, that helps them to home to tissues (Dusseaux 
et al., 2011, Jeffery et al., 2016). Interestingly, expression of both CCR6 and CXCR6 by ld-
MAIT cells was reduced following TCR activation. Downregulation of CCR6 was also evident 
upon cytokine stimulation. However, the functional significance of altered CCR6 and CXCR6 
expression following activation of tissue resident MAIT cells is unknown. In a recent study, 
Lee et al. demonstrated diminished CCR6 expression on MAIT cells following siRNA mediated 
known-down of CCAAT/enhancer binding protein delta (CEBPδ) (Lee et al., 2018). Consistent 
with this, we found that expression of CEBPD (which encodes CEBPδ) was downregulated in 
ld-MAIT cells after TCR stimulation which might have contributed to the reduced expression 
of CCR6.  
The transcriptional response of ld-MAIT cells stimulated via their TCR stimuli or by cytokines 
were similar to those of blood MAIT cells, which we recently reported (Lamichhane et al., 
2019b). In both studies, E. coli or 5-A-RU ± MG stimulated MAIT cells showed considerable 
overlap in their transcriptome and clustered separately from unactivated and cytokine activated 




cells  and ld-MAIT cells with stimulation were also evident in the transcriptional response. 
Consistent with this, modulation of transcription factor and histone demethylase KDM6B 
expression with different modes of activation, were also similar in blood and ld-MAIT cells 
(Lamichhane et al., 2019b).  The transcriptome of activated and non-activated blood and ld-
MAIT cells clustered firstly by treatment. Tissue specific clusters were also evident within the 
main clusters formed by treatments, reflecting some basic differences in blood and ld-MAIT 
cells. For example, high expression of ITGAE (CD103) and CD38 (an activation marker) were 
noted in ld-MAIT cells compared to blood MAIT cells, with or without activation (Sandoval-
Montes and Santos-Argumedo, 2005). Along with CD69, which was more highly expressed by 
unstimulated ld-MAIT cells, expression CD103 has been associated with tissue residency of 
MAIT cells (Sobkowiak et al., 2019). A recent comparison of blood and thoracic duct lymph 
infiltrating MAIT cells, demonstrated equivalent TCR diversity despite basic differences in 
their phenotype suggesting recirculation between blood and tissues (Voillet et al., 2018). With 
the observation of strikingly similar response to TCR stimulation and equally expressed 
circulatory/tissue residency signature between blood and ld-MAIT cells, our study would be 
consistent with re-circulation of MAIT cells between blood and liver. However, the increased 
responsive to cytokines and the clustering of ld-MAIT cells separately to blood MAIT cells 
suggests that the hepatic environment may modulate MAIT cell function. Single cell sequencing 
focusing on TCR repertoire diversity and mouse parabiosis studies are warranted to shed more 
light on the migratory pattern of MAIT cells at resting state and possible circulation between 
liver and blood. 
Consistent with our recent finding (Lamichhane et al., 2019b), type I IFN signaling was 
significantly enriched in bacterially stimulated ld-MAIT cells compared to activation by 5-A-
RU/MG alone. High expression of IFNAR1 and IFNAR2 by ld-MAIT cells, observed by RNA 
sequencing in this study, and increased degranulation and perforin production by ld-MAIT cells 
in response to treatment with IFNβ alone (Lamichhane et al., 2019a), suggests a possible direct 
effect of type I IFNs, as was demonstrated for blood MAIT cells (Lamichhane et al., 2019a). 
Supporting this, we observed significant downregulation of both IFNAR1 and IFNAR2 
expression in E. coli activated MAIT cells indicating endocytosis following binding of type I 
IFNs (Shiba et al., 2009).  
We demonstrated enrichment of a tissue repair signature in TCR stimulated ld-MAIT cells. 
Similar enrichment of tissue repair genes in human blood MAIT cells following TCR 




recently been demonstrated (Hinks et al., 2019, Lamichhane et al., 2019b, Leng et al., 2019). 
Consistent with these reports, the tissue repair signature was not significantly enriched by 
cytokine alone treatment (Hinks et al., 2019, Lamichhane et al., 2019b, Leng et al., 2019). 
Interestingly, mice lacking MAIT cells suffered from severe liver steatosis and inflammation 
compared to wild type mice (Li et al., 2018). This highlights the importance of MAIT cells in 
vivo in controlling inflammatory liver disease. However, two recent studies demonstrated TCR 
activation of MAIT cells and cell-to-cell contact is essential to trigger proliferation of hepatic 
stellate cells (HSCs) and myofibroblasts, while their activation dependent on production of 
TNFα and IL-17 by MAIT cells (Hegde et al., 2018, Bottcher et al., 2018). HSCs, 
nonparenchymal liver cells, are transformed into extracellular matrix secreting myofibroblasts 
following activation and are central to hepatic fibrosis (Bottcher et al., 2018). In our study, we 
found that both TNFα and IL-17 were highly expressed by MAIT cells stimulated by E. coli or 
5-A-RU/MG, which also suggests a possible role for TCR-mediated MAIT cell activation 
during liver inflammation. Therefore, to determine the precise role of MAIT cells in liver 
pathologies, more in vivo studies are warranted. 
In summary, MAIT cells are enriched in liver and express limited markers of tissue residency, 
and undergo rapid transcriptomic changes following TCR or cytokine stimulation, similar to 
blood MAIT cells. While liver-derived MAIT cells were more responsive to cytokine-mediated 
activation, there was no significant difference in the response of blood and ld-MAIT cells to 
TCR stimulation. Similarities in their response to stimulation and the equivalent expression of 
circulatory/tissue residency signature suggests a possible recirculation of MAIT cells between 
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Chapter 4. Type I interferons as 
important co-stimulatory signals 
during T cell receptor mediated 




Mucosal associated invariant T (MAIT) cells are abundant unconventional T cells which can 
be stimulated either via their T cell receptor (TCR) or by innate cytokines. The MAIT cell TCR 
recognises a pyrimidine ligand, derived from riboflavin synthesising bacteria, bound to MR1. 
In infection, bacteria not only provide the pyrimidine ligand but also co-stimulatory signals, 
such as Toll-like receptor agonists, that can modulate TCR-mediated activation. Recently, type 
I interferons (T1-IFNs) have been identified as contributing to cytokine-mediated MAIT cell 
activation. However, it is unknown whether T1-IFNs also have a role during TCR-mediated 
MAIT cell activation. In this study, we investigated the co-stimulatory role of T1-IFNs during 
TCR-mediated activation of MAIT cells by the MR1 ligand 5-amino-6-D-
ribitylaminouracil/methylglyoxal (5-A-RU/MG). We found that T1-IFNs were able to boost 
interferon-γ and granzyme B production in 5-A-RU/MG-stimulated MAIT cells. Similarly, 
influenza virus-induced T1-IFNs enhanced TCR-mediated MAIT cell activation. An essential 
role of T1-IFNs in regulating MAIT cell activation by riboflavin synthesising bacteria was also 
demonstrated.  The co-stimulatory role of T1-IFNs was also evident in liver-derived MAIT 
cells. Overall, our findings establish an important immunomodulatory role of T1-IFNs during 






MAIT cells are recently recognised unconventional T cells which express a semi-invariant T 
cell receptor (TCR) (most commonly Vα7.2-Jα33 in humans and Vα19-Jα33 in mice) and are 
restricted to antigen presented by MHC class I related protein, MR1 (Tilloy et al., 1999, Treiner 
et al., 2003, Huang et al., 2005). MR1 is an evolutionally conserved MHC Ib like molecule and 
presents unstable pyrimidine intermediates derived from 5-amino-6-D-ribitylaminouracil (5-A-
RU), a precursor of riboflavin, triggering MAIT cell activation via their TCR (Corbett et al., 
2014, Kjer-Nielsen et al., 2012). Consistent with this, MAIT cells have been shown to be 
activated by a diverse range of riboflavin synthesising bacteria, including Escherichia coli, 
Pseudomonas aeruginosa, Klebsiella pneumoniae, and Staphylococcus aureus, as well as some 
yeasts, including Candida albicans and  Saccharomyces cerevisiae (Dias et al., 2017, Le 
Bourhis et al., 2013, Le Bourhis et al., 2010). Additionally, MAIT cells express high amounts 
of the interleukin (IL)-18 receptor and the IL-12 receptor and respond to cytokine signals (IL-
12 and IL-18) independent of their TCR (Jo et al., 2014, Ussher et al., 2014, Le Bourhis et al., 
2010). Upon activation, MAIT cells produce pro-inflammatory cytokines such as tumour 
necrosis factor alpha (TNFα), interferon gamma (IFNγ), and IL-17A, as well as cytotoxic 
molecules (granzymes and perforin) (Billerbeck et al., 2010, Dusseaux et al., 2011, Le Bourhis 
et al., 2013, Kurioka et al., 2015). The range of effector functions expressed depends upon the 
mode of activation; for example, TCR stimulation results in production of more pro-
inflammatory cytokines and chemokines than cytokine stimulation, and is associated with 
expression of genes involved in tissue repair (Leng et al., 2019, Lamichhane et al., 2019, Hinks 
et al., 2019). Many in vivo studies have established an important role for MAIT cells in 
protection against bacterial infections (Chua et al., 2012, Georgel et al., 2011, Meierovics et al., 
2013, Wang et al., 2018) and more recently against viruses (Wilgenburg et al., 2018). Therefore, 
MAIT cells are an important innate-like T cells that bridge the innate and adaptive arms of the 
immune system.  
MAIT cells are abundant in blood and liver in humans but have also been isolated from various 
mucosal sites, including the intestine (Dusseaux et al., 2011, Leeansyah et al., 2014). Since 
robust activation can be achieved by both pathogenic and commensal bacteria (Salerno-
Goncalves et al., 2014, Tastan et al., 2018), MAIT cell activation should be tightly controlled 
to prevent the hyperactivation by commensals and subsequent tissue damage. Indeed, sustained 
MAIT cell activation following TCR stimulation requires additional innate signals (Slichter et 




signals that can modulate TCR-mediated MAIT cell activation are IL-7 (Tang et al., 2013, 
Leeansyah et al., 2015), Toll-like receptor (TLR) agonists (Chen et al., 2017, Ussher et al., 
2016), TNFα (Banki et al., 2019), and IL-1β+IL-23 (Tang et al., 2013). 
Type I interferons (T1-IFNs) have been previously shown to enhance Th1 responses of 
conventional CD8+ and CD4+ T cells, and role of T1-IFNs have been implied in the context of 
inflammatory autoimmune diseases as a suppressor (in multiple sclerosis) or an aggressor (in 
Sjögren's syndrome, system lupus erythematosus, rheumatoid arthritis and psoriasis) (Axtell et 
al., 2013, Hall and Rosen, 2010). T1-IFNs are among the newest and least explored innate 
signals during MAIT cell activation. It was first shown by van Wilgenburg et al. that adding 
either IFNα or IFNβ to IL-12 or IL-18 resulted in IFNγ production by MAIT cells (van 
Wilgenburg et al., 2016). Additionally, T1-IFN signalling was shown to be important for MAIT 
cell activation during viral infection in both humans and mice (van Wilgenburg et al., 2016, 
Wilgenburg et al., 2018). However, it is unknown if T1-IFNs also have a co-stimulatory 
function in TCR-mediated activation of MAIT cells. 
In this study, we have shown that the early response of MAIT cells to a TCR signal can be 
greatly enhanced by T1-IFNs. By using influenza A virus infection as a potent inducer of T1-
IFNs and by blocking the T1-IFNs with vaccinia virus receptor B18R, we have confirmed that 
the overall response of MAIT cells to a TCR signal can be boosted by T1-IFNs produced during 
viral infections. Furthermore, we demonstrated that T1-IFNs are important during early MAIT 
cell activation by riboflavin synthesising bacteria. This co-stimulatory effect of T1-IFNs was 
also evident in liver derived (Ld-) MAIT cells. Further, T1-IFNs meidated co-stimulatory effect 
was independent of TNFα. Together our findings suggest a significant role for T1-IFNs in 
driving MAIT cell activation during bacterial, viral, and inflammatory diseases. 
4.2 Materials and Methods 
4.2.1 Mononuclear cell isolation from blood and liver 
Peripheral blood was collected from healthy donors and peripheral blood mononuclear cells 
(PBMCs) were isolated by LymphoprepTM (Axis-Shield PoC AS, Oslo, Norway) density 
gradient centrifugation. Isolated PBMCs were stored in liquid nitrogen until use. For each 
experiment frozen PBMCs were washed and rested overnight in RPMI 1640 pre-supplemented 
with L-glutamine (Life Technologies Corporation, Carlsbad, USA), 10% fetal calf serum 
(Gibco, New Zealand), and 100 units/mL Penicillin + 100 µg/mL Streptomycin (Gibco, 




colorectal metastases and one patient with focal nodular hyperplasia undergoing liver resection. 
A piece of normal liver tissue as far away from the tumour as possible was excised fresh from 
the main surgical specimen and was cut into smaller pieces, digested with 0.05 mg/mL Liberase 
TL (Roche, Basel, Switzerland) + 10 units/mL Benzonase nuclease (Merck, Kenilworth, USA) 
and passed through a 70 µm cell strainer. Liver derived mononuclear cells (LDMCs) were then 
isolated using LymphoprepTM density gradient centrifugation. Isolated LDMCs were not 
cryopreserved but were rested overnight prior to stimulation.  
Collection of blood from healthy donors was approved by the University of Otago Human 
Ethics Committee (H14/046) with prior consultation with the Ngāi Tahu Research Consultation 
Committee and collection of liver from patients undergoing hepatic resection was approved by 
the New Zealand Health and Disability Ethics Committee (16/STH/83).  Written informed 
consent was obtained from each donor.  
4.2.2 Bacteria, virus and MAIT cell ligand 
An overnight culture of Escherichia coli (E. coli) HB101 grown in Luria-Bertani (LB) broth 
was fixed with 2% paraformaldehyde for 20 mins at 4°C, washed, and resuspended in phosphate 
buffered saline (PBS) (Oxoid Ltd, Basingstoke, UK). Fixed bacteria were quantified by flow 
cytometry using 123 count eBeads (eBioscience, San Diego, USA) on a FACS CantoTM II (BD 
biosciences, San Jose, USA) and 10 bacteria per cell (BpC) were used for the experiments. 
Influenza virus A/PR/8/34 (H1N1) strain (now onwards referred to as IAV) was supplied by 
Husain Lab at the Department of Microbiology and Immunology, University of Otago. Briefly, 
IAV propagated in 10 day embryonated chicken eggs and titrated on MDCK cells to determine 
plaque forming units (PFU)/mL. Aliquots of the viral suspension were stored at -80 °C and 
irradiated under 30W UV bulb for 30 mins before use in experiments. (Nagesh et al., 2017).  
MR1 ligand 5-amino-6-D-ribitylaminouracil (5-A-RU) was synthesised as previously reported 
(Lamichhane et al., 2019). 5-A-RU were stored as single use aliquots at -80 °C. Prior to use, 5-
A-RU was mixed with methylglyoxal (MG) at a 1:50 molar ratio (5-A-RU/MG from now 
onwards) and used immediately. 
4.2.3 MAIT cell activation 
A total of 5x105 PBMCs or LDMCs were treated with 1 nM 5-A-RU/MG alone or in 
combination with either 450 IU/mL human interferon alpha 2a (IFNα 2a) (NR-3083, BEI 
Resources, Manassas, USA), 375 IU/mL human interferon beta (IFNβ) (NR-3080, BEI 




activation markers (CD69 and 4-1BB) and effector functions (TNFα, IFNγ, CD107a, CD40L, 
granzyme B, and perforin) were assessed by flow cytometry; IFNα 2a, IFNβ or IAV only 
treatment or no treatment controls were included as appropriate. 
4.2.4 Blocking antibodies and inhibitors 
Anti-MR1 antibody (clone 26.5, BioLegend, San Diego, USA) at 2.5 µg/mL was used to block 
the MR1-TCR interaction. T1-IFNs were blocked using 1 µg/mL Vaccinia virus B18R 
recombinant protein (34-8185-81, eBioscience). Brefeldin A (BioLegend) at 5 µg/mL was used 
to block ER-golgi transport of protein for the assessment of cytokines and cytotoxic molecules. 
TNFα was blocked with 5 µg/mL anti-TNFα antibody (Mab11, BioLegend); IgG1 isotype 
control (MOPC-21, BioLegend) was also included. Concentration of anti-TNFα antibody was 
used based on the blocking experiments performed at Ussher Lab. 
4.2.5 Flow cytometry 
At the end of the treatment, cells were washed twice with PBS, stained with near IR live/dead 
stain (Invitrogen, Carlsbad, USA) and antibodies targeting surface markers at 4 oC for 25 mins, 
followed by two washes with PBS, before fixation with 2% paraformaldehyde at 4 oC for 20 
mins. Cells were then washed with PBS and then permeabilization buffer (BioLegend) and 
stained in permeabilization buffer with antibodies targeting MAIT cell TCR components 
(Vα7.2 TCR, CD3, and CD8) and intracellular proteins at room temperature for 25 mins. 
Following additional washes with permeabilization buffer and then PBS, cells were 
resuspended in PBS. Antibodies used were: CD3 PE-Cy7 (UCHT1, BioLegend), CD3 BV510 
(OKT3, BioLegend), CD8 eFluor450 (RPA-18, eBioscience), TCR Vα7.2 PE or PE-Cy7 
(3C10, BioLegend), CD161 APC (191B8, Miltenyi Biotec), TNFα FITC (Mab11, BioLegend), 
IFNγ PerCP-Cy5.5 (4S.B, BioLegend), CD107a PE (H4A3, BioLegend), granzyme B FITC 
(QA16AO2, BioLegend), perforin PerCP-Cy5.5 (B-D48, BioLegend), CD40L FITC (24-31, 
BioLegend), 4-1BB PE or BV421 (4B4-1, BioLegend), CD14 APC (HCD14, BioLegend), 
HLA-DR AF488 (L243, BioLegend). 
Samples were acquired on a FACSCantoTM II with three laser system (blue (488 nm), red (633 
nm) and violet (405 nm)) or a LSRFortessaTM with four laser system (blue (488 nm), green (561 
nm), red (640 nm) and violet (405 nm)) (both from BD) and analysis was performed in 
FlowJoTM V10 (TreeStar, Ashland, USA). MAIT cells were identified using TCR Vα7.2 PE or 




Flow cytometry experiments were conducted in line with recently published guidelines 
(Cossarizza et al., 2017).  
4.2.6 Gene expression analysis 
RNA sequencing data from our recent publication was analysed to assess the expression of 
IFNAR1, IFNAR2, IL12RB1, IL12RB2, IL18R1, and IL18RAP (Lamichhane et al., 2019). 
Briefly, MAIT cells were isolated from treated and untreated PBMCs by fluorescence activated 
cell sorting; PBMCs were treated with formaldehyde-fixed E. coli (10 BpC) or 5-A-RU (5 µM) 
for 6 hours or IL-12+IL-18 (50 ng/mL each) for 24 hours. RNA sequencing and analysis were 
recently described (Lamichhane et al., 2019).  
4.2.7 Statistical analysis 
Data were analysed in GraphPad Prism V7.03 and are presented as mean and standard error of 
mean (SEM). For statistical comparison, repeated measures one-way or two-way analysis of 
variance (ANOVA) with Sidak’s multiple comparison test between treatments or paired two-
tailed t-test between two treatments were used. A two-sided P value of <0.05 was considered 
significant. 
4.3 Results 
4.3.1 T1-IFNs are important modulators of MAIT cell activation and function 
To test whether T1-IFNs can activate MAIT cells and if they have a co-stimulatory role in TCR 
mediated MAIT cell activation, we treated human PBMCs with IFNα 2a or IFNβ alone or with 
the TCR signal, 5-A-RU/MG (Figure 4.1); representative flow cytometry plots are shown in 
Figure S4.1. Interestingly, treatment with either T1-IFN alone significantly increased the 
surface expression of CD69, an early activation marker, on MAIT cells compared to the 
unstimulated control, however, the expression of CD69 in response to either T1-IFN alone was 
less than to 5-A-RU/MG (Figure 4.1B); the response to T1-IFNs alone was largely restricted to 
MAIT cells (Figure S4.2). Both T1-IFNs further enhanced 5-A-RU/MG triggered CD69 
expression on MAIT cells, which upon MR1 blocking was significantly reduced to the level of 
treatment with T1-IFNs alone (Figure 4.1B). This suggested that the enhanced CD69 expression 
in response to 5-A-RU/MG plus T1-IFNs was due to the combination of both TCR-dependent 
and -independent mechanisms. No enhancement was seen in the expression of 4-1BB, another 
marker of early TCR activation (Wolfl et al., 2007), with either T1-IFN. In contrast, the 
percentage of MAIT cells expressing 4-1BB was reduced upon treatment with T1-IFNs and 




T1-IFNs in combination with IL-12 or IL-18 have previously been shown to stimulate IFNγ 
production by MAIT cells (van Wilgenburg et al., 2016). Therefore, we examined whether T1-
IFNs can modulate cytokine production by MAIT cells treated with 5-A-RU/MG. Indeed, both 
IFNα 2a and IFNβ substantially increased the percentage of IFNγ or TNFα producing MAIT 
cells in response to 5-A-RU/MG (Figure 4.1D and E). No production of IL-17 was seen with 5-
A-RU/MG alone or in combination with IFN (data not shown). Neither IFNα 2a or IFNβ by 
itself induced any cytokine production by MAIT cells (Figure 4.1D and E). This prompted us 
to investigate if other effector functions can also be boosted by T1-IFNs. In response to 5-A-
RU/MG or T1-IFNs alone, more MAIT cells were granzyme B positive than when unstimulated 
(Figure 4.1F). Compared to treatment with 5-A-RU/MG alone, the percentage of MAIT cells 
expressing granzyme B increased by almost four-fold with 5-A-RU/MG + IFNα 2a or 5-A-
RU/MG + IFNβ co-treatments (Figure 4.1F). Interestingly, perforin production in MAIT cells 
was significantly increased following T1-IFN treatment but not by 5-A-RU/MG (Figure 4.1G). 
Adding IFNα 2a or IFNβ to 5-A-RU/MG did not further enhance perforin production compared 
to treatment with the T1-IFNs alone. T1-IFNs alone significantly induced MAIT cell 
degranulation, as measured by surface expression of CD107a; compared to treatment with 5-A-
RU/MG alone, treatment of MAIT cells with a combination of T1-IFNs and 5-A-RU/MG 
further increased the proportion of MAIT cells that were CD107a positive (Figure 4.1H). In 
contrast, T1-IFNs did not significantly affect CD40L expression, either alone or in combination 
with 5-A-RU/MG (Figure 4.1I). 
Both CD8+ and CD8- MAIT cells responded similarly to T1-IFNs alone or in combination with 
5-A-RU/MG, however, CD8- MAIT cells displayed significantly less functional capacity upon 
activation compared to CD8+ MAIT cells, consistent with the recent observation by Dias J et 
al. (Dias et al., 2018) (Figure S4.3). Taken together, T1-IFNs can directly induce modest MAIT 





Figure 4.1. T1-IFNs activate MAIT cells and enhance their response to 5-A-RU/MG. (A) Representative flow 
cytometry plots showing gating strategy for the identification of MAIT cells (CD3+CD161++Vα7.2TCR+) in human 
PBMCs; the percentage of parent population is also shown. (B-I) PBMCs were treated with 1nM 5-A-RU/MG or 
T1-IFNs (450 IU/mL IFNα 2a or 375 IU/mL IFNβ) alone or in combination for 6 hours and (B) CD69 expression, 
and the percentage of MAIT cells expressing (C) 4-1BB, (D) TNFα, (E) IFNγ, (F) granzyme B, (G) perforin, (H) 
CD107a, and (I) CD40L were assessed by flow cytometry. MR1 mediated MAIT cell activation was blocked by 
the addition of anti-MR1 antibody during the treatment (B). Data are presented as mean and S.E.M. and are pooled 
from two independent experiments (n=7 for B, n=8 for C-I). Each data point represents an individual healthy donor. 











Figure S4.1. T-1 IFNs modulate MAIT cell activation and their response to 5-A-RU/MG. MAIT cells were 
identified as CD3+ T cells expressing the Vα7.2 TCR and CD161++ as in Figure 4.1A. Representative flow 
cytometry plots of CD69, 4-1BB, TNFα, IFNγ, granzyme B, perforin, CD107a, and CD40L expression on blood 
derived MAIT cells following treatment of PBMCs with 1nM 5-A-RU/MG or T1-IFNs (450 IU/mL IFNα 2a or 




Figure S4.2. MAIT cells are the predominant CD3+ T cell population that are activated by T1-IFNs at 6 
hours. (A) MAIT cells and non-MAIT T cell populations were separated based on Vα7.2 TCR and/or CD161 
expression on CD3+ lymphocytes and (B and C) CD69 expression was compared before and after T1-IFN (450 
IU/mL IFNα 2a or 375 IU/mL IFNβ) stimulation for 6 hours; representative flow cytometry plot (B) and 
cumulative data are shown (C). The data presented in Figure 4.1B for MAIT cells with no treatment or T1-IFN 
treated (IFNα 2a or IFNβ) are presented here again for comparison with non-MAIT cells. Data are presented as 
mean and S.E.M. and are pooled from two independent experiments (n=7). Each data point represents an individual 
healthy donor. Repeated measures one-way ANOVA with Sidak’s multiple comparison tests were performed for 







Figure S4.3. Both CD8+ and CD8- MAIT cells are modulated similarly by T1-IFNs. (A) MAIT cells 
(CD3+Vα7.2+CD161++ T cells) were gated as described in Figure 4.1A and sub-divided into CD8+ and CD8- 
populations based on CD8 expression; representative flow cytometry plot and cumulative data are shown. (B-E) 
Percentage of CD8+ and CD8- MAIT cells expressing (B) TNFα, (C) IFNγ, (D) granzyme B, and (E) perforin  were 
compared following treatment of PBMCs with 1nM 5-A-RU/MG or T1-IFNs (450 IU/mL IFNα 2a or 375 IU/mL 
IFNβ) alone or in combination for 6 hours. Data are presented as mean and S.E.M. and are pooled from two 
independent experiments (n=8). Each data point represents an individual healthy donor. Repeated measures two-
way ANOVA with Sidak’s multiple comparison tests were performed for assessing statistical significance (B-E). 
*p<0.05 **p<0.01, ***p<0.001, ****p<0.0001, ns = non-significant. 
4.3.2 Virus modulates the activation and function of TCR-activated MAIT cells  
T1-IFNs are produced by infected cells during viral infection (Perry et al., 2005, Stetson and 
Medzhitov, 2006). Therefore, we assessed if virus infection can modulate MAIT cell activation 




combination with 5-A-RU/MG; uninfected allantoic fluid (AF) was included as a control. IAV 
alone triggered MAIT cell activation as measured by CD69 surface expression; the activation 
was specific to IAV treatment as an equivalent volume of AF had no effect on CD69 expression 
(Figure 4.2A). Interestingly, adding IAV, but not AF, to 5-A-RU/MG further enhanced CD69 
expression on MAIT cells compared to 5-A-RU/MG alone. In PBMCs treated with 5-A-
RU/MG + IAV, blocking MR1 significantly reduced CD69 expression, but not completely 
compared to unstimulated MAIT cells; the level of CD69 expression was similar to the level 
induced by IAV alone (Figure 4.2A). IAV alone had little effect on 4-1BB expression on MAIT 
cells but reduced the 4-1BB expression when added with 5-A-RU/MG compared to 5-A-
RU/MG alone (Figure 4.2B). Neither TNFα nor IFNγ was produced by MAIT cells with IAV 
alone, however, the percentage of MAIT cells producing IFNγ, but not TNFα, was significantly 
increased when PBMCs were co-treated with 5-A-RU/MG and IAV compared with 5-A-
RU/MG and AF (Figure 4.2C and D). A small but non-significant increase in granzyme B 
production was seen with IAV or 5-A-RU/MG stimulation alone. In contrast, IAV together with 
5-A-RU/MG triggered robust production of granzyme B in MAIT cells compared to 5-A-
RU/MG alone or co-treatment with 5-A-RU/MG + AF (Figure 4.2E). Perforin production in 
MAIT cells was increased by IAV alone, but this did not reach significance; co-treatment with 
IAV and 5-A-RU/MG resulted in a significant increase in perforin expression compared to 5-
A-RU/MG alone or co-treatment with 5-A-RU/MG + AF (Figure 4.2F). MAIT cells also rapidly 
degranulated in response to IAV; co-treatment with IAV and 5-A-RU/MG resulted in a greater 
proportion of MAIT cells degranulating than with 5-A-RU/MG alone (Figure 4.2G). Similarly, 
co-treatment with IAV and 5-A-RU/MG resulted in a significant increase in CD40L expression 
by MAIT cells compared to 5-A-RU/MG treatment alone (Figure 4.2H). Taken together, signals 
during virus infection induce activation and degranulation of MAIT cells and can further 
enhance activation, cytokine production, and the cytotoxic potential of MAIT cells stimulated 





Figure 4.2. Virus activates MAIT cells and enhances their response to 5-A-RU/MG. PBMCs were treated with 
1nM 5-A-RU/MG, UV-irradiated IAV at a MOI of 2,  or the equivalent volume of allantoic fluid (AF) alone or in 
combination for 6 hours and (A) CD69 expression,  and the percentage of MAIT cells (gated as in Figure 4.1A) 
expressing (B) 4-1BB, (C) TNFα, (D) IFNγ, (E) granzyme B, (F) perforin, (G) CD107a, and (H) CD40L were 
assessed by flow cytometry. MR1-mediated MAIT cell activation was blocked by adding anti-MR1 antibody 
during the 5-A-RU/MG + IAV co-treatment (A-D). Allantoic fluid (AF) was included as a control in some 
experiments (A-F). Data are presented as mean and S.E.M. and are pooled from two independent experiments (n=8 
for A-D, G, and H and n=7 for E-F). Each data point represents an individual healthy donor. Repeated measures 
one-way ANOVA with Sidak’s multiple comparison tests were performed for assessing statistical significance (A-





4.3.3 Virus induced MAIT cell activation, degranulation, and response to TCR 
signal is T1-IFN dependent 
To confirm whether the enhanced TCR response of MAIT cells in the presence of IAV was 
mediated via virus induced T1-IFNs, we treated PBMCs with IAV + 5-A-RU/MG and 
neutralised T1-IFNs with Vaccinia virus protein B18R. Inhibiting T1-IFNs completely 
abrogated the viral enhancement of CD69, IFNγ, granzyme B, perforin, CD107a, and CD40L 
expression by TCR-stimulated MAIT cells (Figure 4.3A, D-H). Furthermore, the reduction of 
4-1BB expression on MAIT cells treated with 5-A-RU/MG + IAV compared with 5-A-RU/MG 
alone was reversed upon B18R addition (Figure 4.3B). Though no enhancement of TNFα 
production was seen with IAV and 5-A-RU/MG, blocking T1-IFNs reduced the percentage of 
MAIT cells producing TNFα (Figure 4.3C). Furthermore, the increased CD69 surface 
expression and degranulation observed in MAIT cells when PBMCs were treated with IAV 
alone were also significantly reduced upon T1-IFN blockade (Figure 4.3I and J). These findings 
confirm that the IAV induced MAIT cell activation and enhanced response to TCR stimulation 





Figure 4.3. T1-IFNs mediate virus-induced MAIT cell activation and enhancement of the MAIT cell 
response to 5-A-RU/MG. (A-H) PBMCs were treated with 1nM 5-A-RU/MG alone or in combination with UV-
fixed IAV at a MOI of 2 ± vaccinia virus B18R protein (1 µg/mL) for 6 hours and (A) CD69 expression, and the 
percentage of MAIT cells (gated as in Figure 4.1A) expressing (B) 4-1BB, (C) TNFα, (D) IFNγ, (E) granzyme B, 
(F) perforin, (G) CD107a, (H) and CD40L were assessed by flow cytometry. (I and J) PBMCs were treated with 
IAV alone at 2 MOI ± vaccinia virus B18R protein for 6 hours and expression of (I) CD69 expression and (J) the 
percentage of MAIT cells expressing CD107a were assessed. Data are presented as mean and S.E.M. and are 
pooled from two independent experiments (n=8 for A-H and n=7 for I and J). Each data point represents an 
individual healthy donor. Repeated measures one-way ANOVA with Sidak’s multiple comparison tests (A-H) or 
paired two-tailed t-tests (I and J) were performed for assessing statistical significance. *p<0.05, **p<0.01, 
***p<0.001, ns = non-significant. MFI = mean fluorescent intensity. 
 
4.3.4 T1-IFNs are important for early activation of MAIT cells by riboflavin 
producing bacteria 
Bacteria can provide both MR1 ligand and co-stimulatory signals leading to robust activation 
of MAIT cells (Chen et al., 2017, Ussher et al., 2016). Recently, we reported that various innate 
signalling pathways, including IFNα/β signalling, were enriched early in MAIT cells upon 
stimulation with E. coli compared to activation with 5-A-RU alone (Lamichhane et al., 2019). 
Therefore, we activated MAIT cells with E. coli for 6 hours with or without B18R to assess the 
role of T1-IFNs during early MAIT cell activation by a riboflavin synthesising bacteria. Upon 
activation by E. coli, MAIT cells rapidly upregulated surface expression of CD69, 4-1BB, 
CD40L, and CD107a, produced TNFα and IFNγ, and increased expression of the cytotoxic 
molecules granzyme B and perforin; all except 4-1BB were reduced upon blocking T1-IFNs, 
although the change in granzyme B did not reach significance (Figure 4.4A-H). Interestingly, 
E. coli induced perforin production in MAIT cells was completely inhibited by blocking T1-
IFNs (Figure 4.4F). Taken together, T1-IFNs are important drivers of MAIT cell activation and 





Figure 4.4: T1-IFN signalling is important for early MAIT cell activation by riboflavin synthesising bacteria. 
PBMCs were treated with paraformaldehyde fixed E. coli at 10 BpC ± 1 µg/mL vaccinia virus B18R protein for 6 
hours; (A) CD69 expression, and the percentage of MAIT cells (gated as in Figure 4.1A) expressing (B) 4-1BB, 
(C) TNFα, (D) IFNγ, (E) granzyme B, (F) perforin, (G) CD107a, and (H) CD40L were assessed by flow cytometry. 
Data are presented as mean and S.E.M. and are pooled from two independent experiments (n=8). Each data point 
represents an individual healthy donor. Repeated measures one-way ANOVA with Sidak’s multiple comparison 
tests were performed for assessing statistical significance. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns = 
non-significant. MFI = mean fluorescent intensity. 
 
4.3.5 Liver derived MAIT cells respond to IAV and IFNβ similarly to MAIT cells 
isolated from blood 
Next, to determine whether T1-IFNs are also co-stimulatory signals for liver-derived MAIT 
cells, we treated liver-derived MAIT cells with IAV, IFNβ or 5-A-RU/MG alone, or in 
combination (Figure 4.5); representative flow cytometry plots are shown in Figure S4.4. Liver-
derived MAIT cells stimulated with IAV or IFNβ rapidly degranulated and produced more 
granzyme B and perforin compared to untreated cells, although only CD107a reached 
significance (Figure 4.5F-H). The percentages of MAIT cells producing IFNγ and granzyme B 
were also increased upon co-treatment with IFNβ and 5-A-RU/MG compared with 5-A-RU/MG 
alone, although only IFNγ reached significance (Figure 4.5E and F). No significant effect was 
seen on TNFα and 4-1BB expression following IFNβ or IAV addition to 5-A-RU/MG compared 




increased CD40L, although this did not reach statistical significance (Figure 4.5I). Taken 
together, MAIT cells from both blood and liver can be similarly modulated in vitro by T1-IFNs. 
 
Figure 4.5. Modulation of liver derived MAIT cell activation by IFNβ and IAV. (A) Representative flow 
cytometry plots showing gating strategy for the identification of MAIT cells (CD3+CD161++Vα7.2TCR+) in human 
liver derived mononuclear cells; the percentage of parent population is also shown. (B-I) Human liver derived 
mononuclear cells were treated with 1nM 5-A-RU/MG or 375 IU/mL IFNβ or IAV at a MOI of 2, alone or in 
combination, for 6 hours and (B) CD69 expression, and the percentage of MAIT cells expressing (C) 4-1BB, (D) 
TNFα), (E) IFNγ, (F) granzyme B, (G) perforin, (H) CD107a, and (I) CD40L were assessed by flow cytometry. 




5-A-RU/MG treatment in B where n=2). Each data point represents an individual donor. Repeated measures one-
way ANOVA with Sidak’s multiple comparison tests were performed for assessing statistical significance (E and 






Figure S4.4. IFNβ and IAV modulates activation of on liver derived MAIT cells. Liver derived MAIT cells 
were identified as CD3+ T cells expressing the Vα7.2 TCR and CD161++ as in Figure 4.5A. Representative flow 




derived MAIT cells following treatment of LDMCs with 1nM 5-A-RU/MG or 375 IU/mL IFNβ or IAV at 2MOI, 
alone or in combination, for 6 hours are shown. Number in the flow cytometry plot indicates the percentage. 
 
4.3.6 T1-IFN mediated enhancement of TCR stimulation is largely TNFα-
ndependent 
Monocytes are important mediators of MAIT cell activation by bacterial, viral, or innate signals 
(Loh et al., 2016, Slichter et al., 2016, Ussher et al., 2016). It is known that monocytes activated 
with T1-IFNs can trigger more robust MAIT cell activation in response to bacteria (Ussher et 
al., 2016). To investigate whether T1-IFNs were activating monocytes, we assessed TNFα 
production by monocytes in PBMCs stimulated with T1-IFNs and/or 5-A-RU/MG. 
Interestingly, IFNβ, but not IFNα 2a or 5-A-RU/MG alone, triggered significant TNFα 
production in monocytes (which were mostly CD14+HLA-DR+) (Figure 4.6A-C). This was 
interesting as neither IFNα 2a nor IFNβ alone induced any TNFα production in MAIT cells 
(Figure 4.1D).  
TNFα has been shown to induce upregulation of surface expression of CD69 on MAIT cells 
(Chiba et al., 2017). Therefore, to test whether the enhanced CD69, CD107a and perforin 
expression by MAIT cells with IFNβ alone was mediated by TNFα production, we added anti-
TNFα antibody with IFNβ treatment. Blocking TNFα had no significant effect on the expression 
of CD69, CD107a or perforin by MAIT cells (Figure 4.6D-F). Recently, TNFα produced during 
treatment of THP1 cells with IgG-opsonized E. coli was shown to enhance IFNγ production by 
MAIT cells (Banki et al., 2019). Therefore, we blocked TNFα in PBMCs co-treated with 5-A-
RU/MG + IFNα 2a or 5-A-RU/MG + IFNβ to test whether the synergistic effect seen was 
mediated by TNFα production. The enhancement of IFNγ production in MAIT cells treated 
with T1-IFNs was TNFα independent whereas a small but significant reduction was observed 






Figure 4.6. T1-IFN mediated enhancement of the MAIT cell response to 5-A-RU/MG is TNFα independent. 
(A-C) PBMCs were treated with 1nM 5-A-RU/MG or T1-IFNs (450 IU/mL IFNα 2a or 375 IU/mL IFNβ) alone 
or in combination for 6 hours and TNFα production by monocytes was assessed by flow cytometry; (A) gating 
strategy for monocytes, (B) representative flow cytometry plot of HLADR and CD14 expression on monocytes, 
and (C) representative flow cytometry plots and cumulative data of TNFα production by monocytes with different 
treatments. Numbers in each flow cytometry plot indicate the percentage. (D-H) Anti-TNFα antibody (5 µg/mL) 
or isotype control was added when PBMCs were treated with 375 IU/mL IFNβ alone (D-F) or co-treated with 1nM 
5-A-RU/MG and either T1-IFN (450 IU/mL IFNα 2a or 375 IU/mL IFNβ) (G and H) for 6 hours. After the 




expressing (E) CD107a, (F) perforin, (G) IFNγ, and (H) granzyme B were assessed by flow cytometry. Data are 
presented as mean and S.E.M. and are pooled from two independent experiments (n=8 for C-F and n=7 for G-H). 
Each data point represents an individual healthy donor. Repeated measures one-way ANOVA with Sidak’s 
multiple comparison tests (C, G and H) and two-tailed paired t-tests (D-F) were performed for assessing statistical 
significance. *p<0.05, **p<0.01, ns = non-significant. MFI = mean fluorescent intensity. 
 
4.3.7 T1-IFNs can directly modulate the response of MAIT cells to TCR 
stimulation 
As the T1-IFN-mediated enhancement of the MAIT cell responses to 5-A-RU/MG was largely 
TNFα-independent (Figure 4.6), we hypothesised that T1-IFNs might exert their co-stimulatory 
effect directly on MAIT cells. We revisited our recent transcriptomic analysis of activated and 
non-activated human MAIT cells and compared the gene expression of T1-IFN receptor subunit 
1/2 (IFNAR1 and IFNAR2) with that of IL-12 receptor (IL12RB1 and IL12RB2) and IL-18 
receptor (IL-18R1 and IL18RAP) (Lamichhane et al., 2019). The level of expression of IFNAR1 
and IFNAR2 in unstimulated MAIT cells was similar to IL-18R1 and IL18RAP and was higher 
than IL12RB1 and IL12RB2 (Figure 4.7A). Interestingly, the expression of IFNAR2 was 
significantly reduced in MAIT cells following activation by E. coli but not by 5-A-RU or IL-
12+IL-18 (Figure 4.7B), which may suggest receptor downregulation following T1-IFN  
signalling (Shiba et al., 2009). 
 
Figure 4.7. MAIT cells express T1-IFN receptor. (A) Comparison of gene expression of IFNAR1, IFNAR2, 
IL12RB1, IL12RB2, IL18R1 and IL18RAP in sorted untreated MAIT cells (CD3+ CD8+ CD161++ Vα7.2TCR+), 
determined by RNA sequencing. (B) PBMCs were either rested or treated with 10 BpC E. coli or 5 µM 5-A-RU 
for 6 hours or IL-12+IL-18 (50 ng/mL each) for 24 hours and expression of IFNAR1 and IFNAR2 were compared 
by RNA sequencing of sorted MAIT cells. Data are presented as mean ± S.E.M. (n=7). Each data point represents 
an individual healthy donor. Repeated measures one-way ANOVA with Sidak’s multiple comparison tests were 






In this study, we demonstrated that MAIT cells can be activated by T1-IFNs alone, and that T1-
IFNs can augment various effector functions of TCR-stimulated MAIT cells. Similar effects on 
MAIT cell activation were seen with viral stimulation, and this was mediated by T1-IFNs. T1-
IFN-mediated enhancement of MAIT cell activation was also seen with bacterial stimulation. 
A similar role for T1-IFNs was demonstrated with liver-derived MAIT cells. Together our 
findings suggest an important role for T1- IFNs in controlling MAIT cell effector responses. 
We found that T1-IFNs alone were able to activate MAIT cells but not induce cytokine 
production or upregulation of co-stimulatory molecules. This is consistent with the previous 
report by Wilgenburg et al., who found that T1-IFNs only induced significant IFNγ production 
when combined with IL-12 or IL-18 (van Wilgenburg et al., 2016). In another study, various 
innate cytokines including IFNα were shown to upregulate CD69 expression on MAIT cells 
(Chiba et al., 2017). Similarly, Spaan et al. demonstrated that adding IFNα or IL-12 to IL-18 
significantly increased CD69 expression and IFNγ production by MAIT cells compared to 
untreated MAIT cells (Spaan et al., 2016). Therefore, T1-IFNs can activate MAIT cells but 
MAIT cell cytokine production requires stimulation with additional cytokines. 
The effect of T1-IFNs on MAIT cell activation has also be shown in vivo. In patients with 
hepatitis C virus (HCV) infection treated with a combination of pegylated IFN and antiviral 
drugs, higher expression of CD69 was seen on MAIT cells compared to patients receiving 
antiviral therapy alone (van Wilgenburg et al., 2016). In another study, IFNα-based therapy for 
chronic HCV infection was shown to increase CD38 expression on MAIT cells (Spaan et al., 
2016). The concentration of IFNα in plasma in patients with systemic lupus erythematous 
positively correlated with CD69 expression on blood MAIT cells (Chiba et al., 2017).  
T1-IFNs also modulated MAIT cell effector functions in response to TCR stimulation. T1-IFNs 
have previously been shown to modulate the function of TCR stimulated T cells. Priming of 
IGRP-specific CD8+ T cells with either IFNα or IFNβ for two hours significantly increased their 
expression of granzyme B and their ability to lyse target human primary islet cells. (Newby et 
al., 2017). Similarly, co-treatment with IFNα2 and anti-CD3 antibody enhanced IFNγ 
production by mouse invariant natural killer T (iNKT) cell hybridomas compared to anti-CD3 
antibody alone (Villanueva et al., 2015). T1-IFNs also boosted TCR-induced IL-10, but not 




It has recently been shown that MAIT cells can be activated during viral infection by cytokines, 
including IL-12, IL-15, IL-18, and T1-IFNs (Loh et al., 2016, van Wilgenburg et al., 2016); this 
has been discussed in detail in a recent review (Ussher et al., 2018). In our study, we looked at 
early events following IAV infection of PBMCs and showed that IAV can weakly activate and 
induce degranulation of MAIT cells in as little as 6 hours, and that this was mediated by T1-
IFNs. In mice, MAIT cells have previously been shown to rapidly upregulate CD69, CD25, and 
granzyme B during influenza challenge; T1-IFN signalling was shown to be required for the 
expression of CD25 on MAIT cells (Wilgenburg et al., 2018). In an in vitro HCV infection 
model, neutralizing T1-IFNs with B18R significantly reduced CD69 expression and production 
of IFNγ and granzyme B by MAIT cells, suggesting T1-IFN co-operate with cytokines such as 
IL-12 and IL-18 during viral infection (van Wilgenburg et al., 2016). The lack of cytokine 
production by MAIT cells in response to IAV alone in our experiments likely reflects the earlier 
time point at which activation was assessed (6 hours vs overnight in the study by van 
Wilgenburg et al). Collectively, T1-IFNs play an important role in MAIT cell activation during 
viral infection. 
Viral infection enhanced the activation of TCR-stimulated MAIT cells, and this effect was T1-
IFN dependent. This may have implications for MAIT cell activation during lower respiratory 
tract infections, where co-infection with bacteria and respiratory viruses are common 
(Kiedrowski and Bomberger, 2018, Lim et al., 2019) and in chronic hepatitis virus infection, 
where gut dysfunction can result in microbial translocation and delivery to the liver via the 
portal circulation (Brenchley and Douek, 2012). However, the fate of MAIT cells during co-
infection could depend on the intensity and duration of the co-stimulatory signal, as this may 
lead to heightened effector responses leading to infection control, benefiting the patient, or may 
trigger tissue damage as a consequence of hyperactivation, leading to immunopathology. 
Bacteria derived TLR agonists have been shown to license APCs and result in enhanced MAIT 
cell activation upon subsequent treatment with E. coli (Ussher et al., 2016). Similarly, in a 
mouse model, co-administration of TLR agonists was required for accumulation of MAIT cells 
in the lung in response to intra-nasal 5-OP-RU (Chen et al., 2017, Ussher et al., 2016). 
Interestingly, we recently reported that T1-IFN signalling pathways are upregulated early in 
MAIT cells activated by E. coli, but not by 5-A-RU (Lamichhane et al., 2019). In this study, 
we demonstrated that T1-IFNs are important early co-stimulatory signals during activation by 
E. coli. Together, this suggests that E. coli induce T1-IFNs, which are an important co-




time point, perforin expression appears to be completely dependent on T1-IFNs. This is 
consistent with two previous studies that show TCR-independent perforin production by MAIT 
cells activated by E. coli for 6 and 24 hours (Kurioka et al., 2015, Lamichhane et al., 2019). 
This indicates the requirement of innate signals, such as T1-IFNs, which are only significantly 
produced during infection, to tightly control the cytotoxic potential and killing of infected cells 
by MAIT cells. 
A similar co-stimulatory role of T1-IFNs was seen with liver derived MAIT cells. Other innate 
co-stimulatory signals have previously been reported to play a role in the activation of liver 
derived MAIT cells. Tang et al reported that treating intrasinusoidal and circulating 
mononuclear cells with IL-7 or a combination of IL-1β+IL-23 boosted the production of TNFα, 
IFNγ, IL-2, and IL-17A by MAIT cells stimulated with anti CD3/CD28-coupled beads (Tang 
et al., 2013). In another study, liver derived MAIT cells were the second highest producers of 
IFNγ, after NK cells, in response to the TLR8 agonist, ssRNA40, with  IFNγ production 
dependent on IL-12 and IL-18 produced by intrahepatic monocytes (Jo et al., 2014). 
Furthermore, the expression of IFNγ, TNFα, IL-17A, granzyme A/B, and perforin by MAIT 
cells was increased when PBMCs were treated with IL-7 alone for 48 hours; IL-7 treatment also 
reversed the MAIT cell effector dysfunction seen in HIV infected patients (Leeansyah et al., 
2015). IL-7 can also synergise with IL-12 to enhance granzyme B production in MAIT cells 
(Wallington et al., 2018). Given that IL-7 can also be induced by T1-IFNs (Sawa et al., 2009) , 
future studies should investigate whether the co-stimulatory effect observed with T1-IFNs is 
mediated at least in part by IL-7. 
TNFα was considered as a mediator of the co-stimulatory effect observed with T1-IFNs. We 
have previously reported that pre-treatment of APCs with IFNα increased their ability to 
stimulate MAIT cells upon subsequent treatment with E. coli (Ussher et al., 2016). Monocytes 
have been shown to produce TNFα when directly activated by IAV-infected epithelium (Loh et 
al., 2016). A recent study found that IFNα induced TNFα production by monocytes at 24 hours 
(Provine et al., 2019). TNFα has been shown to directly enhance surface CD69 expression on 
MAIT cells (Chiba et al., 2017), and to be required for IFNγ production by MAIT cells in 
response to IL-18 and IFNα or to a replication-incompetent adenoviral vector (Provine et al., 
2019). Recently,  opsonisation of E. coli with IgG was shown to boost IFNγ production by 
MAIT cells in a TNFα dependent manner (Banki et al., 2019). We also observed significant 
TNFα production by monocytes following treatment with IFNβ, but not IFNα, which could be 




on monocytes (Jaitin et al., 2006). However, the enhancement of 5-A-RU/MG-mediated MAIT 
cell activation by T1-IFNs in our study at 6 hours was not mediated by TNFα, as neutralising 
TNFα had minimal effect on MAIT cell activation. A longer incubation (24 hours) with the T1-
IFNs might lead to a stronger production of TNFα, as observed by Provine et al., which could 
have bigger impact on MAIT cell activation by 5-A-RU/MG (Provine et al., 2019).  
The T1-IFN mediated co-stimulatory effect on the TCR-dependent MAIT cell activation 
observed in this study could occur in two ways. Firstly, T1-IFNs could act on the APCs 
(including in an autocrine fashion in infection) leading to increased expression of other co-
stimulatory molecules and MR1 expression. Indeed, T1-IFN treatment of dendritic cells has 
been shown to enhance their T cell stimulatory activity through increased expression of CD86 
and CD40 and by enhancing MHC-I expression and cross-presentation (Montoya et al., 2002, 
Spadaro et al., 2012). Alternatively, T1-IFNs could act directly on MAIT cells and modulate 
their response as has previously been demonstrated with murine CD8+ T cells (Le Bon et al., 
2006) and IGRP-specific human CD8+ T cells (Newby et al., 2017). Consistent with this, MAIT 
cells expressed IFNAR1 and IFNAR2 at high levels. Therefore, T1-IFNs may mediate their co-
stimulatory effect by acting directly on MAIT cells. However, this does not rule out additional 
indirect effects of T1-IFNs via activation of APCs or the involvement of other co-stimulatory 
signals such as IL-7. 
In summary, the MAIT cell response to TCR stimulation is restricted and a co-stimulatory 
signal, such as that provided by T1-IFNs, is essential for full activation. While commensal 
bacteria may act as a source of MAIT cell TCR ligands, partially activating tissue resident 
MAIT cells (Leng et al., 2018, Tang et al., 2013, Sobkowiak et al., 2019), pro-inflammatory 
signals, including T1-IFNs, produced during infection/inflammation may synergise with the 





Figure 4.8. Model of the role of T1-IFNs in MAIT cell activation. The response of MAIT cells to a pure TCR 
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Chapter 5: Regulation of TCR-






MAIT cells are an abundant, innate-like T cell subset in humans which express a semi-invariant 
T cell receptor (TCR) (Vα7.2-Jα12/20/33) and are restricted to antigen presented by MHC class 
I related protein, MR1. MR1 on antigen presenting cells binds pyrimidines antigens derived 
from 5-amino-6-D-ribitylaminouracil (5-A-RU), an intermediate of riboflavin synthesis, and 
activates MAIT cells. Previous studies have reported that Toll-like receptor (TLR) agonists 
from bacteria modulate MAIT cell activation, both in vitro and in vivo, however it remains 
unclear whether bacteria also provide other accessory signals. In this study, we utilized E. coli 
∆ribD, a strain of E. coli that does not produce 5-A-RU, to investigate the bacteria-derived 
accessory signals that modulate MAIT cell activation. E. coli ∆ribD was able to enhance 
activation marker expression and IFNγ production by 5-A-RU-activated MAIT cells. While 
bacterial lysates or TLR agonists could enhance the response of 5-A-RU-activated MAIT cells 
to some extent, a greater response was seen with the combination of 5-A-RU and intact E. coli 
∆ribD; NF-κB and STAT3/5 signalling in APC was important for the enhancing effect. The 
bacteria-mediated synergistic effect was still evident when 5-A-RU was premixed with 
exogenous methylglyoxal to form the pyrimidine ligand. This finding was confirmed with two 
naturally riboflavin deficient bacteria, Listeria monocytogenes and Enterococcus faecalis. 
Finally, we demonstrated that the E. coli ∆ribD mediated increase in activation, production of 
cytokines and cytotoxic molecules, and degranulation in TCR activated MAIT cells was 





Mucosal associated invariant T (MAIT) cells are highly abundant unconventional T cells that 
in humans are numerous in blood, liver and various mucosal tissues (Treiner et al., 2003, 
Dusseaux et al., 2011, Leeansyah et al., 2014). In contrast to the highly variable T cell receptor 
(TCR) of conventional T cells, MAIT cells express a semi-invariant TCR, commonly Vα7.2-
Jα12/20/33 in combination with limited Vβ diversity (Gherardin et al., 2018, Lepore et al., 2014, 
Porcelli et al., 1993, Reantragoon et al., 2013, Tilloy et al., 1999, Treiner et al., 2003). MAIT 
cells respond to bacteria derived vitamin B2 intermediate metabolites presented by MHC class 
Ib related (MR1) protein on antigen presenting cells (APCs) (Kjer-Nielsen et al., 2012, Patel et 
al., 2013). The MAIT cell ligands are the pyrimidines 5-(2-oxoethylideneamino)-6-D-
ribitylaminouracil (5-OE-RU) and 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-
RU),  which are derived by condensation of 5-amino-6-D-ribitylamino uracil (5-A-RU), an 
intermediate in riboflavin metabolism, with glyoxal and methylglyoxal respectively (Corbett et 
al., 2014). Riboflavin is synthesized by many bacterial and fungal species (Corbett et al., 2014, 
Davey et al., 2014, Gold et al., 2010, Jo et al., 2014, Le Bourhis et al., 2011, Le Bourhis et al., 
2010). Interestingly, MR1 expression and presence of commensal bacteria has been shown to 
be important for the development of MAIT cells, suggesting bacterial regulation of MAIT cell 
ontogeny (Treiner et al., 2003, Martin et al., 2009, Koay et al., 2016). 
In addition to activation via their TCR, MAIT cells can also be activated independently of their 
TCR by cytokines such as IL-12, IL-15, IL-18, and type I interferons, which can be  produced 
by APCs exposed to bacteria or viruses (Chua et al., 2012, Ussher et al., 2014a, Sattler et al., 
2015, Ussher et al., 2016, van Wilgenburg et al., 2016). In vitro studies have established that 
MAIT cells are activated by bacterially infected cells in a TCR dependent manner during the 
early phase (usually around 4-8 hours) and via both TCR dependent and independent 
mechanisms at later timepoints (20-24 hours) (Ussher et al., 2014a, Ussher et al., 2016, Jo et 
al., 2014). Bacteria represents a complex stimulus, incorporating both the MAIT cell activating 
ligand, 5-A-RU/5-OP-RU, as well as various  pathogen associated molecular patterns (PAMPs) 
such as toll like receptor (TLR) agonists, that can modulate antigen presentation and T cell 
activation (Celhar et al., 2016, Wagner and Cresswell, 2012). Interestingly, APCs treated 
overnight with agonists of TLR1 or TLR6 triggered better cytokine production by MAIT cell 
in response to subsequent bacterial stimulation (Ussher et al., 2016). The requirement of TLR9 
for MR1 surface expression and subsequent IFNγ production by MAIT cells in response to E. 




ligand has allowed researchers to dissect the impact of bacteria associated signals during MAIT 
cell activation by the MR1 ligand (Chen et al., 2017). Chen et al., demonstrated an increase in 
expression of the activation marker CD69 and  accumulation of murine MAIT cells in the lungs 
when 5-OP-RU was intranasally administered together with the TLR2/6 agonist Pam2Cys 
(Chen et al., 2017). In addition to TLR signaling, various innate signaling pathways such as 
type I interferon signaling, RIG-I like receptor signaling and NOD-like receptor signaling were 
enriched in MAIT cells following early TCR mediated activation by E. coli compared to 
activation by 5-A-RU alone (Lamichhane et al., 2019b). Therefore, MAIT cell activation is 
likely to be controlled by a network of different signals and signaling pathways during bacterial 
infection. 
In this study, we have investigated the effect of bacterial signals on MAIT cells, with or without 
TCR activation by 5-A-RU or its derivative formed with methylglyoxal (5-A-RU/MG). We 
found that bacterial signals alone can induce cytokine-dependent MAIT cell activation. 
Importantly, bacteria, irrespective of their ability to synthesize 5-A-RU, can enhance activation 
and boost IFNγ production by MAIT cells activated via their TCR. Finally, we report that 
bacteria-mediated enhancement of TCR activation of MAIT cells is predominantly mediated by 
type I interferons (T1-IFNs). 
5.2 Materials and Methods 
5.2.1 Peripheral blood mononuclear cells (PBMCs) isolation and cell culture 
Peripheral blood was collected from health volunteers with approval from the University of 
Otago Human Ethics Committee and prior consultation with the Ngāi Tahu Research 
Consultation Committee; written informed consent was obtained from all participants. PBMCs 
were isolated by density gradient centrifugation using LymphoprepTM (Axis-Shield PoC AS, 
Oslo, Norway). First, blood was diluted 1:2 with phosphate buffered saline (PBS) (Oxoid Ltd, 
Basingstoke, UK), carefully layered over Lymphoprep, and centrifuged at 800 g for 30 mins 
with acceleration set at 5 with no brake. PBMCs were carefully removed from the interface 
between Lymphoprep and diluted serum and transferred to a new 50 mL tube with a Pasteur 
pipette. Cells were then pelleted by centrifugation at 350 g for 10 mins. Following one wash 
with 50 mL PBS and two washes with 10 mL PBS, isolated PBMCs were counted, resuspended 
in cryopreservation media (fetal calf serum + 10% DMSO), aliquoted at 1x107 PBMCs/mL per 
cryovial and transferred to a -80 °C freezer inside a storing box containing isopropanol. The 




thawed, washed, and rested overnight in RPMI 1640 pre-supplemented with L-glutamine (Life 
Technologies Corporation, Carlsbad, USA), 10% fetal calf serum (Gibco, New Zealand), and 
100 units/mL Penicillin + 100 µg/mL Streptomycin (Gibco, ThermoFisher Scientific, Waltham, 
USA) (referred to as R10 from now onwards). 
To isolate CD8+ T cells, PBMCs were defrosted, rested overnight, and positively selected with 
anti-CD8 magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany) using MS column 
(Miltenyi Biotech); average purity was > 95%.  THP1 monocytic cells were maintained in R10. 
5.2.2 Bacterial culture  
E. coli HB101 and E. coli ∆ribE were grown in Luria-Bertani (LB) broth, E. coli ∆ribD were 
grown in LB broth supplemented with 20 mg/mL riboflavin (Sigma-Aldrich, St. Louis, USA), 
L. monocytogenes were grown in Brain-Heart Infusion broth, and E. faecalis were grown in 
Tryptic Soy broth. Overnight cultures were centrifuged at 8000 g for 10 mins and washed once 
with PBS before fixing with 5mL 2% paraformaldehyde  for 20 mins at 4°C. The fixed bacteria 
were washed twice with PBS and resuspended in 1-2 mL PBS. The final concentration of fixed 
bacteria in suspension was quantified using 123 count eBeads (eBioscience, San Diego, USA) 
by FACS CantoTM II (BD biosciences, San Jose, USA). Bacterial lysates were prepared by 
sonication using an Ultrasonic Processor VCX-500W (Sonics, Newtown, USA); 1 X 1 min 
pulse and 2 X 30s pulses were used. Lysates were then filtered through a 0.2M syringe filter 
(Sigma-Aldrich) prior to use. Bacterial lysates were freshly prepared for each experiment. 
5.2.3 Preparation of 5-A-RU and 5-A-RU/MG 
5-amino-6-D-ribitylaminouracil (5-A-RU) was synthesized in School of Pharmacy, University 
of Otago as previously described (Lamichhane et al., 2019b) and stored immediately at -80 °C.  
Quality was checked by NMR and aliquoted in small single use vials under liquid nitrogen 
vapor, kept at -80 °C until the vials were transferred to Department of Microbiology and 
Immunology, University of Otago. Immediately prior to use, defrosted 5-A-RU was mixed with 
methylglyoxal (MG) (Sigma) at a 1:50 molar ratio (referred to as 5-A-RU/MG) and diluted with 
milliQ water to the desired concentration. 
5.2.4 MAIT cell activation 
A total of 1x106 PBMCs were treated with either bacteria (one of either E. coli HB101, E. coli 
∆ribE, E. coli ∆ribD, E. faecalis, or L. monocytogenes) at a concentration of 10 bacteria per cell 
(BpC), the MR1 ligand (1 µM 5-A-RU or 1nM 5-A-RU/MG unless otherwise indicated) or the 




for 6 hours. Expression of CD69, production of cytokines (TNFα and IFNγ) and cytotoxic 
molecules (granzyme B and perforin), and degranulation (CD107a surface expression) by 
MAIT cell post stimulation were assessed by flow cytometry.  MAIT cells were identified as 
CD8+CD161++Vα7.2+ T cells in PBMCs (for the gating strategy see Figure S5.1). For ligand 
titration experiments, PBMCs were treated with different concentrations of 5-A-RU ± MG or 
5-A-RU/MG ± E. coli ∆ribD (10 BpC) for 6 hours and cytokine production by MAIT cells was 
assessed by flow cytometry. For TCR independent activation of MAIT cells, PBMCs were 
treated with 10 BpC E. coli ∆ribD or E. faecalis, or a combination of 50ng/mL recombinant 
human IL-12 (Miltenyi Biotech) and 50 ng/mL recombinant human IL-18 (R & D Systems) for 
24 hours. For assessing the role of TLR agonists, PBMCs were treated with 1 µM 5-A-RU ± 1 
µg/mL agonists for TLR 1 (Pam3CSK, Invivogen, San Diego, USA) and/or 1 µg/mL TLR 6 
(FSL1, Invivogen)  for 6 hours. When assessing cytokine or cytotoxic molecule production, 
brefeldin A (5 µg/mL) was added for final four hours. Effect of TCR signaling was assessed by 
blocking MR1 with 2.5 µg/mL anti-MR1 antibody (clone 26.5, BioLegend, San Diego, USA) 
in some experiments. Experiments were performed in round bottom 96 well-plates. 
To probe the signaling mechanism, THP1 monocytes were stimulated with 5-A-RU ± intact E. 
coli ∆ribD for six hours; pharmacological inhibitors of different signaling pathways (2 µM 
SP600125 (JNK1/2/3 inhibitor), 10 µM SB203580 (p38 MAPK inhibitor), 10 µM LY294002 
(PI3 Kinase p100a/d/b inhibitor), 5 µM S7337 (STAT3/5 inhibitor) [all from Selleck Chemicals, 
Houston, USA], and 5 µM IKK inhibitor VII [Merck-Millipore, Darmstadt, Germany]) were 
also added. After six hours, the THP1 cells were washed and co-cultured with isolated CD8+ T 
cells, which includes MAIT cells, for four hours; brefeldin A was added for the final 3 hours. 
Cells were then stained for TNFα and IFNγ production. Experiments were performed in round 
bottom 96 well-plates. 
5.2.5 Flow cytometry 
All samples were stained with near IR live/dead stain (Invitrogen, Carlsbad, USA) and 
antibodies against surface proteins, followed by fixation with 2% paraformaldehyde, 
permeabilization with 1x permeabilization buffer (BioLegend), and intracellular staining for the 
MAIT cell TCR complex and intracellular proteins (Vα7.2 TCR, CD3, CD8, TNFα, IFNγ, 
granzyme B, and perforin). PBS was used for washing steps and for the final resuspension. To 
stain for CD107a, the antibody was added to the culture at the start of the experiment. 
Antibodies used were: anti-CD3 PE-Cy7 (UCHT1, BioLegend), anti-CD3 BV510 (OKT3, 




(3C10, BioLegend), anti-CD161 APC (191B8, Miltenyi Biotec), anti-TNFα FITC (Mab11, 
BioLegend), anti-IFNγ PerCP-Cy5.5 (4S.B, BioLegend), anti-CD107a PE (H4A3, BioLegend), 
anti-granzyme B FITC (QA16AO2, BioLegend), anti-perforin PerCP-Cy5.5 (B-D48, 
BioLegend). Samples were acquired on a FACSCantoTM II or a LSRFortessaTM (both BD 
Biosciences) and analysed using FlowJoTM V10 (TreeStar, Ashland, USA). Flow cytometric 
gating for MAIT cells is shown in Figure S5.1. 
5.2.6 Statistical analysis 
Statistical analyses were performed in GraphPad Prism V7.03 using paired one-way ANOVA 
with Sidak’s multiple comparison test between treatments or paired two-tailed t-test between 
two treatments. Data are presented as mean ± standard error of mean (SEM). 
5.3 Results 
5.3.1 Ligand deficient E. coli ∆ribD triggers late activation of MAIT cells 
Early (6 hours) MAIT cell activation in response to bacteria is due to TCR signaling (Ussher et 
al., 2014a). Only bacteria that produce 5-A-RU, an intermediate in the riboflavin biosynthesis 
pathway, can trigger TCR mediated MAIT cell activation (Ussher et al., 2016, Soudais et al., 
2015). Therefore, we compared the ability of 5-A-RU deficient (E. coli ∆ribD) (Soudais et al., 
2015) and 5-A-RU producing (E. coli ∆ribE) strains of E. coli (Soudais et al., 2015) to activate 
and induce cytokine production by MAIT cells. Treatment with E. coli ∆ribD mutant for 6 hours 
failed to induce TNFα or IFNγ production by MAIT cells, consistent with the lack of 5-A-RU 
production (Figure 5.1A). In contrast, the ligand producing E. coli ∆ribE triggered significant 
TNFα or IFNγ production by MAIT cells in a MR1-dependent manner (Figure 5.1A). 
Late MAIT cell activation (20-24 hours) in response to bacteria, is due to the combination of 
TCR signaling and cytokine-mediated activation. Combinations of inflammatory cytokines, 
such as IL-12 and IL-18 produced by bacteria challenged APCs, activate MAIT cells 
independently of TCR signalling (Ussher et al., 2014b, Ussher et al., 2016). Therefore, we 
treated human PBMCs with E. coli ∆ribD for 24 hours and assessed cytokine production by 
MAIT cells; a combination of IL-12+IL-18 was used as a positive control. Interestingly, almost 
one third of MAIT cells were activated and produced either TNFα or IFNγ in response to E. 
coli ∆ribD stimulation for 24 hours (Figure 5.1B). Of note, the profile of TNFα+, TNFα+ 
IFNγ+, and IFNγ+ MAIT cells against E. coli ∆ribD was similar to that following IL-12+IL-18 





Figure S5.1. Flow cytometry gating strategy for identification of MAIT cells in human PBMCs. Live 
lymphocytes were gated on single cells (excluding doublets) from total PBMCs. MAIT cells were identified as 






Figure 5.1. E. coli ∆ribD triggers late cytokine production by MAIT cells. (A) Production of TNFα and IFNγ 
by MAIT cells following treatment of PBMCs with 10 BpC E. coli ∆ribD or E. coli ∆ribE for 6 hours in the 
presence or absence of anti-MR1 antibody. (B) Production of TNFα and/or IFNγ by MAIT cells following 
treatment of PBMCs with 10 BpC E. coli ∆ribD or IL-12+IL-18 (50 ng/mL each) for 24 hours; percentage of 
cytokine positive MAIT cells and proportion of MAIT cells producing TNFα only, IFNγ only, or both TNFα and 
IFNγ are shown. Data are pooled from two independent experiments (n=8) and mean ± SEM is shown. Each 
symbol represents an individual healthy donor. Statistical analysis was performed with repeated measures one-
way ANOVA using Sidak’s multiple comparison tests. *p<0.05, **p<0.01, ns = non-significant.  
 
5.3.2 MAIT cells upregulate cytotoxic proteins upon late activation by E. coli 
∆ribD in a TCR independent manner  
Next, we assessed changes in cytotoxic protein content of activated MAIT cells; the frequency 
of cells containing granzyme B and perforin following activation with E. coli ∆ribD or E. coli 
HB101, which has an intact riboflavin pathway, was assessed. A significant increase in the 
number of MAIT cells containing granzyme B was seen at both 6 and 24 hours following 
activation with E. coli HB101; more granzyme B production was observed at 24 hours (Figure 
5.2A and C). In contrast, E. coli ∆ribD failed to induce granzyme B production in MAIT cells 
at 6 hours but triggered some MAIT cells to produce granzyme B at 24 hours (Figure 5.2A and 
C). Although, few MAIT cells produced perforin following either E. coli HB101 or E. coli 
∆ribD treatment for 6 hours, the majority of MAIT cells contained perforin by 24 hours with 
both stimuli (Figure 5.2B and D). A similar pattern was observed for the average amount of 
granzyme B and perforin per MAIT cell (as assessed by mean fluorescent intensity [MFI]) 
following stimulation with E. coli ∆ribD or E. coli HB101 (Figure S5.2). Production of 
granzyme B and perforin in MAIT cells following 24 hours stimulation by E. coli ∆ribD was 
TCR independent (Figure 5.2C and D, and Figure S5.2C and D). Therefore, bacterial signals 





Figure 5.2. E. coli ∆ribD triggers substantial granzyme B and perforin production by MAIT cells at 24 hours 
in a TCR independent manner. Production of (A and C) granzyme B and (B and D) perforin were assessed by 
flow cytometry following treatment of PBMCs with 10 BpC E. coli ∆ribD or E. coli HB101 for 6 hours (A and B) 
or 24 hours (C and D). Anti-MR1 antibody was also added with E. coli ∆ribD treatment for 24 hours (C and D). 
Representative flow cytometry plots gated on CD8+ T cells (left panel) and cumulative data (right panel) are shown. 
Data are pooled from two independent experiments (n=8 for A and B, n=7 for C and D) and mean ± SEM is shown. 








Figure S5.2. E. coli ∆ribD induces granzyme B and perforin production by MAIT cells at 24 hours. Mean 
fluorescent intensity of (A and C) granzyme B and (B and D) perforin in MAIT cells following treatment of PBMCs 
with 10 BpC E. coli ∆ribD or E. coli HB101 for 6 hours (A and B)  or 24 hours (C and D) was assessed by flow 
cytometry. The effect of blocking TCR signaling with anti-MR1 during E. coli ∆ribD treatment for 24 hours was 
also assessed (C and D). Data are pooled from two independent experiments (n=8 for A and B, n=7 for C and D) 
and mean ± SEM is shown. Each symbol represents an individual healthy donor. Statistical analysis was performed 
with repeated measures one-way ANOVA using Sidak’s multiple comparison tests (A-D). *p<0.05, **p<0.01, ns 
= non-significant. 
 
5.3.3 E. coli ∆ribD enhances MAIT cell responses to 5-A-RU 
Salmonella typhimurium ∆ribDH, which does not produce 5-A-RU, when administered 
intranasally together with 5-OP-RU, has been shown to enhance accumulation of MAIT cells 
in the murine lungs, while 5-OP-RU alone failed to do so (Chen et al., 2017). To investigate 
whether ligand deficient bacteria can enhance cytokine production by TCR activated MAIT 
cells, we assessed the production of TNFα or IFNγ by MAIT cells following treatment with E. 




significant number of MAIT cells to produce TNFα or IFNγ, whereas, consistent with the 
observation in Figure 5.1, E. coli ∆ribD by itself did not induce any cytokine production (Figure 
5.3A and B). Surprisingly, when E. coli ∆ribD and 5-A-RU were added in combination, the 
percentage of MAIT cells producing TNFα or IFNγ was significantly increased compared to 
activation with 5-A-RU alone (Figure 5.3A and B). Of note, the overall production of TNFα or 
IFNγ by MAIT cells at 6 hours in response to treatment with the combination of E. coli ∆ribD 
and 5-A-RU was predominantly MR1-mediated. We observed similar MR1-dependent 
enhancement of IFNγ production by MAIT cells when stimulated with the combination of 
Enterococcus faecalis, a naturally riboflavin non-synthesizing bacteria (Corbett et al., 2014), 
and 5-A-RU compared to 5-A-RU treatment alone (Figure S5.3A and B). Like E. coli ∆ribD, 
E. faecalis could only activate MAIT cells in a TCR independent manner (Figure 5.3A-C). 
For robust MAIT cell activation, phagocytosis of intact riboflavin synthesizing bacteria is 
required (Ussher et al., 2016). Therefore, to investigate whether intact bacteria are essential for 
the synergistic effect, we treated human PBMCs with E. coli ∆ribD or equivalent amount of 
bacterial lysate in combination with 5-A-RU. Addition of intact E. coli ∆ribD with 5-A-RU 
triggered robust TNFα and IFNγ production by MAIT cells which was comparable to the 
response against intact ligand producing E. coli (Figure 5.3C and D). Interestingly, replacing 
intact E. coli ∆ribD with the equivalent amount of lysate reduced the percentage of MAIT cells 
producing TNFα or IFNγ, however, the percentage of MAIT cells producing cytokines was still 
higher than with activation by 5-A-RU alone. (Figure 5.3C and D). Therefore, greater 





Figure 5.3. Ligand deficient bacteria enhance activation and cytokine production by TCR-stimulated MAIT 
cells. (A and B) Percentage of MAIT cells producing (A) TNFα and (B) IFNγ was assessed by flow cytometry 
following treatment of PBMCs with either 10 BpC E. coli ∆ribD or 1 µM 5-A-RU alone or in combination for 6 
hours. Anti-MR1 antibody was also added in the E. coli ∆ribD and 5-A-RU co-treatment. (C and D) PBMCs were 
treated with 1 µM 5-A-RU alone or in combination with 10 BpC intact E. coli ∆ribD or equivalent volume of E. 
coli ∆ribD lysate for 6 hours and production of (C) TNFα and (D) IFNγ by MAIT cells was assessed; data are 
normalized against samples treated with 10 BpC E. coli HB101 alone. Data are pooled from three independent 
experiments (n=12 for A and B, n=11 for C and D) and mean ± SEM is shown. Each symbol represents an 
individual healthy donor. Statistical analysis was performed with repeated measures one-way ANOVA using 






Figure S5.3. E. faecalis enhances IFNγ production by 5-A-RU stimulated MAIT cells. (A and B) Percentage 
of MAIT cells producing (A) TNFα and (B) IFNγ was assessed by flow cytometry following treatment of PBMCs 
with either 10 BpC E. faecalis or 1 µM 5-A-RU alone or in combination for 6 hours. The effect of blocking TCR 
signaling with anti-MR1 antibody in the E. faecalis and 5-A-RU co-treatment was also assessed. (C) 
Representative flow cytometry plot showing TNFα and IFNγ production by MAIT cells following treatment of 
PBMCs with 10 BpC E. faecalis or IL-12+IL-18 (50 ng/mL each) for 24 hours (n=3). Data are pooled from two 
independent experiments (n=9) and mean ± SEM is shown. Each symbol represents an individual healthy donor. 
Statistical analysis was performed with repeated measures one-way ANOVA using Sidak’s multiple comparison 
tests. *p<0.05, **p<0.01, ns = non-significant.  
 
Agonists of TLR 1 and TLR 6  have previously been shown to enhance IFNγ production by 
MAIT cells in response to E. coli (Ussher et al., 2016). To assess the ability of TLR agonists to 
enhance 5-A-RU mediated MAIT cell activation, either TLR 1 or 6 agonists or both were added 
with 5-A-RU to PBMCs. Adding TLR 1 or 6 agonists alone or in combination significantly 
increased 5-A-RU mediated MAIT cell activation as measured by CD69 surface expression 
(Figure S5.4A). No significant enhancement was seen in TNFα or IFNγ production (Figure 
S5.4B-C). The combination of 5-A-RU and E. coli ∆ribD resulted in greater CD69 expression 




Therefore, the synergy observed with the E. coli ∆ribD and 5-A-RU co-treatment is unlikely to 
be explained by TLR signaling alone. 
 
 
Figure S5.4. TLR agonists enhance CD69 expression on MAIT cells activated by 5-A-RU. (A) CD69 surface 
expression and production of (B) TNFα and (C) IFNγ by MAIT cells was assessed by flow cytometry following 
treatment of PBMCs with 1 µM 5-A-RU alone or in combination with either TLR1 or TLR6 agonists or TLR1 and 
TLR6 agonists together (both 1 µg/mL) for 6 hours. Data are normalized against samples treated with 1 µM 5-A-
RU/MG + 10 BpC E. coli ∆ribD. Data are pooled from two independent experiments (n=7) and mean ± SEM is 
shown. Each symbol represents an individual healthy donor. Statistical analysis was performed with repeated 
measures one-way ANOVA using Sidak’s multiple comparison tests. *p<0.05, **p<0.01, ****p<0.0001. MFI = 
mean fluorescent intensity. 
 
Activation of MAIT cells by E. coli treated THP1 monocytes has previously been shown to be 
dependent upon NF-κB signaling (Ussher et al., 2016). Therefore, to probe the mechanism by 
which E. coli ∆ribD enhances MAIT cell response to 5-A-RU, we inhibited several signalling 




IKK inhibitor VII completely abrogated the production of TNFα and IFNγ by MAIT cells in 
response to 5-A-RU ± E. coli ∆ribD, confirming previous finding that NF-κB signaling is 
prerequisite for the antigen presenting cell’s ability to activate MAIT cells (Figure S5.5). In 
addition to NF-κB, blocking PI3 kinase and STAT3/5 signaling also significantly inhibited 
IFNγ production by MAIT cells when stimulated with a combination of 5-A-RU and E. coli 
∆ribD, but not 5-A-RU alone (Figure S5.5B and D). Inhibition of STAT3/5 signaling also 
resulted in a small but significant reduction in the production of TNFα by MAIT cells activated 
by 5-A-RU and E. coli ∆ribD (Figure S5.5C). Taken together, NF-κB signaling in APCs is 
critical for the ability of APCs to activate MAIT cells via their TCR, while STAT3/5 and PI3K 
signaling pathways play a role in the bacteria mediated synergistic effect. 
 
 
Figure S5.5: STAT3/5 and PI3K signalling in APC is important for the bacteria mediated synergy. THP1 
monocytic cells were pre-treated with (A and B) 5-A-RU or (C and D) 5-A-RU and intact E. coli ∆ribD mutant 
(1000 BpC) along with different signaling inhibitors for 6 hours and co-cultured with CD8+ T cells for a further 4 
hours; TNFα (A and C)  and IFNγ (B and D) production by MAIT cell was assessed by flow cytometry; data were 




from two independent experiments (n=5) and mean ± SEM is shown. Each symbol represents an individual healthy 
donor. Statistical analysis was performed with repeated measures one-way ANOVA using Sidak’s multiple 
comparison tests (A-D). **p<0.01, ****p<0.0001 
 
5.3.4 Ligand deficient bacteria enhance MAIT cell responses to 5-A-RU/MG 
5-A-RU is an intermediate compound of riboflavin synthesis and undergoes condensation with 
glyoxal or methylgloxal (MG), both byproducts of glycolysis, to form unstable pyrimidines 5-
OE-RU or 5-OP-RU respectively, that are able to bind to MR1 (Corbett et al., 2014). Given that 
MG is a byproduct of glycolysis (Corbett et al., 2014), and bacterial triggering of APCs leads 
to activation and enhanced glycolysis (Eisenreich et al., 2017, Kelly and O'Neill, 2015), the 
observed synergy with 5-A-RU and E. coli ∆ribD co-treatment could be due to increased 5-A-
RU conversion to 5-A-RU/MG. Therefore, we assessed whether bacterial enhancement was 
abolished when 5-A-RU was premixed with MG (1:50 molar ratio).  
Consistent with earlier reports (Soudais et al., 2015), 5-A-RU/MG was a more potent activator 
of MAIT cells than 5-A-RU alone, inducing superior production of TNFα and IFNγ (Figure 
5.4A and B). No MAIT cell activation was seen with MG alone (data not shown). Next, we 
added E. coli ∆ribD with different concentrations of 5-A-RU/MG and assessed MAIT cell 
activation. At lower  concentration of 5-A-RU/MG (0.1 nM), addition of E. coli ∆ribD resulted 
in a small enhancement of the production of TNFα; this effect was not evident at higher 5-A-
RU/MG concentrations (Figure 5.4C). In contrast, consistent enhancement of IFNγ production 
by MAIT cells was seen at all the concentrations of 5-A-RU/MG tested when E. coli ∆ribD was 
added (Figure 5.4D). For subsequent experiments, 1nM 5-A-RU/MG was used as this was the 
concentration at which the difference in IFNγ production was most evident (Figure 5.4D). The 
synergy with bacteria and 5-A-RU/MG was further confirmed with two naturally riboflavin 
non-synthesizing bacteria, E. faecalis (Corbett et al., 2014) and Listeria monocytogenes (Gold 
et al., 2010, Davey et al., 2014) (Figure 5.4E and F). Consistent with the observation with 5-A-
RU, the synergy seen with bacterial and 5-A-RU/MG stimulation was completely dependent 





Figure 5.4. Ligand deficient bacteria enhance activation and cytokine production by MAIT cells stimulated 
with either 5-A-RU or 5-A-RU/MG. (A and B) Production of (A) TNFα and (B) IFNγ by MAIT cells was 
assessed following treatment of PBMCs with different concentrations of 5-A-RU ± MG for 6 hours. (C and D) 
PBMCs were treated with different concentrations of 5-A-RU/MG (concentration expressed as the concentration 
of the 5-A-RU component) with or without 10 BpC E. coli ∆ribD for 6 hours and the percentage of MAIT cells 
producing (C) TNFα and (D) IFNγ was assessed. IFNγ production by MAIT cells treated with 1nM 5-A-RU/MG 
± E. coli ∆ribD is shown separately (D). (E and F) Production of (E) IFNγ and (F) CD69 surface expression on 
MAIT cells were assessed by flow cytometry following treatment of PBMCs with either 1 nM 5-A-RU/MG alone, 
or 10 BpC E. faecalis ± 1 nM 5-A-RU/MG, or 10 BpC L. monocytogenes ± 1 nM 5-A-RU/MG for 6 hours; the 
effect of anti-MR1 antibody was also assessed. Data are normalized against samples treated with 1nM 5-A-RU/MG 




for C and D, n=9 for F) and mean ± SEM is shown. Each symbol represents an individual healthy donor. Statistical 
analysis was performed with repeated measures one-way ANOVA using Sidak’s multiple comparison tests (E and 
F) and paired two-tailed t-test (D). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. MFI = mean fluorescent 
intensity. 
 
5.3.5 E. coli ∆ribD mediated enhancement of MAIT cell responses to 5-A-RU/MG 
is type I interferon dependent 
We recently demonstrated an important role of T1-IFN signaling during TCR mediated MAIT 
cell activation, including by ligand producing bacteria (Lamichhane et al., 2019a). Blocking 
STAT3/5 signalling in APCs significantly reducing IFNγ production by MAIT cells stimulated 
by 5-A-RU and E. coli ∆ribD (Figure S5.5D). STAT3 is also important for T1-IFN signalling 
(Lu et al., 2019). Together, this suggested a role of T1-IFNs in the bacterial-mediated synergy. 
To determine whether E. coli ∆ribD mediated enhancement of MAIT cell responses to 5-A-
RU/MG was mediated by T1-IFNs, we treated PBMCs with 5-A-RU/MG + E. coli ∆ribD and 
blocked T1-IFNs with the vaccinia virus protein B18R. Co-treatment with 5-A-RU/MG + E. 
coli ∆ribD resulted in increased expression of CD69, granzyme B, perforin, and IFNγ 
production; increased MAIT cell degranulation was also seen (Figure 5.5A-G). B18R treatment 
completely abolished the enhanced production of granzyme B, perforin, and IFNγ, as well as 
increased CD107a expression on MAIT cells treated with both 5-A-RU/MG and E. coli ∆ribD 
(Figure 5.5C and E-G); significant reductions in CD69 expression and TNFα production were 
also observed (Figure 5.5A and B). Interestingly, compared to 5-A-RU/MG mediated 
activation, which favoured TNFα production, 5-A-RU/MG + E. coli ∆ribD treatment shifted 
the cytokine production towards IFNγ; fewer TNFα mono-producers but more TNFα and IFNγ 
double-producers and some IFNγ mono-producers were observed with the addition of E. coli 
∆ribD (Figure 5.5D). Inhibition of T1-IFNs with B18R had no effect on the frequency of TNFα 
mono-producers (Figure 5.5D). Interestingly, the increased frequency of TNFα and IFNγ 
double-producers and, although not significant, IFNγ mono-producers observed following 5-A-
RU/MG + E. coli ∆ribD treatment also disappeared (Figure 5.5D). Taken together, E. coli 





Figure 5.5. E. coli ∆ribD mediated enhancement of MAIT cell responses to 5-A-RU/MG is type I interferon 
dependent. PBMCs were treated with either 1 nM 5-A-RU/MG alone or in combination with 10 BpC E. coli 
∆ribD ± 1 µg/mL vaccinia virus recombinant protein B18R for 6 hours and the percentage of MAIT cells 
expressing (A) CD69, (B-D) TNFα and/or IFNγ, (E) CD107a, (F) granzyme B, and (G) perforin assessed. (D) 
Representative flow cytometry plots and cumulative data for production of TNFα only, IFNγ only, and both TNFα 
and IFNγ by MAIT cells are shown (D). Data are pooled from two independent experiments (n=8 for all) and mean 




repeated measures one-way ANOVA using Sidak’s multiple comparison tests. *p<0.05, **p<0.01, ****p<0.0001, 
ns = non-significant. MFI = mean fluorescent intensity. 
 
5.4 Discussion 
MAIT cells are innate-like T cells that possess the antibacterial function upon activation by 
bacterially infected cells (Le Bourhis et al., 2010, Kurioka et al., 2015). The discovery and 
synthesis of the bacteria derived MAIT cell activating ligand was a major breakthrough, 
allowing the study of the regulation of TCR mediated MAIT cell activation (Corbett et al., 2014, 
Kjer-Nielsen et al., 2012). In this study, we have used 5-A-RU±MG and 5-A-RU-deficient 
bacteria to dissect the accessory bacterial signals that regulate TCR mediated MAIT cell 
activation. We found that intact but not lysed bacteria enhanced TCR mediated MAIT cell 
activation and that this was mediated by T1-IFNs. 
Riboflavin-synthesising bacteria activate MAIT cells via their TCR at 6 hours and via a 
combination of TCR and inflammatory cytokines at 24 hours (Ussher et al., 2014a, Ussher et 
al., 2016). In the absence of the riboflavin synthetic pathway in bacteria, only late activation via 
cytokines is possible. Here we showed that bacteria that lack either the ability to synthesize 5-
A-RU (E. coli ∆ribD) or the entire riboflavin synthesis pathway (E. faecalis and L. 
monocytogenes) can trigger MAIT cell activation and robust IFNγ production in a TCR 
independent manner. Furthermore, the profile of cytokines induced by E. coli ∆ribD or E. 
faecalis and IL-12+IL-18 were similar, suggesting that the ligand deficient bacteria trigger APC 
activation and production of innate cytokines such as IL-12, IL-15, or IL-18. Consistently, late 
activation by E. coli ∆ribD increased granzyme B and perforin production by MAIT cells in a 
TCR independent manner. This is consistent with previous reports (Ussher et al., 2016, Kurioka 
et al., 2015, Lamichhane et al., 2019b). Therefore, MAIT cell activation via cytokine receptors 
represents an unbiased response to all bacteria.   
MR1 binds pyrimidine derivates of 5-A-RU, an intermediate metabolite of bacterial riboflavin 
synthesis (Corbett et al., 2014). 5-A-RU is converted to 5-OE-RU or 5-OP-RU by non-
enzymatic condensation with glyoxal or methylglyoxal respectively; 5-OE-RU and 5-OP-RU 
covalently bind to MR1 and are recognized by the MAIT cell TCR (Corbett et al., 2014). It is 
not fully understood whether bacteria predominantly furnish preformed 5-OE-RU or 5-OP-RU 
or 5-A-RU, which gets converted to 5-OE-RU or 5-OP-RU by condensation with host derived 




activation (Corbett et al., 2014), we observed robust activation and cytokine production by 
human MAIT cells in response to 5-A-RU, albeit at significantly higher concentrations than 
when 5-A-RU was premixed with MG. Premixing of 5-A-RU with MG resulted in activation 
of MAIT cells at concentrations a thousand fold lower than 5-A-RU alone; this suggests that 
the conversion of 5-A-RU to 5-OP-RU or 5-OE-RU in APCs is inefficient. While bacteria are 
likely to increase glycolysis and the production of MG in the APC (Eisenreich et al., 2017, 
Kelly and O'Neill, 2015), bacteria still enhanced the response to preformed 5-A-RU/MG, 
indicating that they provide co-stimulatory signals other than increased glycolysis and MG 
production.   
Phagocytosis of riboflavin producing bacteria into acidified endocytic compartments has 
previously been shown to be important for MAIT cell activation (Ussher et al., 2016). In a 
previous study, intact E. coli but not the equivalent amount of lysate or supernatant led to robust 
MAIT cell activation (Ussher et al., 2016). In our study, the addition of intact fixed ligand 
deficient bacteria (E. coli ∆ribD, E. faecalis or L. monocytogenes) to 5-A-RU or 5-A-RU/MG 
resulted in increased MAIT cell activation. In contrast, the addition of a lysate of E. coli ∆ribD 
to 5-A-RU had minimal effect on cytokine production compared with 5-A-RU alone. Though 
not investigated directly, a possible explanation is assisted delivery of 5-A-RU±MG to 
endocytic compartments during phagocytosis of bacteria, resulting in more efficient loading 
and presentation of 5-OP-RU on MR1, an effect that is abrogated with the use of bacterial lysate. 
However, this hypothesis is challenged by Ussher et al who found that E. faecalis did not 
enhance the stimulatory capacity of E. coli supernatant, which otherwise triggered modest IFNγ 
production by MAIT cells (Ussher et al., 2016); the amount of MR1 ligand in E. coli supernatant 
is unknown however and may be rate-limiting. Bacterial components (e. g. various agonists for 
TLRs) already present in the bacterial culture supernatant used by Ussher et al. could also 
enhance MAIT cell activation (Ussher et al., 2016 and this study) and thus could be one of the 
main reasons behind the lack of an enhancing effect of E. faecalis during E. coli supernatant 
treatment. 
The importance of NF-κB signaling in the APC for MR1-mediated MAIT cell activation was 
recently shown (Ussher et al., 2016). MR1 surface expression on THP1 cells and subsequent 
MAIT cell activation was completely abrogated when NF-κB signaling was inhibited in THP1 
cells by IKK inhibitor VII during overnight E. coli treatment (Ussher et al., 2016). Consistently, 
we demonstrated complete inhibition of MAIT cell activation against 5-A-RU ± E. coli ∆ribD 




activation remained unaltered by other signaling inhibitors, E. coli ∆ribD mediated cytokine 
production was also significantly affected by a STAT3/5 signaling inhibitor, suggesting the 
STAT3/5 signaling pathway is important for the synergistic effect mediated by bacteria. Since 
STAT3 has been broadly associated with innate signalling mechanisms, including signalling 
via TLRs and type I IFNs, how blocking this pathway is specifically affecting MAIT cell 
activation against the combination treatment is difficult to answer (Yu et al., 2016, Lu et al., 
2019). One way to distinguish the effect would be treating the APCs with STAT3/5 inhibitors 
prior to adding agonists of TLRs or type I IFNs and assessing MAIT cell activation against a 
TCR signal (5-A-RU or 5-A-RU/MG). Future experiments should assess APCs following 
STAT3/5 inhibition for any change in protein expression (flow cytometry or immunoassays) or 
gene expression (by RNA sequencing) to study precise effect of inhibiting STAT signaling. 
Bacteria derived TLR agonists are among the most studied innate co-stimulatory signals during 
bacterial activation of MAIT cells (Chen et al., 2017, Ussher et al., 2016). Mouse MAIT cells 
expressed more CD69 following addition of TLR 2/6 agonist Pam2Cys during 5-OP-RU 
treatment, both in vitro and in vivo (Chen et al., 2017). Consistent with this, we showed 
enhanced CD69 expression on the surface of MAIT cells when agonists of TLR 1 (Pam3Cys) 
or 6 (FSL1) were added, either alone or with 5-A-RU. However, in our experiments IFNγ 
production by 5-A-RU stimulated MAIT cells was not significantly affected, which is in 
contrast to the observation made by Ussher et al. who showed that MAIT cells produced more 
IFNγ in response to E. coli when APCs were first primed with TLR agonists (Ussher et al., 
2016). This may be due to the differences in the experimental setup between the two studies; 
Ussher et al primed APCs with TLR agonists overnight prior to activation with E. coli for 7 
hours (Ussher et al., 2016), while in the current study TLR agonists and 5-A-RU were added 
together for 6 hours only. However, the observation of enhanced IFNγ production by MAIT 
cells in response to 5-A-RU in the presence of bacterial lysate and only partial inhibition of the 
elevated CD69 expression upon blocking type I IFNs during co-treatment with intact E. coli 
∆ribD and 5-A-RU/MG, suggests the role of signals, such as via TLRs, in activating APCs 
which leads to enhanced MAIT cell activation (Ussher et al., 2016). In addition to TLR agonists, 
bacteria provide a plethora of other pathogen associated molecular patterns which, either alone 
or in combination, may be modulating MR1 mediated MAIT cell activation (Banki et al., 2019, 
Lamichhane et al., 2019b). Of note, the production of cytokines by MAIT cells in response to 
5-A-RU or 5-A-RU/MG +/- riboflavin deficient bacteria was completely MR1 mediated, which 




producing bacteria (Ussher et al., 2016, Ussher et al., 2014a, Lamichhane et al., 2019b). 
Together, this supports the hypothesis that TCR signals and bacteria derived signals (sensed by 
the APC) co-operatively regulate the MAIT cell effector responses.  
Type I IFNs are important co-stimulatory signals during early TCR mediated activation of 
MAIT cells by E. coli (Ussher et al., 2016, Lamichhane et al., 2019a). Here, using 5-A-RU/MG, 
E. coli ∆ribD, and type I IFN inhibitor vaccinia virus protein B18R, we confirmed that type I 
IFN produced during bacterial treatment is a key co-stimulatory signal modulating the MAIT 
cell response to a pure TCR signal. Interestingly, the lower concentration of 5-A-RU/MG used 
in these experiments triggered significant activation, degranulation, and cytokine production by 
MAIT cells, but failed to induce the expression of granzyme B and perforin. Nevertheless, the 
production of granzyme B and perforin was boosted by almost five-fold following addition of 
E. coli ∆ribD and was mediated by T1-IFNs. This was consistent with our recent observation 
of strong granzyme B and perforin production by 5-A-RU/MG activated MAIT cells in the 
presence of recombinant type I IFNs or influenza A virus (Lamichhane et al., 2019a). The 
production of perforin in MAIT cells was completely inhibited following T1-IFN blockade in 
this and our previous study (Lamichhane et al., 2019a) but unaffected by MR1 blocking 
(Kurioka et al., 2015, Lamichhane et al., 2019b), which confirms the TCR-independent nature 
of perforin production in MAIT cells and suggests the requirement of strong innate signaling 
for its upregulation. This is an interesting finding as this suggest strict control of the MAIT cell 
cytotoxic response which is only triggered by type I IFNs or proinflammatory cytokines (IL-
12+IL-18) in the context of actual infection. Moreover, IFNγ production by TCR-activated 
MAIT cells was also upregulated by E. coli ∆ribD in a type I IFN-dependent manner. IFNγ 
production was recently demonstrated to be critical for the MAIT cell mediated protection of 
mice against lethal doses of Legionella longbeachae and influenza virus (Wang et al., 2018, 
Wilgenburg et al., 2018).  
In summary, we have demonstrated an essential role for bacteria-derived accessory signals in 
modulating TCR mediated MAIT cell activation. Co-treatment of PBMCs with 5-A-RU+/-MG  
and 5-A-RU-deficient bacteria significantly increased MAIT cell cytotoxic potential and IFNγ 
production. Therefore, harnessing the overall antimicrobial potential of MAIT cells by 
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Since their discovery, MAIT cells have emerged as a distinct unconventional T cell population 
that are abundant in humans and that not only possess antibacterial function but are also 
activated during various viral, fungal, and autoimmune diseases. Co-incidentally, the MR1 
precursor ligand 5-A-RU, which is furnished by riboflavin producing bacteria and fungi, and 
MR1-independent MAIT cell activation by innate cytokines, were both first reported in 2014, 
a year before the start of this study. While a few studies attempted to explore the functional 
potential of MAIT cells in response to either bacterial or cytokine mediated activation, a 
comprehensive investigation of the full range of effector functions of MAIT cells, activated via 
their TCR or by cytokines, was still lacking. By focusing on specific and genome wide 
responses of blood and ld-MAIT cells to the two modes of activation, and by deciphering the 
major innate signals essential for early TCR-mediated MAIT cell activation, this study provides 
important new insights into the immunobiology of these abundant antimicrobial effector cells. 
MAIT cells are not merely responders but coordinate the immune response 
TCR activation of both blood and liver derived MAIT cells, by either synthetic MR1 ligand or 
riboflavin synthesizing bacteria, triggered a robust polyfunctional response with upregulation 
of multiple cytokines (TNFα, IFNγ, IL-17A, and IL-22) and robust productions of various 
chemokines, including CCL3, CCL4, and CCL20 as early as 6 hours after activation. In 
contrast, MAIT cells responded more slowly to cytokine stimulation, resulting in both an 
inflammatory (IFNγ) and cytotoxic phenotype (granzymes and perforin). Together, cytokine 
and TCR activating signals can magnify the MAIT cell effector response, as evident by MAIT 
cells stimulated with riboflavin-synthesising E. coli or 5-ARU/MG and E. coli ribD. However, 
what this implies for bacterial infection in vivo, where the early phase of MAIT cell activation 
is via fast activating TCR signals, while later both TCR and slower acting cytokine signals are 
involved, is difficult to answer. Given the enrichment of MAIT cells in mucosal tissues, their 
ability to reach inflamed site within few minutes in vivo (Lee et al., 2018), and the rapid release 
of chemokines by MAIT cells following activation, it can only be speculated that MAIT cells 
are one of the early responders to infection and their immediate release of multiple pro-
inflammatory cytokines and chemokines could potentially recruit other immune cells to the site 
of infection, including conventional T cells (both CD4+ and CD8+) (Meierovics et al., 2013, 
Meierovics and Cowley, 2016) and neutrophils, as we recently demonstrated in vitro (Appendix 
section, paper 2). During the later phases of infection, MAIT cells become more cytotoxic and 




2013, Le Bourhis et al., 2010) or activate the infected cell through the production of IFNγ, 
promoting killing of intracellular bacteria (Wang et al., 2018). Thus, we propose that TCR and 
cytokine stimulated MAIT cells, both in the blood and in tissues, can co-ordinate immune 
response. 
MAIT cells are tissue repairing T cells 
TCR-activated blood and ld-MAIT cells were not only proinflammatory but additionally 
upregulated genes involved in tissue repair (TNF, VEGFA, PDGFA), suggesting their potential 
to act as tissue repair promoting T cells in humans (Linehan et al., 2018). Using a transcriptomic 
approach, we and others demonstrated that these tissue repair genes are not enriched by cytokine 
stimulation alone, either with the combination of IL-12 and IL-18 (used in this study) or the 
combination of IL-12+IL-18+IL-15+TL1A (Leng et al., 2019), but are induced by bacterial 
challenge in vitro and in vivo (Hinks et al., 2019, Lamichhane et al., 2019, Leng et al., 2019). 
Therefore, the tissue repair function is controlled by TCR stimulation, which was also 
demonstrated by Leng et al. in vitro through a cell scratch assay (Leng et al., 2019). The 
observation that mice lacking MAIT cells develop severe liver steatosis and inflammation (Li 
et al., 2018) and lose gut integrity (Rouxel et al., 2017), and that MAIT cells are able to induce 
peritoneal mesothelial cells remodelling in vitro (Liuzzi et al., 2016), strongly supports a tissue 
remodelling and homeostatic function of MAIT cell in vivo. Together, these studies suggest that 
MAIT cells are equivalent to a class of commensal specific murine H2-M3 specific Tc17 cells 
that promote homeostatic immunity and accelerate wound healing (Linehan et al., 2018). 
Further investigations are required to confirm this hypothesis. 
T1-IFNs are an important co-stimulatory signal during TCR-mediated MAIT cell 
responses 
A recent study by van Wilgenberg et al established T1-IFNs as a strong signal controlling 
cytokine-mediated MAIT cell activation during viral infection (van Wilgenburg et al., 2016). 
Through a systematic set of stimulation and blocking experiments in vitro with or without TCR 
signal, the current study reports for the first time that T1-IFNs, which are actively produced 
during bacterial and viral infections, are important cues for TCR mediated MAIT cell activation. 
We demonstrated both direct stimulatory (upregulation of CD69, CD107, and perforin) and co-
stimulatory (production of IFNγ and granzyme B) effects of T1-IFNs on MAIT cells, with a 
dichotomy between a strong modulation of cytotoxic molecules (granzyme B and perforin) and 




Previous studies by Ussher et al. and Chen et al. argued that TLR agonists are modulators of 
TCR-mediated MAIT cell responses (Chen et al., 2017, Ussher et al., 2016). In this study, TLR 
agonists were weak stimulators of the MAIT cell TCR response when added together with 5-
A-RU, which suggests a requirement for either longer incubations with TLR agonists and TCR 
signal or pretreatment of APCs prior to TCR activation, as Ussher et al. demonstrated (Ussher 
et al., 2016). Interestingly, when T1-IFNs were blocked by vaccinia virus recombinant protein 
B18R in our study, the activation and effector response of MAIT cells induced by E. coli was 
significantly reduced. Furthermore, B18R treatment completely blocked E. coli ∆ribD mediated 
enhancement of the MAIT cell response to 5-A-RU/MG. These results demonstrate strong 
control of MAIT cell activation by T1-IFNs and suggest that T1-IFNs are the major innate 
signal that regulates early MAIT cell activation by bacteria. Given that TLR signalling is 
essential for MAIT cell accumulation in infected lungs in mice (Chen et al., 2017), it would be 
interesting to assess the effect of T1-IFNs on MAIT cell proliferation. 
Blood and ld-MAIT cells are not that different 
On the whole, MAIT cells from blood and liver, despite their differences in tissue origin, were 
remarkably similar in their response to TCR or cytokine stimulation. No significant difference 
in their expression of circulatory or tissue residency genes, suggests the possible recirculation 
of MAIT cells between these two compartments, where MAIT cells are abundant. A recent 
study of blood and ld-MAIT cells reported subtle differences in their tissue residency, but no 
significant differences in the circulatory signature (Salou et al., 2019). During steady state, it 
has been suggested that tissue MAIT cells recirculate via lymph nodes (Voillet et al., 2018). 
Existence of highly overlapping MAIT cell clonotypes between blood and lymph, despite their 
differential activation state, suggests that MAIT cells could also recirculate through blood 
(Voillet et al., 2018). Future studies will be required to define the recirculation of tissue MAIT 
cells. 
6.2 Limitations of this study 
Tc17 function of MAIT cells could not be assessed at the protein level 
One of the interesting findings of this study is the change in the expression of transcription 
factors with activation, especially RORγt (encoded by RORC) which controls the expression of 
IL17A (IL-17A production). We demonstrated enhanced expression of IL17A in MAIT cells 
following TCR stimulation, but could not detect significant levels of IL-17A in the supernatant 




hours of stimulation with either E. coli or 5-A-RU±MG. Stimulation of MAIT cells with both 
T1-IFNs and 5-A-RU/MG resulted in marked enhancement of Tc1 responses. While attempts 
were made to assess IL-17A production by intracellular cytokine staining and flow cytometry 
of MAIT cells activated with T1-IFN and 5-A-RU/MG, no IL-17A production could be 
detected. This suggests stringent control of IL-17A production by MAIT cells, consistent with 
previous reports (Tang et al., 2013, Bottcher et al., 2018). Other signals may be important for 
enhancing IL-17A production by MAIT cells. In addition, the timing of activation (6 hours), 
which resulted in maximal triggering of Tc1 cytokines and chemokines, may not have been 
optimal for Tc17 responses and IL-17A production. Nevertheless, we were able to demonstrate 
TCR biased expression of IL17A in MAIT cells. 
No optimisation experiments for ld-MAIT cells were performed before RNA 
sequencing  
MAIT cells from blood are relatively easy to isolate, allowing their manipulation in vitro. In 
comparison, liver samples were more difficult to acquire and isolation of LMDCs, including 
MAIT cells, was more labour intensive. While, the transcriptomic study of peripheral MAIT 
cells was performed following rigorous optimization to determine the maximal timing of 
activation and effector molecule production, at both protein and transcript levels, in response to 
different stimuli, similar optimization could not be performed for ld-MAIT cells. Appreciating 
the difficulty in obtaining liver samples, the complexity of the isolation procedure, and poor 
viability of LMDCs following cryopreservation (a significant number of samples were lost due 
to this reason), no prior optimisation of the strength or timing of stimulation could be performed. 
Therefore, we used stronger TCR signals (25 BpC E. coli and 100 nM 5-A-RU/MG) than those 
used for blood (10 BpC E. coli and 5 µM 5-A-RU) and isolated bulk MAIT cells (CD3+), rather 
than CD8+ MAIT cells, to get reasonable numbers of maximally activated cells for RNA 
sequencing. However, equivalent activation and comparable effector response of donor 
matched blood and ld-MAIT cells towards TCR stimulation, as assessed by flow cytometry, 
suggests that our experimental approach was reasonable and that the transcriptome of blood and 
ld-MAIT cells could be compared. 
Blood and ld-MAIT cell RNA sequencing data sets were merged despite their 
differences 
The RNA sequencing of blood (CD8+) and ld-MAIT (CD3+) cells was performed at different 




same RNA isolation protocol, the same RNA sequencing procedures (the same Ampliseq kit 
was used for library preparation and sequencing was performed on the same instrument), and 
with all treatments from the same donor sequenced on the same chip. Therefore, we merged the 
two datasets and attempted to compare the transcriptome of blood and liver MAIT cells. Raw 
read counts post sequencing were subjected to normalization in R Bioconductor package 
DESeq2, which stabilizes the data by accounting for sequence depth and RNA composition 
using median of ratios method (Love et al., 2014). Comparison of normalized expression also 
demonstrated a good fusion of datasets as we were able to reproduce similar alteration of gene 
expression between blood and liver. Tight clustering of TCR- or cytokine-activated and non-
activated blood and ld-MAIT cells following the fusion justified our approach. 
6.3 Future directions 
This study paves the way for future studies to address the following: 
• Reproduce the current in vitro findings in vivo in mice to validate the immune 
coordinating function of MAIT cells during bacterial and viral infections. This 
would involve the use of wild-type mice and MR1-/- mice as well as adoptive transfer 
of MAIT cells from wild-type mice to MR1-/- mice and assessing MAIT cell effector 
response as well as quantification of other cell types during different 
infection/stimulation scenarios.   
• With the observation of comparable functional and transcriptomic response of TCR 
stimulated blood and ld-MAIT cells, perform comparative single cell sequencing 
and TCR sequencing of MAIT cells from donor matched blood and liver samples. 
Comparable TCRαβ diversity and usage will support that blood and ld-MAIT cells 
have the same origin with possible recirculation of MAIT cells between 
compartments. Mice parabiosis experiments could further support the findings, 
however given the differences in MAIT cells in humans and mice, the trafficking 
pattern of MAIT cells may differ. 
• With the observation of increased KDM6B expression in MAIT cells upon 
activation, which is important for H3K27 demethylation, it will be interesting to 
explore the effects of KDM6B inhibition on global gene expression by RNA 
sequencing in response to different stimuli.  
• Given the direct bacterial killing ability of IL-26 in vitro, quantify and assess the 
functional role of IL-26 in the supernatant of late activated MAIT cells. IL-26 could 




range of gram positive and gram negative bacteria in the presence of supernatant 
from activated MAIT cells (direct killing) and/or a sub-optimal concentration of 
antibiotics (killing augmentation). 
• Assess the functional significance of bi-phasic CD40L expression on TCR-activated 
MAIT cells. Bi-phasic CD40L expression could be a result of different signals (e.g. 
IL-2) involved in regulating early and late CD40L expression upon TCR 
stimulation. The effect of bi-phasic expression of CD40L on MAIT cells could be 
investigated by co-culturing MAIT cells with MR1 ligand or E. coli treated primary 
monocyte derived DCs for 6 and 24 hours (or longer if needed) and assessing DC 
activation and maturation, with or without blocking the CD40L (on MAIT cells) - 
CD40 (on DCs) interaction. 
• Assess the effect of bacterial signals and the cytokines they induce, such as T1-IFNs, 
on MR1 expression on antigen presenting cells. Given that MR1 is increased on the 
surface of antigen presenting cells in the presence of bacteria or TLR agonists and 
blocking MR1 completely inhibits enhancing effect of T1-IFN during 5-A-RU/MG 
mediated MAIT cell activation, it will be interesting to assess the effect of T1-IFN 
and other bacteria-induced cytokines on MR1 expression on APCs by flow 
cytometry. 
• Assess the effect of T1-IFNs on modulating other effector functions (including IL-
17A and chemokines) and transcription factor expression by MAIT cells. 
Experiments examining chemokine production and transcription factor expression 
by MAIT cells following 5-A-RU/MG mediated activation in the presence or 
absence of T1-IFNs would further our understanding of the impact of T1-IFNs on 
MAIT cell activation. A different experimental approach examining later time points 
and/or tissue derived MAIT cells may be needed to assess the effect of T1-IFNs on 
IL-17A expression as little IL-17A production by MAIT cells was seen in the current 
study.  
6.4 Conclusion 
TCR stimulation of MAIT cells rapidly induces production of chemokines and cytokines, 
alteration of cytotoxic granule content and transcription factor expression, and upregulation of 
co-stimulatory molecules, while cytokine stimulation provokes a slower and more limited 
effector response. T1-IFNs are identified as the major co-stimulatory signal controlling MAIT 




mediated activation than blood MAIT cells but share a similar effector response. Transcriptomic 
analysis suggests that MAIT cells may move between the liver and the blood. Bacterial presence 
triggers better activation and effector response of MAIT cells against TCR stimulation. Overall, 
this study provides a valuable resource that will pave the way for future studies that probe the 
multi-faceted role of MAIT cells in bacterial infection, viral infection and inflammation.  
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Appendix 1. Antibody titration, compensation and gating for functional 
analysis 
Appendix 1.1 Few examples of antibody titration 
1. Gated under CD3+ T cells (without any treatment). 
 
2. Gated under CD3+ CD161++Vα7.2+ (MAIT cells) following E. coli treatment for 6 hours 
 
Red box denotes selected antibody concentration/volume. 







Appendix 1.3 Example of gating for functional analysis 
 
Appendix 2. Expression and trafficking of MR1 
Appendix 3. TCR- or Cytokine-activated CD8+ mucosal-associated invariant 
T cells are rapid polyfunctional effectors that can coordinate immune 
responses 
Appendix 4. Type I interferons are important co-stimulatory signals during T 
cell receptor mediated human MAIT cell activation 
 
 
Expression and trafficking of MR1
Rajesh Lamichhane and
James E. Ussher
Department of Microbiology and Immunology,
University of Otago, Dunedin, New Zealand
doi:10.1111/imm.12744
Received 12 February 2017; revised 5 April
2017; accepted 7 April 2017.
Correspondence: James E. Ussher,
Department of Microbiology and Immunol-
ogy, University of Otago, Dunedin, New
Zealand. Email: james.ussher@otago.ac.nz
Senior author: James E. Ussher
Summary
MHC class I-related gene protein (MR1) is a non-polymorphic MHC class IB
antigen-presenting molecule that is the restricting molecule for mucosal-asso-
ciated invariant T (MAIT) cells, a prominent population of innate-like antibac-
terial T cells. The MAIT cell–MR1 axis represents a new paradigm in antigen
presentation, with the MR1 ligand derived from vitamin B compounds or their
metabolic precursors. Many bacteria and some fungi produce the activating
ligand for MR1. In evolution, MR1 is highly conserved in most, but not all,
mammals. In humans and rodents it is expressed in a broad range of cell types,
both haematopoietic and non-haematopoietic, although cell surface expression
has been difficult to detect. Although MR1 trafficking shares features with
both the MHC class I and MHC class II pathways, it is distinct. Several strands
of evidence suggest that the intracellular location where MR1 is loaded differs
for soluble ligand and for ligand derived from intact bacteria. The regulation
of MR1 surface expression may also vary between different cell types. This
paper will review what is currently known about the expression and trafficking
of MR1 and propose a model for the loading and trafficking of MR1.
Keywords: antigen presentation/processing; bacterial; T cells.
Introduction
MHC class I-related gene protein (MR1) is an evolutionarily
conserved, non-polymorphic MHC class IB antigen-present-
ing molecule that is required for the ontogeny and T-cell
receptor (TCR) -mediated activation of mucosal-associated
invariant T (MAIT) cells, a prominent population of anti-
bacterial innate-like T cells.1 MR1 covalently binds unstable
pyrimidine intermediates and presents them to the MAIT
cell TCR.2,3 These pyrimidines, 5-(2-oxoethylideneamino)6-
D-ribitylaminouracil (5-OE-RU) and 5-(2-oxopropylidenea-
mino)-6-D-ribitylaminouracil (5-OP-RU), are formed by the
non-enzymatic condensation of 5-amino-6-D-ribitylami-
nouracil (5-A-RU), an intermediate in the biosynthesis of
riboflavin, with glyoxal or methylglyoxal, respectively prod-
ucts of other metabolic pathways.3 A diverse range of bacte-
ria and fungi, but not mammalian cells, are able to
synthesize riboflavin, and hence provide the ligand for
MR1.2,4 Therefore MR1 and the MAIT cell TCR together
form a pattern recognition system for riboflavin biosynthe-
sis, and 5-A-RU is a pathogen-associated molecular pattern.
MR1 is highly conserved in mammals
MR1 is highly conserved in most mammals, including
humans, non-human primates, mice, rats, hamsters,
guinea pigs, cows and several marsupials, including the
Tasmanian devil (Sarcophilus harrisii), grey short-tailed
opossum (Monodelphis domestica) and the tammar wal-
laby (Macropus eugenii).5–9 It is, however, lacking from
carnivores, rabbits and the armadillo.10 There is 90% and
89% homology of the a1 and a2 chains between mice
and humans, much higher than for other MHC class I
related genes, whereas the homology of the a3 domain,
which is not involved in the antigen-binding region, is
lower (73%).2,8,9 The similarity is also high between a1
and a2 domains in cattle and mice (81%) and humans
(85%).11
Similar to MHC class I proteins, MR1 has conserved
cysteine residues and b2-microglobulin (b2m)and CD8
contact sites;5 in humans, interaction with CD8 appears
to be important for activation of CD8+ Mycobacterium
tuberculosis-reactive MAIT cells.12 Of note, however, the
cytoplasmic tail of MR1 is longer in rodents than in pri-
mates and contains a conserved motif that could be asso-
ciated with endocytosis, suggesting that there may be
differences in MR1 trafficking between species.13
MR1 is encoded outside the MHC region. In humans
it is found on chromosome 1q25.3, in close proximity to
the CD1 genes,6 whereas in mice and in rats it is found
in homologous segments (chromosome 1 and chromo-
some 13, respectively).5,9 In humans, MR1 has been
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shown to be non-polymorphic. In a study of 10 Africans,
five Asians and five Caucasians, the MR1 sequence was
identical in all but one individual who had two synony-
mous mutations.14
MR1 mRNA is widely expressed
The expression of MR1 mRNA has been assessed in dif-
ferent tissues and cell lines in several different species. In
rats, MR1 expression was seen in homogenates of thy-
mus, liver, spleen, lung, kidney, testis, brain and heart.5
Similarly, MR1 mRNA has been demonstrated in liver,
spleen, lung, kidney, testis, brain, heart and skeletal mus-
cle in mice,8 and in placenta, lung, liver, kidney, spleen,
thymus, prostate, testis, ovary, small intestine, colon and
peripheral blood leucocytes in humans.6 It is not possi-
ble, however, to tell from these studies which cell types
within tissues express MR1, nor whether expression is
restricted to haematopoietic cells. One recent study has
examined the expression of MR1 mRNA by cells in the
mouse thymus. MR1 mRNA was found to be highly
expressed in double-positive thymocytes, with levels of
expression 25-fold higher than in single-positive or dou-
ble-negative thymocytes or in thymic epithelium.15
Although there are no other studies that assess MR1
mRNA expression in purified primary cells, it has been
examined in cell lines. MR1 mRNA expression has been
demonstrated in haematopoietic cell lines of the T-cell
(Jurkat) and B-cell (Molt-4, Raji) lineages and in
multiple non-haematopoietic cell lines of mesenchymal
(HT-1080, SK-LMS-1, U-373) and epithelial (HeLa and
HT-29) origin.8
In addition to the 1263 bp long mRNA that transcribes
the 341 amino acid MR1 protein (also known as MR1A),
several other MR1 transcripts have been described in
multiple tissues.5,6 All of these transcripts can also be
detected in multiple human cell lines of different lin-
eages,8 as well as multiple mouse and rat tissues.5,8
Although the 1263-bp transcript (MR1A) encodes the 341
amino acid MR1, three alternative transcripts (MR1B,
MR1C and MR1D) encode proteins that lack the a3
domain. The MR1C (1578 bp) transcript contains a stop
codon after the a2 domain, and the encoded protein is
predicted to be soluble. In contrast MR1B (776 bp) and
MR1D (2046 bp) retain the transmembrane domain and
the encoded proteins are predicted to be membrane
bound.8 Three predominant MR1 mRNA transcripts are
also seen in cows: a full-length 1100-bp product and two
splice variants (900 and 550 bp). In sheep there is no
550-bp transcript. The 900-bp splice variant lacks the a1
exon and the 550-bp transcript lacks the a1 and a3
exons.11 The function of the alternative MR1 splice vari-
ants (MR1B-D) is only beginning to be addressed and
will not be discussed further in this review.16
MR1 protein expression
Several studies have assessed the expression of MR1 pro-
tein. Using anti-MR1 antibody 26.5, which only recog-
nizes MR1 in a folded (presumed to be ligand-bound)
form,17 surface expression of MR1 was seen at 37° on
some (C1R, L721.221) but not all (JY) B-cell-derived cell
lines, to a lesser degree on some (Jurkat and SupT1) but
not all (Molt4, Peer) T-cell lines, and was absent from
myeloid (U937, HL-60, K562, NB4) and epithelial cell
lines (Caco2, T84).18 Using antibody 12.2, which also
only recognizes MR1 in a folded form,17 MR1 expression
was seen on the L721.221 B-cell line and Jurkat and
SupT1 T-cell lines, and at low levels on C1R and JY B-cell
lines.19 Of note, increased surface expression of MR1 was
seen at 26° in some cell lines (SupT1 and Jurkat),
whereas it became detectable in others (JY, Molt4, Peer),
suggesting that at lower temperature MR1 that is
unloaded or bound to low-affinity ligand may be
expressed at the surface.20 MR1 has also been detected at
the surface of the human bronchial epithelial cell line,
BEAS-2B.21,22 Therefore, surface expression of MR1 seems
to differ between different human cell types.
In mice, a study using the 4E3 antibody clone, which
recognizes a linear epitope in murine MR1, found no
surface expression of MR1 on splenocytes, thymocytes
and several murine cell lines by flow cytometry.23 Fur-
thermore, despite being able to detect transfected MR1,
MR1 could not be demonstrated in cell lysates from
non-transfected cell lines or primary tissues by Western
blot with either 4E3 or antisera raised against the C-
terminal peptide of murine MR1.23,24 However, following
immunoprecipitation with the 26.5 anti-MR1 antibody,
MR1 could be detected by Western blot with antibody
4E3 in the cell lysates of a range of murine cell lines
(WT3 embryonic fibroblasts, F5M and DC2.4 dendritic
cells, CH27 B cells, P815 mast cells and the CMT 64.5
lung carcinoma cell line).25 Expression was also seen in
a wide variety of mouse tissues. Therefore, although
MR1 protein appears to be expressed in a wide range of
murine tissues and cell lines, it is expressed at low levels.
In cows, no MR1 could be detected in blood, thymus,
spleen, colon, ileum or lymph node using an anti-human
MR1 antibody clone 20 that recognized the bovine MR1
on transfected cells.11,17
Surface expression of MR1 has also been difficult to
detect on isolated primary human cells by flow cytometry.
Surface expression of MR1 was not seen on primary
peripheral blood leucocytes, monocyte-derived macro-
phages or dendritic cells using conformation-dependent
monoclonal antibodies, 12.2 and 26.5, or a rabbit poly-
clonal serum, RAMRN-2,19 although in other studies,
small amounts of MR1 were detected at the surface of
dendritic cells and B cells by flow cytometry.21,26 MR1
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has also been detected on the surface of normal human
bronchial epithelial cells.26
Only one study has examined expression of MR1 by
different cell types in situ in tissue. Using monoclonal
antibody 26.5, Gozalbo-Lopez et al.19 demonstrated
expression of MR1 within the lamina propria of the
ileum, appendix and colon by immunohistochemistry.19
MR1+ cells were located outside lymphoid follicles, were
negative for myeloid markers (CD14, CD68, CD11c) and
a T-cell marker (CD3) but were positive for the B-cell
lineage marker, CD19. MR1+ lamina propria cells were
also HLA-DR+, CD38+, CD138+ and IgA+, suggesting that
they were IgA-producing plasmablasts or plasma cells. It
is worth noting that only a subset of
IgA+ CD38+ CD138+ cells expressed MR1. These findings
are consistent with dependence on B cells for MAIT cell
expansion in vivo.27,28
In the study by Gozalbo-Lopez et al. MR1 expression
was restricted to CD19+ cells, but it is likely that other
cells also express MR1 in vivo, even if not detected by
immunohistochemistry. For example, the authors were
unable to detect MR1 expression in human thymus by
immunohistochemistry.19 Nonetheless, MR1 must be
expressed in the thymus as double-positive thymocytes
have been shown to be important for the thymic selection
of MAIT cells, in an MR1-dependent fashion.15 MR1
expression has also been detected by flow cytometry in
single-cell suspensions of human thymus, with expression
restricted to CD3+ CD45+ cells, predominantly the
CD4+ CD8+ subset.12 Similarly, MR1 is likely to be
expressed on cell types other than B cells in vivo, as pri-
mary human and mouse myeloid cells (monocytes, den-
dritic cells, macrophages) and epithelial cells have been
shown to activate MAIT cells in vitro in an MR1-depen-
dent fashion.4,22,29,30
Factors affecting surface expression of MR1
Transient trafficking of endogenous MR1 to the plasma
membrane was recently demonstrated using a novel mon-
oclonal antibody (8H9.D11) that stabilized folded murine
MR1 at the surface of cells.31 This allowed the activation
of autoreactive mouse MAIT cell clones in the absence of
exogenous ligand. Using this antibody, transient surface
expression of MR1 was demonstrated in double-positive
thymocytes, macrophages and dendritic cells.31 This is
consistent with the requirement of MR1 expression by
double-positive thymocytes for MAIT cell development.15
Increased surface expression of MR1 has been reported
following treatment with riboflavin-producing bacteria.
Using a rabbit polyclonal anti-MR1 antibody, infection
with Escherichia coli or Salmonella Typhi was shown to
induce surface expression of MR1 on an Epstein–Barr
virus-transformed lymphoblastoid B-cell line (B-LCL),
HCT-8 epithelial cells and primary B cells; similar
staining was seen in B-LCL with a polyclonal goat anti-
MR1 antibody and with antibody 26.5.32 In the B-LCL,
the amount of MR1 expressed on the surface correlated
with the level of infection. Interestingly, MR1 surface
expression was inhibited by cytochalasin D, which inhi-
bits actin polymerization and hence phagocytosis.32 In
another study MR1 could be detected at the surface of a
B-LCL with antibody 26.5, but was not increased follow-
ing exposure to fixed E. coli.30 In contrast, MR1 could
only be detected on the surface of THP1 cells, a myeloid
cell line, after exposure to E. coli.30 Surface expression of
MR1 has also been detected in M. tuberculosis-infected,
but not uninfected, A549 epithelial cells.4 Therefore,
infection with ligand-producing bacteria increases surface
expression of MR1 in most, but not all, cell lines.
MR1 surface expression is also increased by ligand
alone. Both stimulatory [reduced 6-hydroxymethyl-8-D-
ribityllumazine (rRL-6-CH2OH), 5-A-RU  glyoxal or
methylglyoxal] and non-stimulatory [6-formyl pterin
(6-FP), acetyl-6-formyl pterin (Ac-6-FP)] MR1 ligands
increase the surface expression of MR1 on C1R cells
transduced with human MR1.2,3,26,33 The non-stimulatory
ligand, 6-FP, can also increase the basal surface expression
of MR1 of the BEAS-2B airway epithelial cell line and
primary normal human bronchial epithelial cells.22
Toll-like receptor (TLR) signalling may also play an
important role in MR1 surface expression. In THP1 cells
transfected with human MR1, increased surface expres-
sion was seen following treatment with heat-killed Listeria
monocytogenes, a TLR2 agonist that lacks riboflavin syn-
thetic capacity, or with fixed Enterococcus faecalis, which
also lacks the ability to synthesize riboflavin.30 Further-
more, the E. coli-induced increase in MR1 surface expres-
sion on THP1 cells was inhibited by IKK inhibitor VII,
an inhibitor of the nuclear factor-jB (NF-jB) signalling
pathway. Interestingly, IKK inhibitor VII also inhibited
basal surface expression of MR1 on both THP1 cells and
B-LCLs. Inhibition of NF-jB signalling also inhibited
subsequent MAIT cell activation.30 Supporting the
importance of TLR signalling, a recent study in mice
found that TLR signalling through TLR2/6 (Pam2Cys),
TLR3 (poly I:C) or TLR9 (CpG oligonucleotides) was
essential for the accumulation of MAIT cells in the lung
in response to ligand (5-OP-RU).34 In contrast, in
another study no MR1 up-regulation was seen upon
treatment with lipid A, the biologically active component
of the TLR4 ligand lipopolysaccharide.32 Therefore, the
nature of TLR stimulation may affect the surface expres-
sion of MR1 and is required for MAIT cell accumulation
in vivo.
Intracellular trafficking of MR1
The intracellular trafficking of MR1 and its loading with
ligand is beginning to be clarified, although most
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published studies pre-date the discovery that MR1 pre-
sents a microbially derived ligand.
Like MHC class I and CD1d, MR1 associates directly
and non-covalently with b2m.
19,23,24,35 Consistent with
this, MR1 expression is not seen in Daudi cells, which
lack b2m.
18 Association of MR1 with b2m is required for
trafficking of MR1 from the endoplasmic reticulum (ER)
to the Golgi35 and is also required for surface expres-
sion.16,23 Increased surface expression of MR1 was seen
when MR1 was covalently attached to b2m.
23 Similarly,
replacing the a3, transmembrane and cytosolic domains
of MR1 with those of Ld, a classical MHC class I mole-
cule, increased surface expression of MR1; replacing just
the transmembrane and cytosolic domains leads to a
smaller increase.23 This suggests that the a3 domain of
MR1 interacts more weakly with b2m than classical MHC
class I molecules and that this, along with the transmem-
brane and cytosolic domains, influences intracellular traf-
ficking and surface expression. Lion et al.16 confirmed
that the surface expression of native MR1 was also b2m-
dependent. MAIT cells are absent in b2m-deficient
mice.28,36
MR1 is reported to be associated with the peptide load-
ing complex (calreticulin, TAP, tapasin and ERp57), even
though the MR1 a3 domain lacks some of the consensus
residues that are required for loading complex interac-
tions.23 Native MR1 co-immunoprecipitated with mem-
bers of the peptide loading complex (calreticulin, tapasin
and ERp57) and other ER proteins (calnexin and protein
disulphide isomerase).16 However, using knockout cell
lines, surface expression of MR1 and subsequent activa-
tion of MAIT cell hybridomas by endogenous antigens
was shown to be independent of TAP, tapasin, calretic-
ulin and MHC class Ia molecules.25 Activation of primary
murine MAIT cells by bacterial antigens was also shown
to be TAP-independent.29 Expression of the TAP inhibi-
tor ICP47 in dendritic cells infected with M. tuberculosis
had no effect on their ability to stimulate human MAIT
cell clones.4 Furthermore, MAIT cells are present in TAP-
deficient humans and mice.28,36 Surface expression and
MR1-mediated MAIT cell activation are also independent
of the proteasome.25,29,32 However, similar to class I pre-
sentation, blocking protein transport past the Golgi with
brefeldin A inhibited both MR1 surface expression and
MR1-mediated MAIT cell hybridoma activation.25 There-
fore, although MR1 shares some features of the MHC
class I pathway, its trafficking pathway is distinct.
MR1 also shares features of the MHC class II pathway.
In a murine fibroblast cell line MR1 co-immunoprecipi-
tated with the invariant chain (Ii) and HLA-DM, which
are molecular chaperones associated with the MHC class
II pathway.25 Although overexpression of Ii with or with-
out HLA-DM failed to increase MR1 surface expression,
it enhanced the stimulation of MAIT cell hybridomas and
the trafficking of MR1 to LAMP+ endosomes. Leupeptin,
which inhibits proteolysis of Ii, led to the retention of
MR1 in LAMP+ endosomes and inhibited surface
expression. Furthermore, reduction in the amount of
endogenous Ii with small interfering RNA (siRNA) in a
non-transfected B-cell line, reduced surface expression of
MR1 and inhibited activation of MAIT cell hybridomas.25
In contrast, however, Ii is not required for the ontogeny
of MAIT cells28 and bone-marrow-derived dendritic cells
from TAP/Ii/ mice were equally efficient at activat-
ing MAIT cells in response to bacteria as cells from wild-
type mice,29 although cytokine-mediated MAIT cell acti-
vation was not excluded.37 Of note, Ii has been reported
to associate with MHC class I molecules in dendritic cells
to mediate trafficking to endolysosomes, enabling cross-
presentation of exogenous peptides.38 In summary,
whereas Ii may play a role in trafficking of MR1 to the
endolysosome it is not essential.
As with MHC class II presentation, inhibition of
phagolysosomal acidification with concanamycin A or
bafilomycin A1 decreased surface expression of MR1 and
inhibited stimulation of a MAIT cell hybridoma.25 Inhibi-
tion of endosomal acidification has also been shown to
inhibit activation of primary MAIT cells in response to
ligand-producing bacteria. Treatment of murine bone-
marrow-derived dendritic cells with chloroquine inhibited
the activation of primary mouse MAIT cells in response
to E. coli.29 Similarly, treatment of the human monocytic
cell line THP1 with bafilomycin A reduced the activation
of primary human MAIT cells in response to E. coli.30
The intracellular location(s) of MR1 in the absence of
ligand is controversial. Whereas most studies have found
little MR1 at the cell surface, some have found it to be
restricted to the ER24,26 and others have also found it in
LAMP+ endosomes.22,25 These differences may reflect
experimental differences, in particular the presence or
absence of folic acid-derived ligands in culture media or
the effects of overexpression or molecular tags on MR1
trafficking. There may also be differences in trafficking
between different cell types or between humans and mice:
as mentioned previously, the cytoplasmic tail of MR1 is
longer in rodents than in primates and contains a con-
served motif that could be associated with endocytosis.13
Two studies suggest that in the absence of ligand, MR1
is retained in the ER. In a study by Yamaguchi and
Hashimoto conducted before the identification of the
MR1 ligand, no MR1 could be detected at the surface of
P388-MR1 cells (a mouse lymphoblastoid cell line trans-
fected with MR1) when surface proteins were biotinylated
and immunoprecipitated;24 cells were cultured in folic-
acid-containing media. MR1 was found to be sensitive to
endoglycosidase-H and to glycopeptidase F, suggesting
that it was retained in a pre-Golgi compartment. This
sensitivity of MR1 to endoglycosidase-H was confirmed
in L-MR1 cells, a mouse fibroblast cell line transfected
with MR1.24 Therefore, in the absence of ligand MR1 did
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not acquire the mature state of glycosylation and was
retained intracellularly. This is consistent with the find-
ings of a recent paper by McWilliam et al.,26 where
biotinylated cell surface MR1 could only be detected on
C1R.hMR1 cells, a human lymphoblastoid B-cell line
transfected with MR1, after treatment with agonist
(5-OP-RU) or antagonist (Ac-6-FP) ligands; cells were
cultured in the absence of folic acid to prevent contami-
nation of the media with 6-FP. Up-regulation of ligand-
bound MR1 at the cell surface was also demonstrated
through binding of MAIT TCR tetramer (agonist ligand
only) and 26.5 antibody (both agonist and antagonist
ligand). In the absence of ligand, MR1 was sensitive to
endoglycosidase-H, whereas after treatment with ligand
most MR1 became resistant to endoglycosidase-H, sug-
gesting trafficking through the Golgi; biotinylated surface
MR1 was found to be endoglycosidase-H resistant, con-
firming translocation to the surface of at least a propor-
tion of ligand-bound MR1.26 In human peripheral blood
mononuclear cells (PBMCs), treatment with ligand also
resulted in MR1 becoming endoglycosidase-H resistant.
Inhibiting protein egress from the ER with brefeldin A
prevented the ligand-mediated increase in surface expres-
sion and led to a gradual decline in basal surface expres-
sion. Inhibition of protein synthesis with cyclohexamide
also led to a decline in basal MR1 surface expression but
had less effect on ligand-mediated increases in surface
expression. Similar effects of brefeldin A and cyclohexam-
ide on surface expression of MR1 were also seen in pri-
mary human B cells, CD14+ cells, T cells and normal
human bronchial epithelial cells. There were differences
in basal surface expression of MR1 in the absence of
ligand, with higher levels seen in bronchial epithelial cells
and B cells. There was no increase, however, in surface
expression of MR1 following infection of C1R.hMR1 cells
with Salmonella enterica, although they were able to acti-
vate MAIT cells. Adherent PBMCs infected with S. enter-
ica were also able to activate MAIT cells, and this was
partially inhibited when the adherent PBMCs were co-
incubated with brefeldin A or, to a lesser extent, cyclo-
hexamide.26 Confocal microscopy confirmed that in the
absence of folic acid in the cell culture medium and
exogenous ligand, MR1-GFP was retained in the ER of
C1R.hMR1 cells, whereas with ligand it was found on the
cell surface. In a pulse–chase experiment, endoglycosi-
dase-H-sensitive MR1 slowly declined in the absence of
ligand, suggesting degradation in the ER.26 Therefore,
trafficking of MR1 through the ER is important for the
presentation of soluble ligands and may also play a role
in the presentation of ligands produced by intracellular
bacteria.
McWilliam et al.26 found that MR1 needed to bind to
ligand before it could bind b2m and exit the ER. In con-
trast with previous papers, which used folate-containing
cell culture media,19,23,24,35 McWilliam et al.26 found little
or no b2m associated with MR1 in C1R.hMR1 cells in the
absence of ligand, suggesting that it was not fully folded.
In human PBMCs, however, a small proportion of MR1
appeared to be associated with b2m, which may reflect
binding of an endogenous ligand in vivo. Overall, this
suggests that folding of MR1 and association with b2m is
required for trafficking to the Golgi. This is consistent
with an earlier study by Huang et al.,17 performed before
the identification of the MR1 ligand, where only folded
MR1 was found at the cell surface. Huang et al. used a
mutated MR1 that had been modified to contain the 64-
3-7 epitope (R46Q for human MR1 and K46Q for mouse
MR1), which is normally found in open forms of Ld
molecules.17,23 MR1 modified to contain the 64-3-7 epi-
tope could be detected in either an open conformation
(with the 64-3-7 monoclonal antibody) or in a folded
conformation (with 26.5 or 12.2 antibodies). Significantly
more of the folded conformation of MR1 was seen at the
cell surface and only folded MR1 could activate MAIT
cell hybridomas. Mutations of the ligand binding groove
significantly reduced surface expression of folded MR1
and stimulation of MAIT cell hybridomas, suggesting that
loading of MR1 with an (endogenous) ligand is required
for efficient surface expression.17
The requirement for ligand binding for MR1 to fold
and reach the cell surface was confirmed by McWilliam
et al.26 When C1R.hMR1 cells were cultured in folate-
deficient media and in the absence of exogenous ligand,
only a small amount of MR1 could be immunoprecipi-
tated with a conformation-dependent anti-MR1 antibody
(8F2.F9). In contrast, large amounts of MR1 could be
immunoprecipitated following addition of ligand Ac-6-
FP, and, in HeLa.hMR1 cells, MR1 could be visualized at
the plasma membrane. When ER–Golgi transport was dis-
rupted with brefeldin A, folded MR1 accumulated in the
ER of cells treated with Ac-6-FP. They found that the for-
mation of a Schiff base between the MR1 ligand and resi-
due K43 of MR1 was required for folding of MR1 and
exit from the ER. If the basically charged lysine at residue
43 (K43) was mutated to an alanine (K43A), neutralizing
the basic charge, the K43A mutant MR1 associated with
b2m, became endoglycosidase-H resistant, and was
expressed at the cell surface of C1R cells in the absence of
ligand. In contrast, the K43R mutant, which retained the
positive charge and was unable to form a Schiff bass with
Ac-6-FP, could not fold, and was unable to leave the
ER.26 Therefore the K43 residue of MR1 prevents com-
plete folding, including association with b2m, and causes
retention in ER until ligand is bound; binding of ligand
to K43 neutralizes the basic charge, allowing folding,
association with b2m, and trafficking to the cell surface.
These experiments also suggest that Ac-6-FP can access
the ER by a yet to be defined mechanism.
Other studies, however, which have used folic-acid-
containing cell culture media, have found MR1 in
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endosomal compartments in the absence of exogenous
ligand.22,25 Harriff et al.22 found that in the BEAS-
2B.MR1-GFP airway epithelial cell line, MR1 with a C-
terminal GFP localized not only to the ER but also to the
ER–Golgi intermediate compartment (ERGIC-53), the
trans-Golgi network (TGN-46), and late endosomes/lyso-
somes (Rab7, LAMP1); MR1-GFP was not found in
Rab5+ early endosomes. The majority of MR1-GFP co-
localized with b2m.
22 This is consistent with another
study that used a mouse B-cell line (CH27) overexpress-
ing mMR1.eGFP, where MR1 was found predominantly
to reside in LAMP1+ endolysosomes and in the ER.25 The
addition of a C-terminal GFP tag did not appear to affect
the function of MR1 in either study. Harriff et al. found
that similar to endogenous MR1, MR1-GFP was detect-
able at the cell surface and, in BEAS-2B cells infected with
mycobacteria, was able to stimulate a MAIT cell clone.
Up-regulation of surface expression of both MR1 and
MR1-GFP was seen following treatment with 6-FP.22 Sim-
ilarly, Huang et al.25 demonstrated that both
CH27.mMR1.eGFP cells and CH27.mMR1 cells expressed
similar levels of MR1 at the cell surface and were equally
able to stimulate MAIT cell hybridomas in the absence of
external ligand. It is still possible, however, that the C-
terminal GFP tag alters the intracellular trafficking of
MR1. Aldemir found that MR1-GFP co-immunoprecipi-
tated with b2m in L721.221 cells but not in 293 or HeLa
cells, yet in 293 and HeLa cells MR1-GFP partially co-
localized with LAMP-1.35 Future studies should determine
the intracellular localization of untagged endogenous
MR1 in various cell types; however, it should be noted
that many of the antibodies available (12.2, 26.5 and
8F2.F9) only recognize folded MR1.17,31
Loading of MR1 with soluble ligand can occur in endo-
somal compartments. Harriff et al.22 found that 6-FP
increased the surface expression of MR1 on both BEAS-
2B cells and normal human bronchial epithelial cells, even
though folate was present in the cell culture media, and
that up-regulation of surface expression was markedly
decreased by brefeldin A. Incubation of cells with 6-FP
also resulted in a decrease in the number of MR1-GFP+
vesicles per cell and a decrease in co-localization with
b2m
+ endosomal compartments. A further reduction in
MR1-GFP+ vesicles was seen when cells were pre-treated
with cyclohexamide before 6-FP.22 Together, this suggests
that 6-FP can displace endogenous ligand in MR1+ b2m
+
endosomal compartments, leading to surface expression.
McWilliam et al. also demonstrated that reloading of
MR1 could occur in endosomal compartments. They
found that ~50% of surface MR1 was internalized within
2–4 hr, and trafficked to either early (EEA1+) or late
(LAMP+) endosomal compartments.26 Only a small
amount (~4%) recycled to the surface. The Schiff base
formed between ligand and K43 is labile at the pH pre-
sent in late endosomes, suggesting the possibility of
exchange of covalently bound ligand during recycling.
Indeed, MR1 pre-loaded with 6-FP could be re-loaded
with 5-OP-RU, with 40% of MR1 at the cell surface bind-
ing 5-OP-RU.26
MR1 can also be loaded at the cell surface. Le Bourhis
et al.29 demonstrated that glutaraldehyde-fixed WT3 cells,
a fibroblast cell line, overexpressing MR1 that were co-
incubated with live bacteria were able to activate primary
MAIT cells. Consistent with this, McWilliam et al.26
showed that MR1 could be loaded at the surface of
C1R.hMR1 cells if they were cultured in the absence of
vitamin B antigens but not if pre-treated with 6-FP.
C1R.hMR1 cells were pre-incubated or not with 6-FP at
37°, then incubated on ice with 5-OP-RU for 20 min;
surface-loaded MR1-5-OP-RU was detected with the TCR
tetramer. This suggests that small amounts of empty MR1
or MR1 bound to non-covalently bound ligand must be
expressed at cell surface, even when cultured in the
absence of folic acid.26 Interestingly, when ligand was
removed from the cell culture media, ligand-bound MR1
was rapidly lost from the cell surface, with ~50% lost in
8 hr.26 Therefore, in C1R cells at least, MR1 only remains
at the cell surface as long as vitamin B antigens are pre-
sent in the environment. There may, however, be differ-
ences in trafficking between cell types. In THP1.hMR1
cells, surface expression of MR1 increased with TLR stim-
ulation, even in the absence of exogenous ligand, and
subsequently declined, regardless of whether ligand was
present or not.30
The loading of ligand from intact bacteria onto MR1
may differ from soluble ligand. Harriff et al. found that
the trafficking molecules involved in loading of MR1 in
M. tuberculosis-infected epithelial cells differ from those
required for loading soluble ligand. To identify trafficking
molecules in airway epithelial cells that are uniquely
required for MR1-dependent MAIT cell activation follow-
ing intracellular infection with M. tuberculosis, Harriff
et al.22 used short hairpin RNA to knock down the
expression of various trafficking molecules in BEAS-2B
airway epithelial cells expressing only endogenous MR1.
BEAS-2B cells were then infected with M. tuberculosis and
production of interferon-c by various T-cell clones was
assessed. Twenty-seven candidate genes were identified
that resulted in decreased responses by the MAIT cell
clone but not by the HLA-E or HLA-B45-restricted
clones. Of these, 10 were further evaluated by siRNA
knockdown and eight (Rab3a, Rab3c, Rab3GAP2, Rab6,
Rab34, Sec22b, syntaxin-18 and Vamp4) were validated.22
Rab proteins are GTPases that regulate membrane traf-
ficking: Rab3a is involved in exocytosis;39 Rab3c is found
in recycling vesicles and is involved in recycling of MHC
class I to the plasma membrane and in cross-presenta-
tion;40 Rab6 is a Golgi-resident protein that regulates
both retrograde and anterograde Golgi transport;41 Rab34
is a Golgi-resident protein involved in intra-Golgi
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transport, the secretory pathway, the repositioning of
lysosomes, and fusion of phagosomes with lysosomes;42,43
Rab3GAP2 is a subunit of a GTPase-activating protein
that is involved in the activation of the Rab3 subfamily of
proteins.44 Sec22b, syntaxin-18 (Stx18) and Vamp4 are
SNARE proteins involved in intracellular membrane traf-
ficking: Sec22b is involved in both anterograde and retro-
grade transport between the Golgi and the ER, in
formation of the autophagosome, and in cross-presenta-
tion via transport of proteins directly from the ER–Golgi
intermediate compartment to the phagosome;45,46 Stx18
is localized to the ER and involved in retrograde Golgi–
ER transport and ER-mediated phagocytosis,47,48 and pos-
sibly post-Golgi-trafficking pathways;22,49 Vamp4 is
involved in Golgi–endosome transport and retrograde
endosome–Golgi transport and may also play a role in
regulated exocytosis.50–52 Of note, both Rab6 and Sec22b
have been found in Mycobacterium bovis bacillus Cal-
mette–Guerin-containing phagosomes,53 Rab34 accumu-
lates in Staphylococcus aureus-containing phagosomes and
is associated with delivery of cathepsin D to M. tuberculo-
sis-containing phagosomes,54 and transcription of Rab34
is up-regulated following infection with Mycobacterium
smegmatis in an NF-jB-dependent manner.55
Although knockdown of Stx18, Vamp4 or Rab6 inhib-
ited MAIT cell activation following intracellular infection
with M. tuberculosis, only knockdown of Stx18 inhibited
(partially) 6-FP-dependent translocation of MR1 to the
cell surface; this was seen in both BEAS-2B-MR1-GFP
cells and the parental BEAS-2B cell line.22 Knockdown of
Stx18, Vamp4 or Rab6 had no effect on basal cell surface
expression of MR1 in either cell line; the effect of knock-
down on MR1 surface expression following infection with
M. tuberculosis was not assessed. This suggests that there
are distinct pathways for the presentation of soluble
exogenous ligand and ligand from intracellular bacteria.
Supporting this hypothesis, incubation of BEAS-2B cells
with M. smegmatis supernatant led to MAIT cell activa-
tion but this could be inhibited by pre-incubation with 6-
FP. In contrast, pre-incubation with 6-FP had little effect
on MAIT cell activation in response to intracellular
M. tuberculosis infection. Stx18, which appeared to be
involved in both pathways, co-localized with MR1 in the
ER, whereas Vamp4, which appeared only to be involved
with presentation of ligand from intracellular bacteria,
co-localized with MR1 in endosomal compartments.22
Harriff et al. suggested that the role of Stx18 in MR1
presentation may be independent of its role in retrograde
Golgi–ER transport and ER-mediated phagocytosis.22
Stx18 forms a complex with additional SNAREs (Sec22b,
BNIP1 and Use1) to regulate these processes.48 The
siRNA knockdown of Sec22b and BNIP1 also inhibited
MAIT cell activation, but knockdown of Use1 had no
effect, although the efficiency of silencing was not
reported.22 Knockdown of Stx18, Sec22b and BNIP1 has
previously been shown to disrupt the structure of the ER
and/or Golgi,56–58 whereas knockdown of the murine
homologue of Use1, D12, had no effect on Golgi struc-
ture or the distribution of the KDEL receptor, which
cycles between the Golgi and the ER.49 Although this
complex is involved in retrograde transport, knockdown
of Stx18, Sec22b, BNIP1 or Use1 have also been reported
to inhibit the constitutive secretory pathway, with cargo
blocked in the ER/Golgi.58 Stx18, Sec22b and Use1 have
also been found in phagosomes;46,48,59 Sec22b was shown
to mediate fusion of the ER–Golgi intermediate compart-
ment with the phagosome through interactions with
Stx4, a plasma membrane syntaxin, and this was shown
to be necessary for cross-presentation in dendritic cells.46
Overall, this suggests that even though no effect was seen
with knockdown of Use1, ER–Golgi transport, either ret-
rograde or anterograde, plays an important role in anti-
gen presentation by MR1; ER-mediated phagocytosis may
also be relevant.
In BEAS-2B-MR1-GFP cells, knockdown of Stx18,
Vamp4 or Rab6 led to an increase in MR1-GFP+ endoso-
mal compartments and the amount of GFP per endo-
some.22 This could represent fragmentation of the ER
and/or Golgi or expansion of multi-vesicular bodies/au-
tophagosomal compartments.57,60,61 Using TGN46 as a
marker of the trans-Golgi, disruption of the trans-Golgi
was seen with knockdown of Stx18 or Vamp4, whereas
knockdown of Rab6 made the trans-Golgi more com-
pact.22 Expansion of multi-vesicular bodies/autophagoso-
mal compartments has been reported following Rab6
knockdown.60
Other data support the existence of separate pathways
for loading MR1. In a recent study, inhibition of endoso-
mal acidification (with bafilomycin A) or phagocytosis
(with cytochalasin D) partially inhibited the ability of
THP1 cells, a human monocytic cell line, to activate pri-
mary human MAIT cells in response to fixed intact
E. coli, but had no effect on the response to E. coli super-
natant.30 This is consistent with a previous report that
found that treatment of mouse bone-marrow-derived
dendritic cells with inhibitors of endocytosis and/or
phagocytosis (Dynasore, cytochalasin D) or of endosomal
acidification (chloroquine) inhibited activation of primary
mouse MAIT cells in response to E. coli.29 THP1 cells
treated with fixed intact bacteria (E. coli or S. enterica)
stimulated more MAIT cells to produce interferon-c than
THP1 cells treated with the equivalent culture volume of
bacterial supernatant; treating cells with both E. coli
supernatant and fixed intact Enterococcus faecalis, which
does not produce ligand, did not enhance MAIT cell acti-
vation.30 This suggests that uptake and loading of soluble
ligand differs to bacteria-associated ligand. The ability of
ligand-producing bacteria with differing infectious cycles
to stimulate MAIT cells also supports loading of MR1 in
an endolysosomal compartment. Using a non-phagocytic
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epithelial cell line (HeLa) as the antigen-presenting cell,
Le Bourhis et al.62 assessed their ability to activate MAIT
cells following infection with E. coli, which does not
invade the cell, Salmonella Typhimurium, which invades
the cell but resides in endosomes by preventing fusion
with lysosomes, or Shigella flexneri, which invades the cell
and resides in the cytoplasm. HeLa cells infected with
E. coli or Salmonella Typhimurium failed to significantly
activate MAIT cells, even at high multiplicity of infection,
whereas those infected with Shigella flexneri readily acti-
vated MAIT cells, with efficient killing of infected HeLa
cells. In contrast, HeLa cells overexpressing hMR1
(HeLa.hMR1) readily activated MAIT cells following
infection with E. coli or Salmonella Typhimurium;
HeLa.hMR1 express high levels of MR1 at the cell surface,
suggesting that in addition to the ER, loading of soluble
ligand may have occurred at the cell surface. Interestingly,
abrogating Shigella flexneri’s ability to invade HeLa cells
by deleting MixD, a virulence protein required for entry
into cells, reduced MAIT cell activation to the minimal
levels seen with E. coli and Salmonella Typhimurium. In
contrast to HeLa cells, primary human monocytes
infected with formaldehyde-fixed E. coli, Salmonella
Typhimurium, or Shigella flexneri readily activated MAIT
cells. These differences suggest that bacteria need to access
the endolysosome for ligand to be efficiently loaded onto
MR1. When bacteria fail to reach the endolysosome,
ligand is not available to MR1. Bacteria residing in the
cytoplasm, such as Shigella flexneri, may be targeted to
the lysosomal compartment by autophagy (xenophagy).63
Finally, several lines of evidence support the existence
of an endogenous MR1 ligand(s). First, MR1-dependent
development of MAIT cells occurs in the thymus in utero;
MAIT cells can be detected in multiple human fetal tis-
sues.15,64 Second, surface expression of folded MR1 can
be detected on a variety of non-transfected cell lines and
primary human PBMCs, albeit at low levels, in the
absence of exogenous ligand and even in the absence of
folic acid in the cell culture medium.19,21,22,26,30 Third,
mutations in the ligand-binding groove of MR1 reduced
surface expression and inhibited the ability of WT3 cells
overexpressing MR1 to stimulate MAIT cell hybrido-
mas.17 Endogenous ligand(s) may be derived from folic

































Figure 1. Model of trafficking of MHC-related protein 1 (MR1) and loading with ligand. (1) In the absence of ligand, empty MR1 molecules
accumulate in the endoplasmic reticulum (ER). (2) Binding of an endogenous ligand, such as 6-FP, to MR1 leads to folding and stable associa-
tion with b2-microglobulin (b2m), allowing exit from the ER. (3) MR1 bound to endogenous ligand translocates through the Golgi and reaches
an endolysosomal compartment, either directly, potentially with the help of the invariant chain (li), or (4) indirectly via cell surface expression
and subsequent endocytosis. (5) The low pH environment of the endolysosomal compartment favours exchange of covalently bound ligand with
exogenous ligand (5-OP-RU or 5-OE-RU) derived from either phagocytosed bacteria or acquired directly from the extracellular environment by
an unknown mechanism. (6) From the endolysosomal compartment, ligand-bound MR1 recycles to the cell surface where it can interact with the
MAIT cell T-cell receptor (TCR). (7) Extracellular soluble exogenous ligand can be loaded onto MR1 at cell surface, either by displacing non-
covalently bound endogenous ligand or by binding to unliganded MR1 (not shown), or (8) can access the ER via an unknown mechanism. In
the ER, exogenous ligand is loaded directly onto empty MR1, allowing its trafficking to the cell surface. (9) Xenophagy may deliver cytoplasmic
bacteria to the endolysosomal compartment, where loading of bacterial-derived ligand can occur. (10) Following surface expression MR1 may
either undergo further rounds of recycling or may traffic to the lysosome for degradation.
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occurs in vivo. The existence of non-folic acid-derived
ligands is suggested by the detection of low levels of the
folded form of MR1 at the cell surface in the absence of
folic acid or an exogenous ligand.26 An endogenous
ligand could covalently bind to MR1 Lys43 through the
formation of a Schiff base, as reported for 6-FP,2 or could
bind non-covalently to MR1 and neutralize Lys43, as
reported for some ribityllumazines, diclofenac and
50-hydroxylated diclofenac.18,65 The existence of a non-
covalently bound ligand would be consistent with the
observation that MR1 can be loaded at the cell sur-
face;26,29 alternatively, surface loading may be explained
by the surface expression of small amounts of unloaded,
open conformation MR1, which has been reported in
cells overexpressing MR1.17
In summary, we propose the following model of MR1
loading and trafficking (Fig. 1). In the absence of any
ligand, including that supplied by folic acid supplementa-
tion of media, most MR1 accumulates in the ER in an
unfolded state. In the ER MR1 binds to an endogenous
ligand, allowing folding and association with b2m. MR1
bound to b2m then trafficks through the Golgi to an
endolysosomal compartment, either directly or via the cell
surface. The invariant chain may assist in this trafficking
but is not necessary. Loading of MR1 with activating
ligands can occur in four ways. First, soluble ligand can
access the ER via an unknown mechanism, resulting in
loading and trafficking to the cell surface, where it can
interact with the MAIT cell TCR; this is the dominant
pathway for loading of soluble ligand. Second, soluble
ligand can replace non-covalently bound endogenous
ligand on MR1 transiently expressed at the cell surface or
covalently bound or non-covalently bound endogenous
ligand on MR1 in endolysosomal compartments. Alterna-
tively, ligand may be able to bind to small amounts of
un-liganded, open conformation MR1 that reach the cell
surface. Given the lack of MR1 at the cell surface, loading
by either mechanism is likely to be a minor pathway.
Third, phagocytosed bacteria can access the MR1-contain-
ing endolysosomal compartment where ligand is released
and exchanges with the endogenous ligand. Finally, cyto-
plasmic bacteria, such as Shigella, may be delivered to the
MR1-containing endolysosomal compartment by xeno-
phagy (autophagy). Ligand-loaded MR1 then trafficks to
the cell surface, where it is transiently expressed, before
recycling to the endolysosomal compartment, where it is
eventually degraded. Ligand exchange could also poten-
tially occur upon recycling. Trafficking of MR1 is also
influenced by TLR signalling, at least in some cell types,
with increased cell surface expression seen even in the
absence of exogenous ligand.
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Mucosal-associated invariant T (MAIT) cells can be
activated via either their T cell receptor (TCR), which
recognizesMR1-bound pyrimidines derived frommi-
crobial riboflavin biosynthesis, or via cytokines.
These two modes of activation may act in concert
or independently, depending upon the stimulus. It is
unknown, however, how MAIT cell responses differ
with the mode of activation. Here, we define tran-
scriptional and effector responses of human CD8+
MAIT cells to TCR and cytokine stimulation. We
report that MAIT cells rapidly respond to TCR stimu-
lation, producing multiple cytokines and chemo-
kines, altering their cytotoxic granule content and
transcription factor expression, and upregulating
co-stimulatory proteins. In contrast, cytokine-medi-
ated activation is slower and results in a more limited
response. Therefore, we propose that, in infections
by riboflavin-synthesizing bacteria, MAIT cells play
a key early role in effecting and coordinating immune
responses, while in the absence of TCR stimulation,
their role is likely to differ.
INTRODUCTION
Mucosal-associated invariant T (MAIT) cells are innate-like
T cells, which are abundant in blood,mucosal surfaces, and liver
in humans (Martin et al., 2009). MAIT cells express a semi-
invariant T cell receptor (TCR) consisting of Va7.2-Ja12/20/33
combined with limited Vb diversity (Gherardin et al., 2016).
MAIT cells were originally discovered as CD4CD8alpha
T cells (Porcelli et al., 1993) but are mostly CD8alpha+, express-
ing an effector memory phenotype (Leeansyah et al., 2014).
They also share some features of natural killer (NK) cells, notably
a high expression of the C-type lectin CD161 (Dusseaux et al.,
2011; Billerbeck et al., 2010; Kurioka et al., 2018).
Unlike conventional T cells, whose TCRs recognize peptides
loaded on major histocompatibility complex (MHC) molecules,Cell Report
This is an open access article under the CC BY-NtheMAIT cell TCR recognizes bacteria-derived vitamin B precur-
sor metabolites, recently identified as pyrimidine derivatives of
5-amino-6-D-ribitylaminouracil (5-A-RU), loaded on the non-
polymorphic MHC class Ib related molecule 1 (MR1) (Corbett
et al., 2014; Huang et al., 2005; Kjer-Nielsen et al., 2012; Treiner
et al., 2003). Consistent with this, many riboflavin-producing
bacteria, but not riboflavin-deficient bacteria, have been shown
to stimulate MAIT cells in a MR1-dependent fashion (Gold
et al., 2010; Le Bourhis et al., 2013). Various studies have re-
ported on the killing of bacterially infected cells by MAIT cells
in vitro (Kurioka et al., 2015; Le Bourhis et al., 2013) and their
importance in controlling bacterial infection in mice and humans,
further establishing MAIT cells as important players in anti-bac-
terial immunity (Chua et al., 2012; Georgel et al., 2011; Grimaldi
et al., 2014; Meierovics et al., 2013; Smith et al., 2014; Le Bourhis
et al., 2010; Wang et al., 2018).
MAIT cells express high amounts of the interleukin-18 receptor
(IL-18R) and IL-12R and are able to respond to cytokine signals
independent of their TCR (Ussher et al., 2014). This was initially
shown with the combination of IL-12 and IL-18 (Ussher et al.,
2014; Jo et al., 2014). IL-15 can also activate MAIT cells, but
IL-15-induced MAIT cell activation is IL-18 dependent (Sattler
et al., 2015). MAIT cells can be activated in a TCR-independent
manner by antigen-presenting cells treated with bacteria (Wall-
ington et al., 2018; Ussher et al., 2016) and by virally infected
cells (Loh et al., 2016; van Wilgenburg et al., 2016). Additionally,
MAIT cells are activated in both acute and chronic viral infections
and in patients with systemic lupus erythematous (van Wilgen-
burg et al., 2016; Chiba et al., 2017). Cytokine-mediated activa-
tion is important in vivo, as demonstrated by a recent study in
mice that showed IL-18-dependent MAIT cell accumulation in
lungs and MAIT cell-specific protection against challenge with
a lethal dose of the influenza virus (Wilgenburg et al., 2018).
The in vivo response to bacteria includes not only a TCR-depen-
dent, but also a TCR-independent component driven by cyto-
kines. The synergy between TCR signals and cytokine-mediated
signals to achieve sustained activation of MAIT cells has also
been observed in vitro (Slichter et al., 2016; Turtle et al., 2011;
Ussher et al., 2014).
In recent years, the phenotype and function of MAIT cells have
been extensively explored (Dias et al., 2017; Kurioka et al., 2017).s 28, 3061–3076, September 17, 2019 ª 2019 The Author(s). 3061
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Based on the expression of CD8 and CD4, the MAIT cell
compartment can be divided into functionally distinct subsets.
CD8+ MAIT cells represent the most abundant subset and
show greater functionality in response to stimulation with bacte-
ria, mitogens, or cytokines than the less-abundant CD8CD4
and CD4+ MAIT cell subsets (Dias et al., 2018; Kurioka et al.,
2017). However, the full array of effector functions of CD8+
MAIT cells upon activation is yet to be completely defined.
Importantly, it remains unclear whether functions driven through
the TCR are distinct from those driven in a TCR-independent
manner. In this study, we have explored the full range of effector
functions of TCR- versus cytokine-activated human CD8+ MAIT
cells. Focusing on early events following triggering, we found
marked differences in the production of cytokines, chemokines,
and cytotoxic granule contents and in the expression of tran-
scription factors in MAIT cells depending upon the mode of acti-
vation. These distinct early functional responses may reflect
different roles for MAIT cells in response to diverse infectious
threats and, potentially, to commensal organisms.
RESULTS
Timing of Maximal Activation and Cytokine Profile of
MAIT Cells Differ between TCR and Cytokine
Stimulation
First, we treated human peripheral blood mononuclear cells
(PBMCs) with E. coli or IL-12+IL-18 and confirmed robust
MAIT cell activation via TCR-dependent and TCR-independent
mechanisms (Figures 1A and 1B). The response to E. coli at
6 h was completely MR1 dependent, while at 24 h, it was only
partially MR1 dependent (Figure 1A). The time course of the re-
sponses to both stimuli was then assessed at both the protein
and the mRNA levels (Figures 1C1F). MAIT cells rapidly re-
sponded to E. coliwith the transcription of multiple inflammatory
cytokines genes (TNF [tumor necrosis factor a (TNFa)], IFNG
[interferon g (IFNg)], IL17A [IL-17A], and IL22 [IL-22]) compared
to the untreated control; the maximum response was observed
at 46 h (Figure 1C). Consistently, production of TNFa and
IFNg peaked at 6 h (Figure 1D). While MAIT cells were also
robustly activated with IL-12+IL-18, the response was domi-
nated by the production of IFNg at both mRNA and protein levels
and peaked at 24 and 20 h, respectively (Figures 1E and 1F). To
determine whether the transcription of other genes followed
similar kinetics to IFNg with IL-12+IL-18 stimulation, we as-
sessed the expression of GZMB (granzyme B), PRF1 (perforin),
CCL3, CCL4, and CCL20. The expression of PRF1, CCL3,
CCL4, and CCL20 peaked at 812 h and then remained stably
expressed at 24 h, while the expression of GZMB gradually
increased and peaked at 24 h (Figure S1C). Of note, the expres-
sion levels of GZMB, PRF1, CCL3, CCL4, and CCL20 were
considerably less than that of IFNG (Figures 1E and S1C). There-
fore, MAIT cells respond rapidly to TCR stimulation and are poly-
functional, producing multiple pro-inflammatory cytokines,
whereas cytokine-driven activation is slower and is dominated
by IFNg production.
Since bacteria provide signals in addition to the MAIT-cell-
activating ligand (Ussher et al., 2016), we assessed the response
to theMR1 precursor ligand, 5-A-RU, as a pure TCR signal. MAIT3062 Cell Reports 28, 3061–3076, September 17, 2019cell activation with 5-A-RU at both 6 and 24 h was predominantly
TCR mediated (Figure 1G). Interestingly, MAIT cells stimulated
with E. coli or 5-A-RU for 6 h showed similar cytokine profiles,
which were markedly different from those obtained by IL-
12+IL-18 stimulation for 24 h; with TCR activation, TNFa
mono-producers and TNFa/IFNg double-producers dominated
while very few IFNg mono-producing cells were observed,
whereas with cytokine stimulation, IFNgmono-producers domi-
nated with very few TNFa/IFNg double-producers seen (Figures
1H and 1I). These similar cytokine profiles of E. coli- and 5-A-RU-
activated MAIT cells and the complete dependence of IFNg pro-
duction on MR1-TCR interaction during early E. coli treatment
(Figure 1A) strongly suggest that the early bacterial activation
of MAIT cells is purely TCR dependent. In contrast, E. coli treat-
ment for 24 h, which involved both TCR-dependent and TCR-in-
dependent mechanisms (Figure 1A), elicited a cytokine profile
similar to that induced by IL-12+IL-18 stimulation, although
TNFa mono-producers were only seen with E. coli (Figures 1H
and 1I). These results suggest that the two MAIT-cell-activating
pathways differ not only in the timing of activation, but also in
the resulting cytokine production profiles.
Distinct Transcriptional Profiles of TCR- and Cytokine-
Stimulated MAIT Cells
To further investigate the differences observed with the two
modes of activation, transcriptomic profiles of MAIT cells acti-
vated via TCR with either E. coli or 5-A-RU for 6 h, or via cytokine
receptors with IL-12+IL-18 for 24 h, were generated by RNA
sequencing; untreatedMAIT cells were included for comparison.
The time points were selected to allow comparison of the
maximal transcriptional responses to TCR and IL-12+IL-18 stim-
ulation (Figures 1C, 1E, and S1C). First, we compared the
response of MAIT cells to different treatments by principal
component analysis. We observed good separation of activated
MAIT cells from non-activated MAIT cells across the first two
principal components that together accounted for 62% of total
variability in the dataset (Figure 2A). MAIT cells activated by
E. coli or 5-A-RU formed overlapping clusters that were sepa-
rated from cytokine-treated MAIT cells; this difference was
largely driven by principal component 1 (PC1). We also observed
some similarity between IL-12+IL-18 and E. coli treatments
in PC2.
Next, differentially expressed genes (DEGs) in activated MAIT
cells with respect to rested MAIT cells were analyzed. Substan-
tial transcriptional changes in MAIT cells were observed with the
treatments; DEGsweremore abundant with either E. coli (775) or
5-A-RU (685) treatments than with IL-12+IL-18 (116) (Figure 2B;
Table S1). Interestingly, more than a quarter of DEGswere down-
regulated with both E. coli and 5-A-RU, but very few (8) with IL-
12+IL-18 (Figure 2B). A significant number of DEGs (53, which
was 45% of total DEGs with cytokine stimulation) were shared
in all three treatments, suggesting a core response of activated
MAIT cells regardless of themode of activation. This was evident
with gene set enrichment analysis (GSEA) pathway analysis, with
pathways such as NK-cell-mediated cytotoxicity (Figure S2A),
cytokine-cytokine receptor interaction, TCR signaling pathway,
apoptosis, nucleotide-binding oligomerization domain (NOD)-
like receptor signaling, and JAK/STAT signaling enriched with
Figure 1. T Cell Receptor- and Cytokine-Activated MAIT Cells Differ in Timing of Maximal Activation and Cytokine Profile
(A, B, and G) IFNg production by MAIT cells following stimulation of PBMCs with (A) 10 BpC E. coli ± anti-MR1 antibody or (G) 10 nM 5-A-RU/MG ± anti-MR1
antibody for 6 and 24 h, or (B) IL-12+IL-18 (50 ng/mL each) for 24 h. Biological replicates from two independent experiments andmean ±SEM are shown (n = 9 for
A and B, n = 8 for G). Repeated-measures one-way ANOVA with Sidak multiple comparison (A and G) and two-tailed paired t test (B).
(CF) Expression of cytokines by MAIT cells following stimulation of PBMCs with E. coli (10 BpC for C and 2 BpC for D) or IL-12+IL-18 (50 ng/mL each; E and F);
assessed by RT-PCR on sorted MAIT cells (n = 3 for C and n = 4 for E) or by flow cytometry (D and F; n = 6). Data are presented as mean ± SEM and are pooled
from two independent experiments.
(H and I) Proportion of MAIT cells producing TNFa or IFNg or both following stimulation with either 10 BpC E. coli or 5 mM5-A-RU for 6 h or IL-12+IL-18 (50 ng/mL
each) for 24 h; (H) representative flow cytometry plots and (I) pie chart show proportion producing each cytokine among the activated MAIT cell population
(n = 911). Data are pooled from two independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, non-significant.
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Figure 2. T Cell Receptor- and Cytokine-
Activated MAIT Cells Have Distinct Tran-
scriptional Profiles
(A) Principal component analysis of MAIT cell
transcriptome following stimulation with different
stimuli; PBMCs were treated with 10 BpC E. coli or
5 mM 5-A-RU for 6 h or IL-12+IL-18 (50 ng/mL
each) for 24 h, then sorted for RNA sequencing.
(B) Venn diagram showing shared and unique
DEGs (fold change > 2 and Padj < 0.05) in TCR-
and cytokine-stimulated MAIT cells; total, upre-
gulated, and downregulated DEGs with each
treatment compared to untreated control were
separately analyzed.
(C) Heatmap and dendrogram of the normalized
expression of total DEGs (1,063) with all treat-
ments compared to untreated control.E. coli, 5-A-RU, and IL-12+IL-18. Of note, IL-12+IL-18-stimu-
lated MAIT cells shared more DEGs (84; 72% of total) with
E. coli-treated MAIT cells but less (61; 52% of total) with 5-A-
RU, suggesting bacteria and innate cytokines activate a similar
response that cannot be triggered by the MR1 ligand alone.
GSEA confirmed that many innate signaling pathways that
were enriched with E. coli when compared to 5-A-RU were
also enrichedwith IL-12+IL-18 (Table S2; Figure S2B). Transcrip-
tomic signatures associated with TCR triggering could also be
identified. A tissue repair signature proposed to be associated
with TCR triggering of MAIT cells (Leng et al., 2019; Hinks
et al., 2019) was enriched in MAIT cells following E. coli or 5-A-
RU stimulation but not with IL-12+IL-18 (Figure S2C).
A heatmap illustrating the normalized expressions of total
DEGs with all stimuli also showed marked differences in the
response of MAIT cells at the transcriptomic level; activation
with E. coli or 5-A-RU had more pronounced effects on gene
expression and was clustered separately from the cluster of un-
treated and cytokine-treated MAIT cells (Figure 2C). Taken
together, our data suggest MAIT cells are differentially regulated
by TCR and cytokine stimuli and possess a distinct transcrip-




We next investigated the effect of E. coli,
5-A-RU, or IL-12+IL-18 on the production
of inflammatory cytokines by MAIT cells.
With all stimuli, increased expression of
TNF and IFNG genes was seen; never-
theless, higher TNF expression was
achieved with TCR stimuli and maximum
IFNG expression with IL-12+IL-18 (Fig-
ure 3A). Consistent with this, more
TNFa was detected in the culture super-
natant following stimulation with E. coli
than with IL-12+IL-18; more TNFa was
produced in response to E. coli than
to 5-A-RU (>10-fold) (Figure 3B). Incontrast, more than 10-fold higher concentration of IFNg was
detected upon IL-12+IL-18 stimulation for 24 h, compared
to stimulation with E. coli for 6 h; 100-fold more IFNg was
produced in response to E. coli than to 5-A-RU (Figure 3B).
MR1 blocking significantly inhibited TNFa and IFNg production
by both E. coli and 5-A-RU-treated MAIT cells (Figure 3B).
TCR stimulation also triggered a significant upregulation of
expression of several other inflammatory genes—notably IL1A,
IL1B, IL2, IL6, IL10, IL17A, IL17F, IL21, IL22, and GMCSF—
while with IL-12+IL-18 stimulation, a significant upregulation
of IL10, IL17A, and IL17Fwas seen, but to a much lesser degree
than with TCR-mediated activation (Figures 3A, 3C, and S3A). Of
the cytokines assayed in the supernatant, we detected MR1-
dependent production of IL-1b, IL-2, IL-6, and IL-10 in response
to E. coli but not 5-A-RU; however, only IL-1b and IL-2 were sig-
nificant (Figure 3D). Low-level production of IL-1b, IL-6, and
IL-10 was detected in response to IL-12+IL-18 (Figure 3D).
Therefore, MAIT cells producemore pro-inflammatory cytokines
in response to TCR stimulation than in response to IL-12+IL-18;
the response to E. coli is stronger than to 5-A-RU.
Interestingly, cytokine stimulation—and, to a lesser degree,
TCR stimulation—triggered a significant upregulation of IL26
Figure 3. TCR Stimulation Results in Pro-
duction of More Inflammatory Cytokines
than IL-12+IL-18 Stimulation
(A and C) Log2-transformed gene counts of (A)
TNF, IFNG, IL17A, and IL22 and (C) IL1B, IL2, IL6,
and IL10 from RNA sequencing of sorted MAIT
cells following stimulation of PBMCs with 10 BpC
E. coli or 5 mM 5-A-RU for 6 h or IL-12+IL-18
(50 ng/mL each) for 24 h. Data are presented as
mean ± SEM (n = 7). Repeated-measures one-
way ANOVAwith Sidak multiple comparison tests.
(B and D) Quantification of cytokines (B: TNFa,
IFNg, IL-17A, and IL-22; D: IL-1b, IL-2, IL-6, and
IL-10) by LEGENDplex in either culture superna-
tant from co-cultures of purified Va7.2+ cells and
THP1 monocytes (1:1 ratio) stimulated with 100
BpC E. coli or 5 mM 5-A-RU for 6 h ± anti-MR1, or
culture supernatant of purified Va7.2+ cells alone
or after IL-12+IL-18 (50 ng/mL each) treatment for
24 h. Data are presented as mean ± SEM and are
pooled from two independent experiments (n = 5).
Paired t test was performed on log-transformed
data.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.gene expression, a proinflammatory cytokine of the IL-10
superfamily (Figure S3B). Likewise, cytokine-activated MAIT
cells expressed IL-26 at the protein level, the highest among
CD8+ T cells (Figures S3C and S3D), but early TCR stimulation
failed to induce detectable IL-26 production (Figures S3E
and S3F). However, IL-26 production was detectable upon
late TCR activation by E. coli and 5-A-RU/MG and was signif-
icantly inhibited by MR1 blocking (Figures S3E and S3F).
At 24 h, both E. coli- and 5-A-RU/MG-treated MAIT cells
produced a small amount of IL-26 in an MR1-independent
fashion (Figures S3E and S3F). IL-26 production was also
observed in NK cells (identified as CD3CD161+Va7.2 cells,
80% of which were CD56+) following stimulation with IL-
12+IL-18 or treatment with E. coli for 24 h; the response to
E. coli was independent of MR1 (Figures S3GS3I). Overall,
this suggests that MAIT cells are the main source of IL-26
among CD8+ T cells in response to IL-12+IL-18, and they
also produce it in response to TCR stimulation, but production
is delayed.
Cytotoxic Profile of MAIT Cells Is Different between the
Two Modes of Activation
MAIT cells can kill bacterially infected cells (Le Bourhis et al.,
2013), which is mostly degranulation dependent (Kurioka et al.,
2015). We asked whether degranulation and the cytotoxic
granule content of MAIT cells differ with the mode of activation.
First, we assessedMAIT cell degranulation by assessing the sur-
face expression of CD107a. CD107a surface expression rapidly
increased with both TCR stimuli and IL-12+IL-18, suggesting
both modes of activation are equally potent at triggering degran-
ulation in MAIT cells (Figure 4A). Consistent with this, E. coli-
mediated CD107a expression at 6 h was significantly reduced
with MR1 blocking, whereas only partial inhibition was observed
at 24 h, confirming the previous finding of both TCR-dependentand TCR-independent late degranulation in MAIT cells (Fig-
ure 4A) (Kurioka et al., 2015).
Next, we compared the cytotoxic granule content of MAIT cells
upon activation. Activated MAIT cells upregulated both GZMB
and PRF1 gene expression irrespective of the mode of activation
(Figure 4B). Likewise, the frequency of MAIT cells expressing
granzyme B significantly increased upon both early TCR and
cytokine stimulation (Figure 4C). While the frequency of MAIT
cells expressing perforin increased with E. coli and cytokines, it
did not with 5-A-RU (Figure 4D). Nevertheless, 5-A-RU treatment
for 24 h induced significant granzyme B and perforin expression,
which was completely TCR mediated (Figures S4A and S4B).
MR1 blockade abolished E. coli-induced granzyme B production
completely at 6 h and partially at 24 h, but had no effect on per-
forin production at 6 h and minimal effect at 24 h (Figures 4C
and 4D). Interestingly, E. coli or 5-A-RU treatment triggered
GZMA (granzyme A) downregulation in MAIT cells, but IL-
12+IL-18 treatment resulted in upregulation (Figure 4B). This
difference in granzyme A expression was also evident at the pro-
tein level; both early and late TCR-mediated activation reduced
granzyme A, whereas IL-12+IL-18 significantly increased expres-
sion (Figure 4E). E. coli-mediated granzyme A downregulation
was reversed completely with MR1 blocking at 6 h and partially
at 24 h (Figure 4E). Granzyme A, granzyme B, and perforin were
detected in the culture supernatant of both TCR- and cytokine-
stimulated MAIT cells; however, more granzyme A was detected
in the supernatant of cytokine-treated MAIT cells (Figure 4F).
Differences were also evident in the gene expression of other
granzymes; GZMK (granzyme K) and GZMM (granzyme M)
followed a similar trend to GZMA, while GZMH (granzyme H)
followed that of GZMB, except it was highest with IL-12+IL-18
stimulation (Figure S4C). Overall, these data suggest that MAIT
cells rapidly degranulate upon activation; however, granule con-
tent differs by the mode and timing of activation.Cell Reports 28, 3061–3076, September 17, 2019 3065
Figure 4. Cytotoxic Granule Content of MAIT Cells Differs with the Mode of Activation
(A and CE) Percentage ofMAIT cells expressing (A) CD107a, (C) granzyme B, (D) perforin, and (E) granzyme A following stimulation of PBMCswith either 10 BpC
E. coli or 5 mM 5-A-RU for 6 h or IL-12+IL-18 (50 ng/mL each) or 10 BpC E. coli for 24 h; with E. coli stimulation, the effect of anti-MR1 was assessed. Biological
replicates from two independent experiments and mean ± SEM are shown (n = 7). Repeated-measures one-way ANOVA with Sidak multiple comparison and
two-tailed paired t tests.
(B) Log2-transformed gene counts ofGZMB, PRF1, and GZMA from RNA sequencing of sorted MAIT cells following stimulation of PBMCs with 10 BpC E. coli or
5 mM5-A-RU for 6 h or IL-12+IL-18 (50 ng/mL each) for 24 h. Data are presented asmean ±SEM (n = 7). Repeated-measures one-way ANOVAwith Sidakmultiple
comparison tests.
(F) Quantification of cytotoxicmolecules by LEGENDplex in either the culture supernatant from co-cultures of purified Va7.2+ cells and THP1monocytes (1:1 ratio)
stimulated with 100 BpC E. coli or 5 mM 5-A-RU for 6 h ± anti-MR1, or the culture supernatant of purified Va7.2+ cells alone or after IL-12+IL-18 (50 ng/mL each)
treatment for 24 h. Data are presented asmean ± SEM and are pooled from two independent experiments (n = 5). Paired t test was performed on log-transformed
data.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, non-significant.Cytotoxic T cells can also kill target cells through expression of
FasL. Both TCR- and cytokine-activatedMAIT cells rapidly upre-
gulated FASLG (FasL) gene expression (Figure S4D). Although3066 Cell Reports 28, 3061–3076, September 17, 2019FasL could not be detected on the surface of early activated
MAIT cells, soluble FasL was detected in the culture supernatant
of early TCR-activated MAIT cells in a MR1-dependent fashion
(Figures S4E and S4F). Late E. coli activation significantly
increased FasL expression on the surface and was only partially
reduced uponMR1 blocking (Figure S4E). IL-12+IL-18 activation
enhanced both FasL surface expression and sFasL release into
the media (Figures S4E and S4F), suggesting both activation
pathways contribute to FasL/sFasL expression.
TCR- and Cytokine-Activated MAIT Cells Express
Different Profiles of Transcription Factors
MAIT cells are characterized by a high expression of the
transcription factors RAR-related orphan receptor gt (RORgt),
promyelocytic leukemia zinc finger protein (PLZF), and eome-
sodermin (EOMES), which make them distinct from other
CD4+ and CD8+ T cells (Figure 5A) (Dias et al., 2017; Leeansyah
et al., 2015). Expression of these transcription factors also
varies among different MAIT cell subsets based on CD4 or
CD8 co-receptor expression, resulting in heterogeneity in
phenotype and function (Figure S5A) (Kurioka et al., 2017).
Therefore, we assessed the expression of various transcription
factors in MAIT cells to investigate whether the transcription
factor profile changes with the mode of activation. Interestingly,
compared to resting MAIT cells, the expression of RORC
(RORgt) and ZBTB16 (PLZF) significantly increased with TCR
activation but not with IL-12+IL-18 (Figures 5B and 5C). At
the protein level, we observed corresponding changes in
RORgt expression, but little change in PLZF expression was
observed (Figures 5AC). Upon activation, MAIT cells ex-
pressed high T-bet regardless of the stimuli, both at RNA
(TBX21) and protein levels (Figures 5A, 5C, and 5D). Interest-
ingly, with TCR stimulation, an increase in MAIT cells express-
ing both RORgt and T-bet or RORgt alone was seen, whereas
following IL-12+IL-18 treatment, an increase in MAIT cells ex-
pressing T-bet alone was observed (Figure 5G). Expression of
the PRDM1 (Blimp1) gene went up with both TCR stimuli and
cytokines; however, an increase at the protein level was only
seen with E. coli and cytokines (Figure 5E). EOMES expression,
both at the mRNA (EOMES) and protein levels, was significantly
reduced by both TCR signals but was unchanged with cyto-
kines (Figure 5F). At the protein level, similar changes in the
transcription factors in response to TCR signals and IL-12+IL-
18 were evident in double-negative and CD4+ MAIT cell
subsets (Figures S5BS5F). Taken together, the profile of tran-
scription factor expression in MAIT cells markedly changes
upon activation and is different in TCR- and cytokine-stimu-
lated MAIT cells.
TCR Stimulation of MAIT Cells Results in Chemokine
Production
Production of chemokines by MAIT cells upon activation has
previously been shown (Lepore et al., 2014; Turtle et al., 2011;
Slichter et al., 2016). Next, we examined the expression of
various chemokines by MAIT cells in response to different stim-
uli. A significant expression of CCL3 (encodes ligand for CCR1,
CCR4, and CCR5), CCL4 (encodes ligand for CCR5), and
CCL20 (encodes ligand for CCR6) was seen with all treatments
but was significantly higher in MAIT cells activated with E. coli
and 5-A-RU than with IL-12+IL-18 (Figure 6A). Consistent with
this, CCL3, CCL4, and CCL20 production was detected in theculture supernatant with E. coli or 5-A-RU treatment and was
reduced by approximately 10-fold upon MR1 blocking, confirm-
ing production was MAIT cell specific (Figure 6B). Cytokine stim-
ulation also triggered significant CCL3 and CCL4 production,
albeit at lower levels (Figure 6B). We also observed enhanced
CXCL9, CXCL10, and CXCL11 gene expression, all encoding
ligands for CXCR3, with 5-A-RU and IL-12+IL-18 treatment,
whereas E. coli treatment resulted in a lesser, non-significant
enhancement (Figure 6C). In contrast, at the protein level,
E. coli stimulated maximum CXCL9, CXCL10, and CXCL11 pro-
duction by MAIT cells, followed by treatment with 5-A-RU and
IL-12+IL-18 (Figure 6D); MR1 blocking completely abolished
the production of CXCL9, CXCL10, and CXCL11 by E. coli-
and 5-A-RU-treated MAIT cells (Figure 6D).
Additionally, E. coli, but not 5-A-RU or IL-12+IL-18, resulted in
an upregulation of CXCL8 (IL-8) gene expression (Figure 6C).
Consistent with this, IL-8 production was highest in the superna-
tant from E. coli-treatedMAIT cells and was significantly blocked
by an anti-MR1 antibody (Figure 6D). 5-A-RU and IL-12+IL-18
stimulation also caused low-level, but significant, IL-8 produc-
tion (Figure 6D). The finding of IL-8 production suggested that
MAIT cells may be some of the first responders to bacterial infec-
tion and may assist in recruiting other immune cells, including
neutrophils (Ribeiro et al., 1991). To investigate whether acti-
vated MAIT cells are able to induce neutrophil migration, super-
natants from E. coli-, 5-A-RU-, or IL-12+IL-18-stimulated MAIT
cells were tested in a transwell migration system. Enhanced
neutrophil migration was only observed in response to the super-
natant of 5-A-RU-stimulated MAIT cells (Figures 6E and 6F).
Blocking MR1 signaling completely abrogated the induced
migration, whereas neutralizing IL-8 had no effect, confirming
that it was mediated by the TCR signaling of MAIT cells but
was independent of IL-8 (Figure 6E). Of note, both CCL2 and
XCL2 were upregulated with 5-A-RU stimulation compared to
other treatments (Figure S3A); both CCL2 and XCL2 can trigger
migration of neutrophils by binding to CCR2 and XCR1, respec-
tively (Fox et al., 2015; Huang et al., 2001; Talbot et al., 2015).
Furthermore, a higher concentration of IFNg was seen with
E. coli and IL-12+IL-18 than with 5-A-RU, and IL-10 with E. coli
(Figures 3B and 3D); both IFNg and IL-10 have previously been
shown to inhibit neutrophil migration (Andrade et al., 2013;
Wang et al., 2013).
Overall, MAIT cells produce multiple chemokines upon activa-
tion by both TCR-dependent and TCR-independent mecha-
nisms; however, chemokine profiles differ according to the
mode of activation.
ActivatedMAIT Cells Rapidly Upregulate Co-stimulatory
Molecules
Recently, MAIT cells were associated with the maturation of
monocyte-derived and primary dendritic cells in a CD40L-
dependent manner (Salio et al., 2017). We next investigated
how CD40L is controlled in MAIT cells upon activation. Both
TCR- and cytokine-stimulated MAIT cells rapidly upregulated
CD40LG gene expression (Figure 7A). Unstimulated MAIT cells
did not express CD40L on the surface, but treatment with E. coli
for 6 h led to significant CD40L surface expression; in contrast,
little upregulation was seen with 5-A-RU (Figure 7B). MR1Cell Reports 28, 3061–3076, September 17, 2019 3067
Figure 5. MAIT Cells Express a Distinct Transcription Factor Profile that Changes upon Activation
(A) Expression of different transcription factors by MAIT cells and non-MAIT CD8+ T cells from PBMCs; the gating strategy for MAIT and non-MAIT cells and
representative histograms with fluorescent minus one (FMO) control is shown.
(BF) Expression of different transcription byMAIT cells was compared following stimulation of PBMCs with 10 BpC E. coli or 5 mM5-A-RU for 6 h or IL-12+IL-18
(50 ng/mL each) for 24 h. Log2-transformed gene counts from RNA sequencing of sorted MAIT cells andmean fluorescent intensity (MFI) of MAIT cells are shown
for (B) RORC/RORgt, (C) ZBTB16/PLZF, (D) TBX21/T-bet, (E) PRDM1/Blimp1, and (F) EOMES/EOMES. Biological replicates from two independent experiments
and mean ± SEM are shown (n = 7 for RNA and n = 8 for protein). Repeated-measures one-way ANOVA with Sidak multiple comparison tests.
(G) Upregulation of RORgt alone or T-bet alone or both in MAIT cells upon TCR or cytokine activation was compared; representative plots are shown.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, non-significant.
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Figure 6. Robust Chemokine Production by MAIT Cells Following TCR Activation
(A and C) Log2-transformed gene counts of (A) CCL3, CCL4, and CCL20 and (C) CXCL8, CXCL9, CXCL10, and CXCL11 from RNA sequencing of sorted MAIT
cells following stimulation of PBMCswith 10BpC E. coli or 5 mM5-A-RU for 6 h or IL-12+IL-18 (50 ng/mL each) for 24 h. Data are presented asmean ±SEM (n = 7).
Repeated-measures one-way ANOVA with Sidak multiple comparison tests.
(B and D) Quantification of chemokines (B: CCL3, CCL4, and CCL20; D: CXCL9, CXCL10, CXCL11, and IL-8) by LEGENDplex in either culture supernatant from
co-cultures of purified Va7.2+ cells and THP1 monocytes (1:1 ratio) stimulated with 100 BpC E. coli or 5 mM 5-A-RU for 6 h ± anti-MR1, or culture supernatant of
purified Va7.2+ cells alone or after IL-12+IL-18 (50 ng/mL each) treatment for 24 h. Data are presented as mean ± SEM and are pooled from two independent
experiments (n = 5). Paired t test was performed on log-transformed data.
(E and F) Migrated neutrophils in the lower chamber of a transwell plate in response to supernatant of (E) TCR- or (F) cytokine-activated MAIT cells were
normalized to that of the positive control (IL-8); supernatants from unactivated MAIT cells or following MR1 blockade with anti-MR1 were included as controls.
Each biological replicate and mean ± SEM are shown; independent experiments were performed with each donor (n = 6 for E, n = 5 for F). Repeated-measures
one-way ANOVA with Sidak multiple comparison (E) and two-tailed paired t test (F).
(G) Effect of anti-IL-8 (2 mg/mL) on a number of migrated neutrophils in the lower chamber in response to supernatants of 5-A-RU-activated MAIT cells or IL-8
(5 ng/mL). Each biological replicate from two independent experiments is shown (n = 5 for 5-A-RU supernatant, n = 4 for IL-8). Two-tailed paired t tests.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, non-significant.blocking completely inhibited E. coli-mediated upregulation of
CD40L surface expression at both 6 h and 24 h (Figure 7B).
Also, significant CD40L was seen on the surface of MAIT cellsfollowing IL-12+IL-18 stimulation (Figure 7B). Soluble CD40L
could not be detected in the culture media with any treatments
(data not shown).Cell Reports 28, 3061–3076, September 17, 2019 3069
Figure 7. TCR and Cytokine Activation
Leads to Increased Expression of Co-stimu-
latory Molecules on MAIT Cells
(A and D) Log2-transformed gene counts of (A)
CD40LG and (D) TNFRSF9 from RNA sequencing
of sorted MAIT cells following stimulation of
PBMCs by 10 BpC E. coli or 5 mM5-A-RU for 6 h or
IL-12+IL-18 (50 ng/mL each) for 24 h. Data are
presented as mean ± SEM (n = 7). Repeated-
measures one-way ANOVA with Sidak multiple
comparison tests.
(B and E) Percentage of MAIT cells expressing (B)
CD40L or (E) 4-1BB following stimulation of
PBMCs with either 10 BpC E. coli or 5 mM 5-A-RU
for 6 h or IL-12+IL-18 (50 ng/mL each) or 10 BpC
E. coli for 24 h; with E. coli treatment, the effect of
anti-MR1 was assessed. Biological replicates
from two independent experiments and mean ±
SEM are shown (n = 6 or 7 for B, n = 7 or 8 for E).
Repeated-measures one-way ANOVA with Sidak
multiple comparison and two-tailed paired t tests.
(C) Percentage of MAIT cells expressing CD40L
and CD69 following stimulation of PBMCs with 10
BpC E. coli (±anti-MR1), 5 mM 5-A-RU, or IL-
12+IL-18 (50 ng/mL each) for the time indicated.
Data are presented as mean ± SEM and are
pooled from two independent experiments (n = 7).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001;
ns, non-significant.To determine the kinetics of CD40L expression, PBMCs were
treated with E. coli, 5-A-RU, or IL-12+IL-18 for different lengths
of time; with E. coli treatment, the contribution of TCR signaling
was assessed by blocking MR1. Interestingly, with both E. coli
and 5-A-RU, CD40L expression increased rapidly, peaking at 6
h, before decreasing to a trough at 12 h and then increasing again
by 24 h (Figure 7C). This biphasic expression of CD40L has pre-
viously been reported on other T cells following TCR stimulation
(Chakrabarty et al., 2011; Snyder et al., 2007). With E. coli stimu-
lation, blocking MR1 completely inhibited CD40L expression on
MAIT cells throughout the time course. In contrast, with IL-
12+IL-18 stimulation, CD40L expression increased steadily
throughout the time course; this was consistent with the observa-3070 Cell Reports 28, 3061–3076, September 17, 2019tion in Figure 7B. In contrast to CD40L,
CD69 expression on MAIT cells gradually
increased throughout the timecoursewith
all treatments (Figure 7C).
We also observed an increased expres-
sion of TNFRSF9 (4-1BB or CD137), a
gene encoding a co-stimulatory molecule
on activated T cells that can trigger matu-
ration, activation, and migration of cells
expressing 4-1BBL, such as dendritic
cells (Lippert et al., 2008), by both TCR-
and cytokine-activated MAIT cells, with
the highest expression seen with TCR
stimuli (Figure 7D). Consistent with this,
high surface expression of 4-1BB was
seen following early TCR activation,
which was completely MR1 mediated(Figure 7E). A small percentage of MAIT cells also expressed
4-1BB upon stimulation by IL-12+IL-18, suggesting cytokines
alone can induce 4-1BB onMAIT cells (Figure 7E). Late TCR acti-
vation by E. coli resulted in a high expression of 4-1BB that was
only partially blocked with an anti-MR1 antibody (Figure 7E).
Therefore, TCR stimulation induces a robust 4-1BB surface
expression on MAIT cells; however, cytokines alone can induce
its expression, albeit to a lesser extent.
Lysine Demethylase 6B Is Important for MAIT Cell
Activation
Finally, expression of KDM6B (lysine demethylase 6B, also
known as Jumonji domain containing protein 3 [JMJD3]) was
specifically enriched upon TCR activation (Figure S6A). Inhibition
of KDM6B by GSK-J4 demonstrated it was important for the up-
regulation of CD69 and 4-1BB following stimulation with E. coli,
but not for TNFa and IFNg production in MAIT cells (Figures
S6BS6F). GSK-J4 treatment had a similar effect on the expres-
sion of CD69 and 4-1BB on 5-A-RU-stimulated MAIT cells (Fig-
ures S6G and S6H). Even though IL-12+IL-18 stimulation
resulted in only a small upregulation of KDM6B expression (Fig-
ure S6A), inhibiting KDM6B also reduced CD69 and 4-1BB
expression at 24 h on IL-12+IL-18-stimulatedMAIT cells (Figures
S6I and S6J). In summary, the histone demethylase KDM6B is
important for the MAIT cell activation.
DISCUSSION
MAIT cells are abundant unconventional T cells that can be acti-
vated either via their TCR or by innate cytokines. Here, we have
characterized their responses to these two modes of activation.
TCR activation of MAIT cells resulted in rapid activation, with
production of multiple proinflammatory cytokines; in contrast,
cytokine-mediated activation was slower and less polyfunc-
tional. Substantial differences in the cytotoxic granule content
upon TCR and cytokine stimulation were also noted. These
differences in effector functions by mode of activation were
underpinned by changes in transcription factors expression.
Production of chemokines and upregulation of co-stimulatory
molecules with activation were also demonstrated and suggest
a role for MAIT cells in coordinating the recruitment and activa-
tion of other immune cells.
Early TCR activation with 5-A-RU or E. coli triggers higher
TNFa production by MAIT cells than IL-12+IL-18. Upon stimula-
tion with IL-12+IL-18, MAIT cell cytokine production shifts to
IFNg. This is consistent with an earlier study where human
PBMCs were activated with either anti-CD3/CD28 beads or a
combination of IL-12/15/18 (Slichter et al., 2016). A similar
response has been reported when hepatic MAIT cells were
stimulated with anti-CD3/CD28 beads (Jo et al., 2014). A
predominance of IFNg production with little TNFa production
was seen when hepatic MAIT cells were treated overnight with
Pseudomonas aeruginosa, a riboflavin-synthesizing bacterium
(Jo et al., 2014); this is consistent with the response we observed
from blood MAIT cells following treatment with E. coli for 24 h.
This highlights that the early MAIT cell response to riboflavin-
synthesizing bacteria differs from the late response and is
consistent between blood and hepatic MAIT cells. With the
observation that production of IFNg, IL-17A, and IL-22 accom-
panies TNFa in early TCR activation, we propose that a TCR
signal is critical for TNFa production and polyfunctionality of
MAIT cells.
While MAIT cells stimulated via their TCR with either E. coli or
5-A-RU showed a considerable overlap in their transcriptional
and functional profiles, there were substantial differences in
DEGs, which were evident in principal component 2 of the prin-
cipal-component analysis (PCA). Of note, cytokine-stimulated
MAIT cells sharedmore DEGs with E. coli than 5-A-RU, suggest-
ing a role for innate signaling. It has now been established that
bacteria furnish co-stimulatory signals, TLR agonists being
most commonly studied, that result in antigen presenting cell(APC) activation and enhancement of MAIT cell activation
(Chen et al., 2017; Ussher et al., 2016). Consistent with this,
pathway analysis demonstrated similarities between E. coli-
and IL-12+IL-18-activated MAIT cells, with the enrichment of
innate signaling pathways including type I IFNs, pattern recogni-
tion receptors, and MYD88/TRIF. However, these signals must
work in concert with TCR signaling to modulate MAIT cell activa-
tion, as the MR1 blockade almost completely inhibited the
early MAIT cell response (IFNg, granzyme B, and chemokines)
to E. coli.
The hypothesis that TCR triggering leads to early polyfunction-
ality in MAIT cells was confirmed by RNA sequencing. In addition
to TNF, IFNG, IL17A, and IL22, the expression of many pro-
inflammatory cytokine genes, including IL1B, IL6, IL21, and
GMCSF, was upregulated with TCR stimulation. However, a
significant production of only TNFa, IFNg, and IL-1b could be
detected in the culture supernatant of E. coli-activated MAIT
cells; GM-CSF was not assayed. These differences between
gene expression and protein production could be due to the
different culture systems used (PBMCs versus a co-culture of
THP1 cells and Va7.2+ cells) and the presence or absence of
necessary additional signals (e.g., IL-7, which enhances IL-17A
production) (Tang et al., 2013). Arguing against this, however,
another study (Bennett et al., 2017) reported a significant detec-
tion of IL-2, IL-6, IL-10, IL-17A/F, IL-21, and IL-22 in the culture
supernatant following overnight stimulation with E. coli using
the same co-culture system as ours. In that study, TCR signaling
was only partially responsible for the production of IL-6, IL-10,
and IL-21. This may be due to the different times post-stimula-
tion at which cytokine production was assessed. Of note, the
major pro-inflammatory mediators TNFa, IL-6, and IL-1b are
highly expressed at both mRNA and protein levels with E. coli
but not with 5-A-RU or IL-12+IL-18 stimulation, suggesting that
TCR activation by riboflavin-synthesizing bacteria is required
for some pro-inflammatory responses by MAIT cells.
A striking difference was observed in the cytotoxic granule
content of MAIT cells with the two modes of activation. Perforin,
granzyme A, and granzyme B were all substantially induced by
IL-12+IL-18, whereas early TCR activation triggered a smaller in-
crease in granzyme B and a decrease in granzyme A. By 24 h,
activation by E. coli triggered substantial granzyme B and
perforin production, which was partially TCR dependent and
partially TCR independent. Activation with 5-A-RU for 24 h
induced significantly more granzyme B and perforin compared
to activation for 6 h; this suggests that changes in the cytotoxic
granule content of MAIT cells is a time-dependent process, and
for a strong response, prolonged activation via the TCR, cyto-
kines, or a combination of both is required. We and others
have demonstrated granzyme A downregulation in MAIT cells
with TCR signals, which was an intriguing finding that demands
further investigation (Kurioka et al., 2015). Conversely, granzyme
A upregulation with cytokines could be important in controlling
viral and bacterial infections: unlike granzyme B, granzyme A
can potently mediate cytolysis in the presence of caspase inhib-
itors (Zhang et al., 2001; Blasche et al., 2013) or, alternatively,
may aid in the inflammatory response, as discussed previously
(Kurioka et al., 2015). Additionally, both modes of activation
result in the upregulation of FasL on the surface of MAIT cells;Cell Reports 28, 3061–3076, September 17, 2019 3071
FasL is involved in death receptor-mediated killing of infected
cells (Varanasi et al., 2014).
MAIT cells may also exercise direct killing of extracellular bac-
teria through the release of antibacterial peptides such as IL-26
(Meller et al., 2015) and antimicrobial chemokines such as
CXCL9 and CXCL10 (Margulieux et al., 2016; Reid-Yu et al.,
2015). This makes MAIT cells one of many cell populations
contributing to the pool of antimicrobial peptides at the site of
infection or inflammation. Indirectly, MAIT cells can assist in bac-
terial killing by recruiting neutrophils to the site of infection, as
suggested in our study, and by augmenting neutrophil survival
via the release of TNFa, IFNg, and GM-CSF (Davey et al.,
2014). In a positive-feedback mechanism, MAIT cells could
also promote dendritic cells (DCs) to produce type I interferons
in an IL-26-dependent manner, which augments IFNg release
by MAIT cells in response to other cytokines (Meller et al.,
2015; vanWilgenburg et al., 2016). IFNg production in MAIT cells
was recently shown to be critical for protection against Legion-
ella longbeachae and influenza virus infection in mice (Wang
et al., 2018; Wilgenburg et al., 2018).
Transcription factor profiling in activated MAIT cells was
consistent with the observed acquired effector functions in pre-
vious studies on MAIT cells. Elevated RORgt expression was
seen with TCR activation and is consistent with increased
IL-17A expression (Wang et al., 2018). Both TCR and cytokine
activation resulted in increased expression of T-bet, which is
consistent with the substantial IFNg production. Increased
Blimp1 expression with E. coli and cytokines was consistent
with more granzyme B production than with 5-A-RU, whereas
reduced EOMES expression following early TCR stimulation
was consistent with an overall lower cytotoxic response of early
TCR-activated MAIT cells compared to IL-12+IL-18 activation
(Kurioka et al., 2017, 2015). Transcription factor profiles were
also assessed in otherMAIT cell populations. At rest, CD4CD8
double-negative (DN) MAIT cells expressed a similar transcrip-
tion factor profile as CD8+ MAIT cells, consistent with the recent
report where DNMAIT cells were shown to be functionally similar
to CD8+ MAIT cells (Kurioka et al., 2017). On the other hand,
CD4+ MAIT cells (<5% of the MAIT cell population) expressed
lower levels of PLZF and EOMES, consistent with the findings
of Kurioka et al. (2017), who demonstrated that they also
possess lower cytotoxic potential than CD8+ and DNMAIT cells.
Although not all changes reached statistical significance, the
trends in changes of transcription factor expression upon activa-
tion were similar in all subsets, suggesting that all MAIT cells un-
dergo similar functional changes during activation, although this
was not formally assessed in this study.
KDM6B is one of the two histone demethylases (the other
being KDM6A or UTX) that removes the methyl mark from
H3K27, relieving the suppression of transcription and inducing
an inflammatory response (Falvo et al., 2013). Murine studies
have confirmed demethylated H3K27 is heavily enriched at
IL17A/IL17F locus in Th17 cells and also controls RORC expres-
sion (Mukasa et al., 2010). Our data suggest that upon TCR stim-
ulation, MAIT cells significantly upregulate KDM6B (>13- and
>10-fold change with E. coli and 5-A-RU, respectively), which
could lead to the subsequent upregulation of RORC and IL17A
expression. We also demonstrated that H3K27me3 is an impor-3072 Cell Reports 28, 3061–3076, September 17, 2019tant epigenetic modification during activation of MAIT cells.
Conversely, IL-12 treatment of Th17 cells was previously re-
ported to lead to a substantial increase in H3K27me3 at the
IL17A/IL17F locus and H3K4me accumulation at the IFNG locus,
leading to a reduction of IL-17 and increased IFNg production,
consistent with our data (Mukasa et al., 2010). Thus, the mode
of activation modulates the fate of MAIT cells by epigenetic
remodeling.
We found that MAIT cells produce multiple chemokines upon
activation that may aid in recruiting various immune subsets to
the site of infection and promoting local inflammation. TCR
signals induced a stronger production of chemokines by MAIT
cells. Previous studies have also reported substantial chemokine
production by MAIT cells upon TCR activation via CD3/CD28
(Turtle et al., 2011; Slichter et al., 2016) or in a co-culture with
bacteria-fed monocytes (Lepore et al., 2014; Wakao et al.,
2013). However, these studies were performed with longer acti-
vation periods (1624 h or overnight). Here, we confirmed that
MAIT cells possess this immune cell recruiting capacity as early
as 6 h after activation. We also showed that IL-12+IL-18 alone
can stimulate modest chemokine production, particularly
CCL3, CCL4, and CXCL10. These chemokines are involved in
lymphocyte trafficking and therefore could contribute to recruit-
ing lymphocytes during infections with viruses or non-riboflavin-
synthesizing bacteria. Moreover, a combination of cytokines and
TCR signals can work in synergy to trigger robust chemokine
production by MAIT cells (Havenith et al., 2012).
In addition to this direct chemokine response, soluble media-
tors in the supernatant from stimulated MAIT cells have been
shown to trigger the production of various chemokines, such
as CCL2, IL-8, and CXCL10, by peritoneal epithelial and fibro-
blast cells (Liuzzi et al., 2016). MAIT cells and gd T cells were
shown to migrate to infected peritoneal tissues in response to
locally elevated levels of CCL2, CCL3, CCL4, and CCL20 (Liuzzi
et al., 2016). High production of CCL3, CCL4, and CCL20, along
with moderate production of CXCL9 and CXCL10 by both TCR-
and cytokine-stimulated MAIT cells, was observed in our study;
combined with high expression of CCR5, CCR6, and CXCR3 on
MAIT cells (Dias et al., 2017; Kurioka et al., 2017), this suggests
that MAIT cells, in the presence of both riboflavin-synthesizing
bacteria and other inflammatory stimuli, may directly recruit
other MAIT cells and/or gd T cells (Figure S7). Furthermore, sig-
nificant production and release of TNFa and IL-1b observed with
bacterial stimulation can further facilitate this process by upregu-
lating E-selectins, I-CAM, and V-CAM on endothelial cells (Kim
et al., 2017). Therefore, activated tissue resident MAIT cells
could recruit peripheral MAIT cells, along with other proinflam-
matory leukocytes, to the site of infection.
Recent studies have demonstrated that MAIT cells do not just
provide defense against invading pathogens, but may also have
a broader role in the regulation of the immune response through
the maturation of primary DCs and providing B cell help (Bennett
et al., 2017; Salio et al., 2017). Both TCR and innate signals were
found to upregulate helpermolecules onMAIT cells. Additionally,
MAIT cells were recently shown to induce local tissue remodel-
ing (Liuzzi et al., 2016). Here, we observed a specific upregula-
tion of genes associated with tissue repair and wound healing,
which was recently described to be a feature of commensal
responsive skin resident CD8+ populations in non-human
primates and mice (Linehan et al., 2018). This response was
evident with TCR activation but not with cytokine activation.
Our finding was consistent with those of Leng et al. (2019),
who demonstrated a similar enrichment of genes involved in tis-
sue repair functions in TCR and TCR+cytokine but not cytokine
triggered peripheral human MAIT cells, and Hinks et al. (2019),
who reported an enrichment of the tissue repair pathway in
5-OP-RU-stimulated human MAIT cells and MAIT cells from
mice acutely infected with L. longbeachae. Together, this
confirms that the tissue repair function is a signature of TCR-acti-
vated MAIT cells. Therefore, it is now becoming clear that MAIT
cells are not just inflammatory and cytolytic T cells, but are also
helper cells involved in tissue repair and maintaining homeosta-
sis at the mucosal barrier and in the liver.
In this paper, we explored the response of TCR- and cytokine-
stimulated MAIT cells from peripheral blood. Future investiga-
tions will shed light on whether effector function profiles of
MAIT cells from different tissues also differ with themode of acti-
vation andwill enable us to understand the role of MAIT cells as a
friend, a foe, or merely a bystander in disease progression. The
limited number of cytokines assessed in the time course studies
gave us a snapshot of the timing of MAIT cell activation; other
effector functions induced by a pure TCR signal should be as-
sessed by a detailed transcriptomic analysis at later time points
to better define the induction and persistence of particular
effector functions following TCR stimulation.
In summary, our findings show that TCRs and cytokines
are both potent modes of triggering MAIT cell activation.
MAIT cells activated via IL-12+IL-18 upregulate T-bet, perforin,
granzyme B, and IFNg and are less pro-inflammatory, consis-
tent with a Tc1-like phenotype, while TCR-activated MAIT cells
robustly and rapidly upregulate RORgt, IL-17A, TNFa, and
many other pro-inflammatory cytokines and chemokines,
consistent with a Tc17 phenotype (Figure S7A). This plasticity
in MAIT cell phenotype and function with the mode of activation
is explained by changes at the transcriptomic and epigenetic
levels. During a bacterial infection, both modes of activation
cooperate to make MAIT cells potent early responders,
combining direct antimicrobial activity with the recruitment
and provision of help to other proinflammatory immune cells
(Figure S7B).STAR+METHODS
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PGC-1alpha-responsive genes involved in oxidative phosphorylation are coor-
dinately downregulated in human diabetes. Nat. Genet. 34, 267–273.
Morissette, M.C., Parent, J., and Milot, J. (2007). Perforin, granzyme B, and
FasL expression by peripheral blood T lymphocytes in emphysema. Respir.
Res. 8, 62.
Mukasa, R., Balasubramani, A., Lee, Y.K., Whitley, S.K., Weaver, B.T., Shi-
bata, Y., Crawford, G.E., Hatton, R.D., and Weaver, C.T. (2010). Epigenetic
instability of cytokine and transcription factor gene loci underlies plasticity of
the T helper 17 cell lineage. Immunity 32, 616–627.
Munk, R.B., Sugiyama, K., Ghosh, P., Sasaki, C.Y., Rezanka, L., Banerjee, K.,
Takahashi, H., Sen, R., and Longo, D.L. (2011). Antigen-independent IFN-g
production by human naı̈ve CD4 T cells activated by IL-12 plus IL-18. PLoS
ONE 6, e18553.
Porcelli, S., Yockey, C.E., Brenner, M.B., and Balk, S.P. (1993). Analysis of
T cell antigen receptor (TCR) expression by human peripheral blood CD4-8-
alpha/beta T cells demonstrates preferential use of several V beta genes
and an invariant TCR alpha chain. J. Exp. Med. 178, 1–16.
Reid-Yu, S.A., Tuinema, B.R., Small, C.N., Xing, L., and Coombes, B.K. (2015).
CXCL9 contributes to antimicrobial protection of the gut during citrobacter
rodentium infection independent of chemokine-receptor signaling. PLoS
Pathog. 11, e1004648.
Ribeiro, R.A., Flores, C.A., Cunha, F.Q., and Ferreira, S.H. (1991). IL-8 causes
in vivo neutrophil migration by a cell-dependent mechanism. Immunology 73,
472–477.
Salio, M., Gasser, O., Gonzalez-Lopez, C., Martens, A., Veerapen, N., Gileadi,
U., Verter, J.G., Napolitani, G., Anderson, R., Painter, G., et al. (2017). Activa-tion of Human Mucosal-Associated Invariant T Cells Induces CD40L-
Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells.
J. Immunol. 199, 2631–2638.
Sattler, A., Dang-Heine, C., Reinke, P., and Babel, N. (2015). IL-15 dependent
induction of IL-18 secretion as a feedback mechanism controlling human
MAIT-cell effector functions. Eur. J. Immunol. 45, 2286–2298.
Slichter, C.K., McDavid, A., Miller, H.W., Finak, G., Seymour, B.J., McNevin,
J.P., Diaz, G., Czartoski, J.L., McElrath, M.J., Gottardo, R., and Prlic, M.
(2016). Distinct activation thresholds of human conventional and innate-like
memory T cells. JCI Insight 1, e86292.
Smith, D.J., Hill, G.R., Bell, S.C., and Reid, D.W. (2014). Reduced mucosal
associated invariant T-cells are associated with increased disease severity
and Pseudomonas aeruginosa infection in cystic fibrosis. PLoS ONE 9,
e109891.
Snyder, J.T., Shen, J., Azmi, H., Hou, J., Fowler, D.H., and Ragheb, J.A. (2007).
Direct inhibition of CD40L expression can contribute to the clinical efficacy of
daclizumab independently of its effects on cell division and Th1/Th2 cytokine
production. Blood 109, 5399–5406.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gil-
lette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Me-
sirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach
for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA
102, 15545–15550.
Talbot, J., Bianchini, F.J., Nascimento, D.C., Oliveira, R.D., Souto, F.O., Pinto,
L.G., Peres, R.S., Silva, J.R., Almeida, S.C., Louzada-Junior, P., et al. (2015).
CCR2 Expression in Neutrophils Plays a Critical Role in Their Migration Into
the Joints in Rheumatoid Arthritis. Arthritis Rheumatol. 67, 1751–1759.
Tang, X.Z., Jo, J., Tan, A.T., Sandalova, E., Chia, A., Tan, K.C., Lee, K.H., Gehr-
ing, A.J., De Libero, G., and Bertoletti, A. (2013). IL-7 licenses activation of
human liver intrasinusoidal mucosal-associated invariant T cells. J. Immunol.
190, 3142–3152.
Treiner, E., Duban, L., Bahram, S., Radosavljevic, M., Wanner, V., Tilloy, F., Af-
faticati, P., Gilfillan, S., and Lantz, O. (2003). Selection of evolutionarily
conservedmucosal-associated invariant T cells byMR1. Nature 422, 164–169.
Turtle, C.J., Delrow, J., Joslyn, R.C., Swanson, H.M., Basom, R., Tabellini, L.,
Delaney, C., Heimfeld, S., Hansen, J.A., and Riddell, S.R. (2011). Innate signals
overcome acquired TCR signaling pathway regulation and govern the fate of
human CD161(hi) CD8a+ semi-invariant T cells. Blood 118, 2752–2762.
Ussher, J.E., Bilton, M., Attwod, E., Shadwell, J., Richardson, R., de Lara, C.,
Mettke, E., Kurioka, A., Hansen, T.H., Klenerman, P., andWillberg, C.B. (2014).
CD161++ CD8+ T cells, including the MAIT cell subset, are specifically acti-
vated by IL-12+IL-18 in a TCR-independent manner. Eur. J. Immunol. 44,
195–203.
Ussher, J.E., van Wilgenburg, B., Hannaway, R.F., Ruustal, K., Phalora, P.,
Kurioka, A., Hansen, T.H., Willberg, C.B., Phillips, R.E., and Klenerman, P.
(2016). TLR signaling in human antigen-presenting cells regulates MR1-
dependent activation of MAIT cells. Eur. J. Immunol. 46, 1600–1614.
van Wilgenburg, B., Scherwitzl, I., Hutchinson, E.C., Leng, T., Kurioka, A., Ku-
licke, C., de Lara, C., Cole, S., Vasanawathana, S., Limpitikul, W., et al.; STOP-
HCV consortium (2016). MAIT cells are activated during human viral infections.
Nat. Commun. 7, 11653.
Varanasi, V., Khan, A.A., andChervonsky, A.V. (2014). Loss of the death recep-
tor CD95 (Fas) expression by dendritic cells protects from a chronic viral infec-
tion. Proc. Natl. Acad. Sci. USA 111, 8559–8564.
Wakao, H., Yoshikiyo, K., Koshimizu, U., Furukawa, T., Enomoto, K., Matsu-
naga, T., Tanaka, T., Yasutomi, Y., Yamada, T., Minakami, H., et al. (2013).
Expansion of functional human mucosal-associated invariant T cells via
reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12,
546–558.
Wallington, J.C., Williams, A.P., Staples, K.J., andWilkinson, T.M.A. (2018). IL-
12 and IL-7 synergize to control mucosal-associated invariant T-cell cytotoxic
responses to bacterial infection. J. Allergy Clin. Immunol. 141, 2182–2195.e6.Cell Reports 28, 3061–3076, September 17, 2019 3075
Wang, H., Feng, D., Park, O., Yin, S., and Gao, B. (2013). Invariant NKT cell
activation induces neutrophil accumulation and hepatitis: opposite regulation
by IL-4 and IFN-g. Hepatology 58, 1474–1485.
Wang, H., D’Souza, C., Lim, X.Y., Kostenko, L., Pediongco, T.J., Eckle, S.B.G.,
Meehan, B.S., Shi, M., Wang, N., Li, S., et al. (2018). MAIT cells protect against
pulmonary Legionella longbeachae infection. Nat. Commun. 9, 3350.3076 Cell Reports 28, 3061–3076, September 17, 2019Wilgenburg, B.V., Loh, L., Chen, Z., Pediongco, T.J., Wang, H., Shi, M., Zhao,
Z., Koutsakos, M., N€ussing, S., Sant, S., et al. (2018). MAIT cells contribute to
protection against lethal influenza infection in vivo. Nat. Commun. 9, 4706.
Zhang, D., Beresford, P.J., Greenberg, A.H., and Lieberman, J. (2001). Gran-
zymes A and B directly cleave lamins and disrupt the nuclear lamina during
granule-mediated cytolysis. Proc. Natl. Acad. Sci. USA 98, 5746–5751.
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies (all human)
anti-MR1 BioLegend (clone: 26.5) Cat#361103; RRID:AB_2563041
anti-IL8 R & D Systems (clone: 6217) Cat#MAB208-SP; RRID:AB_2249110
anti-CD3 PE-Cy7 BioLegend (clone: UCHT1) Cat#300420; RRID:AB_439781
anti-CD3 BV510 BioLegend (clone: OKT3) Cat#317332; RRID:AB_2561943
anti-CD8 eFluor450 eBioscience (clone: RPA-T8) Cat#48-0088-42, RRID:AB_1272062
anti-TCR Va7.2 PE BioLegend (clone: 3C10) Cat#351706, RRID:AB_10899577
anti-TCR Va7.2 PE-Cy7 BioLegend (clone: 3C10) Cat#351712; RRID:AB_2561994
anti-TCR Va7.2 AF700 BioLegend (clone: 3C10) Cat#351728, RRID:AB_2566337
anti-CD161 APC Miltenyi Biotech (clone: 191B8) Cat#130-092-678, RRID:AB_871629
anti-CD161 BV605 BioLegend (clone: HP-3G10) Cat#339916; RRID:AB_2563607
anti-TCR gd BV510 BioLegend (clone: B1) Cat#331220, RRID:AB_2564275
anti-CCR7 PerCP-Cy5.5 BioLegend (clone: G043H7) Cat#353220; RRID:AB_10916121
anti-TNFa FITC BioLegend (clone: Mab11) Cat#502906; RRID:AB_315258
anti-IFNg PerCP-Cy5.5 BioLegend (clone: 4S.B3) Cat#502526 RRID:AB_961355
anti-IL-26 PE R & D Systems (clone: 510414) Cat#IC13751P; RRID:AB_10640282
anti-CD56 APC-Cy7 BioLegend (clone: HCD56) Cat#318332, RRID:AB_10896424
anti-CD107a PE BioLegend (clone: H4A3) Cat#328608; RRID:AB_1186040
anti-granzyme A PE BioLegend (clone: CB9) Cat#507206; RRID:AB_315472
anti-granzyme B FITC BioLegend (clone: QA16AO2) Cat#372206; RRID:AB_2687030
anti-perforin PerCP-Cy5.5 BioLegend (clone: B-D48) Cat#353314, RRID:AB_2571971
anti-FasL PE BioLegend (clone: NOK-1) Cat#306407; RRID:AB_2100664
anti-CD40L FITC BioLegend (clone: 24-31) Cat#310804; RRID:AB_314827
anti-4-1BB PE BioLegend (clone: 4B4-1) Cat#309804; RRID:AB_314783
anti-RORgt PE BD Biosciences (clone: Q21-559) Cat#563081; RRID:AB_2686896
anti-PLZF AF647 BD Biosciences (clone: R17-809) Cat#563490; RRID:AB_2738238
anti-T-bet PECy7 BioLegend (clone: 4B10) Cat#644824; RRID:AB_2561761
anti-EOMES eFluor660 eBiosciences (clone: WD1928) Cat#50-4877-42; RRID:AB_2574229
anti-Blimp1 PECF594 BD Biosciences (clone: 6D3) Cat#565274; RRID:AB_2739147
Bacterial and Virus Strains
Escherichia coli HB101 Ireton Lab (PI: Keith Ireton) N/A
Biological Samples
Human blood Healthy Individuals N/A
Chemicals, Peptides, and Recombinant Proteins
5-A-RU This paper N/A
Human IL-12 Miltenyi Biotech Cat#130-096-704
Human IL-18 R & D Systems Cat# 9124-IL-010
Human IL-8 Thermo Fischer Scientific Cat#KHC0081
GSK-J4 Sigma-Aldrich Cat#SML0701
Brefeldin A BioLegend Cat#420601
Intracellular Staining Permeabilization Buffer BioLegend Cat#421002
Foxp3/Transcription factor Staining buffer set Invitrogen Cat#00-5523-00
(Continued on next page)
Cell Reports 28, 3061–3076.e1–e5, September 17, 2019 e1
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Critical Commercial Assays
LEGENDplex Human CD8/NK mix and match sub-panel BioLegend N/A
LEGENDplex Human Proinflammatory Chemokine mix
and match sub-panel
BioLegend N/A
LEGENDplex Human Custom panel BioLegend N/A
Nucleospin RNA (isolation kit) Macherey-Nagel 740955.50
Superscript IV system Invitrogen Cat#18091050
SYBR FAST Universal qPCR kit KAPA BIOSYSTEMS KK4601
Deposited Data
RNA sequencing data This paper NCBI SRA:
PRJNA559574
Experimental Models: Cell Lines
Human leukemia monocytic cell line THP1 ATCC TIB-202TM
Experimental Models: Organisms/Strains
Human PBMCs Healthy Individuals N/A
Oligonucleotides (Human)
Primer for TNF Forward: AGCCTCTTCTCCTTCCTGATCGTG
Reverse: GGCTGATTAGAGAGAGGTCCCTGG
Giribaldi et al., 2010 N/A
Primer for IFNG Forward: TGACCAGAGCATCCAAAAGA
Reverse: CTCTTCGACCTCGAAACAGC
Munk et al., 2011 N/A
Primer for IL17A Forward: AACCGATCCACCTCACCTT
Reverse: GGCACTTTGCCTCCCAGAT
Guenova et al., 2015 N/A
Primer for IL22 Forward: GCAGGCTTGACAAGTCCAACT
Reverse: GCCTCCTTAGCCAGCATGAA
Guenova et al., 2015 N/A
Primer for CCL3 Forward: TTCCGTCACCTGCTCAGAAT
Reverse: GCAGCAAGTGATGCAGAGAA
Kefaloyianni et al., 2016 N/A
Primer for CCL4 Forward: CCCAGCCAGCTGTGGTATTC
Reverse: AGCAGCTCAGTTCAGTTCCA
Kefaloyianni et al., 2016 N/A
Primer for CCL20 Forward: CTGGCTGCTTTGATGTCAGT
Reverse: CGTGTGAAGCCCACAATAAA
Kao et al., 2005 N/A
Primer for GZMB Forward: TGGGGGACCCAGAGATTAAAA
Reverse: TTTCGTCCATAGGAGACAATGC
Morissette et al., 2007 N/A
Primer for PRF1 Forward: CGCCTACCTCAGGCTTATCTC
Reverse: CCTCGACAGTCAGGCAGTC
Morissette et al., 2007 N/A
Primer for GAPDH Forward: CAACAGCGACACCCACTCCT
Reverse: CACCCTGTTGCTGTAGCCAAA



















expression/ (Babicki et al., 2016)
RRID:SCR_016974
(Continued on next page)
e2 Cell Reports 28, 3061–3076.e1–e5, September 17, 2019
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER







R Bioconductor - DESeq2 Love et al., 2014 RRID:SCR_015687
Other
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Anti-CD8 microbeads Miltenyi Biotech Cat#130-045-201LEAD CONTACT AND MATERIALS AVAILABILITY
This study did not generate new unique reagents. Any requests for the reagent or resources should be directed to and will be fulfilled
by the Lead Contact, James E. Ussher (james.ussher@otago.ac.nz).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Peripheral blood was collected from healthy donors (n = 55; 53% male; median age = 25, range 20-64) with approval from the
University of Otago Human Ethics Committee (H14/046); written informed consent was obtained from all donors. Subgroup analyses
based on sex/gender were not performed as there are no reports of differences inMAIT cell phenotype or function by sex/gender and
the study was not powered for subgroup analyses. PBMCs were elutriated by density gradient centrifugation using LymphoprepTM
(Axis-Shield PoC AS, Oslo, Norway) and stored in liquid nitrogen. Each experiment was performed after overnight resting of thawed
and washed PBMCs in RPMI 1640 supplemented with L-glutamine (Life Technologies Corporation, Carlsbad, USA), 10% fetal calf
serum (GIBCO, New Zealand and Sigma-Aldrich, St. Louis, USA), and Penicillin-Streptomycin (Sigma-Aldrich) (now onward referred
to as R10).
For some experiments, Va7.2+ cells were isolated from PBMCs by labeling with anti-Va7.2-PE antibody (Clone; 3C10, BioLegend,
San Diego, USA) followed by separation with anti-PE magnetic beads using MS columns (both from Miltenyi Biotec, Bergisch Glad-
bach, Germany). THP1 monocytic cells were maintained in R10 and used as antigen presenting cells to activate MAIT cells.
Escherichia coliHB101was cultured overnight in Luria-Bertani (LB) broth, washedwith PBS (Oxoid Ltd, Basingstoke, UK) and fixed
with 2% formaldehyde for 20 minutes at 4C. After washing, fixed bacteria were resuspended in PBS and quantified with 123count
eBeadsTM (eBioscience, San Diego, USA) by flow cytometry using a FACSCanto II (BD biosciences, San Jose, USA).
METHOD DETAILS
5-A-RU synthesis (also refer to Figure S8)
a) (2R,3S,4S)-5-Aminopentane-1,2,3,4-tetrol
Hydroxylamine hydrochloride (4.24 g, 0.061 mmol) was diluted in anhydrous ethanol (24 mL) and two drops of a 1% phenolphthalein
in ethanol solution were added at room temperature. A solution of sodiummethoxide (25%wt in methanol, 13 mL) was added slowly
to the suspension, uponwhich awhite precipitate formed. Addition of the sodiummethoxidewas haltedwhen themixture stayed pink
for approximately 1 min. The mixture was stirred for 3 min and filtered. The filtrate was warmed to 70C and D-(-)-ribose ((2R,3R,4R)-
2,3,4,5-tetrahydroxypentanal) (26.64 mmol, 4.00 g) was added in 3 batches. The mixture was stirred at 70C until the sugar had
completely dissolved, then cooled to room temperature. Upon cooling a precipitate formed, which was filtered and washed to
give the oxime (3.39 g, 20.56 mmol, 77%) as a white solid. HRMS (m/z): [M+Na]+ calcd. C5H11NNaO5 188.0529; found, 188.0517.
To a mixture of Pt (IV)O2 (0.06 g) in glacial acetic acid (20 mL) was added the (D)-ribose oxime (0.60 g, 3.6 mmol). The mixture was
shaken on a Parr apparatus at 45 psi hydrogen gas atmosphere for 24 h. The now clear mixture was filtered through celite and
concentrated. The crude residue was dissolved in water (20 mL) and loaded onto a Dowex 50W X8 100-200 hydrogen form ion
exchange column packed in water. The column was washed with water (80 mL) and then the desired ribose amine was eluted
with 3N NH4OH solution (80 mL). The alkaline fraction was concentrated to give (2R,3S,4S)-5-aminopentane-1,2,3,4-tetrol (0.52 g,
3.4 mmol, 94%) as a light brown syrup. HRMS (m/z): [M+Na]+ calcd.C5H13NNaO4, 174.0737; found, 174.0723.
b) 6-{[(2S,3S,4R)-2,3,4,5-Tetrahydroxypentyl]amino}-1,2,3,4-tetrahydropyrimidine-2,4-dione
A mixture of (2R,3S,4S)-5-aminopentane-1,2,3,4-tetrol (D-ribitylamine) (0.35 g, 2.28 mmol) and 6-chloro-1,2,3,4-
tetrahydropyrimidine-2,4-dione (6-chlorouracil) (0.17 g, 1.16 mmol) was heated in a pressure tube at 120C for 3 h. The reaction
was cooled to give a brown oil (0.51 g), which was used as such in the next reaction without purification. HRMS (m/z): [M+Na]+
calcd.C9H15N3NaO6, 284.0853; found, 284.0831.Cell Reports 28, 3061–3076.e1–e5, September 17, 2019 e3
c) 5-Nitroso-6-{[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino}-1,2,3,4-tetrahydropyrimidine-2,4-dione
The ribitylaminouracil-containing residue (0.22 g) was dissolved in water (10 mL) at room temperature and sodium nitrite (0.17 g,
2.52mmol) was added. The solution was adjusted to pH 4.6 with 3N acetic acid, stirred for 2 h, and then concentrated under vacuum.
The resulting red-brown residue was dissolved in 0.15N NH4OH (10mL) and loaded onto a Biorad AG1-X8 resin column (formate
form, 200-400 mesh). The column was washed with water (20 mL) then 0.01M formic acid (35 mL). Treatment of the column with
0.1M formic acid (400mL) resulted in movement and discharge of a red eluate from the column, that was collected and concentrated
under vacuum. The residue was recrystallized fromwater to give 5-nitroso-6-{[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino}-1,2,3,4-
tetrahydropyrimidine-2,4-dione (0.17 g, 70% from (2R,3S,4S)-5-aminopentane-1,2,3,4-tetrol) as red crystals. HRMS (m/z): [M+H]+
calcd.C9H13N4O7, 289.0790; found, 289.0769.
d) 5-amino-6-{[(3S,4R)-3,4,5-trihydroxypentyl]amino}-1,2,3,4 tetrahydropyrimidine-2,4-dione (5-A-RU)
5-Nitroso-6-{[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]amino}-1,2,3,4-tetrahydropyrimidine-2,4-dione (20.3 mg, 0.070 mmol) was
suspended in milliQ water (2 mL) and heated to 80C under nitrogen. Sodium dithionite (40.3 mg, 0.23 mmol) was added to the
red solution resulting in a color change to pale yellow. After stirring at 80C for 5 min the solution was cooled in an ice bath. Analysis
of this solution revealed that 5-A-RU had formed, and all starting material was consumed. HRMS (m/z): [M+H]+ calcd.C9H17N4O6,
277.1143; found, 277.1126.
Under a cloud of nitrogen, the chilled solution was diluted to make a 5 mM solution. Aliquots (10 mL) were dispensed into micro-
centrifuge tubes, and the headspace of each tube was filled with nitrogen gas. The tubes were immediately sealed and stored at
80C. Before thawing an aliquot for biological testing, mass spectrometry of an aliquot was carried out to ensure that 5-A-RU
had not degraded after storage.
MAIT cell activation
Viable PBMCs were counted by a Neubauer hemocytometer excluding dead cells using Trypan Blue (Invitrogen, Carlsbad, USA) and
106 PBMCs/200 mL were seeded in U-bottom 96 well-plates. Formaldehyde-fixed Escherichia coli, 5-A-RU, or the combination of
50 ng/mL IL-12 (Miltenyi Biotec) and 50 ng/mL IL-18 (R & D Systems, Minneapolis, USA), were added at the start of each experiment.
Other than in the time course experiments, PBMCs were treated with 5-A-RU or E. coli for 6 or 24 hours or IL-12+IL-18 for 24 hours.
Some experiments were performed with 10nM 5-A-RU/MG (5-A-RU and methyl glyoxal (MG, from Sigma-Aldrich) mixed at a molar
ratio of 1:50 immediately prior to use) which was equivalent to 5mM 5-A-RU at triggering TNFa and IFNg production by MAIT cells
(Figure S1B). For assessing the role of KDM6B, 105 CD8+ T cells were treated overnight with 5 mM GSK-J4 (Sigma-Aldrich) and
then either co-cultured for 6 hours with 105 THP1 monocytes treated with 100 bacteria per cell (BpC) E. coli or 5 mM 5-A-RU, or stim-
ulated directly with IL-12+IL-18 (50 ng/mL each) for 24 hours. MR1 mediated activation of MAIT cells was blocked with 2.5 mg/mL
anti-MR1 antibody (clone 26.5, BioLegend, San Diego, USA). When assessing cytokine production and cytotoxic granule content
by flow cytometry, brefeldin A (BioLegend) was added at 5 mg/mL for final 4 hours of culture.
Flow cytometry
Cells were stained for surface markers, followed by fixing in 2% paraformaldehyde (except in sorting experiments), and treated with
permeabilization buffer (BioLegend) for intracellular staining of cytokines and cytotoxic molecules or Foxp3/transcription factor
buffer set (eBioscience) for transcription factors. MAIT cells were identified as CD8+ T cells expressing semi-invariant TCR Va7.2
and high levels of CD161 (Dusseaux et al., 2011); the gating strategy is shown in Figure S1A. In some experiments, double negative
and CD4+ MAIT cells were also examined. In all flow cytometry experiments, dead cells were excluded by live/dead fixable near IR
(Invitrogen) staining. Please, refer key resources table for the list of antibodies used for surface, intracellular and intranuclear proteins.
Samples were acquired on a FACSCantoII, LSR Fortessa, or in sorting experiments a FACSAria II (all BD Biosciences), and analyzed
by FlowJoTM V10 (TreeStar, Ashland, USA).
Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR)
A total of 107 human PBMCs were treated with formaldehyde-fixed E. coli (10 BpC) or 5-A-RU (5 mM) or IL-12+IL-18 (50 ng/mL each)
for different durations or were left untreated. Cells were stained with fluorescently-labeled antibodies and MAIT cells
(CD3+CD8+TCRgd-CCR7-CD161++Va7.2+ cells) were isolated by fluorescence activated cell sorting on a FACSAriaTM II. RNA from
sorted MAIT cells was isolated using the Nucleospin RNA isolation kit (Macherey-Nagel, D€uren, Germany) as per the manufacturer’s
instructions and stored at 80C. cDNA was synthesized using the Superscript IV system (Invitrogen) using oligo-dT primers. Real
time PCR for gene expression was performed using the KAPA SYBR FAST mastermix on a ViiA7 or QS6 Real-Time system (Applied
Biosystems, Foster City, USA). Previously published primers were used: TNF (Giribaldi et al., 2010); IFNG (Munk et al., 2011); IL17A
(Guenova et al., 2015); IL22 (Guenova et al., 2015); CCL3 (Kefaloyianni et al., 2016); CCL4 (Kefaloyianni et al., 2016); CCL20 (Kao
et al., 2005); GZMB (Morissette et al., 2007); PRF1 (Morissette et al., 2007); GAPDH (Maess et al., 2010).
RNA Sequencing
A total of 107 human PBMCs per donor (n = 7) were treated with formaldehyde-fixed E. coli (10 BpC) or 5-A-RU (5 mM) for 6 hours or
IL-12+IL-18 (50 ng/mL each) for 24 hours. MAIT cells were isolated from treated and untreated PBMCs by fluorescence activated cell
sorting. RNA was extracted and sent to the Molecular Genetics Facility at the Liggins Institute, Auckland, New Zealand for librarye4 Cell Reports 28, 3061–3076.e1–e5, September 17, 2019
preparation and sequencing. Libraries were prepared with the Ion AmpliSeq Transcriptome Human Gene Expression Kit and were
sequenced on an Ion Proton. Read count data files were generated with Torrent SuiteTM software. Downstream analysis for
differentially expressed genes (DEG) were performed using DESeq2 package in R-Bioconductor (Love et al., 2014). Log2 fold change
and adjusted p value (Padj) were arbitrarily set at 1 (fold change 2) and 0.05 respectively as cut-offs during DEG analysis. Principal
component analysis (PCA) plot was generated in DESeq2. Venn-diagrams were created from DEGs in an online tool developed by
Bioinformatics & Evolutionary genomics, VIB/UGent. Normalized gene expression values of total and custom lists of DEGs against all
stimuli were used to generate heat-maps on Heatmapper (Babicki et al., 2016) employing the average linkage clustering and
Spearman rank correlation distancemeasurementmethods. Gene set enrichment analysis was performed onGSEA software version
3.0 (Mootha et al., 2003; Subramanian et al., 2005) using normalized gene expression values of all genes from 28 samples as the
expression database and compared either with the curated gene set databases KEGG or Reactome, provided in the software/
website, or the tissue repair gene dataset obtained from the publication by Linehan et al. (2018).
LEGENDplex immunoassays
A total of 105 column purified Va7.2+ MAIT cells per donor were co-cultured with 105 THP1 monocytes and stimulated with either
formaldehyde-fixed E. coli (100 BpC) or 5-A-RU (5 mM) ± anti-MR1 antibody for 6 hours; for controls, THP1 monocytes were treated
with E. coli or 5-A-RU or were co-cultured with Va7.2+ cells without any treatment. For cytokine stimulation, 105 Va7.2+ MAIT cells
were treated with IL-12+IL-18 for 24 hours; untreated Va7.2+ cells were used as a control. Cytokines, chemokines, and cytotoxic
molecules in the supernatant were quantified by LEGENDplex bead-based immunoassay (BioLegend) following the manufacturer’s
instructions using three multiplex panels: Human Proinflammatory Chemokine (mix and match 7-plex subpanel for CCL3, CCL4,
CCL20, IL-8, CXCL9, CXCL10, and CXCL11), Human CD8/NK (mix and match 11-plex subpanel for IL-2, IL-6, IL-10, IL-17A,
TNFa, IFNg, sFasL, granzyme A, granzyme B, perforin, and granulysin), and Human custom panel (IL-1a, IL-1b, IL-17F, IL-21,
IL-22, IL-23, and sCD40L).
Neutrophil migration assay
Neutrophils were freshly isolated from peripheral blood by a two-stepmethod of dextran (Thermo Fischer Scientific) sedimentation of
erythrocytes followed by LymphoprepTM gradient centrifugation and removal of low-density PBMCs (Kuhns et al., 2015). Residual
erythrocytes from the high-density neutrophil fraction were removed by lysis with water. 3x105 neutrophils in 200 mL R10 were added
into the upper compartment of a transwell system incorporating polycarbonate membrane insert (5 mm pore size, Corning), with
500 mL diluted supernatant (1:2.5 in R10) of TCR- or cytokine-stimulated MAIT cells (obtained as mentioned in LEGENDplex immu-
noassays) in the lower compartment; 5 ng/mL IL-8 (BD Biosciences) was used as positive control for neutrophil migration. After
incubation at 37C for 1 hour, the transwell insert was carefully removed and the number of neutrophils in the lower compartment
were counted using a hemocytometer. To neutralize IL-8, 2mg/mL anti-IL-8 antibody (R & D Systems) was added to the supernatant.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were analyzed using GraphPad Prism V7.03. Statistical significance was assessed with a one-way repeated-measures ANOVA
with Sidak’s multiple comparison tests for multiple groups and paired two tailed t tests for two groups. Data were normalized, or log
transformed in some cases when not normally distributed. Mean ± standard error of mean (SEM) are shown throughout.
DATA AND CODE AVAILABILITY
The accession number for the RNA sequences reported in this paper is NCBI SRA: PRJNA559574.Cell Reports 28, 3061–3076.e1–e5, September 17, 2019 e5
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Mucosal associated invariant T (MAIT) cells are abundant unconventional T cells that
can be stimulated either via their TCR or by innate cytokines. The MAIT cell TCR recog-
nises a pyrimidine ligand, derived from riboflavin synthesising bacteria, bound to MR1.
In infection, bacteria not only provide the pyrimidine ligand but also co-stimulatory sig-
nals, such as TLR agonists, that can modulate TCR-mediated activation. Recently, type
I interferons (T1-IFNs) have been identified as contributing to cytokine-mediated MAIT
cell activation. However, it is unknown whether T1-IFNs also have a role during TCR-
mediated MAIT cell activation. In this study, we investigated the co-stimulatory role of
T1-IFNs during TCR-mediated activation of MAIT cells by the MR1 ligand 5-amino-6-D-
ribitylaminouracil/methylglyoxal. We found that T1-IFNs were able to boost interferon-γ
and granzyme B production in 5-amino-6-D-ribitylaminouracil/methylglyoxal-stimulated
MAIT cells. Similarly, influenza virus-induced T1-IFNs enhanced TCR-mediated MAIT cell
activation. An essential role of T1-IFNs in regulating MAIT cell activation by riboflavin
synthesising bacteria was also demonstrated. The co-stimulatory role of T1-IFNs was also
evident in liver-derived MAIT cells. T1-IFNs acted directly on MAIT cells to enhance their
response to TCR stimulation. Overall, our findings establish an important immunomod-
ulatory role of T1-IFNs during TCR-mediated MAIT cell activation.
Keywords: co-stimulation  influenza virus  mucosal associated invariant T cells  TCR activation
 type I interferons
 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
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Introduction
Mucosal associated invariant T (MAIT) cells are recently recog-
nised unconventional T cells which express a semi-invariant TCR
(most commonly Vα7.2-Jα33 in humans and Vα19-Jα33 in mice)
and are restricted to antigen presented by MHC class I related
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protein, MR1 [1–3]. MR1 is an evolutionally conserved MHC Ib
like molecule and presents unstable pyrimidine intermediates,
formed by the condensation of 5-amino-6-D-ribitylaminouracil
(5-A-RU), a precursor of riboflavin, with glyoxal or methylglyoxal
(MG), triggering MAIT cell activation via their TCR [4, 5].
Consistent with this, MAIT cells have been shown to be activated
by a diverse range of riboflavin synthesising bacteria, including
Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae,
and Staphylococcus aureus, as well as some yeasts, including Can-
dida albicans and Saccharomyces cerevisiae [6–8]. Additionally,
MAIT cells express high amounts of the IL-18 receptor and the IL-
12 receptor and respond to cytokine signals (IL-12 and IL-18) inde-
pendent of their TCR [8–10]. Upon activation, MAIT cells produce
pro-inflammatory cytokines such as TNF-α, IFN-γ, and IL-17A, as
well as cytotoxic molecules (granzymes and perforin) [7, 11–13].
The range of effector functions expressed depends upon the mode
of activation; for example, TCR stimulation results in production of
more pro-inflammatory cytokines and chemokines than cytokine
stimulation, and is associated with expression of genes involved
in tissue repair [14–16]. Many in vivo studies have established
an important role for MAIT cells in protection against bacterial
infections [17–20] and more recently against viruses [21].
Therefore, MAIT cells are an important innate-like T cells that
bridge the innate and adaptive arms of the immune system.
MAIT cells are abundant in blood and liver in humans but have
also been isolated from various mucosal sites, including the intes-
tine [12, 22]. Since robust activation can be achieved by both
pathogenic and commensal bacteria [23, 24], MAIT cell activa-
tion should be tightly controlled to prevent the hyperactivation
by commensals and subsequent tissue damage. Indeed, sustained
MAIT cell activation following TCR stimulation requires additional
innate signals [16, 25–27]. Some recognised innate signals that
can modulate TCR-mediated MAIT cell activation are IL-7 [26, 28],
TLR agonists [29, 30], TNFα [31], and IL-1β+IL-23 [26].
Type I interferons (T1-IFNs) are among the newest and least
explored innate signals during MAIT cell activation. It was first
shown by van Wilgenburg et al. that adding either IFN-α or IFN-β
to IL-12 or IL-18 resulted in IFN-γ production by MAIT cells [32].
Additionally, T1-IFN signalling was shown to be important for
MAIT cell activation during viral infection in both humans and
mice [21, 32]. However, it is unknown if T1-IFNs also have a
co-stimulatory function in TCR-mediated activation of MAIT cells.
In this study, we have shown that the early response of MAIT
cells to a TCR signal can be greatly enhanced by T1-IFNs. By using
influenza A virus infection as a potent inducer of T1-IFNs and
by blocking the T1-IFNs with vaccinia virus receptor B18R, we
have confirmed that the overall response of MAIT cells to a TCR
signal can be boosted by T1-IFNs produced during viral infections.
Furthermore, we demonstrated that T1-IFNs are important during
early MAIT cell activation by riboflavin synthesising bacteria. This
co-stimulatory effect of T1-IFNs was also evident in liver derived
(Ld-) MAIT cells. Further, T1-IFNs had a direct effect on MAIT cells
and the co-stimulatory effect was independent of TNF-α. Together
our findings suggest a significant role for T1-IFNs in driving MAIT
cell activation during bacterial, viral, and inflammatory diseases.
Results
T1-IFNs are important modulators of MAIT cell
activation and function
To test whether T1-IFNs can activate MAIT cells and if they have
a co-stimulatory role in TCR mediated MAIT cell activation, we
treated human PBMCs with IFN-α 2a or IFN-β alone or with
the TCR signal, 5-amino-6-D-ribitylaminouracil/methylglyoxal
(5-A-RU/MG) (Fig. 1); representative flow cytometry plots are
shown in Supporting Information Fig. S1. Interestingly, treatment
with either T1-IFN alone significantly increased the surface
expression of CD69, an early activation marker, on MAIT cells
compared to the unstimulated control, however, the expression
of CD69 in response to either T1-IFN alone was less than to
5-A-RU/MG (Fig. 1B); the response to T1-IFNs alone was largely
restricted to MAIT cells (Supporting Information Fig. S2). Both
T1-IFNs further enhanced 5-A-RU/MG triggered CD69 expression
on MAIT cells, which upon MR1 blocking was significantly
reduced to the level of treatment with T1-IFNs alone (Fig. 1B).
This suggested that the enhanced CD69 expression in response
to 5-A-RU/MG plus T1-IFNs was due to the combination of both
TCR-dependent and -independent mechanisms. No enhancement
was seen in the expression of 4-1BB, another marker of early TCR
activation [33], with either T1-IFN. In contrast, the percentage
of MAIT cells expressing 4-1BB was reduced upon treatment
with T1-IFNs and 5-A-RU/MG compared to 5-A-RU/MG alone
(Fig. 1C).
T1-IFNs in combination with IL-12 or IL-18 have previously
been shown to stimulate IFN-γ production by MAIT cells [32].
Therefore, we examined whether T1-IFNs can modulate cytokine
production by MAIT cells treated with 5-A-RU/MG. Indeed, both
IFN-α 2a and IFN-β substantially increased the percentage of IFN-γ
or TNF-α producing MAIT cells in response to 5-A-RU/MG (Fig. 1D
and E). No production of IL-17 was seen with 5-A-RU/MG alone
or in combination with IFN-β (data not shown). Neither IFN-α
2a or IFN-β by itself induced any cytokine production by MAIT
cells (Fig. 1D and E). This prompted us to investigate if other
effector functions can also be boosted by T1-IFNs. In response to
5-A-RU/MG or T1-IFNs alone, more MAIT cells were granzyme B
positive than when unstimulated (Fig. 1F). Compared to treatment
with 5-A-RU/MG alone, the percentage of MAIT cells expressing
granzyme B increased by almost fourfold with 5-A-RU/MG + IFN-
α 2a or 5-A-RU/MG + IFN-β co-treatments (Fig. 1F). Interestingly,
perforin production in MAIT cells was significantly increased fol-
lowing T1-IFN treatment but not by 5-A-RU/MG (Fig. 1G). Adding
IFN-α 2a or IFN-β to 5-A-RU/MG did not further enhance perforin
production compared to treatment with the T1-IFNs alone. T1-
IFNs alone significantly induced MAIT cell degranulation, as mea-
sured by surface expression of CD107a; compared to treatment
with 5-A-RU/MG alone, treatment of MAIT cells with a combina-
tion of T1-IFNs and 5-A-RU/MG further increased the proportion
of MAIT cells that were CD107a positive (Fig. 1H). In contrast, T1-
IFNs did not significantly affect CD40L expression, either alone or
in combination with 5-A-RU/MG (Fig. 1I).
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Figure 1. T1-IFNs activate MAIT cells and enhance their response to 5-A-RU/MG. (A) Representative flow cytometry plots showing gating strategy
for the identification of MAIT cells (CD3+ CD161++ Vα7.2TCR+) in human PBMCs; the percentage of parent population is also shown. (B–I) PBMCs
were treated with 1nM 5-A-RU/MG or T1-IFNs (450 IU/mL IFN-α 2a or 375 IU/mL IFN-β) alone or in combination for 6 h and (B) CD69 expression,
and the percentage of MAIT cells expressing (C) 4-1BB, (D) TNF-α, (E) IFN-γ, (F) granzyme B, (G) perforin, (H) CD107a, and (I) CD40L were assessed by
flow cytometry. MR1 mediated MAIT cell activation was blocked by the addition of anti-MR1 antibody during the treatment (B). Data are presented
as mean and SEM and are pooled from two independent experiments (n = 7 for B, n = 8 for C–I). Each data point represents an individual healthy
donor. Repeated measures one-way ANOVA with Sidak’s multiple comparison tests were performed for assessing statistical significance (B–I).
*p < 0.05, **p < 0.01, ***p < 0.001, ns = nonsignificant.
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Both CD8+ and CD8− MAIT cells responded similarly to T1-
IFNs alone or in combination with 5-A-RU/MG, however, CD8−
MAIT cells displayed significantly less functional capacity upon
activation compared to CD8+ MAIT cells, consistent with the
recent observation by Dias J et al. [34] (Supporting Information
Fig. S3). Enhancement of 5-A-RU/MG-mediated MAIT cell activa-
tion was seen with 90 IU/mL of T1-IFN (Supporting Information
Fig. S4), similar to levels in vivo during infection [35, 36]. Taken
together, T1-IFNs can directly induce modest MAIT cell activa-
tion and augment effector and helper responses of TCR-stimulated
MAIT cells.
Virus modulates the activation and function
of TCR-activated MAIT cells
T1-IFNs are produced by infected cells during viral infec-
tion [37, 38]. Therefore, we assessed if virus infection can
modulate MAIT cell activation and effector functions. PBMCs
were either treated with UV-inactivated influenza A virus (IAV)
alone or in combination with 5-A-RU/MG; uninfected allantoic
fluid (AF) was included as a control. IAV alone triggered MAIT cell
activation as measured by CD69 surface expression; the activation
was specific to IAV treatment as an equivalent volume of AF had
no effect on CD69 expression (Fig. 2A). Interestingly, adding IAV,
but not AF, to 5-A-RU/MG further enhanced CD69 expression on
MAIT cells compared to 5-A-RU/MG alone. In PBMCs treated with
5-A-RU/MG + IAV, blocking MR1 significantly reduced CD69
expression, but not completely compared to unstimulated MAIT
cells; the level of CD69 expression was similar to the level induced
by IAV alone (Fig. 2A). IAV alone had little effect on 4-1BB expres-
sion on MAIT cells but reduced the 4-1BB expression when added
with 5-A-RU/MG compared to 5-A-RU/MG alone (Fig. 2B). Nei-
ther TNF-α nor IFN-γ was produced by MAIT cells with IAV alone,
however, the percentage of MAIT cells producing IFN-γ, but not
TNF-α, was significantly increased when PBMCs were co-treated
with 5-A-RU/MG and IAV compared with 5-A-RU/MG and AF
(Fig. 2C and D). A small but nonsignificant increase in granzyme
B production was seen with IAV or 5-A-RU/MG stimulation
alone. In contrast, IAV together with 5-A-RU/MG triggered robust
production of granzyme B in MAIT cells compared to 5-A-RU/MG
alone or co-treatment with 5-A-RU/MG + AF (Fig. 2E). Perforin
production in MAIT cells was increased by IAV alone, but this did
not reach significance; co-treatment with IAV and 5-A-RU/MG
resulted in a significant increase in perforin expression compared
to 5-A-RU/MG alone or co-treatment with 5-A-RU/MG + AF
(Fig. 2F). MAIT cells also rapidly degranulated in response to
IAV; co-treatment with IAV and 5-A-RU/MG resulted in a greater
proportion of MAIT cells degranulating than with 5-A-RU/MG
alone (Fig. 2G). Similarly, co-treatment with IAV and 5-A-RU/MG
resulted in a significant increase in CD40L expression by MAIT
cells compared to 5-A-RU/MG treatment alone (Fig. 2H). Taken
together, signals during virus infection induce activation and
degranulation of MAIT cells and can further enhance activation,
cytokine production, and the cytotoxic potential of MAIT cells
stimulated via their TCR, similar to T1-IFNs.
Virus induced MAIT cell activation, degranulation,
and response to TCR signal is T1-IFN dependent
To confirm whether the enhanced TCR response of MAIT cells
in the presence of IAV was mediated via virus induced T1-IFNs,
we treated PBMCs with IAV + 5-A-RU/MG and neutralised T1-
IFNs with vaccinia virus protein B18R; concentrations of T1-
IFNs induced by IAV were not determined. Inhibiting T1-IFNs
completely abrogated the viral enhancement of CD69, IFN-γ,
granzyme B, perforin, CD107a, and CD40L expression by TCR-
stimulated MAIT cells (Fig. 3A, D–H). Furthermore, the reduction
of 4-1BB expression on MAIT cells treated with 5-A-RU/MG + IAV
compared with 5-A-RU/MG alone was reversed upon B18R addi-
tion (Fig. 3B). Though no enhancement of TNF-α production was
seen with IAV and 5-A-RU/MG, blocking T1-IFNs reduced the per-
centage of MAIT cells producing TNF-α (Fig. 3C). Furthermore, the
increased CD69 surface expression and degranulation observed in
MAIT cells when PBMCs were treated with IAV alone were also
significantly reduced upon T1-IFN blockade (Fig. 3I and J). These
findings confirm that the IAV induced MAIT cell activation and
enhanced response to TCR stimulation was T1-IFNs mediated.
T1-IFNs are important for early activation of MAIT
cells by riboflavin producing bacteria
Bacteria can provide both MR1 ligand and co-stimulatory signals
leading to robust activation of MAIT cells [29, 30]. Recently, we
reported that various innate signalling pathways, including IFN-
α/β signalling, were enriched early in MAIT cells upon stimula-
tion with E. coli compared to activation with 5-A-RU alone [15].
Therefore, we activated MAIT cells with E. coli for 6 h with or
without B18R to assess the role of T1-IFNs during early MAIT cell
activation by a riboflavin synthesising bacteria. Upon activation
by E. coli, MAIT cells rapidly upregulated surface expression of
CD69, 4-1BB, CD40L, and CD107a, produced TNF-α and IFN-γ,
and increased expression of the cytotoxic molecules granzyme B
and perforin; all except 4-1BB were reduced upon blocking T1-
IFNs, although the change in granzyme B did not reach signifi-
cance (Fig. 4A–H). Interestingly, E. coli induced perforin produc-
tion in MAIT cells was completely inhibited by blocking T1-IFNs
(Fig. 4F). Taken together, T1-IFNs are important drivers of MAIT
cell activation and effector functions during early TCR stimulation
by riboflavin synthesising bacteria.
Liver derived MAIT cells respond to IAV and IFN-β
similarly to MAIT cells isolated from blood
Next, to determine whether T1-IFNs are also co-stimulatory sig-
nals for liver-derived MAIT cells, we treated liver-derived MAIT
cells with IAV, IFN-β, or 5-A-RU/MG alone, or in combination
(Fig. 5); representative flow cytometry plots are shown in Support-
ing Information Fig. 5. Liver-derived MAIT cells stimulated with
IAV or IFN-β rapidly degranulated and produced more granzyme
B and perforin compared to untreated cells, although only CD107a
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Figure 2. Virus activates MAIT cells and enhances their response to 5-A-RU/MG. PBMCs were treated with 1 nM 5-A-RU/MG, UV-irradiated IAV
at a MOI of 2, or the equivalent volume of AF alone or in combination for 6 h and (A) CD69 expression, and the percentage of MAIT cells (gated
as in Fig. 1A) expressing (B) 4-1BB, (C) TNF-α, (D) IFN-γ, (E) granzyme B, (F) perforin, (G) CD107a, and (H) CD40L were assessed by flow cytometry.
MR1-mediated MAIT cell activation was blocked by adding anti-MR1 antibody during the 5-A-RU/MG + IAV co-treatment (A–D). AF was included
as a control in some experiments (A–F). Data are presented as mean and SEM and are pooled from two independent experiments (n = 8 for A–D,
G, and H and n = 7 for E–F). Each data point represents an individual healthy donor. Repeated measures one-way ANOVA with Sidak’s multiple
comparison tests were performed for assessing statistical significance (A–H). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns = nonsignificant.
reached significance (Fig. 5F–H). The percentages of MAIT cells
producing IFN-γ and granzyme B were also increased upon co-
treatment with IFN-β and 5-A-RU/MG compared with 5-A-RU/MG
alone, although only IFN-γ reached significance (Fig. 5E and
F). No significant effect was seen on TNF-α and 4-1BB expres-
sion following IFN-β or IAV addition to 5-A-RU/MG compared to
5-A-RU/MG alone (Fig. 5C and D). Co-treatment with IAV and
5-A-RU/MG also increased CD40L, although this did not reach
statistical significance (Fig. 5I). Taken together, MAIT cells from
both blood and liver can be similarly modulated in vitro by
T1-IFNs.
T1-IFN mediated enhancement of TCR stimulation
is largely TNF-α independent
Monocytes are important mediators of MAIT cell activation by
bacterial, viral, or innate signals [25, 30, 39]. It is known that
monocytes activated with T1-IFNs can trigger more robust MAIT
cell activation in response to bacteria [30]. To investigate whether
T1-IFNs were activating monocytes, we assessed TNF-α produc-
tion by monocytes in PBMCs stimulated with T1-IFNs and/or 5-
A-RU/MG. Interestingly, IFN-β, but not IFN-α 2a or 5-A-RU/MG
alone, triggered significant TNF-α production in monocytes (which
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Figure 3. T1-IFNs mediate virus-induced MAIT cell activation and enhancement of the MAIT cell response to 5-A-RU/MG. (A–H) PBMCs were
treated with 1 nM 5-A-RU/MG alone or in combination with UV-fixed IAV at a MOI of 2 ± vaccinia virus B18R protein (1 µg/mL) for 6 h and (A)
CD69 expression, and the percentage of MAIT cells (gated as in Fig. 1A) expressing (B) 4-1BB, (C) TNF-α, (D) IFN-γ, (E) granzyme B, (F) perforin, (G)
CD107a, and (H) CD40L were assessed by flow cytometry. (I, J) PBMCs were treated with IAV alone at 2 MOI ± vaccinia virus B18R protein for 6 h
and expression of (I) CD69 expression and (J) the percentage of MAIT cells expressing CD107a were assessed. Data are presented as mean and SEM
and are pooled from two independent experiments (n = 8 for A–H and n = 7 for I and J). Each data point represents an individual healthy donor.
Repeated measures one-way ANOVA with Sidak’s multiple comparison tests (A–H) or paired two-tailed t-tests (I, J) were performed for assessing
statistical significance. *p < 0.05, **p < 0.01, ***p < 0.001, ns = nonsignificant.
were mostly CD14+HLA-DR+) (Fig. 6A–C). This was interesting as
neither IFN-α 2a nor IFN-β alone induced any TNF-α production
in MAIT cells (Fig. 1D).
TNF-α has been shown to induce upregulation of surface
expression of CD69 on MAIT cells [40]. Therefore, to test whether
the enhanced CD69, CD107a, and perforin expression by MAIT
cells with IFN-β alone was mediated by TNF-α production, we
added anti-TNF-α antibody with IFN-β treatment. Blocking TNF-α
had no significant effect on the expression of CD69, CD107a, or
perforin by MAIT cells (Fig. 6D–F). Recently, TNF-α produced dur-
ing treatment of THP1 cells with IgG-opsonized E. coli was shown
to enhance IFN-γ production by MAIT cells [31]. Therefore, we
blocked TNF-α in PBMCs co-treated with 5-A-RU/MG + IFN-α 2a
or 5-A-RU/MG + IFN-β to test whether the synergistic effect seen
was mediated by TNF-α production. The enhancement of IFN-γ
production in MAIT cells treated with T1-IFNs was TNF-α inde-
pendent whereas a small but significant reduction was observed
in granzyme B production upon TNF-α blocking (Fig. 6G and H).
T1-IFNs can directly modulate the response of MAIT
cells to TCR stimulation
As the T1-IFN-mediated enhancement of the MAIT cell responses
to 5-A-RU/MG was largely TNF-α-independent (Fig. 6), we
hypothesised that T1-IFNs might exert their co-stimulatory effect
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 00: 1–14 Innate immunity 7
Figure 4. T1-IFN signalling is important for early MAIT cell activation by riboflavin synthesising bacteria. PBMCs were treated with paraformalde-
hyde fixed E. coli at 10 BpC ± 1 µg/mL vaccinia virus B18R protein for 6 h; (A) CD69 expression, and the percentage of MAIT cells (gated as in
Fig. 1A) expressing (B) 4-1BB, (C) TNF-α, (D) IFN-γ, (E) granzyme B, (F) perforin, (G) CD107a, and (H) CD40L were assessed by flow cytometry. Data
are presented as mean and SEM and are pooled from two independent experiments (n = 8). Each data point represents an individual healthy
donor. Repeated measures one-way ANOVA with Sidak’s multiple comparison tests were performed for assessing statistical significance. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001, ns = nonsignificant.
directly on MAIT cells. We revisited our recent transcriptomic
analysis of activated and nonactivated human MAIT cells and
compared the gene expression of T1-IFN receptor subunit 1/2
(IFNAR1 and IFNAR2) with that of IL-12 receptor (IL12RB1 and
IL12RB2) and IL-18 receptor (IL-18R1 and IL18RAP) [15]. The
level of expression of IFNAR1 and IFNAR2 in unstimulated MAIT
cells was similar to IL-18R1 and IL18RAP and was higher than
IL12RB1 and IL12RB2 (Supporting Information Fig. 6A). Interest-
ingly, the expression of IFNAR2 was significantly reduced in MAIT
cells following activation by E. coli but not by 5-A-RU or IL-12+IL-
18 (Supporting Information Fig. 6B), which may suggest receptor
downregulation following T1-IFN signalling [41].
To investigate the direct effect of T1-IFNs on MAIT cells, we
isolated Vα7.2+ T cells from human PBMCs and activated them
with anti-CD3/CD28 beads alone or in combination with IFN-α 2a
or IFN-β. MAIT cells produced IFN-γ and granzyme B upon acti-
vation by anti-CD3/CD28 beads, but not with either T1-IFN alone
(Fig. 7A and B). Interestingly, both IFN-α 2a and IFN-β signifi-
cantly increased production of IFN-γ or granzyme B in CD3/CD28-
stimulated MAIT cells compared to CD3/CD28 stimulation alone
(Fig. 7A and B). This confirmed that T1-IFNs can directly act on
MAIT cells to enhance their response to TCR stimulation.
Discussion
In this study, we demonstrated that MAIT cells can be activated
by T1-IFNs alone, and that T1-IFNs can augment various effector
functions of TCR-stimulated MAIT cells. Similar effects on MAIT
cell activation were seen with viral stimulation, and this was medi-
ated by T1-IFNs. T1-IFN-mediated enhancement of MAIT cell acti-
vation was also seen with bacterial stimulation. A similar role
for T1-IFNs was demonstrated with liver-derived MAIT cells. A
direct co-stimulatory effect of T1-IFNs on MAIT cells was also
established. Together our findings suggest an important role for
T1-IFNs in controlling MAIT cell effector responses.
We found that T1-IFNs alone were able to activate MAIT
cells but not induce cytokine production or upregulation of
co-stimulatory molecules. This is consistent with the previous
report by Wilgenburg et al., who found that T1-IFNs only induced
significant IFN-γ production when combined with IL-12 or
IL-18 [32]. In another study, various innate cytokines including
IFN-α were shown to upregulate CD69 expression on MAIT
cells [40]. Similarly, Spaan et al. demonstrated that adding IFN-α
or IL-12 to IL-18 significantly increased CD69 expression and
IFN-γ production by MAIT cells compared to untreated MAIT
cells [42]. Therefore, T1-IFNs can activate MAIT cells but MAIT
cell cytokine production requires stimulation with additional
cytokines.
The effect of T1-IFNs on MAIT cell activation has also be shown
in vivo. In patients with HCV infection treated with a combination
of pegylated IFN and antiviral drugs, higher expression of CD69
was seen on MAIT cells compared to patients receiving antiviral
therapy alone [32]. In another study, IFN-α-based therapy for
chronic HCV infection was shown to increase CD38 expression on
MAIT cells [42]. The concentration of IFN-α in plasma in patients
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
8 Rajesh Lamichhane et al. Eur. J. Immunol. 2019. 00: 1–14
Figure 5. Modulation of liver derived MAIT cell activation by IFN-β and IAV. (A) Representative flow cytometry plots showing gating strategy
for the identification of MAIT cells (CD3+CD161++Vα7.2TCR+) in human liver derived mononuclear cells; the percentage of parent population is
also shown. (B–I) Human liver derived mononuclear cells were treated with 1 nM 5-A-RU/MG or 375 IU/mL IFN-β or IAV at a MOI of 2, alone or
in combination, for 6 h and (B) CD69 expression, and the percentage of MAIT cells expressing (C) 4-1BB, (D) TNF-α, (E) IFN-γ, (F) granzyme B, (G)
perforin, (H) CD107a, and (I) CD40L were assessed by flow cytometry. Data are presented as mean and SEM and are pooled from three independent
experiments (n = 3 except IFN-β ± 5-A-RU/MG treatment in B where n = 2). Each data point represents an individual donor. Repeated measures
one-way ANOVA with Sidak’s multiple comparison tests were performed for assessing statistical significance (E and H). *p < 0.05.
with systemic lupus erythematous positively correlated with CD69
expression on blood MAIT cells [40].
T1-IFNs also modulated MAIT cell effector functions in
response to TCR stimulation. T1-IFNs have previously been shown
to modulate the function of TCR stimulated T cells. Priming of
IGRP-specific CD8+ T cells with either IFN-α or IFN-β for 2 h
significantly increased their expression of granzyme B and their
ability to lyse target human primary islet cells. [43]. Similarly,
co-treatment with IFN-α2 and anti-CD3 antibody enhanced IFN-γ
production by mouse invariant natural killer T cell hybridomas
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Figure 6. T1-IFN mediated enhancement of the MAIT cell response to 5-A-RU/MG is TNF-α independent. (A–C) PBMCs were treated with 1 nM
5-A-RU/MG or T1-IFNs (450 IU/mL IFN-α 2a or 375 IU/mL IFN-β) alone or in combination for 6 h and TNF-α production by monocytes was assessed
by flow cytometry; (A) gating strategy for monocytes, (B) representative flow cytometry plot of HLADR and CD14 expression on monocytes, and
(C) representative flow cytometry plots and cumulative data of TNF-α production by monocytes with different treatments. Numbers in each
flow cytometry plot indicate the percentage. (D–H) Anti-TNF-α antibody (5 µg/mL) or isotype control was added when PBMCs were treated with
375 IU/mL IFN-β alone (D–F) or co-treated with 1 nM 5-A-RU/MG and either T1-IFN (450 IU/mL IFN-α 2a or 375 IU/mL IFN-β) (G and H) for 6 h.
After the treatment, expression of (D) CD69 expression, and the percentage of MAIT cells (gated as in Fig. 1A) expressing (E) CD107a, (F) perforin,
(G) IFN-γ, and (H) granzyme B were assessed by flow cytometry. Data are presented as mean and SEM and are pooled from two independent
experiments (n = 8 for C–F and n = 7 for G–H). Each data point represents an individual healthy donor. Repeated measures one-way ANOVA with
Sidak’s multiple comparison tests (C, G, and H) and two-tailed paired t-tests (D–F) were performed for assessing statistical significance. *p < 0.05,
**p < 0.01, ns = nonsignificant.
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Figure 7. T1-IFNs act directly on MAIT cells. Purified Vα7.2+ cells (average purity > 85%) were incubated with anti-CD3/CD28 beads at a ratio of 1:1,
or with T1-IFNs (450 IU/mL IFN-α 2a or 375 IU/mL IFN-β) alone, or in combination for 6 h. After treatment, the percentage of MAIT cells producing (A)
IFN-γ, and (B) granzyme B were assessed by flow cytometry data are presented as mean and SEM and are pooled from two independent experiments
(n = 5–6). Each data point represents an individual healthy donor. Repeated measures one-way ANOVA with Sidak’s multiple comparison tests
were performed for assessing statistical significance. *p < 0.05, ****p < 0.0001.
compared to anti-CD3 antibody alone [44]. T1-IFNs also boosted
TCR-induced IL-10, but not IFN-γ, production in näıve CD4+ T
cells [45].
It has recently been shown that MAIT cells can be activated
during viral infection by cytokines, including IL-12, IL-15, IL-18,
and T1-IFNs [32, 39]; this has been discussed in detail in a recent
review [46]. In our study, we looked at early events following IAV
infection of PBMCs and showed that IAV can weakly activate and
induce degranulation of MAIT cells in as little as 6 h, and that
this was mediated by T1-IFNs. In mice, MAIT cells have previously
been shown to rapidly upregulate CD69, CD25, and granzyme B
during influenza challenge; T1-IFN signalling was shown to be
required for the expression of CD25 on MAIT cells [21]. In an
in vitro HCV infection model, neutralizing T1-IFNs with B18R
significantly reduced CD69 expression and production of IFN-γ
and granzyme B by MAIT cells, suggesting T1-IFN co-operate with
cytokines such as IL-12 and IL-18 during viral infection [32]. The
lack of cytokine production by MAIT cells in response to IAV alone
in our experiments likely reflects the earlier time point at which
activation was assessed (6 h versus overnight in the study by van
Wilgenburg et al.). Collectively, T1-IFNs play an important role in
MAIT cell activation during viral infection.
Viral infection enhanced the activation of TCR-stimulated
MAIT cells and this effect was T1-IFN dependent. This may have
implications for MAIT cell activation during lower respiratory tract
infections, where co-infection with bacteria and respiratory viruses
are common [47, 48] and in chronic hepatitis virus infection,
where gut dysfunction can result in microbial translocation and
delivery to the liver via the portal circulation [49].
Bacteria derived TLR agonists have been shown to license
APCs and result in enhanced MAIT cell activation upon subse-
quent treatment with E. coli [30]. Similarly, in a mouse model,
co-administration of TLR agonists was required for accumula-
tion of MAIT cells in the lung in response to intra-nasal 5-
(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) [29,
30]. Interestingly, we recently reported that T1-IFN signalling
pathways are upregulated early in MAIT cells activated by E. coli,
but not by 5-A-RU [15]. In this study, we demonstrated that T1-
IFNs are important early co-stimulatory signals during activation
by E. coli. Together, this suggests that E. coli induce T1-IFNs, which
are an important co-stimulatory signal during early TCR-mediated
MAIT cell activation. Intriguingly, at this early time point, perforin
expression appears to be completely dependent on T1-IFNs. This is
consistent with two previous studies that show TCR-independent
perforin production by MAIT cells activated by E. coli for 6 and
24 h [13, 15].
A similar co-stimulatory role of T1-IFNs was seen with liver
derived MAIT cells. Other innate co-stimulatory signals have previ-
ously been reported to play a role in the activation of liver derived
MAIT cells. Tang et al. reported that treating intrasinusoidal
and circulating mononuclear cells with IL-7 or a combination of
IL-1β + IL-23 boosted the production of TNF-α, IFN-γ, IL-2, and
IL-17A by MAIT cells stimulated with anti CD3/CD28-coupled
beads [26]. In another study, liver derived MAIT cells were the
second highest producers of IFN-γ, after NK cells, in response to
the TLR8 agonist, ssRNA40, with IFN-γ production dependent on
IL-12 and IL-18 produced by intrahepatic monocytes [9]. Further-
more, the expression of IFN-γ, TNF-α, IL-17A, granzyme A/B, and
perforin by MAIT cells was increased when PBMCs were treated
with IL-7 alone for 48 h; IL-7 treatment also reversed the MAIT
cell effector dysfunction seen in HIV infected patients [28]. IL-7
can also synergise with IL-12 to enhance granzyme B production
in MAIT cells [50]. Given that IL-7 can also be induced by T1-IFNs
[51], future studies should investigate whether the co-stimulatory
effect observed with T1-IFNs is mediated at least in part by IL-7.
TNF-α was considered as a mediator of the co-stimulatory effect
observed with T1-IFNs. We have previously reported that pre-
treatment of APCs with IFN-α increased their ability to stimulate
MAIT cells upon subsequent treatment with E. coli [30]. Mono-
cytes have been shown to produce TNF-α when directly activated
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Figure 8. Model of the role of T1-IFNs in MAIT cell activation. The response of MAIT cells to a pure TCR signal (e.g. 5-A-RU/MG), T1-IFNs alone,
and the combination of TCR signal and T1-IFNs is shown.
by IAV-infected epithelium [39]. A recent study found that IFN-α
induced TNF-α production by monocytes at 24 h [52]. TNF-α has
been shown to directly enhance surface CD69 expression on MAIT
cells [40], and to be required for IFN-γ production by MAIT cells in
response to IL-18 and IFN-α or to a replication-incompetent ade-
noviral vector [52]. Recently, opsonisation of E. coli with IgG was
shown to boost IFN-γ production by MAIT cells in a TNF-α depen-
dent manner [31]. However, the enhancement of 5-A-RU/MG-
mediated MAIT cell activation by T1-IFNs in our study was not
mediated by TNF-α, as neutralising TNF-α had minimal effect on
MAIT cell activation.
The T1-IFN mediated co-stimulatory effect on the TCR-
dependent MAIT cell activation observed in this study could occur
in two ways. First, T1-IFNs could act on the APCs (including in
an autocrine fashion in infection) leading to increased expression
of other co-stimulatory molecules and MR1 expression. Indeed,
T1-IFN treatment of dendritic cells has been shown to enhance
their T cell stimulatory activity through increased expression of
CD86 and CD40 and by enhancing MHC-I expression and cross-
presentation [53, 54]. Alternatively, T1-IFNs could act directly
on MAIT cells and modulate their response as has previously
been demonstrated with murine CD8+ T cells [55] and IGRP-
specific human CD8+ T cells [43]. Consistent with this, MAIT cells
expressed IFNAR1 and IFNAR2 at high levels and T1-IFNs were
able to enhance the response of isolated MAIT cells to TCR stimu-
lation. Therefore, T1-IFNs can mediate their co-stimulatory effect
by acting directly on MAIT cells. However, this does not rule out
additional indirect effects of T1-IFNs via activation of APCs or the
involvement of other co-stimulatory signals such as IL-7.
In summary, the MAIT cell response to TCR stimulation is
restricted and a co-stimulatory signal, such as that provided by
T1-IFNs, is essential for full activation. While commensal bacteria
may act as a source of MAIT cell TCR ligands, partially activating
tissue resident MAIT cells [16, 26, 56], pro-inflammatory signals,
including T1-IFNs, produced during infection/inflammation may
synergise with the TCR signal and tune the overall MAIT cell effec-
tor response (Fig. 8).
Materials and methods
Mononuclear cell isolation from blood and liver
Peripheral blood was collected from healthy donors and PBMCs
were isolated by LymphoprepTM (Axis-Shield PoC AS, Oslo,
Norway) density gradient centrifugation. Isolated PBMCs were
stored in liquid nitrogen until use. For each experiment frozen
PBMCs were washed and rested overnight in RPMI 1640 pre-
supplemented with L-glutamine (Life Technologies Corporation,
Carlsbad, USA), 10% fetal calf serum (Gibco, New Zealand),
and 100 units/mL Penicillin + 100 µg/mL Streptomycin (Gibco,
ThermoFisher Scientific, Waltham, USA). Liver tissue was
obtained from two patients with colorectal metastases and one
patient with focal nodular hyperplasia undergoing liver resection.
A piece of normal liver tissue as far away from the tumour as
possible was excised fresh from the main surgical specimen and
was cut into smaller pieces, digested with 0.05 mg/mL Liberase
TL (Roche, Basel, Switzerland) + 10 units/mL Benzonase nucle-
ase (Merck, Kenilworth, USA) and passed through a 70 µm cell
strainer. Liver derived mononuclear cells (LDMCs) were then iso-
lated using LymphoprepTM density gradient centrifugation. Iso-
lated LDMCs were not cryopreserved but were rested overnight
prior to stimulation.
Collection of blood from healthy donors was approved by the
University of Otago Human Ethics Committee (H14/046) and col-
lection of liver from patients undergoing hepatic resection was
approved by the New Zealand Health and Disability Ethics Com-
mittee (16/STH/83). Written informed consent was obtained from
each donor.
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Bacteria, virus, and MAIT cell ligand
An overnight culture of E. coli HB101 grown in Luria–Bertani was
fixed with 2% paraformaldehyde for 20 min at 4°C, washed, and
resuspended in PBS (Oxoid Ltd, Basingstoke, UK). Fixed bacteria
were quantified by flow cytometry using 123 count eBeads (eBio-
science, San Diego, USA) on a FACS CantoTM II (BD biosciences,
San Jose, USA) and 10 bacteria per cell (BpC) were used for the
experiments.
Influenza virus A/PR/8/34 (H1N1) strain (now onwards
referred to as IAV) was propagated in 10 day embryonated chicken
eggs and titrated on MDCK cells to determine PFU/mL [57].
Aliquots of the viral suspension were stored at −80°C and irra-
diated under 30 W UV bulb for 30 min before use in experiments.
MR1 ligand 5-A-RU was synthesised as previously reported
[15]. 5-A-RU was stored as single use aliquot at −80°C. Prior to
use, 5-A-RU was mixed with methylglyoxal (MG) at a 1:50 molar
ratio (5-A-RU/MG from now onwards) and used immediately.
MAIT cell activation
A total of 5 × 105 PBMCs or LDMCs were treated with 1 nM 5-
A-RU/MG alone or in combination with either 450 IU/mL human
IFN-α 2a (NR-3083, BEI Resources, Manassas, USA), 375 IU/mL
human IFN-β (NR-3080, BEI Resources) or UV-inactivated IAV
(MOI of 2) for 6 h and MAIT cell activation markers (CD69 and
4-1BB) and effector functions (TNF-α, IFN-γ, CD107a, CD40L,
granzyme B, and perforin) were assessed by flow cytometry;
IFN-α 2a, IFN-β, or IAV only treatment or no treatment controls
were included as appropriate. For some experiments, PBMCs
were treated with E. coli (10 BpC) for 6 h. For APC free activation,
Vα7.2+ cells were isolated from PBMCs prestained with Vα7.2-PE
(3C10, BioLegend) using anti-PE magnetic beads and MS columns
(both from Miltenyi Biotech, Bergisch Gladbach, Germany).
Isolated Vα7.2+ cells were activated with DynabeadsTM human
T-activator CD3/CD28 (Gibco, ThermoFisher Scientific) at a ratio
of 1:1, with or without IFN-α 2a or IFN-β, for 6 h.
Blocking antibodies and inhibitors
Anti-MR1 antibody (clone 26.5, BioLegend, San Diego, USA) at
2.5 µg/mL was used to block the MR1-TCR interaction. T1-IFNs
were blocked using 1 µg/mL vaccinia virus B18R recombinant
protein (34-8185-81, eBioscience). Brefeldin A (BioLegend) at
5 µg/mL was used to block ER-golgi transport of protein for
the assessment of cytokines and cytotoxic molecules. TNF-α was
blocked with 5 µg/mL anti-TNF-α antibody (Mab11, BioLegend);
IgG1 isotype control (MOPC-21, BioLegend) was also included.
Flow cytometry
At the end of the treatment, cells were washed twice with PBS,
stained with near IR live/dead stain (Invitrogen, Carlsbad, USA)
and antibodies targeting surface markers at 4°C for 25 min,
followed by two washes with PBS, before fixation with 2%
paraformaldehyde at 4°C for 20 min. Cells were then washed with
PBS and then permeabilization buffer (BioLegend) and stained in
permeabilization buffer with antibodies targeting MAIT cell TCR
components (Vα7.2 TCR, CD3, and CD8) and intracellular proteins
at room temperature for 25 min. Following additional washes with
permeabilization buffer and then PBS, cells were resuspended in
PBS. Antibodies used were: CD3 PE-Cy7 (UCHT1, BioLegend),
CD3 BV510 (OKT3, BioLegend), CD8 eFluor450 (RPA-18, eBio-
science), TCR Vα7.2 PE or PE-Cy7 (3C10, BioLegend), CD161 APC
(191B8, Miltenyi Biotec), TNF-α FITC (Mab11, BioLegend), IFN-γ
PerCP-Cy5.5 (4S.B, BioLegend), CD107a PE (H4A3, BioLegend),
granzyme B FITC (QA16AO2, BioLegend), perforin PerCP-Cy5.5
(B-D48, BioLegend), CD40L FITC (24-31, BioLegend), 4-1BB PE
or BV421 (4B4-1, BioLegend), CD14 APC (HCD14, BioLegend),
and HLA-DR AF488 (L243, BioLegend).
Samples were acquired on a FACSCantoTM II with three laser
system (blue (488 nm), red (633 nm), and violet (405 nm)) or
a LSRFortessaTM with four laser system (blue (488 nm), green
(561 nm), red (640 nm), and violet (405 nm)) (both from BD)
and analysis was performed in FlowJoTM V10 (TreeStar, Ashland,
USA). MAIT cells were identified using TCR Vα7.2 PE or PE-Cy7
in combination with CD161 APC (Fig. 1A).
Flow cytometry experiments were conducted in line with
recently published guidelines [58].
Gene expression analysis
RNA sequencing data from our recent publication was analysed
to assess the expression of IFNAR1, IFNAR2, IL12RB1, IL12RB2,
IL18R1, and IL18RAP [15]. Briefly, MAIT cells were isolated
from treated and untreated PBMCs by fluorescence activated cell
sorting; PBMCs were treated with formaldehyde-fixed E. coli (10
BpC) or 5-A-RU (5 µM) for 6 h or IL-12+IL-18 (50 ng/mL each) for
24 h. RNA sequencing and analysis were recently described [15].
Statistical analysis
Data were analysed in GraphPad Prism V7.03 and are presented
as mean and SEM. For statistical comparison, repeated measures
one-way or two-way ANOVA with Sidak’s multiple comparison test
between treatments or paired two-tailed t-test between two treat-
ments were used. A two-sided p-value of 0.05 was considered
significant.
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